_			
1			
2	UNITED STATES DISTRICT COURT		
3	NORTHERN DISTRICT OF CALIFORNIA		
4	SAN JOSE DIVISION		
5	UNITED STATES OF AMERICA,)		
6) CR-18-00258-EJD PLAINTIFF,)		
7) SAN JOSE, CALIFORNIA VS.		
8) MAY 3, 2022 RAMESH "SUNNY" BALWANI,)		
9	DEFENDANT.)		
10			
11			
12	TRANSCRIPT OF TRIAL PROCEEDINGS BEFORE THE HONORABLE EDWARD J. DAVILA		
13	UNITED STATES DISTRICT JUDGE		
14	APPEARANCES:		
15	FOR THE PLAINTIFF: UNITED STATES ATTORNEY'S OFFICE BY: JOHN C. BOSTIC		
16	JEFFREY B. SCHENK 150 ALMADEN BOULEVARD, SUITE 900		
17	SAN JOSE, CALIFORNIA 95113		
18	BY: ROBERT S. LEACH 1301 CLAY STREET, SUITE 340S		
19	OAKLAND, CALIFORNIA 94612		
20	(APPEARANCES CONTINUED ON THE NEXT PAGE.)		
21	OFFICIAL COURT REPORTERS: IRENE L. RODRIGUEZ, CSR, RMR, CRR		
22	CERTIFICATE NUMBER 8074 LEE-ANNE SHORTRIDGE, CSR, CRR		
23	CERTIFICATE NUMBER 9595		
24	PROCEEDINGS RECORDED BY MECHANICAL STENOGRAPHY TRANSCRIPT PRODUCED WITH COMPUTER		
25			

1	APPEARANCES:	(CONT'D)
2	FOR DEFENDANT BALWANI:	ORRICK, HERRINGTON & SUTCLIFFE LLP BY: MOLLY MCCAFFERTY
3		SHAWN ESTRADA
4		THE ORRICK BUILDING 405 HOWARD STREET
5		SAN FRANCISCO, CALIFORNIA 94105
		BY: JEFFREY COOPERSMITH
6		AARON BRECHER AMANDA MCDOWELL
7		701 FIFTH AVENUE, SUITE 5600 SEATTLE, WASHINGTON 98104
8		BY: STEPHEN CAZARES
9		77 SOUTH FIGUEROA STREET, SUITE 3200 LOS ANGELES, CALIFORNIA 90017
10		BY: AMY WALSH
11		51 W 52ND STREET
12		NEW YORK, NEW YORK 10019
13	ALSO PRESENT:	OFFICE OF THE U.S. ATTORNEY
14		BY: MADDI WACHS, PARALEGAL SARA SLATTERY, PARALEGAL
15		ORRICK, HERRINGTON & SUTCLIFFE JENNIFER CYGNOR, PARALEGAL
16		·
17		PROLUMINA BY: COREY ALLEN
18		2200 SIXTH AVENUE, SUITE 425 SEATTLE, WASHINGTON 98121
19		UNITED STATES POSTAL INSPECTION SERVICE
20		BY: CHRISTOPHER MCCOLLOW
21		FEDERAL BUREAU OF INVESTIGATION BY: MARIO C. SCUSSEL
22		UNITED STATES FOOD & DRUG
23		ADMINISTRATION BY: GEORGE SCAVDIS
24		
25		

1	INDEX OF PROC	CEEDINGS	
2	GOVERNMENT'S:		
3			
4	SHANE WEBER	D 4521	
5	DIRECT EXAM BY MR. LEACH CROSS-EXAM BY MR. CAZARES	P. 4531 P. 4570	
6	REDIRECT EXAM BY MR. LEACH	P. 4597	
7	SARAH BENNETT		
8	DIRECT EXAM BY MR. LEACH CROSS-EXAM BY MR. CAZARES	P. 4602 P. 4693	
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			

1				
2		INDEX OF E	XHIBITS	
3		IDENT.	EVIDENCE	
4	GOVERNMENT'S			
5	143		4537	
6	159 162		4544 4551	
7	167 174		4556 4564	
8	5831 5830		4626 4633	
	5450		4640	
9	5451 5453		4644 4646	
10	4533		4651	
10	4621		4662	
11				
12				
13				
14				
15				
16	DEFENDANT'S			
17	10561		4585	
18	15041 7350		4597 4697	
19				
20				
21				
22				
23				
24				
25				

	1	SAN JOSE, CALIFORNIA MAY 3, 2022
	2	PROCEEDINGS
08:41AM	3	(COURT CONVENED AT 8:41 A.M.)
08:41AM	4	(JURY OUT AT 8:41 A.M.)
08:41AM	5	THE COURT: WE'RE BACK ON THE RECORD IN THE BALWANI
08:41AM	6	MATTER.
08:41AM	7	ALL COUNSEL ARE PRESENT. MR. BALWANI IS ALSO PRESENT.
08:41AM	8	WE'RE OUTSIDE OF THE PRESENCE OF THE JURY.
08:41AM	9	AND WE SHOULD TALK ABOUT DOCUMENT 1419 AND 1420, WHICH ARE
08:41AM	10	MR. BALWANI'S MOTION AND THE GOVERNMENT'S OPPOSITION.
08:41AM	11	COULD I KNOW THE SCHEDULE TODAY OF WITNESSES? DO WE KNOW
08:41AM	12	THAT?
08:41AM	13	GOOD MORNING.
08:41AM	14	MR. LEACH: YES, YOUR HONOR. I'LL SPEAK TO THAT.
08:41AM	15	THE FIRST WITNESS IS SHANE WEBER, WHO YOU KNOW FROM THE
08:41AM	16	FIRST TRIAL AND WHO IS THE SUBJECT OF THE FILINGS YESTERDAY.
08:41AM	17	THE COURT: RIGHT.
08:41AM	18	MR. LEACH: THE SECOND WITNESS IS SARAH BENNETT WHO
08:42AM	19	IS AN EMPLOYEE OF CMS.
08:42AM	20	THE COURT: RIGHT. OKAY. THANK YOU.
08:42AM	21	THIS IS THE DEFENSE MOTION TO PRECLUDE ANY MENTION OF THE
08:42AM	22	LETTER, THE PFIZER LETTER, ITS SOURCES OR ANY ATTRIBUTION, I
08:42AM	23	EXPECT, AS TO MR. BALWANI.
08:42AM	24	IS THAT IT, MR. BRECHER?
08:42AM	25	MR. BRECHER: GOOD MORNING. YES, YOUR HONOR.

08:42AM	1	IT'S CLOSE. I DON'T THINK WE'RE SAYING TO EXCLUDE THE
08:42AM	2	LETTER, OR A REPORT AS MS. VOLKAR WILL REMIND US A VERSION OF
08:42AM	3	THAT, THE ENHANCED VERSION IS ALREADY IN EVIDENCE AND IT CAME
08:42AM	4	INTO EVIDENCE THROUGH MS. PETERSON'S TESTIMONY.
08:42AM	5	WHAT WE ARE TALKING ABOUT IS THE LOGO, THE ATTRIBUTION
08:42AM	6	ISSUE THAT WE DESCRIBED.
08:42AM	7	THE COURT: OKAY.
08:42AM	8	MR. BRECHER: I JUST DO NOT WANT TO REPEAT BECAUSE I
08:42AM	9	KNOW WE DISCUSSED THIS SEVERAL TIMES.
08:42AM	10	THE COURT: RIGHT.
08:42AM	11	MR. BRECHER: BUT I DO WANT TO FOCUS WHERE WE ARE
08:42AM	12	AND WHERE WE ARE NOT IN TERMS OF THE EVIDENCE YOU DID ALLOW ON
08:43AM	13	APRIL 6TH, EVIDENCE THROUGH DR. CULLEN, YOU DID ALLOW THAT
08:43AM	14	EVIDENCE TO COME IN AS TO THE ENHANCED OR THE ORIGINAL
08:43AM	15	UNALTERED REPORT.
08:43AM	16	BUT THE BASIS FOR THE COURT'S RULING THERE, AND THIS IS IN
08:43AM	17	OUR MOTION AND WE QUOTE THE COURT'S PRECISE LANGUAGE, WAS SOME
08:43AM	18	KNOWLEDGE, WHETHER ACTUAL OR CONSTRUCTIVE, THAT MR. BALWANI HAD
08:43AM	19	BY BEING THE RECIPIENT, ALBEIT AS A CC WITH BOTH VERSIONS OF
08:43AM	20	THE REPORT AT TWO DIFFERENT TIMES.
08:43AM	21	THAT'S NOT TRUE OF THE OTHER PHARMACEUTICAL REPORT. IT'S
08:43AM	22	CERTAINLY NOT TRUE OF THE PFIZER REPORT.
08:43AM	23	THE COURT: IN THAT HE'S NOT A RECIPIENT?
08:43AM	24	MR. BRECHER: THAT'S CORRECT, YOUR HONOR.
08:43AM	25	THE COURT: RIGHT.

MR. BRECHER: THE ONLY VERSION OF THE PFIZER REPORT 1 08:43AM 2 THAT MR. BALWANI HAS EVER SEEN, AND THIS IS TRUE NOT ONLY OF 08:43AM THE EVIDENCE THAT CAME IN THE HOLMES TRIAL, THE EVIDENCE THAT 3 08:43AM 08:44AM 4 IS IN SO FAR IN THIS TRIAL, BUT SO FAR AS I'M AWARE, AND I THINK SO FAR AS THE GOVERNMENT IS AWARE, ALL OF THE EVIDENCE 08:44AM THAT THE PARTIES HAVE EXCHANGED IN DISCOVERY HAS SHOWN THAT 08:44AM 6 08:44AM 7 MR. BALWANI HAS ONLY SEEN THAT ENHANCED VERSION. SO THE PARTICULAR BASIS FOR THE COURT'S RULING VIS-À-VIS 8 08:44AM DR. CULLEN IS NOT AVAILABLE HERE. 08:44AM 9 08:44AM 10 NOW, THE GOVERNMENT SUGGESTS, AND I THINK WE ACKNOWLEDGE 08:44AM 11 IN OUR BRIEF, THAT THERE MAY BE ANOTHER BASIS, AND THAT IS SOME 08:44AM 12 SORT OF VICARIOUS LIABILITY, WHETHER IT'S COCONSPIRATOR LIABILITY OR COSCHEMER LIABILITY. 08:44AM 13 AND AGAIN, WITHOUT REPEATING THESE ARGUMENTS AD NAUSEAM, 08:44AM 14 08:44AM 15 THE CORE OF OUR ARGUMENT IS TWO-FOLD. ONE IS THAT THIS CONDUCT, THE UNAUTHORIZED USE OF THIS LOGO, THIS CHANGE WAS 08:44AM 16 08:44AM 17 MADE IN APRIL OF 2010, AND THE GOVERNMENT CANNOT SHOW BY A 08:44AM 18 PREPONDERANCE OF THE EVIDENCE THAT A CONSPIRACY OR A SCHEME TO 08:44AM 19 DEFRAUD EXISTED AT THAT POINT IN TIME. 08:44AM 20 SO THAT'S NUMBER ONE. AND THEN NUMBER TWO IS THE 403 ARGUMENT, THIS FUNDAMENTAL 08:44AM 21 08:44AM 22 UNFAIRNESS THAT WE KNOW AND, FRANKLY, EVERYONE EXCEPT THE JURY 08:45AM 23 WILL KNOW THAT THERE IS THIS CONTEXT SURROUNDING WHO PUT THE 08:45AM 24 LOGO ON THAT PFIZER REPORT. 08:45AM 25 AND WITHOUT SERIOUSLY COMPROMISING MR. BALWANI'S TRIAL

RIGHTS, NOT ONLY WILL WE NOT BE ABLE TO PUT IN THAT CONTEXT IN 1 08:45AM GENERAL, WE CERTAINLY WON'T BE ABLE TO FOLLOW UP ON IT AND SEEK 2 08:45AM MORE ADMISSIONS THAT WOULD BE HELPFUL AND EXCULPATORY HERE. 3 08:45AM 08:45AM 4 THE COURT: SURE. MR. BRECHER: SO THAT'S SORT OF WHERE WE ARE IN 08:45AM 08:45AM 6 TERMS OF THE LAY OF THE LAND. 08:45AM 7 I DO WANT TO RESPOND TO SOME POINTS THAT THE GOVERNMENT RAISED IN ITS OPPOSITION BRIEF. 08:45AM 8 FIRST, THE POINT THAT MR. BALWANI DOES NOT ADDRESS BUT THE 08:45AM 9 08:45AM 10 GOVERNMENT MAY SEEK TO SEEK TO INTRODUCE THIS EVIDENCE TO SHOW 08:45AM 11 FALSITY. 08:45AM 12 I KNOW WHEN WE DISCUSSED THIS BEFORE, BOTH ON MARCH 11TH AND ON APRIL 6TH, I ACKNOWLEDGED REPEATEDLY THAT THAT'S A 08:45AM 13 PERFECTLY FINE USE OF THE EVIDENCE OF THE PHARMACEUTICAL 08:45AM 14 08:45AM 15 RELATIONSHIPS. 08:45AM 16 MR. WEBER, I BELIEVE IT IS IN FACT DR. WEBER, BUT HE WENT 08:45AM 17 BY MR. WEBER IN THE HOLMES TRIAL, DID TESTIFY THERE, AND I 08:46AM 18 STRONGLY SUSPECT IS GOING TO TESTIFY THIS MORNING THAT PFIZER 08:46AM 19 DID NOT COMPREHENSIVELY VALIDATE THE TECHNOLOGY. 08:46AM 20 THE COURT: YOU HAVE NO ISSUE WITH THAT. 08:46AM 21 MR. BRECHER: I HAVE NO ISSUE WITH THAT, YOUR HONOR, 08:46AM 22 IN PART BECAUSE THAT WHOLE STUDY WAS DONE BEFORE MR. BALWANI 08:46AM 23 JOINED THE COMPANY, AND AS I THINK THE COURT KNOWS, MR. BALWANI 08:46AM 24 RECEIVED THESE EXACT SAME REPRESENTATIONS. 08:46AM 25 SO THERE'S JUST NO TETHER TO IT THERE.

08:46AM	1	AND IF THE GOVERNMENT WANTS HIM TO SAY THAT AGAIN, FINE.
08:46AM	2	THERE WON'T BE ANY OBJECTION.
08:46AM	3	THE COURT: AND HE'LL TESTIFY ABOUT THE DOCUMENT AND
08:46AM	4	SAY, NO, THAT'S NOT WHAT WE DID. WE DIDN'T GIVE OUR IMPRIMATUR
08:46AM	5	ON THIS. NO, IT'S NOT WE DIDN'T PUT OUR LOGO ON THIS. WE
08:47AM	6	DIDN'T AUTHORIZE THEM TO PUT OUR LOGO ON THAT.
08:47AM	7	MR. BRECHER: THAT'S WHERE I GET OFF THE RAMP,
08:47AM	8	YOUR HONOR, IT'S THE LAST TWO POINTS ABOUT THE LOGO AND THE
08:47AM	9	UNAUTHORIZED USE OF THE LOGO.
08:47AM	10	THE COURT: SO CAN'T HE SAY, AND YOU'LL TELL ME
08:47AM	11	RIGHT NOW, NO, TO MY KNOWLEDGE WE DID NOT PUT OUR LOGO ON THERE
08:47AM	12	AND THAT'S NOT AN AUTHORIZED PFIZER DOCUMENT WITH OUR APPROVAL?
08:47AM	13	WHY CAN'T HE SAY THAT?
08:47AM	14	MR. BRECHER: WELL, I THINK, YOUR HONOR
08:47AM	15	THE COURT: I'M SORRY TO INTERRUPT YOU.
08:47AM	16	MR. BRECHER: NO, NOT AT ALL.
08:47AM	17	THE COURT: WITHOUT SAYING THAT IT, ACCUSING AND
08:47AM	18	POINTING A FINGER, BECAUSE HE DOESN'T KNOW THAT.
08:47AM	19	MR. BRECHER: WELL, YOU'RE RIGHT, YOUR HONOR, HE
08:47AM	20	CERTAINLY DOESN'T KNOW THAT, AND I DON'T THINK THAT WILL BE HIS
08:47AM	21	TESTIMONY AND I DON'T THINK THE GOVERNMENT WILL ELICIT THAT
08:47AM	22	TESTIMONY.
08:47AM	23	THE COURT: EXACTLY. SO WHY CAN'T HE SAY, NOPE,
08:47AM	24	THIS IS NOT SOMETHING TO MY KNOWLEDGE IN MY CAPACITY AND
08:47AM	25	EMPLOYMENT AT PFIZER THAT WE EVER ENDORSED, AND THAT'S ALL, AND

1 08:47AM 2 08:47AM 3 08:47AM 08:47AM 4 08:47AM 08:47AM 08:47AM 8 08:47AM 08:47AM 9 08:48AM 10 08:48AM 11 08:48AM 12 08:48AM 13 08:48AM 14 08:48AM 15 08:48AM 16 08:48AM 17 08:48AM 18 08:48AM 19 08:48AM 20 08:48AM 21 08:48AM 22 08:48AM 23 08:48AM 24 08:48AM 25

I DON'T KNOW HOW IT HAPPENED AND IF IT'S A PRANK OR WHATEVER, WE DIDN'T DO IT AND ENDORSE IT, AND THAT'S IT.

MR. BRECHER: THE REASON WHY I DON'T THINK THAT GETS US WHERE WE NEED TO BE, YOUR HONOR, IS PRECISELY BECAUSE MR. BALWANI IS THE ONLY ONE HERE. HE'S THE ONLY DEFENDANT IN THE COURTROOM.

WHEN THERE'S EVIDENCE OF WRONGDOING AND UNAUTHORIZED USE AND THE JURY HEARS THAT EVIDENCE, IN PARTICULAR WITH THE CONTEXT THAT WE ALL KNOW EXISTS, WHICH COULD BE INCULPATORY IF THE JURY CONCLUDES THAT THERE WAS A CONSPIRACY OR A SCHEME THAT MR. BALWANI WAS A PART OF, OR COULD BE QUITE EXCULPATORY IF THE JURY DOES NOT SO CONCLUDE, AND THAT'S THEIR PREROGATIVE, YOUR HONOR.

WITHOUT THAT CONTEXT, THE ONLY NATURAL ASSUMPTION THAT THE JURY HEARS, BOTH AS THEY'RE LISTENING TO THE TESTIMONY AND IN PARTICULAR AS THEY'RE LISTENING TO CLOSING ARGUMENT, IS, WELL, GOSH, SOMETHING REALLY FUNNY HAPPENED HERE. THAT'S THE GUY THAT WE'RE LOOKING AT. THAT'S THE GUY WHOSE CONDUCT WE'RE HERE TO ASSESS AND TO JUDGE.

I JUST DON'T THINK THAT YOU CAN GET OVER THAT FUNDAMENTAL FAIRNESS POINT.

SO THAT'S THE 403 POINT.

THE COURT: SO DOES THE INSTRUCTION, THE FINAL INSTRUCTION CURE THAT IF THERE'S NO -- ASSUMING THAT THE GOVERNMENT CANNOT MAKE A CONSPIRACY, PRIMA FACIE SHOWING OF A

08:48AM	1	CONSPIRACY THAT EXISTED DURING THE TIME PERIOD, APRIL, IS IT,
08:48AM	2	2010, SOMETHING LIKE THAT?
08:48AM	3	MR. BRECHER: APRIL 14TH, 2010. I BELIEVE IT WAS
08:49AM	4	APRIL 14TH OF 2010.
08:49AM	5	MS. HOLMES TESTIFIED THAT SHE ADDED THE LOGO, QUOTE, JUST
08:49AM	6	BEFORE.
08:49AM	7	THE COURT: CORRECT, SENDING THEM.
08:49AM	8	MR. BRECHER: I DON'T KNOW WHETHER THAT MEANS AN
08:49AM	9	HOUR BEFORE OR A DAY BEFORE.
08:49AM	10	THE COURT: RIGHT.
08:49AM	11	MR. BRECHER: THERE'S NOT A LOT OF CONTEXT THERE,
08:49AM	12	WHICH IS PART OF THE PROBLEM.
08:49AM	13	THE COURT: RIGHT. IF THE GOVERNMENT CANNOT, CANNOT
08:49AM	14	ESTABLISH A PRIMA FACIE WHICH DOESN'T TAKE MUCH, DOES IT?
08:49AM	15	IF THEY CAN'T ESTABLISH, EXCUSE ME, A PRIMA FACIE SHOWING OF A
08:49AM	16	CONSPIRACY AT THAT TIME PERIOD, THEN ISN'T THE REMEDY AN
08:49AM	17	INSTRUCTION, A FINAL INSTRUCTION TO THE JURY THAT THEY CANNOT
08:49AM	18	CONSIDER SOME LANGUAGE THAT I'M SURE YOU'LL BE VERY CREATIVE
08:49AM	19	ABOUT CREATING THAT SAYS THAT THEY CAN'T USE THAT AGAINST
08:49AM	20	MR. BALWANI BECAUSE THERE'S NO EVIDENCE PROOF?
08:49AM	21	MR. BRECHER: YOUR HONOR, WE HAD DISCUSSED, I THINK
08:49AM	22	ON MARCH 11TH, THE POSSIBILITY OF AN INSTRUCTION.
08:49AM	23	I DON'T THINK AT THE TIME THAT THERE WAS LANGUAGE I
08:49AM	24	THINK WE KICKED SOME AROUND INFORMALLY WITH THE COURT. I DON'T
08:50AM	25	THINK THERE WAS LANGUAGE THAT SATISFIED BOTH THE DEFENSE AND

1 08:50AM 2 08:50AM 3 08:50AM 08:50AM 4 08:50AM 08:50AM 08:50AM 08:50AM 08:50AM 9 08:50AM 10 08:50AM 11 08:50AM 12 08:50AM 13 08:50AM 14 08:50AM 15 08:50AM 16 08:50AM 17 08:50AM 18 08:50AM 19 08:51AM 20 08:51AM 21 08:51AM 22 08:51AM 23 08:51AM 24 08:51AM 25

THE GOVERNMENT.

OBVIOUSLY YOUR HONOR MAY SETTLE ON SOMETHING THAT SATISFIES BOTH OR NEITHER. I THINK THAT'S POSSIBLE.

BUT I DON'T THINK THAT THAT'S GOING TO CURE THE ISSUE OF THE PREJUDICE THAT IS GOING TO HAPPEN THIS MORNING WHEN THE GOVERNMENT, AS I EXPECT IT WILL, ELICITS THAT TESTIMONY ABOUT THE UNAUTHORIZED USE.

THE COURT: SURE.

MR. BRECHER: AND THEN THE SECOND POINT I JUST WANT TO RESPOND VERY BRIEFLY, YOU'RE RIGHT THAT A PRIMA FACIE CASE IS NOT AN ESPECIALLY HEAVY BURDEN.

BUT I THINK IT'S IMPORTANT TO PUT OUT WHAT THAT BURDEN IS PRECISELY. IT IS A PREPONDERANCE STANDARD. AND THAT'S BOURJAILY, AND I KNOW THAT THE BOURJAILY DECISION WAS NOT -- IT SPOKE ABOUT COCONSPIRATOR STATEMENTS, BUT AS I THINK THE ADVISORY COMMITTEE NOTES AS WE CITED IN OUR PAPERS POINT OUT, THAT'S THE GENERAL STANDARD FOR ALL 104 PRELIMINARY QUESTIONS.

AND AS TO APRIL 2010, I DON'T THINK THAT THAT'S THERE. AND PART OF THE REASON THAT I DON'T THINK THAT THAT'S THERE, YOUR HONOR, IS IF YOU LOOK AT THE GOVERNMENT'S OPPOSITION, THEY CITE ALL KINDS OF FACTS FROM 2013 AND 2014 AND 2015, BUT DATES MATTER, OTHERWISE THE TEMPORAL RESTRICTIONS ON VICARIOUS LIABILITY WOULD NOT HAVE ANY MEANING.

THE COURT: WELL, I KNOW IT WILL SURPRISE YOU TO SAY THAT I'M GOING TO TASK MS. VOLKAR, IN JUST A MOMENT, TO TELL ME

WHAT THE CONSPIRACY IS IN 2010, AND WE'LL SEE IF SHE'S UP TO 1 08:51AM 08:51AM 2 THE TASK. I DON'T KNOW. MR. BRECHER: WELL, I WOULDN'T BE SURPRISED, 3 08:51AM 08:51AM 4 YOUR HONOR. 08:51AM 5 BUT I WOULD BE SURPRISED, GIVEN THE STATE OF THE EVIDENCE, 08:51AM 6 AND I THINK THAT THE ONLY OTHER THING THAT I WOULD POINT OUT 08:51AM 7 ABOUT THE DATES OF THIS EVIDENCE IS THAT I WANT TO MAKE SURE THAT THERE'S NO CONFUSION HERE ON PAGE 3 OF THE GOVERNMENT'S 08:51AM 8 BRIEF, LINE 7 TO 8, THERE'S A STATEMENT, "DEFENDANT ALSO 08:51AM 9 08:51AM 10 REGULARLY SENT THE ALTERED PFIZER RELATED REPORT TO THE 08:51AM 11 INVESTORS AND DISCUSSED DOING SO WITH DEFENDANT HOLMES." 08:51AM 12 I JUST WANT TO MAKE SURE THAT THE RECORD IS COMPLETELY CLEAR ON THAT POINT. THE ALTERED VERSION OF THE REPORT IS THE 08:52AM 13 ONLY ONE THAT MR. BALWANI HAD, AND THE QUOTE WHICH THEY'RE 08:52AM 14 08:52AM 15 ALLUDING TO IS A TEXT WHICH SAYS I'M GOING TO SEND BDT THE PFIZER REPORT AND MR. BALWANI SAYS GREAT. 08:52AM 16 08:52AM 17 IF I TELL MY SISTER I'M GOING TO SEND IN MY RESUME FOR 08:52AM 18 THIS GREAT NEW JOB AND SHE SAYS GREAT, UNLESS THERE'S SOME 08:52AM 19 SHOWING THAT SHE KNOWS THAT I HAVE SECRETLY ALTERED MY RESUME 08:52AM 20 TO BUMP UP MY CLASS RANKING, THAT'S A HYPOTHETICAL, YOUR HONOR. 08:52AM 21 I HAVEN'T DONE SO. 08:52AM 22 THE COURT: YOU DON'T NEED TO DO THAT. WE ALL KNOW 08:52AM 23 THAT. WE ALL KNOW THAT. IT DOESN'T GET ANY HIGHER THAN YOUR 08:52AM 24 RANK, MR. BRECHER. 08:52AM 25

THAT DOESN'T IMPLICATE MY SISTER. SHE'S NOT ON THE HOOK. 1 08:52AM 2 08:52AM 3 08:52AM 08:53AM 4 08:53AM 08:53AM 6 08:53AM 7 CONTRARY. 08:53AM 8 THANK YOU. 08:53AM 9 08:53AM 10 THE COURT: OKAY. THANK YOU. 08:53AM 11 08:53AM 12 08:53AM 13 08:53AM 14 08:53AM 15 08:53AM 16 AS WE DISCUSSED EARLIER FOR FALSITY. 08:53AM 17 08:53AM 18 08:53AM 19 08:53AM 20 08:53AM 21 08:54AM 22 08:54AM 23 08:54AM 24 SOMETHING ELSE FOR ITS PREPARATION. 08:54AM 25 MR. BRECHER: I APPRECIATE THAT.

I WANT TO MAKE SURE THAT'S CLEAR FOR THE RECORD. AND IF THE GOVERNMENT CANNOT ESTABLISH A PRIMA FACIE CASE BY THE RELEVANT STANDARD, THAT PREPONDERANCE STANDARD AS OF APRIL 2010, THEN THERE IS NO BASIS FOR THE JURY TO HEAR EVIDENCE ABOUT DOCTORING OR ALTERING OF THIS REPORT OF WHICH MR. BALWANI HAD NO KNOWLEDGE AND THERE'S NO SHOWING TO THE SO I JUST -- YOU KNOW, IN THE SPIRIT OF JUST FULL DISCLOSURE, I LOOK AT -- I'M CONSIDERING THAT ARGUMENT, CONSIDERING IT WHEN I READ THE PLEADINGS AND THOUGHT, YOU KNOW, TO MYSELF, YOU KNOW, WHAT IS THE SHOWING IN APRIL OF 2010? MS. VOLKAR IS EAGER TO TELL US ALL ABOUT THAT. BUT IF THERE IS NO SHOWING, AT A MINIMUM IT SHOULD COME IN WHAT IS THE RELEVANCE OF IT, JUDGE? WHY SHOULD HE BE ASKED ABOUT THIS LETTER? BECAUSE IF IT'S NOT RELEVANT TO MR. BALWANI, IF HE DIDN'T DO IT, THEN WHAT IS ITS PURPOSE IN THIS CASE? WHICH MS. VOLKAR WILL ALSO EDUCATE US ON AS WELL. BUT IT SEEMS TO ME, IN READING THE PAPERS, IF NOTHING ELSE IT COMES IN FOR FALSITY FOR PERHAPS PROPHYLACTIC LANGUAGE OR

1 08:54AM 2 08:54AM 3 08:54AM 08:54AM 4 08:54AM 08:54AM 6 08:54AM 7 08:54AM 8 08:54AM 9 08:54AM 10 08:54AM 11 08:54AM 12 08:54AM 13 08:55AM 14 08:55AM 15 08:55AM 16 08:55AM 17 08:55AM 18 08:55AM 19 08:55AM 20 08:55AM 21 08:55AM 22 08:55AM 23 08:55AM 24 08:55AM 25

I WANT TO FLAG AGAIN THAT I HAVE NO PROBLEM WITH THE TESTIMONY THAT PFIZER DID NOT, IN FACT, VALIDATE THE TECHNOLOGY OR STAND BEHIND THE CONCLUSIONS IN THE REPORT.

I THINK THAT'S FINE, AND I THINK THAT'S ALL THE GOVERNMENT NEEDS TO DO TO SHOW FALSITY.

BUT ANYTHING BEYOND THAT AND ANYTHING ABOUT DOCTORING WOULD TRANSGRESS THESE BOUNDARIES THAT WE HAVE TALKED ABOUT TODAY.

THE COURT: OKAY. GREAT. THANK YOU.

SO, MS. VOLKAR, I -- MR. BRECHER INFORMS US OF HIS DOCUMENT 1419 AND HE TALKS ABOUT ECF PAGE 5, AND IT'S LINES 11 THROUGH 15 AND 16 WHERE HE SUGGESTS THAT THE GOVERNMENT HAS NOT MET THEIR BURDEN FOR CONSPIRACY PURPOSES, AND HE TALKS AND SAYS IN HIS MEMO THAT THE EVIDENCE IS MR. BALWANI'S EMPLOYMENT, ROMANTIC RELATIONSHIP, AND NEITHER OF WHICH INDEPENDENTLY OR COLLECTIVELY ESTABLISH A CONSPIRACY OR A SCHEME, AND THAT PREFACES MY QUESTION AND -- OF COURSE I WANT TO HEAR WHAT YOU HAVE TO SAY, BUT WHAT IS THE EVIDENCE AT THIS TIME PERIOD THAT WOULD ALLOW A SHOWING, A FINDING BY A PREPONDERANCE THAT A CONSPIRACY OR A SCHEME EXISTED?

NOW, LET ME SAY, THERE IS OTHER EVIDENCE IN THE CASE THAT WE HAVE HEARD, 2014, 2015, THAT THROUGH TEXTS, THROUGH EMAILS, THROUGH WITNESS TESTIMONY THAT I BELIEVE DOES SHOW A PRIMA FACIE, AT LEAST A PRIMA FACIE CONSPIRACY AS TO THOSE COUNTS IN THE 2014, THE 2015 PERIOD REGARDING THOSE TRANSACTIONS. WE'VE

1 08:55AM 2 08:56AM 3 08:56AM 08:56AM 4 08:56AM 08:56AM 08:56AM 08:56AM 08:56AM 9 08:56AM 10 08:56AM 11 08:56AM 12 08:56AM 13 08:56AM 14 08:56AM 15 08:56AM 16 08:56AM 17 08:57AM 18 08:57AM 19 08:57AM 20 08:57AM 21 08:57AM 22 08:57AM 23 08:57AM 24 08:57AM 25

SEEN THOSE FROM THE TEXTS THAT WERE EXCHANGED BETWEEN THE PARTIES, TESTIMONY ABOUT CONDUCT OF THE PARTIES. AND BY "THE PARTIES" I MEAN MR. BALWANI, AND MS. HOLMES AS WELL.

AND FOR PURPOSES OF INFERENCE, AND I THINK THERE IS A STRONG EVIDENCE, AND THE EVIDENCE ESTABLISHES FOR THE COURT'S PURPOSE THAT A PRIMA FACIE SHOWING HAS BEEN MADE FOR CONSPIRACY AS TO THOSE COUNTS.

BUT THE 2010 IS WHAT I'M CURIOUS ABOUT, AND MAYBE WE HAVEN'T HEARD IT YET, WHICH THEN MIGHT HAVE TO PROVIDE ANOTHER REMEDY OR SOLUTION TO OUR DILEMMA THIS MORNING.

MS. VOLKAR.

MS. VOLKAR: THANK YOU, YOUR HONOR.

I WOULD LIKE TO DIRECTLY ANSWER YOUR QUESTION, BUT BEFORE IT ESCAPES MY MIND, I WANT TO PICK UP ON THE LAST THING MY COLLEAGUE, MR. BRECHER, SAID, WHICH IS WITH RESPECT TO THE FALSITY, IT SOUNDS LIKE THEY DON'T CONTEST THE EVIDENCE COMING IN FOR FALSITY, EXCEPT THEY DON'T WANT US TO BE ABLE TO ASK THE WITNESS ABOUT WHETHER OR NOT HE AUTHORIZED THE LOGO BEING PUT ON THE DOCUMENT.

AND I JUST WANT TO SAY THAT THERE IS NO LOGICAL BASIS FOR PRECLUDING JUST THOSE QUESTIONS IF WE'RE TALKING ABOUT FALSITY.

THERE'S BEEN TESTIMONY FROM INVESTORS, INCLUDING MS. PETERSON, THAT THE LOGO MATTERED TO THEM. PART OF THE GOVERNMENT PROVING THE FALSITY IS SHOWING THAT PFIZER ALSO DIDN'T AUTHORIZE THAT LOGO TO BE PUT ON THERE. SO I WANT TO

08:57AM	1	MAKE SURE THAT I DON'T LOSE THAT POINT.
08:57AM	2	THE COURT: LET ME STOP YOU THERE.
08:57AM	3	MR. BRECHER, ARE YOU OKAY WITH THAT?
08:57AM	4	MR. BRECHER: WITH WHICH POINT, YOUR HONOR?
08:57AM	5	THE COURT: WELL, WITH WHOEVER THE WITNESS IS
08:57AM	6	TESTIFYING THAT THEY DIDN'T AUTHORIZE THAT LOGO BEING PUT ON
08:57AM	7	THERE?
08:57AM	8	MR. BRECHER: NO, YOUR HONOR.
08:57AM	9	THE COURT: RIGHT.
08:57AM	10	MR. BRECHER: AND I HAVE ANOTHER RESPONSE, BUT I
08:57AM	11	WANT TO MAKE SURE THAT MS. VOLKAR COMPLETES HER COMMENTS.
08:57AM	12	THE COURT: OKAY. SO I DIDN'T THINK THERE WAS AN
08:57AM	13	ISSUE WITH THAT, WITH THE WITNESS BEING ABLE TO SAY WE DIDN'T
08:57AM	14	DO IT, WE DIDN'T AUTHORIZE IT.
08:57AM	15	MS. VOLKAR: I AGREE, YOUR HONOR, BUT THE PARTIES DO
08:57AM	16	NOT AGREE ON THAT POINT. SO THANK YOU FOR THAT.
08:57AM	17	ON THE CONSPIRACY POINT, AND I WANT TO START BY SAYING
08:58AM	18	THAT EVERYBODY HERE AGREES THAT THE PRIMA FACIE BURDEN IS NOT
08:58AM	19	VERY HIGH.
08:58AM	20	BUT WHERE THE PARTIES DIFFER IS THAT THE DEFENSE WANTS THE
08:58AM	21	GOVERNMENT TO BE ABLE TO HAVE DIRECT EVIDENCE THAT BALWANI KNEW
08:58AM	22	OF THE UNALTERED REPORT IN 2010. WE DID HAVE THAT FOR THE
08:58AM	23	SCHERING-PLOUGH REPORT.
08:58AM	24	I'M NOT HERE SAYING THAT WE HAVE EVIDENCE THAT HE HAD THE
08:58AM	25	UNALTERED PFIZER REPORT SAVED IN HIS COMPUTER FILES IN THE SAME

08:58AM	1	WAY, BUT OUR POSITION IS THAT THROUGH CIRCUMSTANTIAL EVIDENCE,
08:58AM	2	THERE IS PROOF OF A CONSPIRACY IN APRIL 2010.
08:58AM	3	INDEED, THE THIRD SUPERSEDING INDICTMENT ALLEGES A
08:58AM	4	CONSPIRACY PERIOD FOR INVESTORS, 2010 TO 2015. AND WE DO
08:58AM	5	BELIEVE THAT WE'VE PROVIDED SOME EVIDENCE OF THAT.
08:58AM	6	THE MAIN EVIDENCE THAT GOES TO THAT IS I WILL WELL, LET
08:58AM	7	ME BACK UP AND SAY, I WILL ADMIT THAT THERE IS LESS EVIDENCE.
08:59AM	8	FOR EXAMPLE, THE TEXT MESSAGES ONLY GO BACK TO ABOUT 2012.
08:59AM	9	THAT'S JUST THE NATURE OF THE COLLECTION HAPPENED IN
08:59AM	10	2017. PEOPLE GET NEW PHONES, PEOPLE DELETE OLD TEXT MESSAGES
08:59AM	11	TO MAKE MORE ROOM.
08:59AM	12	THERE JUST WASN'T THOSE OLDER TEXT MESSAGES AVAILABLE AT
08:59AM	13	THE TIME THE TEXT MESSAGES WERE COLLECTED. THAT'S JUST A FACT.
08:59AM	14	SIMILARLY, WE HAVE THE DOCUMENTS THAT WE HAVE AND WE HAVE
08:59AM	15	TO BE ABLE TO DRAW INFERENCES FROM THEM.
08:59AM	16	SO I WANT TO TEMPER THE COURT'S EXPECTATIONS, WE DON'T
08:59AM	17	HAVE AS ROBUST OF EVIDENCE
08:59AM	18	THE COURT: RIGHT.
08:59AM	19	MS. VOLKAR: AS WE DO FOR LATER TIME PERIODS.
08:59AM	20	THE COURT: RIGHT. THAT'S THE INQUIRY HERE IS, WHAT
08:59AM	21	WAS THE EVIDENCE?
08:59AM	22	MS. VOLKAR: SO HERE'S WHAT WE DO HAVE, YOUR HONOR.
08:59AM	23	WHAT WE DO HAVE IS WE KNOW THEY WERE IN A ROMANTIC RELATIONSHIP
08:59AM	24	LONG BEFORE 2009 FOR SEVERAL YEARS.
08:59AM	25	WE KNOW THAT IN 2009 WHEN THE COMPANY IS RUNNING OUT OF

1 08:59AM 2 08:59AM 3 09:00AM 09:00AM 4 09:00AM 09:00AM 09:00AM 7 8 09:00AM 09:00AM 9 09:00AM 10 09:00AM 11 09:00AM 12 09:00AM 13 09:00AM 14 09:00AM 15 09:00AM 16 09:00AM 17 09:00AM 18 09:00AM 19 09:00AM 20 09:00AM 21 09:01AM 22 09:01AM 23 09:01AM 24 09:01AM 25

MONEY, MR. BALWANI ESSENTIALLY COMES IN TO SAVE IT. THEY'VE ASKED SEVERAL WITNESSES ABOUT THIS, DID YOU KNOW THAT MR. BALWANI GAVE A -- PERSONALLY GUARANTEED A LOAN TO THERANOS IN 2009 WHEN THE COMPANY OTHERWISE WOULD HAVE GONE UNDER.

I'M SURE I AM NOT ASKING THE QUESTION AS WELL AS THEY DID DURING CROSS, BUT THEY ASKED THAT MULTIPLE TIMES OF MULTIPLE WITNESSES REPEATEDLY, THAT MR. BALWANI CAME IN AND SAVED THIS COMPANY FROM FINANCIAL RUIN.

WHAT WAS THE BUSINESS OF THE COMPANY UP UNTIL THAT POINT? PHARMACEUTICAL COMPANIES.

MR. BALWANI MAY HAVE RECEIVED THESE REPORTS AND THIS DUE DILIGENCE FROM MS. HOLMES, BUT HE ALSO COMES IN KNOWING THAT THE COMPANY IS NOT ABLE TO SUSTAIN ITSELF FROM THE REVENUES OF THESE PHARMACEUTICAL COMPANIES.

THEN IN EARLY 2010, WHEN HE'S BOTH PERSONALLY INVESTED THROUGH HIS RELATIONSHIP WITH MS. HOLMES AND PROFESSIONALLY INVESTED BECAUSE HE'S GUARANTEED THIS LOAN OF \$10 MILLION, HE IS PUT IN CHARGE OF THE RETAIL, AND THAT INCLUDES THESE EMAILS THAT GO TO WAL-MART, WALGREENS, AND SAFEWAY.

WHAT DO WE SEE AS THE DIFFERENCE BETWEEN THOSE?

FIRST EMAIL, THE MARCH 2010 EMAIL IS AN EMAIL THAT HAS THE UNALTERED SCHERING-PLOUGH REPORT. THAT RELATIONSHIP GOES NOWHERE.

ONE MONTH LATER, APRIL 2010, MS. HOLMES SENDS, COPYING BALWANI AGAIN, AN EMAIL TO WALGREENS AND SAFEWAY NOW INCLUDING

THREE ALTERED PHARMACEUTICAL REPORTS. AND BY "ALTERED" I MEAN 1 09:01AM ADDING THE LOGOS OF THE PHARMACEUTICAL COMPANIES. 09:01AM 2 THE COURT: THAT'S IN EVIDENCE? 3 09:01AM 09:01AM 4 MS. VOLKAR: YES. 09:01AM 5 MY RECOLLECTION IS THAT DURING THE SCHERING-PLOUGH, BOTH 09:01AM 6 OF THESE EMAILS THAT I'M TALKING ABOUT WERE ADMITTED. I'M NOT 09:01AM 7 SURE THE SAFEWAY EMAIL WAS YET ADMITTED, BUT THE WAL-MART AND THE WALGREENS EMAIL WERE. 09:01AM 8 ONE MONTH LATER, THE REPORT IS SENT TO WALGREENS, AND THAT 09:01AM 9 09:01AM 10 RELATIONSHIP GOES SOMEWHERE. AND OF COURSE THE WALGREENS 09:01AM 11 RELATIONSHIP IS ITS OWN PIECE OF THIS. 09:01AM 12 OUR ASSERTION IS BASED ON THE INFERENCE AND BASED ON -- I 09:02AM 13 KNOW THIS IS BASED ON MR. BALWANI'S TESTIMONY TO THE S.E.C., BUT HE TOOK CHARGE OF THE RETAIL RELATIONSHIP. 09:02AM 14 09:02AM 15 ONE CAN INFER AT THE VERY LEAST THAT HE WOULD HAVE ASKED QUESTIONS, THAT HE WOULD HAVE TALKED TO MS. HOLMES. 09:02AM 16 09:02AM 17 AND DO WE HAVE THE EXACT TEXT MESSAGES BETWEEN THE TWO OF 09:02AM 18 THEM IN THIS 2010 TIME PERIOD? WE DO NOT. 09:02AM 19 BUT WHAT WE DO HAVE, YOUR HONOR, IS A WEALTH OF EVIDENCE 09:02AM 20 IN THE 2013 AND 2014 TIME PERIOD THAT I WOULD SAY AT LEAST 09:02AM 21 SUPPORT THE INFERENCE, EVEN IF IT'S CIRCUMSTANTIAL EVIDENCE, 09:02AM 22 THAT SIMILAR COMMUNICATION WOULD HAVE OCCURRED IN APRIL 2010. 09:02AM 23 AND NOW I WANT TO CLEARLY SHIFT TO 2013, 2014 BECAUSE 09:02AM 24 THERE IS MUCH MORE, A WEALTH OF EVIDENCE THERE, AND I DON'T 09:02AM 25 WANT TO CONFUSE IN ANY WAY THAT I'M SAYING THAT THIS EVIDENCE

09:02AM	1	IS TETHERED EXACTLY TO APRIL OF 2010.
09:02AM	2	I'M JUST SAYING ONE CAN DRAW AN INFERENCE FROM IT.
09:02AM	3	THE COURT: RIGHT. THANK YOU. THANKS FOR THAT
09:02AM	4	CLARITY.
09:02AM	5	BECAUSE I LOOKED AT THAT, AND AS I SAID EARLIER, THERE IS
09:02AM	6	ROBUST EVIDENCE FOR THE LATER PERIODS OF TIME, AND ARE WE
09:03AM	7	PERMITTED TO LOOK BACK AND SOMEHOW ATTRIBUTE THAT TO SEVEN
09:03AM	8	YEARS PREVIOUS? HOW DOES THAT WORK? AND IS THAT PERMITTED?
09:03AM	9	IS THAT POSSIBLE?
09:03AM	10	I KEEP ASKING MULTIPLE QUESTIONS, SO STAY WITH ME.
09:03AM	11	BUT IN 2010, IS THERE EVIDENCE THAT MR. BALWANI TOOK OVER
09:03AM	12	THE RETAIL, PARTICULARLY THE WALGREENS FUNCTION IN 2010? AND
09:03AM	13	WHAT IS THE EVIDENCE OF THAT?
09:03AM	14	BECAUSE WE DO KNOW THAT THERE IS SOME CONNECTION WITH HIM.
09:03AM	15	MR. JHAVERI, WHO HAS NOT FINISHED HIS TESTIMONY, AND THAT MIGHT
09:03AM	16	SHED SOME LIGHT TO THIS AS WELL, ALTHOUGH I THINK HE'S ONLY
09:03AM	17	TESTIFIED ABOUT 2013, 2014 MATTERS.
09:03AM	18	MR. BRECHER: THAT'S CORRECT, YOUR HONOR.
09:03AM	19	THE COURT: SO THAT'S ANOTHER SIDE ISSUE HERE.
09:03AM	20	I DON'T KNOW IF HE'LL COME IN TOMORROW AND TELL US
09:03AM	21	ANYTHING MORE.
09:03AM	22	BUT SORRY, MS. VOLKAR. THOSE ARE MY FEW QUESTIONS NOW.
09:04AM	23	MS. VOLKAR: THANK YOU, YOUR HONOR.
09:04AM	24	I THINK WHAT THE COURT IS ASKING IS, IS THERE EVIDENCE IN
09:04AM	25	THIS TRIAL, BECAUSE I DON'T THINK THAT THERE IS ANY DISPUTE

09:04AM	1	THAT THERE IS CERTAINLY EVIDENCE AVAILABLE, NAMELY, MR. BALWANI
09:04AM	2	ADMITTED TO IT IN HIS S.E.C. TESTIMONY, THAT HE TOOK CHARGE IN
09:04AM	3	EARLY 2010 OF THE RETAIL RELATIONSHIP, AND THAT WAS WHAT WE
09:04AM	4	CITED IN OUR 1337.
09:04AM	5	I AM NOT AWARE OF TESTIMONY HAS THAT COME IN YET THROUGH
09:04AM	6	THIS TRIAL.
09:04AM	7	BUT I WOULD SAY FOR RULE 104 PURPOSES, IF THAT'S THE LAND
09:04AM	8	WE'RE IN FOR ADMISSIBILITY, IS CAN THE GOVERNMENT SHOW AND CAN
09:04AM	9	IT MEETS ITS BURDEN?
09:04AM	10	AND I WOULD POINT THE COURT TO THE S.E.C. TO SAY WE
09:04AM	11	ABSOLUTELY CAN MEET OUR BURDEN, AND IF WE NEED TO CALL ANY
09:04AM	12	WITNESSES IN DURING THIS TRIAL, WE HAVE MANY WITNESS WHO CAN DO
09:04AM	13	SO. AND WE'RE TRYING TO PRESENT THE MOST STREAMLINED CASE THAT
09:04AM	14	WE CAN, AND THEREFORE, IT IS A DECENT CHUNK OF TIME, AND PEOPLE
09:05AM	15	COME AND GO AND FILL DIFFERENT ROLES IN DIFFERENT COMPANIES.
09:05AM	16	AND OF COURSE YOUR HONOR DID HEAR FROM WADE MIQUELON
09:05AM	17	DURING THE HOLMES TRIAL, WHO TESTIFIED THAT MR. BALWANI WAS HIS
09:05AM	18	MAIN POINT OF CONTACT THROUGHOUT THE RELATIONSHIP.
09:05AM	19	THE COURT: RIGHT. I DID NOTE THAT.
09:05AM	20	SO THAT WAS THE NATURE OF MY QUESTION, WHERE IS THE
09:05AM	21	EVIDENCE IN THIS TRIAL FOR A 2010 RELATIONSHIP?
09:05AM	22	MS. VOLKAR: I WILL SAY, WITH AN ASSIST FROM MY
09:05AM	23	TEAMMATE, THAT JHAVERI ALSO TESTIFIED THAT HE GAVE A TOUR OF
09:05AM	24	THE WALGREENS STORE TO BOTH HOLMES AND BALWANI IN 2010.
09:05AM	25	THE COURT: WAS THAT 2010 OR 2013? I LOOKED AT MY

1 09:05AM 2 09:05AM 3 09:05AM 09:05AM 4 09:05AM 09:06AM 09:06AM 8 09:06AM 09:06AM 9 09:06AM 10 09:06AM 11 09:06AM 12 09:06AM 13 09:06AM 14 09:06AM 15 09:06AM 16 09:06AM 17 09:06AM 18 09:06AM 19 09:06AM 20 09:06AM 21 09:06AM 22 09:06AM 23 09:06AM 24 09:07AM 25

NOTES. PERHAPS MY NOTES ARE INCORRECT. IT WAS 2010, THE TOUR? MS. VOLKAR: MY ASSIST IS 2010, AND I'M HAPPY TO PULL THE RECORD CITE FOR THAT, YOUR HONOR.

THE COURT: I DID NOTE THAT IN HIS TESTIMONY, AT LEAST MY NOTES. I DIDN'T READ THE TRANSCRIPT. I SHOULD HAVE. OKAY. THANK YOU. THAT'S IMPORTANT.

MS. VOLKAR: THANK YOU, YOUR HONOR.

I JUST WANT TO END, BECAUSE I DON'T WANT TO GET AWAY FROM THIS POINT, I THINK WHAT THE DEFENSE IS TRYING TO HOLD THE GOVERNMENT TO IS DIRECT EVIDENCE OF EACH PIECE JUST FOR THE ADMISSIBILITY OF DOCUMENTS TO COME IN, AND AGAIN, THAT IS A LOW BAR. I THINK WE ALL AGREE THAT IT IS A LOW BAR.

AND WHAT THE GOVERNMENT IS SAYING IN RESPONSE IS THAT THERE IS A LOT OF EVIDENCE FROM WHICH THE JURY CAN INFER THAT BALWANI HAD KNOWLEDGE, AND, OF COURSE, THAT IS THE JURY'S PROVINCE.

SO THE QUESTION REALLY BEFORE THE COURT IS ADMISSIBILITY. AND AGAIN, GOING BACK TO FALSITY WHERE THERE IS MUCH LESS OF A DISPUTE, I THINK THERE IS VERY LITTLE QUESTION ABOUT WHETHER OR NOT THE DOCUMENTS ARE ADMISSIBLE.

IT'S REALLY COMING DOWN TO WHAT QUESTIONS CAN THE GOVERNMENT ASK, AND THERE ARE NUMEROUS WAYS THAT THIS INFORMATION CAN AND SHOULD BE BROUGHT OUT, BUT WHAT WE ARE ARGUING IS THAT THERE REALLY SHOULDN'T BE ANY LIMITATION, IT SHOULD BE AVAILABLE FOR USE FOR US TO ARGUE AS WE SEE FIT, IN

09:07AM	1	LARGE PART BECAUSE THERE IS ALL OF THIS CIRCUMSTANTIAL EVIDENCE
09:07AM	2	FROM WHICH THE COURT AND THE JURY COULD MAKE THE REASONABLE
09:07AM	3	INFERENCE THAT BALWANI WAS PART OF THE CONSPIRACY STARTING IN
09:07AM	4	2010.
09:07AM	5	THE COURT: OKAY. SO LET'S REVIEW.
09:07AM	6	SO THERE'S A RELATIONSHIP. HE IS A FINANCIAL SAVIOR. HE
09:07AM	7	COMES IN. HE GUARANTEES A SUBSTANTIAL AMOUNT OF MONEY.
09:07AM	8	HE IS, PERHAPS CONCURRENT WITH THAT, SHORTLY THEREAFTER
09:07AM	9	MADE COO. WE KNOW THAT. THERE'S NO DISPUTE ABOUT THAT, I TAKE
09:07AM	10	IT.
09:07AM	11	IS THAT RIGHT, MR. BRECHER?
09:07AM	12	MR. BRECHER: ACTUALLY, YOUR HONOR, THERE IS A
09:07AM	13	RELEVANT DISPUTE, I DON'T KNOW IF IT'S A RELEVANT DISPUTE, BUT
09:07AM	14	THERE'S A FACTUAL CONTEXT THAT MR. BALWANI JOINS THE COMPANY IN
09:07AM	15	2009 AS A BOARD MEMBER AND EMPLOYEE AT LARGE.
09:07AM	16	THE COURT: CORRECT.
09:07AM	17	MR. BRECHER: HE BECOMES COO AND PRESIDENT IN JULY
09:07AM	18	OF 2010, MONTHS AFTER THIS ALTERATION, AND THAT CAME IN THROUGH
09:08AM	19	THE CROSS-EXAMINATION OF MS. SPIVEY. I DON'T THINK IT IS
09:08AM	20	DISPUTED.
09:08AM	21	THE COURT: BUT THERE IS SOME CONNECTION AT SOME
09:08AM	22	POINT IN TIME IN 2010 THAT HE DOES TAKE CHARGE OF RETAIL AND
09:08AM	23	MR. JHAVERI'S TESTIMONY ABOUT WHEN AND ALL OF THAT IS
09:08AM	24	INTERESTING.
09:08AM	25	MS. VOLKAR: AND AGAIN, YOUR HONOR, JUST TO SPELL

09:08AM	1	OUT THE INFERENCE THAT CAN BE DRAWN FROM THE FACTS THAT
09:08AM	2	YOUR HONOR JUST POINTED OUT, HE INVESTED A LARGE AMOUNT OF
09:08AM	3	MONEY. HE KNEW THAT THE COMPANY WAS FAILING. THE PHARMA
09:08AM	4	REVENUE WAS NOT SUPPORTING THE COMPANY.
09:08AM	5	HE HAD KNOWLEDGE OF THAT BECAUSE HE WAS THAT SAVIOR AND
09:08AM	6	CAME IN AND HAD TO LOAN THAT MONEY.
09:08AM	7	WHAT DO THEY DO? THEY PIVOT TO RETAIL, A NEW AREA TO
09:08AM	8	POTENTIALLY GENERATE MORE REVENUE.
09:08AM	9	HE'S ON THE EMAIL TO WAL-MART. IT GOES NOWHERE. THAT
09:08AM	10	CAME IN THROUGH DR. CULLEN.
09:08AM	11	HE'S ON THE EMAIL TO WALGREENS, AND THAT GOES SOMEWHERE.
09:08AM	12	AND AT THE VERY LEAST, IT APPEARS AT LEAST SOME TESTIMONY
09:08AM	13	FROM JHAVERI ABOUT HIS INVOLVEMENT IN 2010 WITH WALGREENS.
09:08AM	14	SO I THINK IT'S A FAIR INFERENCE FROM THOSE FACTS THAT HE
09:09AM	15	KNEW HE HAD TO DRIVE REVENUE SOMEHOW FOR THE COMPANY. AND ONE
09:09AM	16	REPORT UNALTERED DIDN'T WORK.
09:09AM	17	ONE SET OF REPORTS ALTERED DID WORK.
09:09AM	18	THE COURT: OKAY. AND SO THE MOTIVATION FOR HIM IS
09:09AM	19	NOT JUST COMPANY LOYALTY, BUT HE HAS A PERSONAL STAKE BECAUSE
09:09AM	20	OF HIS GUARANTEEING FINANCIAL INTEREST IN THE COMPANY.
09:09AM	21	MS. VOLKAR: THAT'S CORRECT, YOUR HONOR.
09:09AM	22	THE COURT: OKAY.
09:09AM	23	MR. BRECHER: SO, FIRST OF ALL, YOUR HONOR, JUST A
09:09AM	24	FACTUAL CLARIFICATION.
09:09AM	25	MS. PETERSON'S TESTIMONY THAT, QUOTE, THE LOGO MATTERED TO

1 09:09AM 2 09:09AM 3 09:09AM 09:09AM 4 09:09AM 09:09AM 09:09AM 8 09:10AM 09:10AM 9 09:10AM 10 09:10AM 11 09:10AM 12 09:10AM 13 09:10AM 14 09:10AM 15 09:10AM 16 09:10AM 17 09:10AM 18 09:10AM 19 09:10AM 20 09:10AM 21 09:10AM 22 09:10AM 23 09:10AM 24

09:10AM 25

HER, THAT WAS DURING THE HOLMES TRIAL. SHE DID NOT SO TESTIFY LAST WEEK, IN PART BECAUSE OF THE GUARDRAILS THAT YOUR HONOR PUT IN PLACE BEFORE HER TESTIMONY.

AS FOR THE TEXT MESSAGES AND THE POINT ABOUT THEM BEGINNING IN 2012 BECAUSE OF THE DATA COLLECTION AND, FRANKLY, ALL OF THE EVIDENCE FROM 2013, 2014, 2015, HOW FAR CAN WE LOOK BACK, WHAT INFERENCES CAN WE DRAW, I'M NOT AWARE OF ANY AUTHORITY THAT BLESSES THE PROPOSITION THAT BECAUSE WE DON'T HAVE EVIDENCE, WE SHOULD ASSUME THAT THERE'S SOME THAT EXISTS. THAT JUST DOESN'T MAKE A LOT OF SENSE TO ME.

BUT I DON'T CONTEST THAT THE JURY IS FREE, AND THE COURT IS FREE IN MAKING THIS THRESHOLD INQUIRY, TO DRAW SOME INFERENCES FROM FACTS THAT ARE ESTABLISHED TO CLOSELY TETHERED FACTS THAT MAYBE AREN'T, BUT WE CAN IMAGINE A TIE.

BUT I WANT TO MAKE SURE THAT WE'RE CLEAR ABOUT WHAT WE'RE TALKING ABOUT HERE. WHEN WE'RE TALKING ABOUT EVIDENCE FROM THREE, FOUR, FIVE YEARS DOWN THE LINE, THAT'S NOT ASKING THE COURT TO DRAW A LINE BETWEEN TWO DOTS. THAT'S ASKING THE COURT TO DRAW A FARMHOUSE AND A PICKET FENCE AND MAYBE A DOG. THE EVIDENCE ISN'T THERE IN APRIL 2010.

AND I WANT TO SPEAK BRIEFLY TO THE RETAIL RELATIONSHIP AS WELL. IN APRIL OF 2010 WHEN THESE MEMORANDA WERE SENT, THERE WAS NO WALGREENS RELATIONSHIP. IT WAS THE START OF COMMUNICATIONS BETWEEN THE TWO COMPANIES.

THE WALGREENS RELATIONSHIP DIDN'T BECOME FORMALIZED UNTIL

JULY OF 2010. INVESTOR FUND RAISING DIDN'T COME INTO PLAY 1 09:11AM UNTIL JULY OF 2010. THE INVESTOR ACCOUNTS DON'T APPEAR UNTIL 2 09:11AM 2013 AND 2014. 3 09:11AM 09:11AM 4 SO WHETHER MR. BALWANI PLAYED A LEADING ROLE IN THE RETAIL PARTNERSHIP, AND MR. JHAVERI'S TESTIMONY ABOUT TAKING A TOUR 09:11AM 09:11AM 6 DOESN'T ESTABLISH THAT, BUT I'LL PUT THAT ASIDE FOR A MOMENT, 09:11AM 7 DOESN'T CONTROL THIS QUESTION. THIS QUESTION IS, ON APRIL 14TH, 2010, IS THERE EVIDENCE, 09:11AM 8 EITHER FROM FACTS THAT WE ALREADY KNEW TO BE THE CASE BEFORE 09:11AM 9 09:11AM 10 THEN OR FACTS THAT ARE SUFFICIENTLY CLOSE IN TIME OR 09:11AM 11 CONCEPTUALLY CLOSE THAT WE CAN REASONABLY LOOK BACK AND SAY, 09:11AM 12 YOU KNOW WHAT, BY A PREPONDERANCE OF THE EVIDENCE, THERE WAS A 09:11AM 13 CONSPIRACY IN APRIL OF 2010. I BELIEVE, YOUR HONOR, THAT THE ANSWER IS NO. 09:11AM 14 09:11AM 15 THE COURT: CAN WE LOOK TO THE CONDUCT THAT, THE LATER CONDUCT? DOES THAT INFORM US THEN ABOUT WHAT HAPPENED 09:11AM 16 EARLIER ULTIMATELY? YOU KNOW, THEY DID THIS, THIS IS WHAT 09:11AM 17 09:11AM 18 HAPPENED, AND WHY DOESN'T THAT INFORM US AS TO CONDUCT IN 2010, 09:12AM 19 EARLIER CONDUCT, THAT THAT WAS FORMATIVE, AND THAT WAS THE 09:12AM 20 LATER TIME PERIOD, AND WHAT HAPPENED WAS THE END RESULT OF 09:12AM 21 THOSE ACTIONS? 09:12AM 22 MR. BRECHER: I DON'T THINK, YOUR HONOR, THAT THERE 09:12AM 23 IS A CATEGORICAL BAR IN LOOKING TO LATER CONDUCT, OR EVEN EVIDENCE THAT AROSE LATER. 09:12AM 24 09:12AM 25 FOR EXAMPLE, YOU COULD IMAGINE A TEXT MESSAGE, AND I SAY

IT, AND AS YOUR HONOR KNOWS, THERE IS SOME CRIMINAL DEFENDANTS 1 09:12AM 2 FOR WHOM YOU DO SEE THIS KIND OF EVIDENCE WHERE A TEXT MESSAGE 09:12AM SAYS, "HEY, REMEMBER TWO YEARS AGO WHEN WE DOCTORED THAT 3 09:12AM 09:12AM 4 REPORT," OR "I WAS THE ONE WHO HAD THE GUN, I HOPE YOU DON'T TELL ANYBODY." WE DO GET -- SEE THOSE TYPES OF EVIDENCE IN 09:12AM CRIMINAL CASES. 09:12AM 09:12AM 7 THERE'S CERTAINLY NOTHING LIKE THAT. BUT I WANT TO POINT OUT, YOUR HONOR, IT IS NOT OUR 09:12AM 8 POSITION THAT DIRECT EVIDENCE OF KNOWLEDGE OF THE ALTERATION OF 09:12AM 9 09:12AM 10 THE PFIZER REPORT IS REQUIRED FOR ADMISSIBILITY. THAT IS 09:12AM 11 REQUIRED, I THINK, FOR ADMISSIBILITY IN TERMS OF MR. BALWANI'S 09:12AM 12 PERSONAL KNOWLEDGE BECAUSE THAT CAN'T BE IMPUTED. 09:13AM 13 BUT WHAT I AM SAYING IS THAT EVIDENCE, WHETHER DIRECT OR CIRCUMSTANTIAL, HAS TO MEET THAT THRESHOLD SHOWING AS OF 09:13AM 14 09:13AM 15 APRIL 2010. IF WE WERE TALKING ABOUT EVENTS IN JULY OF 2010, I WOULD 09:13AM 16 09:13AM 17 BE ON MUCH WEAKER FOOTING SAYING, NO, YOUR HONOR, WE CAN'T LOOK 09:13AM 18 BACK. 09:13AM 19

BUT WHEN WE'RE TALKING ABOUT EVENTS IN 2013, 2014, 2015,

VICARIOUS LIABILITY HAS TEMPORAL LIMITS PRECISELY BECAUSE IT IS THE EXCEPTION UNDER THE LAW, NOT THE RULE.

IF WE'RE LOOKING BACK THREE OR FOUR YEARS BECAUSE WE CAN'T OTHERWISE MAKE THE CASE, THEN THOSE TEMPORAL LIMITATIONS DON'T MEAN ANYTHING. I JUST DON'T THINK THAT THEY DO.

THE COURT: NO, I -- AND I THINK MS. VOLKAR WOULD

09:13AM 25

09:13AM 20

09:13AM 21

09:13AM 22

09:13AM 23

09:13AM 24

CONCEDE, THERE'S SOME DANGER IN DOING THAT, HOW FAR BACK DO YOU 1 09:13AM 2 GO AND THE CONNECTION GETS DILUTED, I'LL JUST USE THAT PHRASE, 09:13AM SOMETIMES. 3 09:13AM 09:13AM 4 MS. VOLKAR. MS. VOLKAR: YOUR HONOR, IF I MAY BE HEARD ON THAT 09:13AM 09:13AM 6 POINT? I'D LIKE TO GIVE WHAT I THINK IS A VERY SPECIFIC 09:13AM 7 EXAMPLE. WE'VE BEEN TALKING ABOUT THE MOTIVATION FOR BALWANI, AND I 09:13AM 8 DON'T THINK THAT THERE'S MUCH DISPUTE THAT BALWANI TOOK A 09:14AM 9 09:14AM 10 LARGER ROLE IN THE FINANCIALS AND THE PROJECTIONS THAT WERE 09:14AM 11 GIVEN OUT, SO I WANT TO FOCUS ON THAT FOR A MOMENT. 09:14AM 12 AS I SAID, HE HAD SOME MOTIVATION, WE THINK THE EVIDENCE 09:14AM 13 SHOWS, IN 2010 TO DRIVE REVENUE AT A COMPANY THAT WAS OTHERWISE RUNNING OUT OF MONEY AND HE HAD TO GUARANTEE THIS PERSONAL 09:14AM 14 09:14AM 15 LOAN. HE KNEW AT THAT POINT IN TIME, WE WOULD ARGUE, THAT PHARMA 09:14AM 16 WAS NOT PROVIDING SUFFICIENT REVENUE. THAT'S WHY THEY RETURNED 09:14AM 17 09:14AM 18 TO RETAIL. I DON'T WANT TO REPEAT WHAT I SAID BEFORE. 09:14AM 19 FAST FORWARD A COUPLE OF YEARS, THEY'RE STILL WORKING WITH 09:14AM 20 RETAIL. NOW THEY'RE LOOKING TO OTHER SOURCES, OTHER INVESTORS 09:14AM 21 TO GET MORE MONEY. 09:14AM 22 AND WHAT IS MR. BALWANI TELLING THEM? HE HAS TOLD 09:14AM 23 MR. MENDENHALL AND MS. PETERSON, IN TWO DIFFERENT WAYS, THAT 09:14AM 24 PHARMA WAS PROVIDING REVENUE AND KEEPING THE COMPANY AFLOAT. 09:14AM 25 HE KNEW FROM THE TIME HE JOINED THE COMPANY THAT THAT WAS

1 09:14AM 2 09:14AM 3 09:15AM 09:15AM 4 09:15AM 09:15AM 6 09:15AM 7 09:15AM 8 09:15AM 9 09:15AM 10 09:15AM 11 09:15AM 12 09:15AM 13 09:15AM 14 09:15AM 15 09:15AM 16 09:15AM 17 09:15AM 18 09:15AM 19 09:16AM 20 09:16AM 21 09:16AM 22 09:16AM 23 09:16AM 24 09:16AM 25

NEVER TRUE. AND HE KNEW THAT THEY NEVER GOT, I DON'T THINK EVEN THINK IT WAS A MILLION DOLLARS FROM PHARMA DURING THAT INTERVENING PERIOD. HE KNEW THERE WAS NO REVENUE FROM PHARMA IN 2013 AT ALL, AND 2014, AND YET HE'S PROVIDING PROJECTIONS TO MS. PETERSON THAT THEY'RE GOING TO, BY THE END OF 2014, HAVE \$40 MILLION IN REVENUE FROM PHARMACEUTICAL COMPANIES.

RECORDS THAT ARE IN EVIDENCE NOW FROM MS. YAM AND OTHERS? MS. VOLKAR: CORRECT. AND I DID PROVIDE CITATIONS TO THOSE IN ECF 1420 TO MAKE SURE THE COURT HAD EVIDENCE FROM

THIS TRIAL THAT COULD TIE THAT.

THE COURT: AND THAT, THAT KNOWLEDGE COMES FROM

WHY IS THAT IMPORTANT? WHAT DOES THAT HAVE TO DO WITH THE ALTERING?

WHAT I WOULD SAY IS THAT THIS IS A BRICK, A FOUNDATION FROM WHICH THE JURY CAN SEE THAT MR. BALWANI HAD KNOWLEDGE THAT THE PHARMACEUTICAL CLINICAL TRIALS WERE NOT DRIVING REVENUE, WERE NOT BRINGING IN, WERE NOT SUFFICIENT TO KEEP THE COMPANY CASH FLOW NEUTRAL, LET ALONE CASH FLOW POSITIVE OR PROFITABLE, AND THAT WOULD ALSO GIVE HIM, AT LEAST THERE'S AN INFERENCE, SOME INDICATION THAT THE CLINICAL TRIALS WEREN'T AS SUCCESSFUL AS THEY CLAIMED TO BE.

AND THAT, PLUS, AGAIN, IF WE GO BACK TO THAT MARCH 2010 EMAIL WHEN HE SAW AN UNALTERED REPORT OF THE SCHERING-PLOUGH REPORT, WOULDN'T THAT LEAD A PERSON TO ASK QUESTIONS? WOULDN'T THAT LEAD SOMEONE TO SAY, WE KEEP SHARING THIS PFIZER REPORT,

09:16AM	1	BUT PFIZER HASN'T GIVEN US A DIME SINCE 2009? I'M TELLING
09:16AM	2	PEOPLE THAT PFIZER AND OTHER PHARMACEUTICAL COMPANIES ARE
09:16AM	3	BRINGING IN ENOUGH REVENUE FOR THIS COMPANY TO BE PROFITABLE.
09:16AM	4	THAT'S HOW THESE THINGS ARE TIED TOGETHER.
09:16AM	5	I KNOW THE DEFENSE WANTS TO PARSE EACH OF THEM APART, BUT
09:16AM	6	IT DOES ADD A BRICK BECAUSE THE PFIZER WITNESS IS GOING TO
09:16AM	7	TESTIFY THEY NEVER AUTHORIZED THAT, BUT MR. BALWANI IS ONLY
09:16AM	8	EVER SHARING THE ALTERED VERSION OF THE PFIZER REPORT WITH
09:16AM	9	INVESTORS. HE'S TALKING ABOUT IT WITH MS. HOLMES, HE'S TALKING
09:16AM	10	TO THEM ABOUT
09:16AM	11	THE COURT: TELL ME THE EVIDENCE THAT I HAVE. WHERE
09:16AM	12	IS THE EVIDENCE THAT HE SHOWED THE ALTERED ENHANCED VERSION AND
09:17AM	13	THAT HE TALKED WITH MS. HOLMES ABOUT THAT?
09:17AM	14	MS. VOLKAR: YES, ABSOLUTELY, YOUR HONOR.
09:17AM	15	I WILL ADMIT A LOT OF THIS EVIDENCE WAS IN 1337, BUT I'LL
09:17AM	16	TRY TO UPDATE IT.
09:17AM	17	FIRST AND FOREMOST, THERE'S ECF 1338-4, SENDING THE
09:17AM	18	REPORTS TO POTENTIAL INVESTOR BDT.
09:17AM	19	THE COURT: 1338 OR 1337?
09:17AM	20	MS. VOLKAR: IT WAS MY DECLARATION AND EXHIBIT, SO
09:17AM	21	1338.
09:17AM	22	THE COURT: OKAY.
09:17AM	23	MS. VOLKAR: BUT IN THIS TRIAL AND I APOLOGIZE, I
09:17AM	24	DON'T HAVE THE TRIAL EXHIBIT ON HAND BUT MS. PETERSON, WHEN
09:17AM	25	SHE WAS TESTIFYING AT THE TAIL END OF HER DEALINGS WITH

THERANOS, MR. BALWANI SENT HER A SOFT COPY OF ALL OF THE DUE 1 09:17AM DILIGENCE MATERIALS, WHICH INCLUDED THE PFIZER REPORT. 2 09:18AM AND SO IN THIS TRIAL WE HAVE MR. BALWANI SENDING THESE 3 09:18AM 09:18AM 4 REPORTS, ALONG WITH OTHER MATERIALS. WE HAVE, IN THE TEXT MESSAGES IN 2013, MS. HOLMES SAYING, 09:18AM 09:18AM 6 I'M GOING TO SEND THIS TO POTENTIAL INVESTORS, PLANNING TO 09:18AM 7 INCLUDE PFIZER REPORT. AND MR. BALWANI SAYS, GREAT. 09:18AM 8 WE HAVE MR. BALWANI TALKING TO INVESTORS ABOUT, IN GREAT 09:18AM 9 09:18AM 10 DETAIL ACCORDING TO MR. MENDENHALL, ABOUT THE CLINICAL TRIALS 09:18AM 11 THAT WERE DONE AND THE TECHNOLOGY THAT WAS USED TO RUN THEM AND 09:18AM 12 THE FINANCIAL SUCCESS THAT CAME FROM THEN. THAT'S ALL FROM MR. MENDENHALL FROM FRIDAY, WHO TESTIFIED ABOUT THAT. 09:18AM 13 09:18AM 14 WE WILL HAVE GOVERNMENT PROFFERS AND WE WILL HAVE 09:18AM 15 INVESTORS TESTIFYING IN THE COMING WEEKS, INCLUDING MR. GROSSMAN WHO, IN THE HOLMES TRIAL, TESTIFIED THAT BALWANI 09:18AM 16 PROVIDES THESE REPORTS, AND MR. MOSLEY. I CAN'T RECALL IF THAT 09:18AM 17 WAS MR. BALWANI OR MS. HOLMES, SO I HESITATE TO MAKE THAT 09:19AM 18 09:19AM 19 REPRESENTATION RIGHT NOW. 09:19AM 20 AND THE LAST TWO THINGS I WANT TO MAKE SURE THE RECORD IS 09:19AM 21 CLEAR ON, MY COLLEAGUE SAID THAT THE INVESTOR COUNTS ARE IN 09:19AM 22 2013 AND 2014. 09:19AM 23 THE INDIVIDUAL WIRE FRAUD COUNTS, THAT IS TRUE. 09:19AM 24 BUT THE GOVERNMENT HAS ALLEGED A CONSPIRACY TO DEFRAUD 09:19AM 25 INVESTORS FROM 2010 TO 2015, AND I WANT TO MAKE SURE THAT

09:19AM	1	THAT'S NOT LOST, AND THE INDICTMENT LAYS OUT HOW A LARGE
09:19AM	2	PORTION OF THAT IS RELATED TO WALGREENS, AND THESE
09:19AM	3	PHARMACEUTICAL REPORTS ARE ONE OF THE KEY WAYS THAT THEY GOT
09:19AM	4	WALGREENS ON THE HOOK IN 2010.
09:19AM	5	MY COLLEAGUE, OR MY TEAMMATE GAVE ME ANOTHER ASSIST. THE
09:19AM	6	JHAVERI TOUR IN 2010 IS PAGE 2883
09:19AM	7	THE COURT: THANK YOU.
09:19AM	8	MS. VOLKAR: OF THE TRIAL TRANSCRIPT, AND THAT
09:20AM	9	WAS ON APRIL 19TH.
09:20AM	10	THE COURT: THANK YOU.
09:20AM	11	SO, MS. VOLKAR, WHAT IS IT YOU INTEND TO DO TODAY
09:20AM	12	REGARDING THE PFIZER DOCUMENT? YOU HAVE HEARD ME TALK ABOUT
09:20AM	13	FALSITY, AND I DO BELIEVE I'M GOING TO ADMIT OR ALLOW THIS
09:20AM	14	TESTIMONY TO COME IN, AT LEAST NOW ON THE ISSUE OF FALSITY.
09:20AM	15	IS THIS YOUR WORK PRODUCT? DID YOU AUTHORIZE? HE'LL
09:20AM	16	ANSWER THOSE QUESTIONS.
09:20AM	17	WERE YOU INTENDING TO DO MORE FROM THIS WITNESS OTHER THAN
09:20AM	18	THAT, OR WAS IT THE INFERENCE THAT YOU WOULD LIKE TO BE ABLE TO
09:20AM	19	ARGUE IN THE FUTURE?
09:20AM	20	MS. VOLKAR: YOUR HONOR, I THINK, AND I WILL TAKE A
09:20AM	21	MOMENT TO CONFER WITH MY COLLEAGUE, BUT I BELIEVE THAT WE WOULD
09:20AM	22	LIKE TO ADMIT THE UNALTERED REPORT THAT MS. HOLMES SENT TO
09:20AM	23	MR. WEBER, AND I BELIEVE IT'S ALREADY IN EVIDENCE, THE ALTERED
09:20AM	24	VERSION THAT WAS SENT TO WALGREENS.
09:20AM	25	AND I BELIEVE, AS WE DID IN THE HOLMES TRIAL, WE WOULD

LIKE TO BE ABLE TO SHOW HIM THE ALTERED VERSION AND ASK WHETHER 1 09:21AM HE EVER AGREED WITH THE CONCLUSIONS, SUPPORTED. OR IF HE 09:21AM 2 AGREED WITH THE CONCLUSIONS, IF HE PLACED THE LOGO ON THE 3 09:21AM 09:21AM 4 DOCUMENT, IF HE AUTHORIZED THE PLACEMENT OF THE LOGO ON THE 09:21AM 5 DOCUMENTS. I REALLY DO THINK IT'S THOSE LAST COUPLE OF QUESTIONS 09:21AM 6 WHERE WE DIFFER FROM THE DEFENSE. WE DO BELIEVE THAT HE SHOULD 09:21AM 7 BE ABLE TO SAY HE DID NOT AUTHORIZE THE LOGO ON THE DOCUMENT 09:21AM 8 THAT WAS SENT TO WALGREENS. 09:21AM 9 09:21AM 10 MR. LEACH: YOUR HONOR, IF I MAY? I DON'T MEAN TO 09:21AM 11 INTERRUPT. I'M HANDLING MR. WEBER'S DIRECT. 09:21AM 12 THE COURT: RIGHT. MY QUESTIONS WERE RELATED TO HIS 09:21AM 13 TESTIMONY, RIGHT. MR. LEACH: YES, AND I THINK MS. VOLKAR'S SUMMARY IS 09:21AM 14 09:21AM 15 FAIR. WE INTEND TO SHOW HIM THE REPORT THAT HE RECEIVED, NOTE 09:21AM 16 09:21AM 17 THE FACT THAT IT HAS ONLY THE THERANOS LOGO, ASK HIM IF PFIZER 09:21AM 18 OR ANYONE ELSE AGREED WITH THESE CONCLUSIONS, ASK HIM IF HE 09:21AM 19 APPROVED PROVIDING THE REPORT THAT THEY RECEIVED TO ANY THIRD 09:21AM 20 PARTIES. I EXPECT THAT HE WILL SAY NO. 09:22AM 21 AND IF PERMITTED, WE WILL SHOW WHAT IS ALREADY IN EVIDENCE 09:22AM 22 THROUGH MS. PETERSON, A COPY OF THE PFIZER REPORT PROVIDED IN 09:22AM 23 2014 TO HER AND ASK IF HE HAS EVER SEEN THAT, IF HE APPROVED 09:22AM 24 IT. 09:22AM 25 I HAVE YET TO DECIDE WHETHER I WOULD REFER TO THE LOGO,

BUT I THINK IT WOULD BE APPROPRIATE TO DO THAT AND REALLY ASK 1 09:22AM IF HE HAD ANYTHING TO DO WITH IT. 2 09:22AM I EXPECT HIS ANSWER WOULD BE NO. 3 09:22AM 09:22AM 4 THAT GOES DIRECTLY TO WHETHER THE REPRESENTATIONS THAT WERE PROVIDED TO MS. PETERSON WERE TRUE OR FALSE. 09:22AM AND THAT WAS THE GOVERNMENT'S INTENTION THERE. 09:22AM 6 AND WHILE I HAVE THE MIKE, I JUST WANTED TO EMPHASIZE A 09:22AM POINT. I THINK THE GOVERNMENT HAS BEEN MAKING -- THE DATE OF 09:22AM 8 THE ALTERING IN 2010 IS REALLY NEITHER HERE OR THERE. 09:22AM 9 09:22AM 10 THE DECEPTIVE ACT IS WHEN THEY PROVIDE IT TO THE 09:22AM 11 INVESTORS, AND THAT IS HAPPENING IN 2014 WITH MS. PETERSON. 09:22AM 12 IT HAPPENS WITH MR. MOSLEY IN THE SAME TIME PERIOD. MS. VOLKAR REFERRED TO EVIDENCE WHERE MR. BALWANI IS 09:22AM 13 PROVIDING THE DOCUMENT REPORT IN 2014 TO BDT, AND THAT IS THE 09:23AM 14 09:23AM 15 DECEPTIVE ACT. AND IF THERE'S A CONSPIRACY IN 2013 TO 2015 -- YOU KNOW, 09:23AM 16 09:23AM 17 WHO KNOWS WHEN IT WAS ACTUALLY ALTERED. THEY COULD HAVE DONE 09:23AM 18 IT, YOU KNOW, IN THEIR OWN OFFICES AND NOT GIVEN IT TO ANYBODY. 09:23AM 19 THAT'S NOT NECESSARILY THE CRIME. 09:23AM 20 THE DECEPTIVE ACT IS IN 2013 AND 2015 WHEN MS. HOLMES AND MR. BALWANI PROVIDE IT TO INVESTORS, AND IF THERE'S A PRIMA 09:23AM 21 09:23AM 22 FACIE CASE OF CONSPIRACY IN 2013 AND 2014 AND 2015, THE 09:23AM 23 REASONABLY FORESEEABLE ACTS OF THE COCONSPIRATOR ARE ADMISSIBLE 09:23AM 24 AND HE'S ACCOUNTABLE FOR THOSE. 09:23AM 25 I THINK THE 2010 IS IMPORTANT, BUT THE DECEPTIVE ACT IS

09:23AM	1	WHENEVER IT'S PROVIDED TO THE INVESTORS.
09:23AM	2	THE COURT: I UNDERSTOOD THAT.
09:23AM	3	AND MY QUESTION WAS, DO WE NEED TO LOOK BACK, AND HOW DO
09:23AM	4	WE LOOK BACK?
09:23AM	5	AND YOU'RE ABSOLUTELY RIGHT, AND I THINK MR. BRECHER WILL
09:23AM	6	AGREE, THEY'RE LIABLE FOR THE CONDUCT. "THEY" MEANING THE
09:24AM	7	COCONSPIRATORS.
09:24AM	8	DO WE LOOK BACK THOUGH? HERE WE'RE STARTING IN 2010 AND
09:24AM	9	GOING FORWARD TO CONDUCT THAT I THINK EVERYBODY IS
09:24AM	10	ACKNOWLEDGING OCCURRED, AND THE WITNESS WILL TESTIFY ABOUT
09:24AM	11	RECEIVING DOCUMENTS.
09:24AM	12	MR. LEACH: I THINK THERE IS SOME LEVEL, YOU KNOW,
09:24AM	13	OF, DOES THE EVIDENCE IN 2013 AND 2014, DOES IT REASONABLY
09:24AM	14	CONNECT TO 2010? IS THERE SOME CHANGE IN THE CIRCUMSTANCES?
09:24AM	15	AND I THINK WHAT THE GOVERNMENT IS SAYING IS THAT WE KNOW
09:24AM	16	THAT MR. BALWANI RECEIVED, YOU KNOW, THE UNALTERED
09:24AM	17	SCHERING-PLOUGH REPORT AND AN ALTERED SCHERING-PLOUGH REPORT.
09:24AM	18	HE KNEW THERE WAS AND WHEN I SAY "KNEW," I THINK THE
09:24AM	19	EVIDENCE SUPPORTS THE INFERENCE THAT HE KNEW AT LEAST ONE
09:24AM	20	REPORT WAS DOCTORED.
09:24AM	21	HE KNEW THAT MS. HOLMES WAS MAKING REPRESENTATIONS TO
09:24AM	22	WALGREENS AND OTHERS ABOUT THE PHARMA RELATIONSHIPS. HE KNOWS
09:24AM	23	THAT IN 2010.
09:24AM	24	BY 2013 AND 2014, HE KNOWS THERE'S NO REVENUE FROM PFIZER.
09:25AM	25	HE KNOWS THERE HAS BEEN NO INTEREST FOR A NUMBER OF YEARS. HE

KNOWS THIS IS BEING HELD OUT TO INVESTORS AS COMPREHENSIVE 1 09:25AM VALIDATION, AND IN ALL OF THEIR POWERPOINTS THEY'RE SAYING, 2 09:25AM WE'VE BEEN COMPREHENSIVELY VALIDATED, YOU CAN COUNT ON THE 3 09:25AM 09:25AM 4 PHARMA COMPANIES. ALL OF THAT PUT TOGETHER SUPPORTS THE INFERENCE THAT HE 09:25AM 09:25AM 6 KNOWS A SIGNIFICANT AMOUNT ABOUT THE PFIZER RELATIONSHIP, KNOWS 09:25AM 7 THAT THERE HAD BEEN SOME ALTERATION OF THE REPORTS IN THE PAST, AND RAISES A FAIR INFERENCE THAT IF THERE'S A CONSPIRACY, WHICH 09:25AM 8 I THINK THERE'S A PRIMA FACIE CASE OF, THE KNOWLEDGE DOESN'T 09:25AM 9 09:25AM 10 NEED TO EXTEND, YOU KNOW, AS DIRECT EVIDENCE TO EACH PARTICULAR 09:25AM 11 GRAIN OF A MULTI PAGE POWERPOINT -- IT DOESN'T NEED TO EXPAND 09:25AM 12 GRANULARLY TO EVERY SINGLE PAGE OF THE POWERPOINT. IF THEY'RE IN FOR A PENNY TO DECEIVE INVESTORS ABOUT PHARMACEUTICAL 09:25AM 13 COMPANIES, THEY'RE IN FOR A POUND. 09:26AM 14 09:26AM 15 SO YOU NEED TO LOOK AT IT AS A WHOLE, BUT I ALSO DON'T WANT TO EMPHASIZE TOO MUCH THE 2010 TIME PERIOD BECAUSE THE 09:26AM 16 09:26AM 17 DECEPTIVE ACT IS REALLY WHEN THE REPORT WAS GIVEN TO THE 09:26AM 18 PHARMACEUTICAL --09:26AM 19 THE COURT: SO THE 2010 IS THE GENESIS, THAT'S THE 09:26AM 20 GENESIS OF THE CONSPIRATORIAL ACTS, AND THE CONDUCT DEVELOPS AS 09:26AM 21 WE SEE IN 2013, 2014, 2015, THE OTHER GERMINATION, IF YOU WILL, 09:26AM 22 OF THE CONSPIRACY. 09:26AM 23 MR. LEACH: YES. 09:26AM 24 MR. BRECHER: THANK YOU, YOUR HONOR. 09:26AM 25 IT'S ALWAYS A PLEASURE TO DO BATTLE WITH TWO OF MY

09:26AM	1	COLLEAGUES.
09:26AM	2	THE COURT: WELL, YOU SHOULD BE HONORED.
09:26AM	3	MR. BRECHER: I AM INDEED, YOUR HONOR.
09:26AM	4	I WANT TO MAKE SURE THAT I KEEP THIS BRIEF, WHILE ALSO NOT
09:26AM	5	GOING TOO QUICKLY TO IMPOSE TOO MUCH ON MS. RODRIGUEZ.
09:26AM	6	SO I JUST NEED TO MARCH THROUGH A FEW THINGS JUST TO MAKE
09:26AM	7	SURE THAT WE'RE CLEAR.
09:27AM	8	FIRST, THERE WAS A CLAIM BY MY FRIEND THAT AT THE TAIL END
09:27AM	9	OF THE INVESTMENT NEGOTIATIONS WITH RDV, MR. BALWANI SENT A
09:27AM	10	SOFT COPY OF ALL OF THE INVESTOR DOCUMENTS TO MS. PETERSON,
09:27AM	11	INCLUDING THE PFIZER REPORT. THAT IS NOT TRUE.
09:27AM	12	THE SOFT COPY OF THE MATERIALS THAT HE SENT INCLUDED ONLY
09:27AM	13	THE BLANK AGREEMENTS FOR SIGNATURE. THERE IS NO MUCH TO THE
09:27AM	14	FRUSTRATION OF, FRANKLY, BOTH PARTIES, THERE IS NO SOFT COPY IN
09:27AM	15	EXISTENCE OF WHAT MS. PETERSON DESCRIBED AS THE DUE DILIGENCE
09:27AM	16	MATERIALS THAT WERE SENT BEFORE THE INVESTMENT.
09:27AM	17	AS TO THOSE MATERIALS THAT DID INCLUDE THE PFIZER REPORT,
09:27AM	18	YOUR HONOR ALLOWED THAT EVIDENCE TO COME IN BASED ON A
09:27AM	19	FOUNDATION THAT MR. BALWANI WAS THE SIGNATORY ON A
09:27AM	20	CONFIDENTIALITY AGREEMENT THAT HELPED FACILITATE THAT EXCHANGE.
09:27AM	21	BUT I WANT TO REMIND THE COURT, AND I THINK I CAN'T SAY
09:27AM	22	THAT MR. LEACH CONCEDED THE POINT, BUT I DIDN'T HEAR HIM
09:27AM	23	ADDRESS IT DIRECTLY THE OTHER DAY WHEN MS. PETERSON WAS ON THE
09:27AM	24	STAND.
09:27AM	25	THERE IS NO EVIDENCE WHATSOEVER THAT MR. BALWANI SENT

THOSE MATERIALS TO MS. PETERSON OR ANY ONE OF THE INVESTORS. 1 09:28AM IN FACT, WHAT WE KNOW FROM MR. EDLIN'S TESTIMONY IS THAT 2 09:28AM MR. EDLIN SENT THE MATERIALS AT THE DIRECTION OF MS. HOLMES, 3 09:28AM 09:28AM 4 WITH ONE EXCEPTION, AND THAT EXCEPTION WAS THE PROVISION OF THE FINANCIAL DOCUMENTS. 09:28AM SO I JUST WANT TO MAKE SURE THAT THE RECORD IS CLEAR ON 09:28AM 6 09:28AM 7 THAT POINT. SECOND, MR. MENDENHALL DID SAY THAT MR. BALWANI -- AND 8 09:28AM AGAIN, THIS IS A CONVERSATION IN LATE 2013, SO THE TIMING 09:28AM 9 09:28AM 10 MATTERS -- HAD A COMMAND OF THE FACTS IN GENERAL, BUT HE DID 09:28AM 11 NOT SAY THAT HE DESCRIBED THE CLINICAL TRIALS IN DETAIL. THAT 09:28AM 12 WASN'T HIS TESTIMONY, AND THAT'S NOT WHAT HIS NOTES REFLECT. INDEED, I DON'T RECALL THE EXHIBIT NUMBER OFFHAND, 09:28AM 13 YOUR HONOR, BUT AS THE COURT WILL KNOW FROM THE BOTTOM OF THAT 09:28AM 14 09:28AM 15 EXHIBIT, AND FROM HIS OWN TESTIMONY, MR. MENDENHALL DESCRIBED 09:28AM 16 HIMSELF AS A COMPULSIVE NOTE-TAKER AND SAID THAT I BELIEVE I 09:28AM 17 WROTE DOWN EVERYTHING THAT HE SAID. 09:28AM 18 HE DIDN'T WRITE THAT DOWN AND HE DIDN'T OFFER THAT 09:28AM 19 TESTIMONY LAST WEEK. 09:28AM 20 NUMBER THREE, I HEARD AN ARGUMENT ABOUT THE TIMING ALLEGED IN THE INDICTMENT. 09:29AM 21 09:29AM 22 WELL, YES, THE INDICTMENT DOES ALLEGE THAT A CONSPIRACY 09:29AM 23 BEGAN IN 2010, BUT THAT'S WHAT WE'RE HERE TO PROVE. THE INDICTMENT IS NOT EVIDENCE. IT DOESN'T PROVE ANYTHING. THE 09:29AM 24 09:29AM 25 COURT HAS ALREADY INSTRUCTED THE JURY ON THAT POINT, AND WILL

1 09:29AM 2 09:29AM 3 09:29AM 09:29AM 4 09:29AM 09:29AM 6 09:29AM 7 8 09:29AM 09:29AM 9 09:29AM 10 09:29AM 11 09:29AM 12 09:30AM 13 09:30AM 14 09:30AM 15 09:30AM 16 09:30AM 17 09:30AM 18 09:30AM 19 09:30AM 20 09:30AM 21 09:30AM 22 09:30AM 23 09:30AM 24 09:30AM 25

DO SO AGAIN I EXPECT.

MORE RELEVANTLY, YOUR HONOR, IN TERMS OF THE 104 CONTEXT, AN INDICTMENT IS, OF COURSE, ISSUED ON A PROBABLE CAUSE STANDARD, NOT THE PREPONDERANCE STANDARD THAT APPLIES HERE.

IT'S ALSO ISSUED IN A PROCESS OVER WHICH THE GOVERNMENT HAS UNIQUE CONTROL WITH WE'LL JUST SAY LIMITED PARTICIPATION BY DEFENDANTS IN MOST INSTANCES.

NUMBER FIVE -- EXCUSE ME, NUMBER FOUR, I WANT TO TALK ABOUT THE RETAIL RELATIONSHIP FOR JUST A MOMENT.

FIRST, THERE'S BEEN NO EVIDENCE TO DATE THAT WALGREENS DID RELY PRIMARILY OR EVEN LARGELY, THERE'S ACTUALLY BEEN NO TESTIMONY ON THIS AT ALL, BUT I'LL RECOGNIZE THAT THERE WAS SOME TESTIMONY IN THIS DIRECTION IN THE HOLMES TRIAL, ON THE PHARMA REPORTS.

IN FACT, THE TESTIMONY THAT IS ALREADY IN EVIDENCE IN BOTH TRIALS ESTABLISHES THAT WALGREENS ENGAGED JOHNS HOPKINS AND A TEAM THERE TO EVALUATE THE TECHNOLOGY, AND THAT ALSO HAPPENED IN 2010.

THERE IS ALSO NO EVIDENCE THAT, QUOTE, THE WALGREENS-WAL-MART RELATIONSHIP WENT NOWHERE. I DON'T KNOW WHAT THOSE ARGUMENTS ARE MEANT TO PROVE, BUT I DON'T THINK THEY GET THE JOB DONE.

FIFTH IS THAT THE GOVERNMENT RAISES AN ARGUMENT THAT THEY HAVE NOT BEFORE RAISED, AND I'M HAPPY TO ADDRESS IT, AND THAT IS THAT IF THERE'S A PRIMA FACIE CASE IN THE 2014, 2015 TIME

1 09:30AM 2 09:30AM 3 09:30AM 09:30AM 09:31AM 09:31AM 6 09:31AM 7 09:31AM 8 09:31AM 9 09:31AM 10 09:31AM 11 09:31AM 12 09:31AM 13 09:31AM 14 09:31AM 15 09:31AM 16 09:31AM 17 09:31AM 18 09:31AM 19 09:31AM 20 09:32AM 21 09:32AM 22 09:32AM 23 09:32AM 24 09:32AM 25

PERIOD, THAT THE RELEVANT ACT OF WHICH VICARIOUS LIABILITY WOULD ATTACH, THE RELEVANT DECEPTIVE ACT WOULD BE SENDING THE PFIZER REPORT IN THOSE TIME PERIODS.

FIRST, JUST TO MAKE SURE THAT WE'RE CLEAR ON THE FACTS, IT WOULD HAVE TO BE VICARIOUS LIABILITY THEN, BECAUSE AS THE COURT KNOWS AND AS I'VE JUST STATED, THERE'S NO EVIDENCE THAT MR. BALWANI DID THAT WITH ANY OF THE INVESTORS THAT HAVE BEEN ADMITTED THUS FAR IN TRIAL. I BELIEVE THERE WAS SOME EVIDENCE THAT DIDN'T COME INTO EITHER TRIAL ABOUT HIM SENDING A REPORT.

I WANT TO EMPHASIZE, I HEARD A GREAT DEAL OF -- WELL, A GREAT DEAL OF EMPHASIS PLACED ON THE PHRASE THAT MR. BALWANI ONLY EVER SHARED THE ALTERED VERSION OF THE PFIZER REPORT.

AND, YES, YOUR HONOR, THAT'S KIND OF OUR POINT. THAT'S THE ONLY VERSION THAT HE EVER HAD, SO THERE'S NOTHING -- IT PROVES TOO MUCH BECAUSE IT PROVES NOTHING.

BUT TURNING BACK TO THE ARGUMENT THAT AN ACT IN 2013 IS WHAT IS RELEVANT AND WHAT MR. BALWANI IS POTENTIALLY ON THE HOOK FOR, THAT FAILS. IT FAILS FOR TWO REASONS.

FIRST, THE -- AS I'VE ALREADY SAID, IF THE GOVERNMENT WANTS TO SAY THAT MS. HOLMES REPRESENTED, OR EVEN MR. BALWANI REPRESENTED, IT'S FINE, THAT PHARMACEUTICAL COMPANIES HAD COMPREHENSIVELY VALIDATED THE TECHNOLOGY, AND THE GOVERNMENT, THEY PUT ON EVIDENCE ALREADY THROUGH DR. CULLEN, I SUSPECT THAT THEY'RE GOING TO PUT ON MORE EVIDENCE THIS MORNING THROUGH MR. WEBER, IF THE GOVERNMENT WANTS TO PUT ON EVIDENCE THAT THAT

REPRESENTATION WAS FALSE, FINE. FINE BY ME. 1 09:32AM BUT THE ACT AT ISSUE IS THE ALTERATION OF THE REPORT, AND 09:32AM THAT HAPPENED IN 2010, SO IT DOESN'T SURPRISE ME TO HEAR 3 09:32AM 09:32AM 4 MR. LEACH SAY TO THE COURT THAT THE GOVERNMENT DOESN'T WANT YOU FOCUSSING ON 2010. IT'S BECAUSE THAT'S WHERE THEIR CASE IS 09:32AM 09:32AM 6 PRETTY THIN AT THIS POINT. 09:32AM 7 SECOND, I HAVE TO MENTION FORESEEABILITY, YOUR HONOR, AND I ALREADY KNOW WHAT THE COURT IS THINKING. NORMALLY 09:32AM 8 FORESEEABILITY IS A LAY UP FOR THE GOVERNMENT. I GET IT. 09:32AM 9 09:32AM 10 BUT HERE THE ANALYSIS IS QUITE DIFFERENT, EVEN IF YOU BUY 09:32AM 11 THE GOVERNMENT'S 2013, 2014 DECEPTIVE ACT THEORY. 09:32AM 12 AND THAT IS BECAUSE WHAT YOU HAVE TO BELIEVE IS THAT IT WAS FORESEEABLE TO MR. BALWANI IN LATE 2014 THAT MS. HOLMES AND 09:33AM 13 OTHERS OF THE BOARD WHO SHARED WITH HIM THE INFORMATION THAT 09:33AM 14 09:33AM 15 THE COMPANY'S TECHNOLOGY HAD BEEN ROBUSTLY VALIDATED IN 2009 HAD DECEIVED HIM, HAD TRICKED HIM INTO JOINING THE COMPANY, AND 09:33AM 16 09:33AM 17 NOW FOUR YEARS LATER WE'RE GOING TO PLAY THAT SAME TRICK ON 09:33AM 18 SOMEONE ELSE, THIS TIME WITH MR. BALWANI'S KNOWING 09:33AM 19 PARTICIPATION. 09:33AM 20 IT'S, FRANKLY, SO CONVOLUTED, YOUR HONOR, I CAN'T EVEN REALLY ARTICULATE IT. BUT THAT'S WHAT I THINK IS GOING ON, AND 09:33AM 21 09:33AM 22 THAT'S WHAT I THINK THE GOVERNMENT HAS TO BE ARGUING. 09:33AM 23 SO LET'S RETURN TO WHERE WE ARE AND TO WHERE WE HAVE TO 09:33AM 24 BE. 09:33AM 25 THIS ALTERATION HAPPENED IN APRIL OF 2010, RIGHT AROUND

09:33AM	1	APRIL 14TH, 2010.
09:33AM	2	WE KNOW THAT SOMEONE ELSE HAS ADMITTED TO DOING IT. WE
09:33AM	3	KNOW THAT MR. BALWANI IS NOT GOING TO BE ABLE TO GET THAT
09:33AM	4	EVIDENCE IN WITHOUT WAIVING HIS CONFRONTATION RIGHTS.
09:33AM	5	WE DON'T KNOW WHAT OTHER CIRCUMSTANCES SURROUNDED THAT
09:34AM	6	PERSON'S CONDUCT. THE PERSON IS NOT LIKELY TO TESTIFY SO FAR
09:34AM	7	AS I'M AWARE, BUT MS. VOLKAR CAN FILL ME IN IF I'M WRONG.
09:34AM	8	IT IS FUNDAMENTALLY UNFAIR TO HAVE THE JURY SEE THE ONE
09:34AM	9	PERSON WHO IS SITTING THERE IN THE DOCS AND SAYING, OH GOSH,
09:34AM	10	SOMETHING REALLY UNTOWARD HAS HAPPENED HERE, I GUESS THIS GUY
09:34AM	11	DID IT.
09:34AM	12	AND INFORMATION FROM YEARS LATER ABOUT FINANCIALS DOESN'T
09:34AM	13	SAY ANYTHING ABOUT WHAT MR. BALWANI'S KNOWLEDGE AND INTENT WAS
09:34AM	14	IN APRIL OF 2010. THAT IS WHAT MATTERS HERE.
09:34AM	15	THANK YOU.
09:34AM	16	THE COURT: OKAY. THANK YOU.
09:34AM	17	MS. VOLKAR: YOUR HONOR, MAY I BE HEARD BRIEFLY,
09:34AM	18	VERY BRIEFLY?
09:34AM	19	THE COURT: SURE.
09:34AM	20	MS. VOLKAR: I THINK WE HEARD A LITTLE BIT OF A
09:34AM	21	PREVIEW OF THE DEFENSE'S CLOSING ARGUMENT, AND I DON'T WANT TO
09:34AM	22	REBUT ALL OF THE FACTUAL POINTS HERE.
09:34AM	23	THERE ARE JUST ONE OR TWO, PERHAPS MISTAKEN, BUT
09:34AM	24	MISCHARACTERIZATIONS OF THE RECORD THAT I DO THINK ARE
09:34AM	25	IMPORTANT TO FLAG.

THE FIRST WAS ABOUT PETERSON, WHAT MS. PETERSON TESTIFIED 1 09:34AM TO WITH THE SOFT COPY. 2 09:35AM ONE, I DON'T KNOW IF SHE -- I THOUGHT SHE REFERENCED THE 3 09:35AM 09:35AM 4 LOGO IN THIS TRIAL, BUT I KNOW SHE SAID SHE THOUGHT PFIZER WROTE IT, SO THAT IS IN THE RECORD. 09:35AM BUT SHE ALSO SAID THAT WHAT MR. BALWANI SENT TO HER IN 09:35AM 6 09:35AM 7 THAT ZIP FILE, WHICH IF WE DIDN'T RECEIVE THAT IN DISCOVERY, THAT'S AN ENTIRELY DIFFERENT DISCUSSION WE DON'T NEED TO HAVE 09:35AM 8 TODAY, BUT SHE TESTIFIED THAT WHAT SHE RECEIVED IN THE ZIP FILE 09:35AM 9 09:35AM 10 FROM MR. BALWANI WAS THE SAME MATERIAL THAT SHE GOT IN THE 09:35AM 11 BINDER, AND THAT'S AT TRANSCRIPT PAGE 3884 TO 3897. AND I 09:35AM 12 APOLOGIZE, I DON'T HAVE A MORE NARROWED PIN CITE THAN THAT. I DIDN'T HAVE THE PAGE NUMBERS WITH ME. 09:35AM 13 THERE IS ALSO A STATEMENT THAT THERE'S NO EVIDENCE THAT 09:35AM 14 09:35AM 15 THE WALGREENS RELATIONSHIP WENT NOWHERE. I WOULD POINT THE COURT TO MR. JHAVERI'S TESTIMONY. I 09:35AM 16 09:35AM 17 DON'T THINK WE NEED TO BELABOR THAT. HE TALKED ABOUT HOW IT 09:35AM 18 FIZZLED OUT BECAUSE THEY COULDN'T BRING THE VEIN DROP 09:35AM 19 PERCENTAGE DOWN. 09:35AM 20 AND THE LAST THING IS THAT THE DEFENSE EMPHASIZES THIS IS 09:36AM 21 ABOUT THE ALTERATION THAT HAPPENED IN APRIL 2010. I JUST WANT TO POINT OUT, WE'RE TRYING TO PARSE THROUGH 09:36AM 22 09:36AM 23 WHAT IS COMING IN THROUGH THIS TRIAL AND WHAT WE SORT OF KNOW 09:36AM 24 IN THE LARGER UNIVERSE. 09:36AM 25 THERE IS NO EVIDENCE IN THIS TRIAL THAT THE ALTERATION

09:36AM	1	HAPPENED IN APRIL OF 2010, AND I DO THINK THAT'S IMPORTANT.
09:36AM	2	MY COLLEAGUE IS SAYING THAT WE KNOW THAT BECAUSE
09:36AM	3	MS. HOLMES TESTIFIED TO IT.
09:36AM	4	THE GOVERNMENT DISPUTES THAT THAT'S SORT OF THE ULTIMATE
09:36AM	5	TRUTH.
09:36AM	6	REGARDLESS, THE JURY CERTAINLY HASN'T HEARD IT.
09:36AM	7	THAT'S ALL I HAVE TO SAY.
09:36AM	8	THE COURT: THANK YOU.
09:36AM	9	MR. BRECHER: YOUR HONOR, I HAVE TO RESPOND VERY
09:36AM	10	BRIEFLY.
09:36AM	11	FIRST OF ALL, AS TO WHAT MS. PETERSON SAID ABOUT RECEIVING
09:36AM	12	A SOFT COPY, I WANT TO BE CLEAR, WE HAVE THAT EMAIL. WE HAVE
09:36AM	13	THAT EXHIBIT, IT CAME INTO EVIDENCE THE OTHER DAY, AND THE
09:36AM	14	COURT CAN SEE FOR ITSELF WHAT ALL WAS ATTACHED TO IT. IT'S
09:36AM	15	JUST THE CONTRACTS. IT IS NOT THE REST OF THE DUE DILIGENCE
09:36AM	16	MATERIALS, SO THAT IS AN UNDISPUTED FACT.
09:36AM	17	WELL, I HAD THOUGHT IT WAS AN UNDISPUTED FACT UNTIL A
09:36AM	18	MOMENT AGO.
09:36AM	19	SECOND, IF I MISSPOKE, I APOLOGIZE, YOUR HONOR.
09:36AM	20	WHAT I HAD MEANT TO SAY WAS THAT THERE WAS NOTICE EVIDENCE
09:36AM	21	THAT THE WAL-MART RELATIONSHIP WENT NOWHERE, EVEN IN THE LAST
09:37AM	22	TRIAL OR THIS ONE.
09:37AM	23	AS FOR THE WALGREENS RELATIONSHIP FIZZLING OUT, ALL I'LL
09:37AM	24	SAY WITHOUT SPOILING EVENTS IS THAT MR. JHAVERI IS STILL ON
09:37AM	25	CROSS. WE'VE GOT MORE TO SAY.

1 09:37AM 2 09:37AM 3 09:37AM 09:37AM 4 09:37AM 09:37AM 6 09:37AM 7 8 09:37AM 09:37AM 9 09:37AM 10 09:37AM 11 09:37AM 12 09:38AM 13 09:38AM 14 09:38AM 15 09:38AM 16 09:38AM 17 09:38AM 18 09:38AM 19 09:38AM 20 09:38AM 21 09:38AM 22 09:38AM 23 09:38AM 24 09:38AM 25

BUT SECOND, THAT HAPPENED, AGAIN, IN 2014 AND 2015, AND GOING INTO OCTOBER OF 2015 IS WHEN THINGS REALLY STALLED IN THE WALGREENS RELATIONSHIP.

AND LAST, THE POINT IS THAT THERE IS NO EVIDENCE THAT IN APRIL 2010 MR. BALWANI HAD ANY KNOWLEDGE OF THIS OR WHAT WAS GOING ON, AND I THINK THAT THIS ISSUE HAS TO RISE AND FALL ON THAT.

THANK YOU.

THE COURT: OKAY. THANK YOU VERY MUCH.

AND MS. VOLKAR, MR. BRECHER SUGGESTS THAT THE PRIMA FACIE IS USUALLY A LAY UP FOR THE GOVERNMENT, AND HE SUGGESTS THAT EVEN A YOUNG MAN NAMED STEPHEN CURRY MISSES A LAY UP EVERY NOW AND THEN, AND SO THE EVIDENCE MAY FAIL IN THIS CASE IN THAT REGARD.

I TO RECOGNIZE THAT MR. JHAVERI IS STILL A WITNESS AND WE HAVEN'T COMPLETED HIS TESTIMONY, AND PART OF HIS RELATIONSHIP WITH MR. BALWANI REFERENCES THE 2010 TIME PERIOD, AND AT LEAST SOME OF HIS TESTIMONY, I THINK, TALKED ABOUT THAT.

I WANT TO LOOK BACK AT THE TRANSCRIPT REGARDING THE TOUR. THAT COULD BE HELPFUL HERE.

THE SHOWING IS, AND WE ALL RECOGNIZE THE PRIMA FACIE SHOWING IS THAT IT'S NOT A VERY HIGH BAR, AND THE LAW SUGGESTS THAT. ACTUALLY, THE LAW STATES THAT. IT DOESN'T SUGGEST IT. IT STATES THAT. IT'S NOT A HIGH BAR. IT'S A PREPONDERANCE STANDARD, WHICH IS A STANDARD OF EVIDENCE THAT MUST BE MET.

1 09:38AM 2 09:38AM 3 09:38AM 09:39AM 4 09:39AM 09:39AM 09:39AM 8 09:39AM 09:39AM 9 09:39AM 10 09:39AM 11 09:39AM 12 09:39AM 13 09:39AM 14 09:39AM 15 09:39AM 16 09:39AM 17 18 09:39AM 09:40AM 19 09:40AM 20 09:40AM 21 09:40AM 22 09:40AM 23 09:40AM 24

09:40AM 25

BUT I WANT TO LOOK AT THESE THINGS THAT YOU'VE TALKED TO ME ABOUT.

AS FAR AS THE WITNESS'S TESTIMONY TODAY, WE'LL GET STARTED WITH HIS TESTIMONY IN JUST A MOMENT, AND I AM GOING TO PERMIT HIM TO TESTIFY ABOUT, AS I SAID EARLIER, AT A MINIMUM AS TO THE FALSITY ISSUE AND QUESTIONS REGARDING WHETHER PFIZER, WHETHER HE'S AUTHORIZED TO TESTIFY ABOUT WHETHER OR NOT PFIZER DID WHAT THE LETTER SAYS IT DID, WHETHER PFIZER CREATED IT, ENDORSED IT, WHETHER THIS IS A PFIZER LETTER.

I'M GOING TO PERMIT HIM TO TESTIFY ABOUT THAT AS TO A MINIMUM ON THE ISSUE, AS I SAID, OF FALSITY.

THE OTHER -- WHETHER OR NOT HE TESTIFIES THAT IT'S -- I DON'T THINK HE CAN SAY IT'S AN ALTERATION, BUT HE CAN SAY WE DIDN'T -- I DIDN'T AUTHORIZE THAT LOGO ON THERE. THAT'S NOT OUR WORK PRODUCT. I DON'T KNOW WHO DID IT, BUT WE DIDN'T.

STANDING PREGNANT, I KNOW YOUR PROBLEM WITH THAT, MR. BRECHER, IS THAT THE ONLY PERSON IN THE ROOM HERE WHO IS ACCUSED IS MY CLIENT, AND, OF COURSE, ALL EYES WILL LOOK AND SAY, WELL, HE MUST HAVE DONE IT.

I'VE TALKED TO YOU ABOUT THERE MAY BE, AS THE EVIDENCE COMES OUT, THE COURT MAY, IN A FINAL INSTRUCTION, SAY THAT YOU CAN'T CONSIDER THAT, AND THE COURT MAY INSTRUCT THE GOVERNMENT, YOU CAN'T ARGUE THAT BECAUSE THERE'S NO EVIDENCE TO SUPPORT THAT.

THAT MIGHT BE THE APPROPRIATE REMEDY, WHICH IS TO SAY, I

09:40AM	1	NEED TO HEAR A LITTLE MORE.
09:40AM	2	BUT I WILL PERMIT THAT TYPE OF TESTIMONY FROM OR QUESTIONS
09:40AM	3	TO COME FROM THE GOVERNMENT AS TO THOSE ISSUES.
09:40AM	4	MR. BRECHER: WE'LL OBJECT AT THE MOMENT,
09:40AM	5	YOUR HONOR, AND STAND ON OUR ARGUMENTS, BUT I UNDERSTAND THE
09:40AM	6	COURT'S DIRECTION. THANK YOU.
09:40AM	7	THE COURT: OKAY.
09:40AM	8	MS. VOLKAR: THANK YOU, YOUR HONOR.
09:40AM	9	THE COURT: OKAY. WHAT ELSE SHOULD WE DISCUSS THIS
09:40AM	10	MORNING BEFORE WE BRING OUR JURY IN?
09:40AM	11	MR. BRECHER: YOUR HONOR, MR. COOPERSMITH HAD
09:40AM	12	ANOTHER MATTER FOR OUR NEXT WITNESS.
09:41AM	13	MR. LEACH: YOUR HONOR, IF I MAY GO FIRST ON THIS
09:41AM	14	ONE?
09:41AM	15	THE COURT: SURE.
09:41AM	16	MR. LEACH: MR. COOPERSMITH EMAILED THE COURTROOM
09:41AM	17	DEPUTY LAST NIGHT ABOUT THREE PARTICULAR EXHIBITS THAT THE
09:41AM	18	GOVERNMENT HAS IDENTIFIED RELATING TO SARAH BENNETT.
09:41AM	19	IT'S NOT CURRENTLY OUR INTENTION TO OFFER THOSE EXHIBITS
09:41AM	20	INTO EVIDENCE. WE'VE MARKED THEM AND DISCLOSED THEM AS
09:41AM	21	POTENTIAL USE WITH MS. BENNETT TO REFRESH HER ON DATES AND
09:41AM	22	TIMING, BUT I'M NOT THERE'S SOME POSSIBILITY THAT THE
09:41AM	23	DEFENSE COULD OPEN THE DOOR TO THE CONTENT OF THOSE EMAILS, BUT
09:41AM	24	IT'S NOT CURRENTLY OUR INTENTION TO ADMIT THE DOCUMENTS
09:41AM	25	REFERENCED.

09:41AM	1	I DON'T KNOW IF THAT ALLAYS THE DEFENSE'S CONCERNS, BUT I
09:41AM	2	THOUGHT I WOULD START WITH THAT.
09:41AM	3	THE COURT: OKAY. THANK YOU.
09:41AM	4	MR. COOPERSMITH: YOUR HONOR, I THINK THAT ADDRESSES
09:41AM	5	THE ISSUE, AND I WILL JUST STAND ON THAT. THANK YOU.
09:41AM	6	THE COURT: OKAY. GREAT.
09:41AM	7	WELL, LET'S SEE IF WE CAN EMULATE THIS.
09:42AM	8	MR. COOPERSMITH: I'M ALWAYS HAPPY WHEN WE AGREE ON
09:42AM	9	SOMETHING, YOUR HONOR.
09:42AM	10	THE COURT: ALL RIGHT. THANK YOU.
09:42AM	11	I'LL STEP DOWN AND WE'LL BRING OUR JURY IN AND WE'LL START
09:42AM	12	OUR DAY OF TESTIMONY.
09:42AM	13	MR. LEACH: THANK YOU, YOUR HONOR.
09:42AM	14	THE COURT: AND WE'RE GOING UNTIL 4:00 TODAY, I
09:42AM	15	BELIEVE.
09:50AM	16	(RECESS TAKEN AT 9:43 A.M. UNTIL 9:50 A.M.)
09:50AM	17	(JURY IN AT 9:50 A.M.)
09:50AM	18	THE COURT: PLEASE BE SEATED. WE'RE BACK ON THE
09:50AM	19	RECORD IN MR. BALWANI'S MATTER.
09:50AM	20	ALL COUNSEL ARE PRESENT. THE JURY IS PRESENT.
09:51AM	21	GOOD MORNING, LADIES AND GENTLEMEN. I'M SORRY FOR THE
09:51AM	22	DELAY.
09:51AM	23	AS I TOLD YOU IN THE PRELIMINARY INSTRUCTIONS, THERE WILL
09:51AM	24	BE TIMES THAT I HAVE TO MEET WITH THE LAWYERS TO GET ADDITIONAL
09:51AM	25	INFORMATION FROM THEM. YOU'VE EXPERIENCED THAT.

09:51AM	1	THERE MAY BE TIMES WHERE YOU EXPERIENCED THAT AND IT HAS
09:51AM	2	HAPPENED AND I APPRECIATE YOUR PATIENCE IN THAT REGARD.
09:51AM	3	SO BEFORE WE START, LET ME ASK YOU, DURING THE BREAK, DID
09:51AM	4	ANY OF YOU HAVE CAUSE TO READ, LISTEN, DISCUSS, OR IN ANY WAY
09:51AM	5	LEARN ANYTHING ABOUT THIS CASE OUTSIDE OF THIS COURTROOM?
09:51AM	6	PLEASE RAISE YOUR HAND IF THAT HAS HAPPENED.
09:51AM	7	I SEE NO HANDS. THANK YOU.
09:51AM	8	I SEE YOU HAVE REVERSED YOUR SEATING AGAIN.
09:51AM	9	OKAY. GOOD. I HOPE THAT'S WORKING WELL FOR YOU.
09:51AM	10	WITH THAT, LET ME CALL ON THE GOVERNMENT TO CALL ANOTHER
09:51AM	11	WITNESS.
09:51AM	12	MR. LEACH: THANK YOU, YOUR HONOR.
09:51AM	13	THE UNITED STATES CALLS SHANE WEBER.
09:52AM	14	THE COURT: GOOD MORNING, SIR.
09:52AM		THE COURT: GOOD MORNING, SIR. IF YOU WOULD STEP FORWARD AND FACE OUR COURTROOM DEPUTY
	15	·
09:52AM	15 16	IF YOU WOULD STEP FORWARD AND FACE OUR COURTROOM DEPUTY
09:52AM 09:52AM	15 16 17	IF YOU WOULD STEP FORWARD AND FACE OUR COURTROOM DEPUTY WHILE YOU RAISE YOUR RIGHT HAND, SHE HAS A QUESTION FOR YOU.
09:52AM 09:52AM 09:52AM	15 16 17 18	IF YOU WOULD STEP FORWARD AND FACE OUR COURTROOM DEPUTY WHILE YOU RAISE YOUR RIGHT HAND, SHE HAS A QUESTION FOR YOU. (GOVERNMENT'S WITNESS, SHANE WEBER, WAS SWORN.)
09:52AM 09:52AM 09:52AM	15 16 17 18 19	IF YOU WOULD STEP FORWARD AND FACE OUR COURTROOM DEPUTY WHILE YOU RAISE YOUR RIGHT HAND, SHE HAS A QUESTION FOR YOU. (GOVERNMENT'S WITNESS, SHANE WEBER, WAS SWORN.) THE WITNESS: I DO.
09:52AM 09:52AM 09:52AM 09:52AM	15 16 17 18 19 20	IF YOU WOULD STEP FORWARD AND FACE OUR COURTROOM DEPUTY WHILE YOU RAISE YOUR RIGHT HAND, SHE HAS A QUESTION FOR YOU. (GOVERNMENT'S WITNESS, SHANE WEBER, WAS SWORN.) THE WITNESS: I DO. THE COURT: PLEASE HAVE A SEAT UP HERE, SIR.
09:52AM 09:52AM 09:52AM 09:52AM 09:52AM	15 16 17 18 19 20 21	IF YOU WOULD STEP FORWARD AND FACE OUR COURTROOM DEPUTY WHILE YOU RAISE YOUR RIGHT HAND, SHE HAS A QUESTION FOR YOU. (GOVERNMENT'S WITNESS, SHANE WEBER, WAS SWORN.) THE WITNESS: I DO. THE COURT: PLEASE HAVE A SEAT UP HERE, SIR. LET ME INVITE YOU TO MAKE YOURSELF COMFORTABLE.
09:52AM 09:52AM 09:52AM 09:52AM 09:52AM 09:52AM	15 16 17 18 19 20 21 22	IF YOU WOULD STEP FORWARD AND FACE OUR COURTROOM DEPUTY WHILE YOU RAISE YOUR RIGHT HAND, SHE HAS A QUESTION FOR YOU. (GOVERNMENT'S WITNESS, SHANE WEBER, WAS SWORN.) THE WITNESS: I DO. THE COURT: PLEASE HAVE A SEAT UP HERE, SIR. LET ME INVITE YOU TO MAKE YOURSELF COMFORTABLE. FEEL FREE TO ADJUST THE CHAIR AND THE MICROPHONE AS YOU
09:52AM 09:52AM 09:52AM 09:52AM 09:52AM 09:52AM 09:52AM	15 16 17 18 19 20 21 22 23	IF YOU WOULD STEP FORWARD AND FACE OUR COURTROOM DEPUTY WHILE YOU RAISE YOUR RIGHT HAND, SHE HAS A QUESTION FOR YOU. (GOVERNMENT'S WITNESS, SHANE WEBER, WAS SWORN.) THE WITNESS: I DO. THE COURT: PLEASE HAVE A SEAT UP HERE, SIR. LET ME INVITE YOU TO MAKE YOURSELF COMFORTABLE. FEEL FREE TO ADJUST THE CHAIR AND THE MICROPHONE AS YOU NEED.
09:52AM 09:52AM 09:52AM 09:52AM 09:52AM 09:52AM 09:52AM	15 16 17 18 19 20 21 22 23 24	IF YOU WOULD STEP FORWARD AND FACE OUR COURTROOM DEPUTY WHILE YOU RAISE YOUR RIGHT HAND, SHE HAS A QUESTION FOR YOU. (GOVERNMENT'S WITNESS, SHANE WEBER, WAS SWORN.) THE WITNESS: I DO. THE COURT: PLEASE HAVE A SEAT UP HERE, SIR. LET ME INVITE YOU TO MAKE YOURSELF COMFORTABLE. FEEL FREE TO ADJUST THE CHAIR AND THE MICROPHONE AS YOU NEED. AND WHEN YOU ARE COMFORTABLE, I'LL ASK YOU TO PLEASE STATE

09:53AM	1	W-E-B-E-R.
09:53AM	2	THE COURT: THANK YOU. COUNSEL.
09:53AM	3	MR. LEACH: THANK YOU, YOUR HONOR.
09:53AM	4	DIRECT EXAMINATION
09:53AM	5	BY MR. LEACH:
09:53AM	6	Q. GOOD MORNING, MR. WEBER.
09:53AM	7	A. GOOD MORNING.
09:53AM	8	Q. IF YOU ARE FULLY VACCINATED, SIR, AND COMFORTABLE, WITH
09:53AM	9	THE COURT'S PERMISSION, YOU CAN TESTIFY WITHOUT A MASK.
09:53AM	10	A. I'M FULLY VACCINATED.
09:53AM	11	Q. AND I'VE REMOVED MY MASK AS WELL.
09:53AM	12	WAS THERE A TIME WHEN YOU WORKED FOR A COMPANY CALLED
09:53AM	13	PFIZER?
09:53AM	14	A. YES.
09:53AM	15	Q. AND WHAT IS THE BUSINESS OF PFIZER?
09:53AM	16	A. PFIZER IS A WORLDWIDE PHARMACEUTICAL DRUG COMPANY.
09:53AM	17	Q. OKAY. WHEN DID YOU WORK FOR PFIZER?
09:53AM	18	A. I WORKED FOR PFIZER MID-2008 THROUGH MID-2014.
09:53AM	19	Q. AT A HIGH LEVEL, WOULD YOU BRIEFLY DESCRIBE YOUR
09:53AM	20	EDUCATIONAL AND PROFESSIONAL BACKGROUND.
09:53AM	21	A. YES. EDUCATIONALLY, I DID AN UNDERGRADUATE IN MOLECULAR
09:53AM	22	BIOLOGY AND BIOCHEMISTRY AT NORTHWESTERN UNIVERSITY.
09:54AM	23	THEN I DID A DOCTORAL IN BIOPHYSICS AT OREGON STATE
09:54AM	24	UNIVERSITY.
09:54AM	25	AND FOLLOWING THAT, I DID A POST-DOCTORAL FELLOWSHIP IN

09:54AM	1	RADIATION BIOLOGY AND BIOPHYSICS AT THE UNIVERSITY OF
09:54AM	2	ROCHESTER.
09:54AM	3	FOLLOWING MY ACADEMIC TRAINING, I WORKED AT A NUMBER OF
09:54AM	4	CORPORATIONS. FIRST I WORKED AT EASTMAN KODAK IN ROCHESTER,
09:54AM	5	NEW YORK FOR TEN YEARS AS A LIFE SCIENTIST.
09:54AM	6	FOLLOWING THAT, I WORKED AT CONNECTICUT AT AN EASTMAN
09:54AM	7	KODAK COMPANY CALLED SCIENTIFIC IMAGING.
09:54AM	8	THEN I WORKED AT PACKARD BIOSCIENCES IN CONNECTICUT.
09:55AM	9	AND THEN I MOVED TO BOSTON, MASSACHUSETTS AND WORKED WITH
09:55AM	10	MILLENNIUM PHARMACEUTICALS.
09:55AM	11	DURING THAT TIME, I ALSO DID SBIR, SMALL BUSINESS
09:55AM	12	INNOVATION REVIEW GRANTS FOR THE NATIONAL INSTITUTE OF HEALTH,
09:55AM	13	AND AT MILLENNIUM I WORKED AS A SCIENTIST.
09:55AM	14	FOLLOWING MILLENNIUM I MOVED TO NEW JERSEY AND WORKED AT
09:55AM	15	ORTHO CLINICAL DIAGNOSTICS, A JOHNSON & JOHNSON DIAGNOSTIC
09:55AM	16	COMPANY.
09:55AM	17	AND THEN AFTER THAT, I MOVED TO PFIZER TO WORK AS A
09:55AM	18	DIRECTOR OF DIAGNOSTICS.
09:55AM	19	Q. THANK YOU, MR. WEBER.
09:55AM	20	LET ME ASK SOME FOLLOW-UP QUESTIONS ABOUT THAT. WE
09:55AM	21	APPRECIATE THE DETAIL.
09:55AM	22	YOU HAVE A PH.D.?
09:55AM	23	A. I DO.
09:55AM	24	Q. AND WHAT IS YOUR PH.D. IN?
09:55AM	25	A. IT'S IN BIOPHYSICS.

- 1 09:55AM 2 09:55AM 3 09:56AM 4 09:56AM 09:56AM 5 09:56AM 09:56AM 8 09:56AM 9 09:56AM 10 09:56AM 09:56AM 11 12 09:56AM 13 09:56AM 14 09:56AM 15 09:56AM 16 09:56AM 17 09:56AM 18 09:56AM 19 09:56AM 20 09:56AM 21 09:57AM 22 09:57AM 23 09:57AM 24 09:57AM 25 09:57AM
- AND WHAT IS BIOPHYSICS? Q.
- BIOPHYSICS IS THE USE OF THE STUDY OF BIOLOGICAL PROCESSES USING PHYSICAL APPROACHES.
- YOU ALSO DESCRIBED A NUMBER OF JOBS THAT YOU'VE HELD AT PLACES LIKE EASTMAN KODAK AND JOHNSON & JOHNSON.

AT A HIGH LEVEL, COULD YOU BRIEFLY DESCRIBE YOUR JOB RESPONSIBILITIES? WHAT WERE YOUR AREAS OF FOCUS?

AT EASTMAN KODAK I DEVELOPED MOLECULAR TECHNOLOGIES FOR ASSAYS FOR BIOPOLYMER, AND I ALSO DID IMAGING SYSTEMS THAT WERE COMMERCIALIZED FOR LABORATORY USE ACROSS THE COUNTRY AND THE WORLD.

AT JOHNSON & JOHNSON I WORKED AT AN ORTHO CLINICAL DIAGNOSTIC, WHICH IS A DIAGNOSTIC COMPANY THERE, AND I WAS A WORLDWIDE DIRECTOR OF DIAGNOSTICS IDENTIFYING NEW ASSAYS AND BUSINESS OPPORTUNITIES THAT COULD POTENTIALLY BE CONVERTED INTO A POTENTIAL PRODUCT.

- Q. THANK YOU. AND YOU JOINED PFIZER IN 2008?
- Α. YES.
- WHAT WERE YOU HIRED TO DO? Q.
- I WAS HIRED AS A DIRECTOR OF DIAGNOSTICS IN THE NEWLY Α. FORMED DIAGNOSTIC GROUP OF PFIZER, AND I WAS HIRED TO IDENTIFY NEW DIAGNOSTIC TECHNOLOGIES THAT WOULD ENABLE CLINICAL TRIALS.
- WHAT DO YOU MEAN BY "DIAGNOSTIC TECHNOLOGY"? Q.
- Α. DIAGNOSTIC TECHNOLOGIES, OR DIAGNOSTICS, ARE, ACCORDING TO

09:57AM	1	THE FDA, THOSE ASSAYS, REAGENTS, INSTRUMENTS AND SYSTEMS FOR
09:57AM	2	THE USE OF THE DIAGNOSIS OF DISEASE OR CONDITIONS OF HEALTH FOR
09:57AM	3	THE PURPOSE OF TREATING, MITIGATING, CURING, OR PREVENTING
09:57AM	4	DISEASE.
09:57AM	5	Q. AND YOU WERE LOOKING FOR A POTENTIAL DIAGNOSTIC TECHNOLOGY
09:57AM	6	THAT MIGHT BE OF INTEREST TO PFIZER?
09:57AM	7	A. YES.
09:57AM	8	Q. AND WHO DID YOU REPORT TO IN THIS 2008 TIME PERIOD?
09:57AM	9	A. I REPORTED TO HAKAN SAKUL, THE DIRECTOR OF DIAGNOSTICS.
09:57AM	10	Q. OKAY. ARE YOU FAMILIAR WITH A COMPANY CALLED THERANOS?
09:58AM	11	A. YES.
09:58AM	12	Q. HOW DID YOU BECOME FAMILIAR WITH THERANOS?
09:58AM	13	A. A NEW YORK CITY COLLEAGUE OF MINE IN MOLECULAR MEDICINES
09:58AM	14	ASKED ME TO EXAMINE SOME TECHNOLOGY OF A COMPANY CALLED
09:58AM	15	THERANOS.
09:58AM	16	Q. AND WHO WAS THE COLLEAGUE?
09:58AM	17	A. HIS NAME IS CRAIG LIPSET.
09:58AM	18	Q. AND YOU MENTIONED SOMETHING CALLED MOLECULAR MEDICINE.
09:58AM	19	WHAT IS THAT? CAN YOU DESCRIBE THAT PART AT PFIZER?
09:58AM	20	A. YES. MOLECULAR MEDICINE IS THE LARGER GROUP THAT HOUSED
09:58AM	21	THE UNIT OF DIAGNOSTICS THAT I WAS HIRED INTO. MOLECULAR
09:58AM	22	MEDICINE, IT WAS A 140-PERSON UNIT IN THE RESEARCH UNIT OF
09:58AM	23	PFIZER.
09:58AM	24	Q. AND WHAT DID MR. LIPSET ASK YOU TO DO?
09:58AM	25	A. HE ASKED ME TO REVIEW SOME PACKAGES OF INFORMATION ON THE

09:58AM	1	THERANOS TECHNOLOGY THAT HE HAD RECEIVED.
09:59AM	2	Q. TO WHAT END?
09:59AM	3	A. I WAS ASKED TO ASSESS ITS CAPABILITY, ITS PLAUSIBILITY,
09:59AM	4	HOW IT POTENTIALLY COULD BE UTILIZED, IF THERE WAS A WAY TO
09:59AM	5	UTILIZE THAT AT PFIZER FOR ITS CLINICAL TRIALS.
09:59AM	6	Q. AND WAS THIS PART OF YOUR JOB RESPONSIBILITIES AT PFIZER?
09:59AM	7	A. YES.
09:59AM	8	Q. AND OVER THE COURSE OF TIME, DID YOU DO THIS FOR OTHER
09:59AM	9	TECHNOLOGIES?
09:59AM	10	A. YES.
09:59AM	11	MR. LEACH: YOUR HONOR, MAY I APPROACH THE WITNESS?
09:59AM	12	THE COURT: YES.
09:59AM	13	MR. LEACH: (HANDING.)
09:59AM	14	Q. MR. WEBER, I'VE PLACED BEFORE YOU A BINDER OF DOCUMENTS
09:59AM	15	AND I'D LIKE YOU TO LOOK AT WHAT WE HAVE MARKED FOR
09:59AM	16	IDENTIFICATION PURPOSES AS TRIAL EXHIBIT 143, WHICH SHOULD BE
09:59AM	17	THE FIRST TAB IN YOUR BINDER.
09:59AM	18	A. YES, I SEE THIS.
10:00AM	19	Q. DOES THIS APPEAR TO BE AN EMAIL FROM ELIZABETH HOLMES TO
10:00AM	20	CRAIG LIPSET AND AIDAN POWER DATED OCTOBER 11TH, 2008?
10:00AM	21	A. IT IS.
10:00AM	22	Q. AND DO YOU RECOGNIZE MR. LIPSET'S EMAIL ADDRESS AT PFIZER?
10:00AM	23	A. I DO.
10:00AM	24	Q. AND WHO IS AIDAN POWER?
10:00AM	25	A. AIDAN POWER WAS THE VICE PRESIDENT OF MOLECULAR MEDICINE.

10:00AM	1	Q. SO WAS HE WITHIN MR. LIPSET AND MR. SAKUL'S ORGANIZATION?
10:00AM	2	A. YES. CRAIG LIPSET AND HAKAN SAKUL WERE PART OF THE TEAM
10:00AM	3	THAT REPORTED TO AIDAN POWER.
10:00AM	4	Q. OKAY. AND THE SUBJECT OF THIS EMAIL IS FOLLOW UP TO OUR
10:00AM	5	MEETING.
10:00AM	6	DO YOU SEE THAT?
10:00AM	7	A. YES, I SEE THAT.
10:00AM	8	Q. OKAY. LET ME DRAW YOUR ATTENTION TO PAGE 3.
10:00AM	9	DO YOU SEE AN ATTACHMENT TO THE EMAIL?
10:00AM	10	A. I SEE THE THERANOS ATTACHMENT STUDY REPORT.
10:01AM	11	Q. OKAY. IN THE COURSE OF YOUR WORK IN EVALUATING THERANOS
10:01AM	12	TECHNOLOGY, WERE YOU ASKED TO REVIEW VARIOUS REPORTS PROVIDED
10:01AM	13	BY THERANOS?
10:01AM	14	A. YES.
10:01AM	15	Q. OKAY.
10:01AM	16	YOUR HONOR, THE GOVERNMENT OFFERS EXHIBIT 143.
10:01AM	17	MR. CAZARES: OBJECTION. 801, 104, 403.
10:01AM	18	MR. LEACH: I'M NOT OFFERING THIS FOR THE TRUTH,
10:01AM	19	YOUR HONOR.
10:01AM	20	THE COURT: IS THIS THE ENTIRETY OF THIS? IT LOOKS
10:01AM	21	LIKE MULTIPLE PAGES, MR. LEACH.
10:01AM	22	MR. LEACH: YES, YOUR HONOR, THE ENTIRE EXHIBIT.
10:01AM	23	THE COURT: IT'S 27 PAGES? 29 PAGES?
10:01AM	24	MR. LEACH: YES, YOUR HONOR.
10:01AM	25	THE COURT: AND YOU'RE OFFERING THIS NOT FOR THE

10:01AM	1	TRUTH OF THE MATTER ASSERTED IN THESE DOCUMENTS?
10:01AM	2	MR. LEACH: CORRECT, YOUR HONOR.
10:01AM	3	THE COURT: BUT ONLY AS TO WHAT ISSUE?
10:01AM	4	MR. LEACH: ONLY TO SHOW THE EXCHANGE OF INFORMATION
10:01AM	5	BETWEEN THERANOS AND PFIZER, NOT FOR THE TRUTH OF THE MATTERS
10:02AM	6	IN THE EMAIL OR THE REPORT, BUT SIMPLY WHAT WAS SAID AND WHEN
10:02AM	7	IT WAS SAID TO PFIZER.
10:02AM	8	THE COURT: ALL RIGHT. THANK YOU.
10:02AM	9	LADIES AND GENTLEMEN, THIS WILL BE ADMITTED.
10:02AM	10	AGAIN, THIS IS NOT ADMITTED THIS DOCUMENT, THE PAGES,
10:02AM	11	29 PAGES, WILL BE ADMITTED, BUT NOT FOR THE TRUTH OF THE MATTER
10:02AM	12	ASSERTED IN THE DOCUMENT, THE LETTER, THE REPORT, AND SOME
10:02AM	13	OTHER INFORMATION THAT YOU MAY SEE. IT'S NOT OFFERED FOR THE
10:02AM	14	TRUTH OF ANY OF THAT, BUT RATHER TO SHOW THAT THERE WAS
10:02AM	15	COMMUNICATION BETWEEN THESE TWO PARTIES.
10:02AM	16	IT WILL BE ADMITTED FOR THAT LIMITED PURPOSE.
10:02AM	17	MR. LEACH: THANK YOU, YOUR HONOR.
10:02AM	18	THE COURT: AND IT MAY BE PUBLISHED.
10:02AM	19	(GOVERNMENT'S EXHIBIT 143 WAS RECEIVED IN EVIDENCE.)
10:02AM	20	BY MR. LEACH:
10:02AM	21	Q. MR. WEBER, JUST TO ORIENT EVERYBODY
10:02AM	22	AND, MS. WACHS, IF WE CAN ZOOM IN ON THE TOP PART OF THIS
10:02AM	23	EMAIL?
10:02AM	24	DO YOU SEE MS. HOLMES'S NAME IN THE FROM LINE?
10:02AM	25	A. I DO.

10:02AM	1	Q. AND YOU'RE NOT ON THIS PARTICULAR EMAIL, ARE YOU,
10:03AM	2	MR. WEBER?
10:03AM	3	A. NO, I AM NOT.
10:03AM	4	Q. BUT YOUR COLLEAGUES ARE? MR. POWER AND MR. LIPSET ARE IN
10:03AM	5	THE TO LINE?
10:03AM	6	A. YES.
10:03AM	7	Q. AND DO YOU SEE WHERE IT SAYS THE SUBJECT IS THE FOLLOW UP
10:03AM	8	TO OUR MEETING?
10:03AM	9	A. YES.
10:03AM	10	Q. AND I DRAW YOUR ATTENTION TO THE SECOND PARAGRAPH, OR THE
10:03AM	11	THIRD PARAGRAPH WHERE IT SAYS, "I AM VERY PLEASED TO PRESENT
10:03AM	12	YOU WITH THE FINAL DATA SEE THE ATTACHED STUDY REPORT."
10:03AM	13	DO YOU SEE THAT LANGUAGE?
10:03AM	14	A. I DO.
10:03AM	15	Q. AND NOW IF WE CAN ZOOM OUT, MS. WACHS.
10:03AM	16	AND DO YOU SEE DOWN AT THE BOTTOM THIS IS SIGNED BY IT
10:03AM	17	APPEARS TO BE SIGNED BY MS. HOLMES.
10:03AM	18	A. YES, I SEE THAT.
10:03AM	19	Q. OKAY. LET'S GO TO PAGE 3, PLEASE.
10:03AM	20	DO YOU SEE THE TITLE, "THERANOS ANGIOGENESIS STUDY
10:03AM	21	REPORT"?
10:03AM	22	A. I DO.
10:03AM	23	Q. AND DO YOU SEE THE THERANOS LOGO IN THE TOP LEFT CORNER?
10:04AM	24	A. YES.
10:04AM	25	Q. AND TO THE RIGHT THE HEADING CONFIDENTIAL?

10:04AM	1	A. YES.
10:04AM	2	Q. AND IN THE COURSE OF YOUR WORK, YOU WERE ASKED TO READ
10:04AM	3	MATERIALS AND UNDERSTAND INFORMATION ABOUT THIS ANGIOGENESIS
10:04AM	4	STUDY REPORT BY THERANOS?
10:04AM	5	A. YES.
10:04AM	6	Q. AND THERE'S A DOCUMENT OUTLINE? DO YOU SEE THAT IN THE
10:04AM	7	TOP
10:04AM	8	A. YES, I SEE THE DOCUMENT OUTLINE.
10:04AM	9	Q. AND THERE'S A BULLET, ANGIOGENESIS PROGRAM OVERVIEW. WHAT
10:04AM	10	IS ANGIOGENESIS?
10:04AM	11	A. ANGIOGENESIS IS THE PROCESS IN CANCER, AS A TUMOR GROWS,
10:04AM	12	IT EXTENDS OUT MICRO BLOOD VESSELS IN THE TUMOR TO FEED ITSELF.
10:04AM	13	Q. AND IF WE CAN ZOOM OUT, MS. WACHS.
10:04AM	14	DO YOU SEE IN THE DOCUMENT OUTLINE THERE'S THREE BULLETS
10:04AM	15	FOR CONCLUSIONS?
10:04AM	16	A. YES.
10:04AM	17	Q. OKAY. CONCLUSIONS INCLUDING GENERAL, TECHNICAL, AND
10:05AM	18	ECONOMIC?
10:05AM	19	A. YES, I SEE THAT.
10:05AM	20	Q. LET'S GO TO PAGE 5 OF THE EXHIBIT, MS. WACHS. AND IF WE
10:05AM	21	CAN ZOOM IN ON THE TOP HALF.
10:05AM	22	DO YOU SEE THE HEADING "ANGIOGENESIS PROGRAM OVERVIEW"?
10:05AM	23	A. YES, I SEE THAT.
10:05AM	24	Q. AND IN THE SECOND PARAGRAPH IT SAYS, "FOR THIS PROGRAM,
10:05AM	25	THERANOS WAS ASKED TO DEVELOP MULTIPLEXED POINT-OF-CARE ASSAYS

10:05AM	1	FOR VEGF AND PLGF FOR USE IN MONITORING PATIENT'S
10:05AM	2	PHARMACODYNAMIC RESPONSE TO ANGIOGENESIS THERAPIES."
10:05AM	3	DO YOU SEE THAT?
10:05AM	4	A. I DO.
10:05AM	5	Q. IS THAT CONSISTENT WITH YOUR UNDERSTANDING OF WHAT
10:05AM	6	THERANOS WAS DOING IN CONNECTION WITH PFIZER?
10:05AM	7	A. YES, IT IS AS I REMEMBER IT.
10:05AM	8	Q. OKAY. WHAT IS VEGF?
10:06AM	9	A. VEGF IS A PROTEIN CALLED I'LL GO SLOWER.
10:06AM	10	VEGF IS A PROTEIN MOLECULE. IT'S THE ABBREVIATION FOR
10:06AM	11	VASCULAR EPIDEMIAL GROWTH FACTOR, AND IT'S ONE OF THE GROWTH
10:06AM	12	FACTORS THAT BINDS A RECEPTOR AND STIMULATES A CELL TO
10:06AM	13	INITIATE, OR A GROUP OF CELLS TO INITIATE THE DEVELOPMENT OF AN
10:06AM	14	EXTENSION OF BLOOD VESSELS TO RECRUIT BLOOD INTO A TUMOR.
10:06AM	15	Q. AND PLGF, WHAT IS THAT?
10:06AM	16	A. THAT STANDS FOR PLACENTAL GROWTH FACTOR. IT IS ALSO ONE
10:06AM	17	OF THE GROWTH FACTORS THAT BINDS A RECEPTOR TO STIMULATE THE
10:06AM	18	GROWTH OUTGROWTH OF BLOOD VESSELS TO RECRUIT BLOOD VESSELS
10:06AM	19	TO GROW INTO THE TUMOR TO FEED ITSELF.
10:07AM	20	Q. AND WAS IT YOUR UNDERSTANDING THAT THERANOS WAS DEVELOPING
10:07AM	21	ASSAYS TO MEASURE VEGF AND PLGF?
10:07AM	22	A. YES.
10:07AM	23	Q. IF WE CAN ZOOM OUT, MS. WACHS.
10:07AM	24	FURTHER DOWN THERE ARE SOME GOALS OF STUDY IN ITALICS.
10:07AM	25	DO YOU SEE THAT, MR. WEBER?

10:07AM	1	A. I DO.
10:07AM	2	Q. AND THE FIRST IS "GENERATE PRELIMINARY DATA ON VEGF AND
10:07AM	3	PLGF TRENDS IN CANCER PATIENTS WHILE ASSESSING THE USE OF
10:07AM	4	THERANOS SYSTEM IN THE HANDS OF CLINICIANS AND PATIENTS."
10:07AM	5	DO YOU SEE THAT LANGUAGE?
10:07AM	6	A. I DO.
10:07AM	7	Q. IS THAT CONSISTENT WITH YOUR UNDERSTANDING OF WHAT THE
10:07AM	8	GOAL OF THE STUDY BY THERANOS WAS?
10:07AM	9	A. YES, AS I REMEMBER IT, YES IT IS HERE.
10:07AM	10	Q. OKAY. LET ME DRAW YOUR ATTENTION TO PAGE 5.
10:07AM	11	A. OKAY. YES, I SEE PAGE 5 HERE.
10:07AM	12	Q. I'M SORRY.
10:08AM	13	A. WE WERE ON PAGE 5.
10:08AM	14	Q. THIS IS PAGE 5 OF THE REPORT. IT'S PAGE 7 OF THE TRIAL
10:08AM	15	EXHIBIT.
10:08AM	16	MY APOLOGIES, MS. WACHS.
10:08AM	17	A. OKAY. ALL RIGHT. I SEE PAGE 7 HERE.
10:08AM	18	Q. OKAY. THERE'S AN IMAGE ROUGHLY HALFWAY DOWN THE PAGE.
10:08AM	19	DO YOU RECOGNIZE THAT?
10:08AM	20	A. I RECOGNIZE IT.
10:08AM	21	Q. OKAY. WHAT DID YOU UNDERSTAND IT TO BE?
10:08AM	22	A. I UNDERSTOOD IT TO BE, FROM THIS REPORT, TO BE THE
10:08AM	23	THERANOS ASSAY PLATFORM BOX.
10:08AM	24	Q. AND WAS THAT THE ASSAY PLATFORM BOX THAT PFIZER WAS
10:08AM	25	EVALUATING?

10:08AM	1	A. IT IS AS I UNDERSTOOD IT FROM THIS REPORT.
10:08AM	2	Q. OKAY. LET'S GO TO PAGE 26 OF THE EXHIBIT.
10:08AM	3	DO YOU SEE THERE'S A LISTING OF CONCLUSIONS, GENERAL,
10:08AM	4	TECHNICAL, AND ECONOMIC.
10:08AM	5	DO YOU SEE THOSE?
10:08AM	6	A. I DO.
10:08AM	7	Q. AND THIS IS ATTACHED TO AN EMAIL FROM MS. HOLMES TO
10:09AM	8	MR. LIPSET AND DR. POWER.
10:09AM	9	MY QUESTION TO YOU, MR. WEBER, IS, ARE THESE CONCLUSIONS
10:09AM	10	THAT YOU EVER REACHED IN YOUR REPORT?
10:09AM	11	A. NO, I DID NOT, IN MY ROLE AS A DIAGNOSTIC EXPERT FOR
10:09AM	12	PFIZER, COME TO THESE CONCLUSIONS.
10:09AM	13	Q. THESE WERE BEING HELD OUT TO YOU AS CONCLUSIONS THAT
10:09AM	14	THERANOS HAD REACHED?
10:09AM	15	A. YES.
10:09AM	16	Q. THANK YOU, MR. WEBER.
10:09AM	17	LET ME DRAW YOUR ATTENTION TO WHAT HAS BEEN MARKED AS 159.
10:09AM	18	DO YOU HAVE THAT EXHIBIT?
10:09AM	19	A. I HAVE EXHIBIT 159, PAGE 1, IN FRONT OF ME HERE.
10:10AM	20	Q. DO YOU SEE THERE APPEARS TO BE AN EMAIL FROM YOU TO AN
10:10AM	21	INDIVIDUAL NAMED GARY FRENZEL?
10:10AM	22	A. I DO, YES.
10:10AM	23	Q. AND WHO IS GARY FRENZEL?
10:10AM	24	A. GARY FRENZEL WAS THE ASSAY DEVELOPMENT POINT PERSON AT
10:10AM	25	THERANOS THAT I WAS INTRODUCED TO BY EMAIL.

10:10AM	1	Q. OKAY. AND WHY WERE YOU EMAILING MR. FRENZEL ON OR ABOUT
10:10AM	2	NOVEMBER 10TH, 2008?
10:10AM	3	A. AS CRAIG LIPSET HANDED ME THIS ASSESSMENT PROCESS, HE HAD
10:10AM	4	INTRODUCED ME BY EMAIL TO GARY FRENZEL, AND GARY FRENZEL AND I
10:10AM	5	WERE PICKING UP THE DIRECT INTERACTION TOGETHER.
10:10AM	6	Q. AND WAS THIS PART OF YOUR EFFORT TO EVALUATE THERANOS
10:10AM	7	TECHNOLOGY?
10:10AM	8	A. IT WAS.
10:10AM	9	Q. AND DID YOU SEND THIS EMAIL IN THE ORDINARY COURSE OF
10:10AM	10	PFIZER'S BUSINESS?
10:10AM	11	A. YES.
10:10AM	12	Q. AND WAS IT KEPT IN THE ORDINARY COURSE OF PFIZER'S
10:10AM	13	BUSINESS?
10:10AM	14	A. YES.
10:10AM	15	MR. LEACH: YOUR HONOR, THE GOVERNMENT OFFERS
10:10AM	16	EXHIBIT 159.
10:11AM	17	MR. CAZARES: 802, 104, 403.
10:11AM	18	THE COURT: AND THIS IS THE ENTIRETY OF THIS
10:11AM	19	EXHIBIT? IT LOOKS LIKE IT'S MULTIPLE PAGES?
10:11AM	20	MR. LEACH: YES, YOUR HONOR.
10:11AM	21	THE COURT: THERE'S NO STIPULATION TO THIS I TAKE
10:11AM	22	IT.
10:11AM	23	MR. LEACH: THERE'S A STIPULATION FOR 901, AND
10:11AM	24	OBJECTIONS UNDER 802, 104, AND 403.
10:11AM	25	THE COURT: RIGHT. I'LL ADMIT THIS. IT MAY BE

10:11AM	1	ADMITTED AND IT MAY BE PUBLISHED OVER OBJECTION.
10:11AM	2	(GOVERNMENT'S EXHIBIT 159 WAS RECEIVED IN EVIDENCE.)
10:11AM	3	MR. LEACH: THANK YOU.
10:11AM	4	MS. WACHS, IF WE CAN PLEASE ZOOM IN ON THE BOTTOM PORTION
10:11AM	5	OF THE EMAIL.
10:11AM	6	Q. MR. WEBER, DO YOU SEE YOUR NAME IN THE FROM LINE?
10:11AM	7	A. YES, I DO.
10:11AM	8	Q. AND THE DATE IS NOVEMBER 10TH, 2008?
10:11AM	9	A. IT IS.
10:12AM	10	Q. IS THAT CONSISTENT WITH YOUR MEMORY OF THE TIME PERIOD
10:12AM	11	WHEN YOU WERE REVIEWING THERANOS TECHNOLOGY?
10:12AM	12	A. IT IS AS I REMEMBER IT.
10:12AM	13	Q. OKAY. AND YOU WROTE TO AND I SEE THE SUBJECT OF THIS
10:12AM	14	EMAIL IS FOLLOW UP TO OUR MEETING.
10:12AM	15	DO YOU SEE THAT?
10:12AM	16	A. YES.
10:12AM	17	Q. I'D LIKE TO GO TO PAGE 4, IF WE COULD, OR PAGE 3.
10:12AM	18	DO YOU SEE DOWN AT THE BOTTOM THERE'S AN EMAIL FROM
10:12AM	19	MR. LIPSET TO ELIZABETH HOLMES, YOURSELF, AND GARY FRENZEL?
10:12AM	20	A. I DO.
10:12AM	21	Q. AND NOW IF WE CAN GO TO PAGE 4, MS. WACHS.
10:12AM	22	AT THE TOP IT SAYS, "GARY PLEASE COORDINATE WITH
10:12AM	23	SHANE WEBER WHO LEADS OUR DIAGNOSTICS GROUP HERE IN NY."
10:12AM	24	AND THEN AT THE BOTTOM, "ALL THE BEST, CRAIG."
10:13AM	25	DO YOU SEE THAT?

10:13AM	1	A. I DO.
10:13AM	2	Q. AND IS THAT MR. LIPSET GIVING YOU AND MR. FRENZEL
10:13AM	3	DIRECTION TO COORDINATE ABOUT THIS TECHNOLOGY?
10:13AM	4	A. IT IS.
10:13AM	5	Q. LET'S GO BACK TO PAGE 3.
10:13AM	6	DO YOU SEE IN THE MIDDLE THERE'S AN EMAIL FROM MR. FRENZEL
10:13AM	7	TO THE SAME GROUP WHERE HE WROTE, "HELLO SHANE,
10:13AM	8	"DO YOU THINK YOUR TEAM WILL BE AVAILABLE MONDAY THE
10:13AM	9	10TH?"
10:13AM	10	DO YOU SEE THAT LANGUAGE?
10:13AM	11	A. YES.
10:13AM	12	Q. AND AT SOME POINT DID YOU PARTICIPATE IN A CONFERENCE CALL
10:13AM	13	WITH FOLKS AT THERANOS ABOUT THE TECHNOLOGY?
10:13AM	14	A. I DID.
10:13AM	15	Q. WE'LL GET TO THAT IN A MINUTE, BUT LET'S COMPLETE OUR
10:13AM	16	REVIEW OF THE EMAIL IF WE COULD, GOING BACK TO PAGE 1.
10:13AM	17	IF WE CAN ZOOM IN ON THE BOTTOM HALF OF THE PAGE.
10:13AM	18	YOU WROTE TO MR. FRENZEL ON NOVEMBER 10TH.
10:14AM	19	"THANKS FOR YOUR PROMPT PHONE CALL TO ME ON FRIDAY. YES,
10:14AM	20	THURSDAY," AND HE GOES ON, "WORKS FOR A TELECONF."
10:14AM	21	"I AM SORRY THAT THERE HAVE BEEN MULTIPLE PFIZER POINTS OF
10:14AM	22	CONTACT OVER THE YEARS FOR THERANOS."
10:14AM	23	DO YOU SEE THAT LANGUAGE?
10:14AM	24	A. YES.
10:14AM	25	Q. AND WHAT DID YOU MEAN BY THAT?

10:14AM	1	A. WHAT I MEANT BY THAT IS HAVING WORKED AT LARGE
10:14AM	2	CORPORATIONS, AS WELL AS STARTUP COMPANIES, I'M SYMPATHETIC TO
10:14AM	3	SMALL COMPANIES INTERACTING WITH LARGE COMPANIES WHERE, OVER
10:14AM	4	TIME, THEIR POINTS OF CONTACTS CHANGE AND MOVE.
10:14AM	5	AND SO I'M JUST TRYING TO KIND OF SMOOTH THE WATER HERE
10:14AM	6	AND SAY, YOU KNOW, I'M FRIENDLY AND LET'S PICK UP THE
10:14AM	7	CONVERSATION AND SEE WHERE THIS GOES.
10:14AM	8	Q. YOU THEN WROTE, "I AM INTERESTED MORE BROADLY AS TO WHAT
10:14AM	9	THE INSTRUMENT IS AND PLANNED TO BE AND NOT JUST IN
10:14AM	10	UNDERSTANDING THE PERFORMANCE AND UTILITY OF THE THERANOS
10:14AM	11	SYSTEM IN THE ONCOLOGY STUDY."
10:14AM	12	DO YOU SEE THAT LANGUAGE?
10:14AM	13	A. I DO.
10:14AM	14	Q. FIRST OF ALL, "THE INSTRUMENT," WHAT DID YOU MEAN BY THAT?
10:14AM	15	A. THE INSTRUMENT, WHAT I MEANT BY THAT IS THE ASSAY BOX THAT
10:15AM	16	WAS SEEN IN THE EARLIER POWERPOINT SLIDE DECK OF THE REPORT
10:15AM	17	THAT WAS SENT TO ME BY THURSDAY THAT WE LOOKED AT TODAY.
10:15AM	18	Q. AND THERE'S A REFERENCE TO AN ONCOLOGY STUDY. WHAT DID
10:15AM	19	YOU MEAN BY THAT?
10:15AM	20	A. THE ONCOLOGY STUDY WAS THE STUDY THAT HAD BEEN INITIATED
10:15AM	21	BY PFIZER WITH THERANOS TO LOOK AT THOSE ANGIOGENESIS
10:15AM	22	BIOMARKERS, THE PLGF AND VEGF.
10:15AM	23	Q. AND BY ONCOLOGY STUDY, ARE YOU USING THAT SYNONYMOUSLY
10:15AM	24	WITH THE ANGIOGENESIS STUDY?
10:15AM	25	A. YES, THAT SPECIFIC STUDY.

10:15AM	1	Q. OKAY. YOU THEN WROTE, "I AM RESPONSIBLE FOR PLATFORMS FOR
10:15AM	2	WHICH PFIZER HAS A DIAGNOSTIC INTEREST AND FOR WHICH THERE IS
10:15AM	3	CLINICAL VALIDATION."
10:15AM	4	IS THAT A FAIR SUMMARY OF YOUR RESPONSIBILITIES AT THE
10:15AM	5	TIME?
10:15AM	6	A. IT IS. IT WAS.
10:15AM	7	Q. AND THEN YOU WROTE, "AS WE AGREED IN OUR DISCUSSION, I WAS
10:16AM	8	TO PROVIDE COPIES OF THE DOCUMENTS THAT I AM WORKING OFF OF SO
10:16AM	9	WE ARE ON THE SAME PAGE AND SOME QUESTIONS OF INTEREST TO START
10:16AM	10	OUR CONVERSATION ON THURSDAY."
10:16AM	11	DO YOU SEE THAT?
10:16AM	12	A. I DO.
10:16AM	13	Q. AND WHY WERE YOU AND THE REFERENCE TO THE CONVERSATION
10:16AM	14	ON THURSDAY, IS THAT THE PHONE CALL THAT YOU HAD WITH THE FOLKS
10:16AM	15	FROM THERANOS?
10:16AM	16	A. THAT WOULD BE I'M REFERRING TO THE CONVERSATION THAT
10:16AM	17	WAS GOING TO FOLLOW THIS.
10:16AM	18	Q. OKAY. YOU THEN WROTE, "FOR ME, THE GOAL IS TO UNDERSTAND
10:16AM	19	THE THERANOS SYSTEM."
10:16AM	20	WAS THAT YOUR GOAL IN DECEMBER OF 2008?
10:16AM	21	A. IT WAS.
10:16AM	22	Q. BENEATH YOUR SIGNATURE YOU WROTE, "I HAVE THE THERANOS
10:16AM	23	SUMMARY TO AIDAN POWER, THE INTRODUCTION TO THERANOS SYSTEMS,
10:16AM	24	THE INFORMED CONSENT AND THE IRB SUBMISSION. I HAVE READ THEM.
10:16AM	25	I ATTACH THESE SO WE ARE ALL WORKING OFF THE SAME VERSIONS OF

10:17AM	1	THE DOCUMENTS."
10:17AM	2	DO YOU SEE THAT LANGUAGE?
10:17AM	3	A. I DO.
10:17AM	4	Q. AND WHY WERE YOU ALERTING MR. FRENZEL TO THAT?
10:17AM	5	A. WHAT I FOUND IN THE COURSE OF MY INITIAL INTERACTIONS WITH
10:17AM	6	OUTSIDE COMPANIES, IT'S ACTUALLY GOOD TO CONFIRM THAT WE'RE
10:17AM	7	ACTUALLY TALKING ABOUT THE SAME DOCUMENTS AND THE SAME DATA
10:17AM	8	SETS. IT CREATES EFFICIENCY IN THE FUTURE DISCUSSIONS.
10:17AM	9	Q. AND DID YOU, IN FACT, ATTACH THOSE TO THE EMAIL THAT YOU
10:17AM	10	SENT TO MR. FRENZEL?
10:17AM	11	A. I DID AS I REMEMBER IT.
10:17AM	12	Q. OKAY. LET'S LOOK AT ONE OF THE ATTACHMENTS BEGINNING ON
10:17AM	13	PAGE 5.
10:17AM	14	DO YOU SEE THE HEADING, "THERANOS ANGIOGENESIS STUDY:
10:17AM	15	REPORT PREPARED FOR DR. AIDAN POWER"?
10:17AM	16	A. I DO.
10:17AM	17	Q. AND DOES THIS APPEAR TO BE SIMILAR TO THE REPORT THAT WE
10:17AM	18	REVIEWED IN EXHIBIT 143?
10:18AM	19	A. IT'S A LONG DOCUMENT, BUT AS I SEE IT HERE, IT APPEARS TO
10:18AM	20	BE LIKE THE OTHER DOCUMENT THAT WE LOOKED AT, THE OTHER
10:18AM	21	THERANOS ANGIOGENESIS STUDY DOCUMENT.
10:18AM	22	Q. AND DID YOU REVIEW THE ATTACHMENT TO EXHIBIT 159,
10:18AM	23	BEGINNING AT PAGE 5, WITH SOME CARE AT THE TIME?
10:18AM	24	A. YES, I DID. IT'S AN EXTENSIVE DOCUMENTATION.
10:18AM	25	Q. OKAY. AND WAS THIS PART OF YOUR REVIEW IN EVALUATING

10:18AM	1	THERANOS TECHNOLOGY?
10:18AM	2	A. IT WAS.
10:18AM	3	Q. LET ME DRAW YOUR ATTENTION TO PAGE 12 OF THE DOCUMENT.
10:19AM	4	DO YOU SEE AT THE BOTTOM THERE ARE A NUMBER OF
10:19AM	5	CONCLUSIONS?
10:19AM	6	A. I DO.
10:19AM	7	Q. AND THE FIRST ONE SAYS, "THE THERANOS SYSTEM PERFORMED
10:19AM	8	WITH EQUIVALENT OR SUPERIOR PERFORMANCE TO REFERENCE ASSAYS
10:19AM	9	WHILE RUNNING IN AN EXTREMELY RUGGED AMBULATORY ENVIRONMENT."
10:19AM	10	DO YOU SEE THAT?
10:19AM	11	A. I DO.
10:19AM	12	Q. WAS THAT YOUR CONCLUSION, MR. WEBER?
10:19AM	13	A. NO, IT WAS NOT.
10:19AM	14	Q. DID YOU EVER TELL THERANOS THAT THE THERANOS SYSTEM
10:19AM	15	PERFORMED WITH EQUIVALENT OR SUPERIOR PERFORMANCE?
10:19AM	16	A. NO, I DID NOT.
10:19AM	17	Q. IF WE CONTINUE ON THE ON PAGE 13, THERE'S A CONCLUSION,
10:19AM	18	"INTER-SYSTEM ACCURACY IS EXCELLENT."
10:19AM	19	DO YOU SEE THAT NUMBER 4?
10:19AM	20	A. I DO.
10:19AM	21	Q. AND IS THAT A CONCLUSION THAT YOU EVER REACHED IN THE
10:19AM	22	COURSE OF YOUR REVIEW?
10:19AM	23	A. NO, I DID NOT.
10:19AM	24	Q. IN NUMBER 5 IT SAYS, "VEGF ASSAY ACCURACY IS GOOD FOR SOME
10:20AM	25	CANCER PATIENT SUBJECTS, BUT SINCE THE SYSTEM RESPONDS TO TOTAL

10:20AM	1	VEGF BUT NOT FREE VEGF, WE WERE NOT ABLE TO VERIFY ACCURACY FOR
10:20AM	2	THE TNONC SAMPLES."
10:20AM	3	DO YOU SEE THAT?
10:20AM	4	A. I DO.
10:20AM	5	Q. IS THIS A CONCLUSION THAT YOU EVER REACHED?
10:20AM	6	A. NO, I DID NOT.
10:20AM	7	Q. AND THEN IN NUMBER 6 IT SAYS, "VEGFR2 ASSAY ACCURACY IS
10:20AM	8	QUITE GOOD FOR TNONC VENOUS SAMPLES."
10:20AM	9	DO YOU SEE THAT?
10:20AM	10	A. I DO.
10:20AM	11	Q. IS THAT A CONCLUSION THAT YOU EVER REACHED?
10:20AM	12	A. NO, I DID NOT.
10:20AM	13	Q. AT SOME POINT YOU HAD A PHONE CALL OR BEFORE WE GET TO
10:20AM	14	THE PHONE CALL, LET ME DRAW YOUR ATTENTION TO EXHIBIT 162.
10:21AM	15	MR. WEBER, DOES THIS APPEAR TO BE AN EMAIL FROM YOU TO
10:21AM	16	GARY FRENZEL WITH THE SUBJECT FINAL REPORT?
10:21AM	17	A. IT DOES.
10:21AM	18	Q. AND THE DATE OF THIS EMAIL IS NOVEMBER 13TH, 2008?
10:21AM	19	A. YES.
10:21AM	20	Q. THIS IS DURING THE TIME PERIOD WHERE YOU WERE REVIEWING
10:21AM	21	THERANOS TECHNOLOGY?
10:21AM	22	A. YES.
10:21AM	23	Q. OKAY. AND DO YOU SEE THAT THERE'S AN ATTACHMENT BEGINNING
10:21AM	24	ON PAGE 3?
10:21AM	25	A. YES, I SEE THIS.

10:21AM	1	Q. DOES THIS APPEAR TO BE ANOTHER ITERATION OF A THERANOS
10:21AM	2	ANGIOGENESIS REPORT?
10:21AM	3	A. IT DOES.
10:21AM	4	Q. SITTING HERE TODAY, DO YOU HAVE A MEMORY OF RECEIVING THIS
10:21AM	5	EMAIL?
10:21AM	6	A. NO, SITTING HERE TODAY, I DON'T REMEMBER RECEIVING THIS
10:21AM	7	EMAIL. BUT CLEARLY I'M ON THIS EMAIL, AND IN THE COURSE OF MY
10:21AM	8	NORMAL PRACTICE, I WOULD HAVE LOOKED AT THIS.
10:21AM	9	Q. DO YOU HAVE ANY REASON TO DOUBT THAT YOU LOOKED AT IT?
10:22AM	10	A. NO.
10:22AM	11	Q. AND DURING THE TIME PERIOD, DID YOU TAKE CARE TO REVIEW
10:22AM	12	ANY INFORMATION YOU COULD FIND ABOUT THERANOS DURING THE COURSE
10:22AM	13	OF YOUR REVIEW?
10:22AM	14	A. YES.
10:22AM	15	MR. LEACH: YOUR HONOR, THE GOVERNMENT OFFERS
10:22AM	16	EXHIBIT 162.
10:22AM	17	MR. CAZARES: OBJECTION. 104, 802 AND 403.
10:22AM	18	THE COURT: THE OBJECTION IS OVERRULED. IT'S
10:22AM	19	ADMITTED, AND IT MAY BE PUBLISHED.
10:22AM	20	(GOVERNMENT'S EXHIBIT 162 WAS RECEIVED IN EVIDENCE.)
10:22AM	21	BY MR. LEACH:
10:22AM	22	Q. MR. WEBER, LET ME DRAW YOUR ATTENTION TO THE FIRST EMAIL
10:22AM	23	DOWN THE CHAIN.
10:22AM	24	IT SAYS, "HI SHANE, IT SEEMS THAT YOU DID NOT HAVE THE
10:22AM	25	FINAL REPORT. I HAVE ATTACHED IT AND THE NDA TO THIS EMAIL.

10:22AM	1	ELIZABETH IS WORKING ON SOME OF THE OTHER DOCUMENTS AND WE WILL
10:22AM	2	BE GETTING THEM TO YOU SOON. LOOKING FORWARD TO THE MEETING ON
10:22AM	3	THURSDAY. GARY."
10:23AM	4	DO YOU SEE THAT LANGUAGE?
10:23AM	5	A. YES.
10:23AM	6	Q. AND THIS WAS DURING THE TIME PERIOD THAT YOU WERE
10:23AM	7	EVALUATING THERANOS TECHNOLOGY?
10:23AM	8	A. YES.
10:23AM	9	Q. AND THERE IS A REFERENCE TO AN NDA. WHAT IS AN NDA?
10:23AM	10	A. NDA STANDS FOR NONDISCLOSURE AGREEMENT.
10:23AM	11	Q. OKAY. AND IF WE CAN LOOK BRIEFLY AT PAGE 3.
10:23AM	12	I'M NOT GOING TO GO THROUGH THE ENTIRE DOCUMENT,
10:23AM	13	MR. WEBER, BUT DO YOU SEE THE HEADING "THERANOS ANGIOGENESIS
10:23AM	14	STUDY REPORT"?
10:23AM	14 15	STUDY REPORT"? A. I DO.
10:23AM 10:23AM	15	A. I DO.
10:23AM 10:23AM	15 16	A. I DO. Q. AND DO YOU SEE "PREPARED BY DR. AIDAN POWER, PFIZER INC.?
10:23AM 10:23AM 10:23AM	15 16 17 18	A. I DO. Q. AND DO YOU SEE "PREPARED BY DR. AIDAN POWER, PFIZER INC.? A. I DO.
10:23AM 10:23AM 10:23AM 10:23AM	15 16 17 18	A. I DO. Q. AND DO YOU SEE "PREPARED BY DR. AIDAN POWER, PFIZER INC.? A. I DO. Q. AND THERE'S A LIST OF CONCLUSIONS IN THE DOCUMENT OUTLINE?
10:23AM 10:23AM 10:23AM 10:23AM	15 16 17 18 19	A. I DO. Q. AND DO YOU SEE "PREPARED BY DR. AIDAN POWER, PFIZER INC.? A. I DO. Q. AND THERE'S A LIST OF CONCLUSIONS IN THE DOCUMENT OUTLINE? A. YES, CONCLUSIONS.
10:23AM 10:23AM 10:23AM 10:23AM 10:23AM	15 16 17 18 19 20	A. I DO. Q. AND DO YOU SEE "PREPARED BY DR. AIDAN POWER, PFIZER INC.? A. I DO. Q. AND THERE'S A LIST OF CONCLUSIONS IN THE DOCUMENT OUTLINE? A. YES, CONCLUSIONS. Q. LIKE WE HAVE SEEN IN SOME OF THE OTHER EXHIBITS?
10:23AM 10:23AM 10:23AM 10:23AM 10:23AM 10:23AM	15 16 17 18 19 20 21 22	A. I DO. Q. AND DO YOU SEE "PREPARED BY DR. AIDAN POWER, PFIZER INC.? A. I DO. Q. AND THERE'S A LIST OF CONCLUSIONS IN THE DOCUMENT OUTLINE? A. YES, CONCLUSIONS. Q. LIKE WE HAVE SEEN IN SOME OF THE OTHER EXHIBITS? A. YES.
10:23AM 10:23AM 10:23AM 10:23AM 10:23AM 10:23AM 10:23AM	15 16 17 18 19 20 21 22 23	A. I DO. Q. AND DO YOU SEE "PREPARED BY DR. AIDAN POWER, PFIZER INC.? A. I DO. Q. AND THERE'S A LIST OF CONCLUSIONS IN THE DOCUMENT OUTLINE? A. YES, CONCLUSIONS. Q. LIKE WE HAVE SEEN IN SOME OF THE OTHER EXHIBITS? A. YES. Q. LET ME NOW ASK YOU ABOUT THE PHONE CALL THAT YOU HAD WITH
10:23AM 10:23AM 10:23AM 10:23AM 10:23AM 10:23AM 10:23AM 10:23AM	15 16 17 18 19 20 21 22 23	A. I DO. Q. AND DO YOU SEE "PREPARED BY DR. AIDAN POWER, PFIZER INC.? A. I DO. Q. AND THERE'S A LIST OF CONCLUSIONS IN THE DOCUMENT OUTLINE? A. YES, CONCLUSIONS. Q. LIKE WE HAVE SEEN IN SOME OF THE OTHER EXHIBITS? A. YES. Q. LET ME NOW ASK YOU ABOUT THE PHONE CALL THAT YOU HAD WITH FOLKS FROM THERANOS.

10:23AM	1	Q. OKAY. WERE THERE OTHERS FROM THERANOS ON THE CALL?
10:23AM	2	A. YES, THERE WERE OTHERS.
10:23AM	3	Q. OKAY. WAS MR. BALWANI ON THE CALL?
10:24AM	4	A. I DON'T KNOW.
10:24AM	5	Q. OKAY. HAVE YOU EVER MET MR. BALWANI?
10:24AM	6	A. NOT THAT I KNOW OF.
10:24AM	7	Q. OKAY. DURING THIS PHONE CALL WITH MS. HOLMES, DID YOU ASK
10:24AM	8	HER QUESTIONS ABOUT HER TECHNOLOGY AND WHAT IT COULD DO?
10:24AM	9	A. I DID.
10:24AM	10	Q. AND BRIEFLY DESCRIBE WHAT HAPPENED.
10:24AM	11	A. IN A ONE HOUR CALL WHERE THERE WERE AT LEAST FIVE OR SIX
10:24AM	12	OTHER THERANOS ATTENDEES, ELIZABETH MS. ELIZABETH HOLMES
10:24AM	13	ONLY SPOKE AND NO ONE ELSE IN THE ROOM SPOKE.
10:24AM	14	AND SHE ANSWERED MS. ELIZABETH HOLMES ANSWERED A NUMBER
10:24AM	15	OF QUESTIONS AND MADE A NUMBER OF STATEMENTS TO ME.
10:24AM	16	Q. OKAY. WHAT DID SHE SAY?
10:24AM	17	MR. CAZARES: OBJECTION. HEARSAY.
10:24AM	18	MR. LEACH: I'M NOT OFFERING THESE FOR THE TRUTH,
10:24AM	19	YOUR HONOR. I'M OFFERING THEM FOR THE REPRESENTATIONS DURING
10:24AM	20	THE COURSE OF HIS EVALUATION, BUT NOT FOR THE TRUTH.
10:25AM	21	THE COURT: SO THIS GOES AS TO HIS EVALUATIONS OF
10:25AM	22	THE REPORT THAT HE WAS TASKED TO ACCOMPLISH?
10:25AM	23	MR. LEACH: YES, YOUR HONOR.
10:25AM	24	THE COURT: ALL RIGHT. SO I'LL ADMIT AND ALLOW
10:25AM	25	MR. WEBER, DR. WEBER TO TESTIFY AS TO THIS CONVERSATION. THE

10:25AM	1	WORDS, HOWEVER, ARE NOT FOR THE TRUTH OF THE MATTER ASSERTED,
10:25AM	2	BUT ONLY AS TO INFORM THE DOCTOR AS TO HIS FINAL REPORT.
10:25AM	3	AND YOU CAN ASK THE QUESTION AGAIN.
10:25AM	4	BY MR. LEACH:
10:25AM	5	Q. WHAT DO YOU RECALL MS. HOLMES SAYING ON THE CALL?
10:25AM	6	A. SHE SAID MANY THINGS, YOU KNOW, MANY SWEEPING THINGS THAT
10:25AM	7	I DIDN'T FEEL WERE SUPPORTED BY THE DATA PACKAGES THAT HER AND
10:25AM	8	HER TEAM HAD SENT TO ME.
10:25AM	9	Q. AND DID YOU USE THIS INFORMATION IN THE PHONE CALL IN THE
10:25AM	10	COURSE OF YOUR EVALUATION OF THERANOS'S TECHNOLOGY?
10:25AM	11	A. I DID. THERE WERE, LIKE, SIX BROAD QUESTIONS THAT I KEPT
10:25AM	12	REPEATEDLY ASKING TO INFORM MY ASSESSMENT.
10:26AM	13	Q. OKAY. DID YOU EVER RECEIVE SATISFACTORY ANSWERS?
10:26AM	14	A. NO.
10:26AM	15	Q. AT SOME POINT IN TIME, DID YOU PREPARE A REPORT FOR YOUR
10:26AM	16	COLLEAGUES AT PFIZER WITH RECOMMENDATIONS ABOUT WHAT TO DO
10:26AM	17	VIS-A-VIS THERANOS?
10:26AM	18	A. I DID.
10:26AM	19	Q. LET ME PLEASE DRAW YOUR ATTENTION TO EXHIBIT 167.
10:26AM	20	DO YOU RECOGNIZE THIS DOCUMENT?
10:26AM	21	A. I DO RECOGNIZE THIS DOCUMENT.
10:26AM	22	Q. WHAT IS IT?
10:26AM	23	A. IT'S A SUMMARY REPORT THAT I PREPARED ON THE THERANOS
10:26AM	24	TECHNOLOGY TO SEND TO MY LINE MANAGERS, HAKAN SAKUL,
10:26AM	25	CRAIG LIPSET, AND DR. AIDAN POWER.

10:26AM	1	Q. DID YOU PREPARE THIS IN THE ORDINARY COURSE OF PFIZER'S
10:26AM	2	BUSINESS?
10:26AM	3	A. YES.
10:26AM	4	Q. DID YOU PREPARE IT AT OR FROM INFORMATION PROVIDED TO
10:26AM	5	YOU BY THERANOS AT OR AROUND THE TIME OF THE REPORT?
10:26AM	6	A. YES.
10:26AM	7	Q. WAS THIS MAINTAINED IN THE ORDINARY COURSE OF PFIZER'S
10:27AM	8	BUSINESS?
10:27AM	9	A. YES.
10:27AM	10	Q. AND WAS IT YOUR PRACTICE TO PREPARE REPORTS AND KEEP THEM
10:27AM	11	IN THE COURSE OF YOUR TECHNOLOGY REVIEWS?
10:27AM	12	A. YES.
10:27AM	13	MR. LEACH: YOUR HONOR, THE GOVERNMENT OFFERS
10:27AM	14	EXHIBIT 167.
10:27AM	15	MR. COOPERSMITH: OBJECTION. RELEVANCE. 702 AND
10:27AM	16	403 AS TO CONCLUSIONS, AND PEJORATIVE
10:27AM	17	THE COURT: SAY AGAIN.
10:27AM	18	MR. CAZARES: 403 AS TO CONCLUSIONS AND PEJORATIVE
10:27AM	19	ASSERTIONS IN THE REPORT.
10:27AM	20	(PAUSE IN PROCEEDINGS.)
10:28AM	21	THE COURT: ALL RIGHT. THANK YOU.
10:28AM	22	I WILL ADMIT THIS OVER OBJECTION. IT MAY BE PUBLISHED.
10:28AM	23	THE PROBATIVE VALUE OF THIS OUTWEIGHS ANY UNFAIR
10:28AM	24	PREJUDICE, AND AS TO ANY PEJORATIVE NATURE, IT'S PART OF THE
10:28AM	25	REPORT AND THE OPINION AND THE REVIEW OF THE DOCTOR.

10:28AM	1	AND SO IT'S ADMITTED AND IT MAY BE PUBLISHED.
10:28AM	2	(GOVERNMENT'S EXHIBIT 167 WAS RECEIVED IN EVIDENCE.)
10:28AM	3	MR. LEACH: THANK YOU, YOUR HONOR.
10:29AM	4	MAY I HAVE A MOMENT, YOUR HONOR?
10:29AM	5	THE COURT: YES.
10:29AM	6	(DISCUSSION AMONGST GOVERNMENT COUNSEL OFF THE RECORD.)
10:29AM	7	MR. LEACH: YOUR HONOR, MAY I USE THE ELMO FOR THIS
10:29AM	8	PARTICULAR EXHIBIT?
10:29AM	9	THE COURT: YES.
10:29AM	10	MR. LEACH: AND, MS. ROBINSON, MAY I RETRIEVE YOUR
10:29AM	11	COPY? MINE HAS MARKS THAT I DON'T THINK ARE APPROPRIATE FOR
10:29AM	12	THE JURY.
10:29AM	13	THE CLERK: (HANDING.)
10:29AM	14	MR. LEACH: THANK YOU SO MUCH.
10:29AM	15	Q. MR. WEBER, ARE YOU ABLE TO SEE THAT ON THE SCREEN?
10:29AM	16	A. I AM.
10:29AM	17	Q. OKAY. AND DO YOU SEE THE HEADING "DIAGNOSTICS REVIEW OF
10:29AM	18	THERANOS'S TECHNOLOGY AND FINAL RECOMMENDATIONS"?
10:29AM	19	A. I DO.
10:29AM	20	Q. AND IS THAT THE AND THIS IS SOMETHING THAT YOU
10:29AM	21	AUTHORED?
10:29AM	22	A. YES, I WROTE THIS.
10:29AM	23	Q. OKAY. YOU WROTE IN THE OVERVIEW, "THERANOS SYSTEMS
10:30AM	24	PURPORTS TO HAVE A PATIENT HOME USE IMMUNOASSAY INVITRO
10:30AM	25	DIAGNOSTIC PLATFORM."

10:30AM	1	DO YOU SEE THAT?
10:30AM	2	A. I DO.
10:30AM	3	Q. AND WAS THAT YOUR UNDERSTANDING OF WHAT THERANOS WAS
10:30AM	4	OFFERING AT THE TIME?
10:30AM	5	A. YES, IT WAS.
10:30AM	6	Q. YOU THEN WROTE, "THE PURPOSE OF THIS REVIEW WAS TO CLOSE
10:30AM	7	THE LOOP ON PREVIOUS EFFORTS FOR THERANOS TO LOOK FOR BUSINESS
10:30AM	8	OPPORTUNITIES WITH PFIZER."
10:30AM	9	DO YOU SEE THAT LANGUAGE?
10:30AM	10	A. I DO.
10:30AM	11	Q. "AND TO MAKE FINAL RECOMMENDATIONS REGARDING POTENTIAL
10:30AM	12	FUTURE ATTEMPT FOR THERANOS TO ENGAGE DIFFERENT PARTS OF PFIZER
10:30AM	13	IN THEIR PLATFORM."
10:30AM	14	IS THAT THE SUMMARY OF THE PURPOSE OF YOUR WORK?
10:30AM	15	A. YES.
10:30AM	16	Q. OKAY. YOU THEN HAVE A NUMBER OF RECOMMENDATIONS.
10:30AM	17	DO YOU SEE THAT?
10:30AM	18	A. I DO.
10:30AM	19	Q. YOU WROTE, "THERANOS DOES NOT AT THIS TIME HAVE ANY
10:30AM	20	DIAGNOSTIC OR CLINICAL INTEREST TO PFIZER."
10:30AM	21	DO YOU SEE THAT LANGUAGE IN NUMBER 1?
10:30AM	22	A. I DO.
10:30AM	23	Q. WAS THAT YOUR RECOMMENDATION?
10:30AM	24	A. IT WAS.
10:30AM	25	Q. WHY WAS THAT YOUR RECOMMENDATION?

	1	
10:30AM	1	A. IT WAS MY RECOMMENDATION THAT THEIR RESEARCH USE ONLY
10:31AM	2	CAPABILITY DID NOT HAVE PERFORMANCE CAPABILITY AND IT WAS NOT A
10:31AM	3	DIAGNOSTIC, AND IT WAS NOT ON THE CLINICAL INTEREST PATH FOR
10:31AM	4	THE PFIZER STUDIES IN ONCOLOGY THAT WE WERE SEARCHING FOR
10:31AM	5	DIAGNOSTICS FOR.
10:31AM	6	Q. YOU THEN WROTE, "IT IS RECOMMENDED THAT NO FURTHER
10:31AM	7	FINANCIAL INVESTMENT OR CLINICAL SAMPLE RESOURCES BE EXTENDED
10:31AM	8	TO THERANOS."
10:31AM	9	DO YOU SEE THAT IN PARAGRAPH 2?
10:31AM	10	A. I DO.
10:31AM	11	Q. AND WAS THAT YOUR RECOMMENDATION?
10:31AM	12	A. YES.
10:31AM	13	Q. AND WHY WAS THAT YOUR RECOMMENDATION?
10:31AM	14	A. IT WAS MY RECOMMENDATION BECAUSE IF THERE'S NO CLINICAL
10:31AM	15	INTEREST USE, NO DIAGNOSTIC INTEREST USE, THERE'S NO POINT
10:31AM	16	INVESTING FURTHER RESOURCES INTO A PLATFORM.
10:31AM	17	Q. YOU THEN WROTE IN NUMBER 3, "GOING FORWARD, THERANOS
10:31AM	18	SHOULD BE MONITORED BY MOLECULAR MEDICINE'S DIAGNOSTIC GROUP."
10:31AM	19	DO YOU SEE THAT?
10:31AM	20	A. I DO.
10:31AM	21	Q. AND WHAT IS THE MOLECULAR MEDICINE'S DIAGNOSTIC GROUP?
10:32AM	22	A. THE MOLECULAR MEDICINE DIAGNOSTIC GROUP IS THE GROUP OF
10:32AM	23	THE THREE OF US INSIDE OF MOLECULAR MEDICINE WHO HAD THE
10:32AM	24	AUTHORITY AND RESPONSIBILITY TO ACT ON ALL DIAGNOSTICS FOR
10:32AM	25	PFIZER.

AND WHY WAS IT YOUR RECOMMENDATION THAT THERANOS SHOULD BE 1 Q. 10:32AM MONITORED BY MOLECULAR MEDICINE'S DIAGNOSTIC GROUP GOING 2 10:32AM 3 FORWARD? 10:32AM 4 IN SMALL RESEARCH COMPANIES, AS THEY WORK ON THEIR 10:32AM PLATFORMS, THINGS EVOLVE, THINGS MIGHT CHANGE, SO WE WANT TO 10:32AM 5 KEEP IN TOUCH. 6 10:32AM Q. OKAY. FURTHER BELOW IN YOUR MEMO, THERE'S A HEADING, 10:32AM "REVIEW AND COMMENTS ON THERANOS PROVIDED INFORMATION." 8 10:32AM DO YOU SEE THAT? 9 10:32AM I DO. 10 Α. 10:32AM YOU THEN WROTE, "THE TECHNICAL ASSESSMENT REVIEW PROCESS 10:32AM 11 Q. 10:32AM 12 CONSISTED OF EXAMINING THERANOS CONFIDENTIAL SUMMARY REPORTS, 13 READING THEIR PUBLIC PATENT PUBLICATIONS, HEARING THEIR STORY 10:32AM 14 IN A ONE HOUR TELECONFERENCE WITH QUESTIONS AND ANSWERS, 10:33AM READING THEIR ANSWERS TO A WRITTEN SET OF TECHNICAL DUE 15 10:33AM 16 DILIGENCE QUESTIONS SUBMITTED TO THEM, SURVEYING THE WEB FOR 10:33AM 17 PUBLIC INFORMATION," AND THEN IT CONTINUES. 10:33AM 18 DO YOU SEE THAT? 10:33AM 10:33AM 19 Α. YES. 20 IS THAT A FAIR SUMMARY OF THE INFORMATION THAT YOU 10:33AM 21 REVIEWED? 10:33AM 22 YES. Α. 10:33AM LET'S GO TO PAGE 2 OF YOUR MEMO. 23 Q. 10:33AM 24 DO YOU SEE WHERE YOU WROTE, "THE INTRODUCTION TO THERANOS 10:33AM 25 SYSTEMS SLIDE DECK DOES NOT CONTAIN SUFFICIENT INFORMATION ON 10:33AM

10:33AM	1	THEIR PLATFORM TO DEMONSTRATE INVITRO DIAGNOSTIC ASSAY OR
10:33AM	2	PLATFORM CAPABILITY."
10:33AM	3	DO YOU SEE THAT?
10:33AM	4	A. I DO.
10:33AM	5	Q. WAS THAT YOUR ASSESSMENT AT THE TIME?
10:33AM	6	A. YES.
10:33AM	7	Q. YOU THEN WROTE, "THERANOS HAS PROVIDED A POORLY PREPARED
10:33AM	8	SUMMARY DOCUMENT OF THEIR PLATFORM FOR HOME PATIENT USE WITH
10:33AM	9	THE ANTI-ANTIGENIC THERAPIES."
10:34AM	10	DO YOU SEE THAT?
10:34AM	11	A. I DO.
10:34AM	12	Q. IS THAT A REFERENCE TO THE ANGIOGENESIS STUDY REPORT THAT
10:34AM	13	WE LOOKED AT PREVIOUSLY?
10:34AM	14	A. IT IS. IT WAS.
10:34AM	15	Q. IN THE BULLETS YOU WROTE, "THERANOS SYSTEMS IN THE SLIDE
10:34AM	16	DECK STATES 'HUGE VARIATION BETWEEN SUBJECTS, BOTH ABSOLUTE
10:34AM	17	LEVELS AND CHANGES OVER TIME VARY GREATLY.' NO DISCUSSION OR
10:34AM	18	RIGOROUS GRAPHICAL MULTI-PARAMETER QUANTITATIVE ANALYSIS OF THE
10:34AM	19	PATIENT COHORT WAS DONE."
10:34AM	20	DO YOU SEE THAT?
10:34AM	21	A. I DO.
10:34AM	22	Q. AND WAS THAT DONE?
10:34AM	23	A. IT WAS.
10:34AM	24	Q. AND YOU THEN WROTE, "THERANOS UNCONVINCINGLY ARGUES THE
10:34AM	25	CASE FOR HAVING ACCOMPLISHED TASKS OF INTEREST TO PFIZER."

10:34AM	1	DO YOU SEE THAT?
10:34AM	2	A. I DO.
10:34AM	3	Q. AND WAS THAT A RECOMMENDATION TO YOUR BOSSES AT THE TIME?
10:34AM	4	A. IT WAS.
10:34AM	5	Q. AND WHY WAS THAT?
10:34AM	6	A. THE DATA AND INFORMATION PROVIDED IN THE SUMMARY REPORT
10:35AM	7	DIDN'T SUPPORT THE LARGE CONCLUSIONS THAT THERANOS HAD LISTED
10:35AM	8	IN THEIR REPORT IN MY PROFESSIONAL DIAGNOSTIC OPINION.
10:35AM	9	Q. YOU THEN WROTE IN 3, "THE NINE CONCLUSIONS IN THEIR
10:35AM	10	SUMMARY DOCUMENT ARE NOT BELIEVABLE BASED ON THE INFORMATION
10:35AM	11	PROVIDED."
10:35AM	12	DO YOU SEE THAT?
10:35AM	13	A. I DO.
10:35AM	14	Q. IS THAT IN REFERENCE TO SOME OF THE CONCLUSIONS THAT WE
10:35AM	15	HAVE REVIEWED PREVIOUSLY?
10:35AM	16	A. YES, IT WAS.
10:35AM	17	Q. LET ME DRAW YOUR ATTENTION TO THE THIRD PAGE. DO YOU SEE
10:35AM	18	THE HEADING "DUE DILIGENCE QUESTIONS VERBALLY ASKED TO THERANOS
10:35AM	19	IN THE NOVEMBER 13TH TELECONFERENCE"?
10:35AM	20	A. YES, I DO.
10:35AM	21	Q. AND IS THAT IN REFERENCE TO THE TELEPHONE CALL THAT YOU
10:35AM	22	HAD WITH MS. HOLMES AND OTHERS ON HER TEAM?
10:35AM	23	A. YES.
10:35AM	24	Q. AND WHY WERE YOU INCLUDING THIS INFORMATION IN THE REPORT?
10:36AM	25	A. I WAS INCLUDING THIS INFORMATION IN THE REPORT TO DOCUMENT

10:36AM	1	WHAT INFORMATION WE WERE SEARCHING FOR AND WHAT WE WERE NOT
10:36AM	2	GETTING IN THE INTERACTION.
10:36AM	3	Q. FURTHER BELOW YOU WROTE, "DUE DILIGENCE QUESTIONS SENT
10:36AM	4	NOVEMBER 17TH TO THERANOS AND THEIR NOVEMBER 27TH ANSWERS."
10:36AM	5	DO YOU SEE THAT?
10:36AM	6	A. YES, I DO.
10:36AM	7	Q. OKAY. AND DOES THIS ACCURATELY SUMMARIZE QUESTIONS THAT
10:36AM	8	YOU PUT TO FOLKS AT THERANOS ABOUT THEIR TECHNOLOGY?
10:36AM	9	A. YES. EACH QUESTION IS LISTED AS I SENT IT TO THEM, AND
10:36AM	10	THEN IMMEDIATELY BEHIND IT IS THE RESPONSE THAT I RECEIVED FROM
10:36AM	11	THERANOS.
10:36AM	12	Q. SO USING THE FIRST QUESTION AS AN EXAMPLE, IN THE SUMMARY
10:36AM	13	DOCUMENT YOU REFER TO MEETING WITH THE PFIZER TEAM.
10:36AM	14	WHO WAS THE PFIZER TEAM?
10:36AM	15	DO YOU SEE THAT?
10:36AM	16	A. I DO.
10:36AM	17	Q. AND WAS THAT YOUR QUESTION?
10:36AM	18	A. THAT WAS MY QUESTION.
10:36AM	19	Q. AND THEN IT SAYS ANGELIKI KOSTIANTI.
10:37AM	20	DO YOU SEE THAT?
10:37AM	21	A. YES, I DO.
10:37AM	22	Q. AND WAS THAT THE ANSWER THAT YOU GOT TO THE QUESTION?
10:37AM	23	A. THAT WAS THE ANSWER I GOT RECEIVED FOR THE QUESTION.
10:37AM	24	Q. OKAY. AND THAT ITERATION WOULD HOLD TRUE FOR THE
10:37AM	25	ADDITIONAL NUMBERS IN THIS REPORT?

10:37AM	1	A. YES.
10:37AM	2	Q. AFTER YOU SENT YOUR REPORT TO WELL, WHO DID YOU SEND
10:37AM	3	THIS REPORT TO?
10:37AM	4	A. I SENT THIS REPORT TO CRAIG LIPSET, HAKAN SAKUL, AND
10:37AM	5	AIDAN POWER, THE HEAD OF MOLECULAR MEDICINE.
10:37AM	6	Q. OKAY. DID PFIZER FOLLOW YOUR RECOMMENDATION?
10:37AM	7	A. YES, AS FAR AS I KNOW.
10:37AM	8	Q. OKAY. DID ANYBODY DISAGREE WITH THE CONCLUSIONS IN YOUR
10:37AM	9	REPORT?
10:37AM	10	A. I RECEIVED NO DISAGREEMENT FROM THE THREE PEOPLE I SENT IT
10:37AM	11	TO.
10:37AM	12	Q. LET ME DRAW YOUR ATTENTION, MR. WEBER, TO WHAT HAS BEEN
10:38AM	13	MARKED AS EXHIBIT 174.
10:38AM	14	A. YES, I SEE THIS.
10:38AM	15	Q. OKAY. IS THIS AN EMAIL BETWEEN YOU AND AIDAN POWER, WITH
10:38AM	16	A COPY TO CRAIG LIPSET AND HAKAN SAKUL AT PFIZER?
10:38AM	17	A. IT IS.
10:38AM	18	Q. AND DO YOU SEE THE SUBJECT, THERANOS WRAP UP?
10:38AM	19	A. YES.
10:38AM	20	Q. AND ARE YOU REPORTING ON A CONVERSATION THAT YOU HAD WITH
10:38AM	21	MS. HOLMES IN OR AROUND JANUARY OF 2009?
10:38AM	22	A. YES.
10:38AM	23	Q. OKAY. DID YOU SEND THIS EMAIL IN THE ORDINARY COURSE OF
10:38AM	24	PFIZER'S BUSINESS?
10:38AM	25	A. YES.

10:38AM	1	Q. DID YOU PREPARE IT AT OR FROM INFORMATION AVAILABLE TO YOU
10:38AM	2	AT THE TIME?
10:38AM	3	A. YES.
10:38AM	4	Q. AND WAS IT PFIZER'S PRACTICE TO KEEP AND RETAIN EMAILS
10:38AM	5	LIKE THIS IN THE ORDINARY COURSE OF ITS BUSINESS?
10:39AM	6	A. YES, IT CLEARLY IS.
10:39AM	7	MR. LEACH: OKAY. YOUR HONOR, THE GOVERNMENT OFFERS
10:39AM	8	EXHIBIT 174.
10:39AM	9	MR. CAZARES: OBJECTION. DOUBLE HEARSAY AND 403,
10:39AM	10	PARTICULARLY AS TO PARAGRAPH 2.
10:39AM	11	MR. LEACH: I THINK WE'VE LAID THE FOUNDATION UNDER
10:39AM	12	803(6), YOUR HONOR.
10:39AM	13	THE COURT: YES, IT'S ADMITTED UNDER 803(6). AND IT
10:39AM	14	MAY BE PUBLISHED.
10:39AM	15	MR. LEACH: THANK YOU, YOUR HONOR.
10:39AM	16	(GOVERNMENT'S EXHIBIT 174 WAS RECEIVED IN EVIDENCE.)
10:39AM	17	BY MR. LEACH:
10:39AM	18	Q. MR. WEBER, DO YOU SEE YOUR NAME IN THE FROM LINE?
10:39AM	19	A. YES, I DO.
10:39AM	20	Q. OKAY. AND IF WE CAN ZOOM IN ON THE TOP HALF. THAT'S
10:39AM	21	GREAT, MS. WACHS.
10:39AM	22	AND THIS IS AN EMAIL THAT YOU SENT TO AIDAN POWER WITH A
10:39AM	23	COPY TO MR. LIPSET AND A COPY TO HAKAN SAKUL?
10:40AM	24	A. YES.
10:40AM	25	Q. AND YOU WROTE, "HI AIDAN,

10:40AM	1	"TODAY I SPOKE WITH ELIZABETH HOLMES, CEO"
10:40AM	2	IS THAT WHAT YOU DID?
10:40AM	3	A. YES.
10:40AM	4	Q "CEO THERANOS AND EXPLAINED TO HER THAT PFIZER DID NOT
10:40AM	5	HAVE AT THIS TIME A FORESEEABLE USE FOR THE THERANOS
10:40AM	6	IMMUNOASSAY DEVICE FOR AT PATIENT SELF USE AT HOME BUT SHE AND
10:40AM	7	I AGREED TO STAY IN TOUCH EVERY SIX MONTHS."
10:40AM	8	IS THAT A FAIR SUMMARY OF WHAT YOU CONVEYED TO MS. HOLMES?
10:40AM	9	A. YES.
10:40AM	10	Q. AND WAS MR. BALWANI ON THAT PHONE CALL?
10:40AM	11	A. NOT AS FAR AS I KNOW, AND NOT AS FAR AS I REMEMBER.
10:40AM	12	Q. OKAY. AND YOU THEN WROTE, "I WAS POLITE, CLEAR, CRISP,
10:40AM	13	AND PATIENTLY FIRM AS SHE PUSHED BACK. SHE ASKED FOR OTHER
10:40AM	14	NAMES AT PFIZER TO APPROACH AND I POLITELY DEFLECTED."
10:40AM	15	IS THAT A FAIR SUMMARY OF WHAT HAPPENED?
10:40AM	16	A. YES.
10:40AM	17	Q. "I DID RECEIVE HER CONFIRMATION THAT THERANOS HAD BEEN
10:40AM	18	PAID IN FULL FOR THE PREVIOUS ALLIANCE CONTRACT."
10:40AM	19	DO YOU SEE THAT?
10:40AM	20	A. YES.
10:40AM	21	Q. AND WHAT DID YOU MEAN BY "THE PREVIOUS ALLIANCE CONTRACT"?
10:41AM	22	A. WHAT I MEANT BY THAT WAS THE FUNDING FOR THE STUDY THAT
10:41AM	23	THERANOS AND PFIZER HAD DONE WAS PAID BY A STRATEGIC ALLIANCE
10:41AM	24	FUND POOL AND THAT IT DID NOT COME FROM THE MOLECULAR MEDICINE
10:41AM	25	BUDGET.

AND YOU WROTE IN THE NEXT PARAGRAPH, "I HAD CONFIRMED THIS 1 Q. 10:41AM BEFOREHAND AND THAT IT CAME OUT OF STRATEGIC ALLIANCE BUDGE, 2 10:41AM AND NOT MM BUDGET." 3 10:41AM 10:41AM 4 WHY WAS THAT INFORMATION RELEVANT? WELL, ONCE AGAIN, HAVING WORKED AT SMALL COMPANIES, AS 10:41AM 5 WELL AS LARGE COMPANIES, I'M SYMPATHETIC TO SMALL COMPANIES 6 10:41AM BEING PAID ON A TIMELY BASIS FOR THEIR WORK. 10:41AM BUT I ALSO, IN A LARGE COMPANY WHERE MASSIVE 8 10:41AM REORGANIZATION WAS ONGOING AT THIS TIME AND BUDGET WAS BEING 9 10:41AM RESTRAINED, I WANTED TO BE RESPECTFUL OF MOLECULAR MEDICINE'S 10 10:41AM BUDGET AND AIDAN POWER'S DIRECTION OF THAT. 10:41AM 11 10:42AM 12 AFTER THIS -- TO YOUR KNOWLEDGE, AFTER SENDING THIS EMAIL 13 IN OR AROUND JANUARY 3RD, 2009, PUTTING ASIDE THE ANGIOGENESIS 10:42AM 14 STUDY, TO YOUR KNOWLEDGE, DID PFIZER EVER PAY THERANOS MONEY IN 10:42AM CONNECTION WITH ANY WORK? 15 10:42AM 16 NOT TO MY KNOWLEDGE. Α. 10:42AM 17 TO YOUR KNOWLEDGE, WERE THERE ANY OTHER STUDIES ANALOGOUS, Q. 10:42AM 18 EXCUSE ME, TO THE ANGIOGENESIS STUDY? 10:42AM 10:42AM 19 Α. NOT TO MY KNOWLEDGE. 20 OKAY. LET ME DRAW -- OR IF WE COULD PLEASE, WITH THE 10:42AM Q. 21 COURT'S PERMISSION, DISPLAY WHAT IS IN EVIDENCE AS 10:42AM 22 EXHIBIT 4858. 10:42AM 23 MR. WEBER, DO YOU SEE THE TITLE THERANOS CONFIDENTIAL 10:42AM 24 OVERVIEW? 10:43AM 25 A. UM --10:43AM

10:43AM	1	Q. IT'S NOT IN YOUR BINDER, SIR. IT'S JUST ON THE SCREEN.
10:43AM	2	A. OH, IT'S JUST ON THE SCREEN.
10:43AM	3	MR. CAZARES: YOUR HONOR, I WAS GOING TO RAISE A
10:43AM	4	FOUNDATION ARGUMENT, OR OBJECTION, TO USE OF THIS EXHIBIT WITH
10:43AM	5	THIS WITNESS REGARDING WHERE I HAD BELIEVE MR. LEACH IS GOING.
10:43AM	6	THE COURT: MR. LEACH, ARE YOU GOING TO ASK SOME
10:43AM	7	FOUNDATIONAL QUESTIONS ABOUT THIS?
10:43AM	8	MR. LEACH: YES, YOUR HONOR. I THINK THIS RELATES
10:43AM	9	TO AN EARLIER DISCUSSION WE HAD.
10:43AM	10	THE COURT: YES.
10:43AM	11	MR. LEACH: THIS IS IN EVIDENCE. I INTEND TO ASK
10:43AM	12	HIM HIS KNOWLEDGE ABOUT PARTICULAR PORTIONS OF THIS.
10:43AM	13	MR. CAZARES: AND I WOULD REITERATE THIS MORNING'S
10:43AM	14	OBJECTIONS, YOUR HONOR.
10:43AM	15	THE COURT: NOTED.
10:43AM	16	YOU CAN CONTINUE.
10:43AM	17	MR. LEACH: THANK YOU.
10:43AM	18	LET'S PLEASE GO TO PAGE 104.
10:43AM	19	IF WE CAN ZOOM IN AT THE TOP HALF CAPTURING THE PORTION,
10:43AM	20	CONCLUSIONS.
10:44AM	21	Q. MR. WEBER, DO YOU SEE THE PFIZER LOGO IN THE TOP LEFT
10:44AM	22	CORNER OF THIS?
10:44AM	23	A. I DO.
10:44AM	24	Q. OKAY. AT ANY POINT DID YOU AUTHORIZE THERANOS TO PUT A
10:44AM	25	PFIZER LOGO ON THE ANGIOGENESIS REPORT?

10:44AM	1	A. NO, I DID NOT.
10:44AM	2	MR. CAZARES: OBJECTION.
10:44AM	3	THE COURT: I'M SORRY?
10:44AM	4	MR. CAZARES: OBJECTION.
10:44AM	5	THE COURT: OVERRULED. THE ANSWER WILL REMAIN.
10:44AM	6	THE WITNESS: NO, I DID NOT APPROVE THE USE OF THE
10:44AM	7	PFIZER LOGO ON THIS DOCUMENT.
10:44AM	8	BY MR. LEACH:
10:44AM	9	Q. OKAY. AT ANY POINT DID YOU APPROVE PROVIDING A THERANOS
10:44AM	10	ANGIOGENESIS STUDY REPORT TO THERANOS INVESTORS?
10:44AM	11	MR. CAZARES: OBJECTION.
10:44AM	12	THE COURT: OVERRULED.
10:44AM	13	THE WITNESS: NO, I DID NOT.
10:44AM	14	BY MR. LEACH:
10:44AM	15	Q. OKAY. LET'S GO TO PAGE, ABOUT 20 PAGES FURTHER. A LITTLE
10:44AM	16	MORE, PLEASE. I THINK IT'S PAGE 26 OF THE REPORT. A LITTLE
10:45AM	17	MORE. THERE WE GO.
10:45AM	18	DO YOU SEE THE HEADING CONCLUSIONS?
10:45AM	19	A. I DO.
10:45AM	20	Q. NUMBER 1 SAYS, "THE THERANOS SYSTEM PERFORMED WITH
10:45AM	21	SUPERIOR PERFORMANCE TO REFERENCE ASSAYS WHILE RUNNING A
10:45AM	22	COMPLEX AMBULATORY ENVIRONMENT."
10:45AM	23	DO YOU SEE THAT?
10:45AM	24	A. I DO.
10:45AM	25	Q. WAS THAT A CONCLUSION THAT PFIZER REACHED?

10:45AM	1	A. NO.
10:45AM	2	Q. OKAY. IN FACT, DID YOU REACH THE OPPOSITE CONCLUSION?
10:45AM	3	A. I REACHED THE OPPOSITE CONCLUSION.
10:45AM	4	Q. OKAY. WERE ANY OF THE CONCLUSIONS LISTED HERE IN THIS
10:45AM	5	DOCUMENT CONCLUSIONS THAT PFIZER REACHED?
10:45AM	6	A. NO.
10:45AM	7	Q. OKAY. DID YOU EVER TELL ANYBODY FROM THERANOS THAT IT HAD
10:45AM	8	REACHED THESE CONCLUSIONS, OR THAT PFIZER HAD REACHED THESE
10:46AM	9	CONCLUSIONS?
10:46AM	10	A. NO, I DID NOT.
10:46AM	11	Q. OKAY. THANK YOU, MS. WACHS. WE CAN TAKE THAT DOWN.
10:46AM	12	WE LOOKED EARLIER AT A REPORT THAT YOU PREPARED FOR
10:46AM	13	MR. LIPSET, MR. SAKUL, THE WORK ON YOUR REPORT RELATING TO
10:46AM	14	THERANOS TECHNOLOGY?
10:46AM	15	A. YES.
10:46AM	16	Q. AFTER YOUR REPORT, TO YOUR KNOWLEDGE, DID PFIZER EVER DO
10:46AM	17	ANY WORK WITH THERANOS?
10:46AM	18	A. NOT TO MY KNOWLEDGE.
10:46AM	19	Q. DID PFIZER EVER PAY MONEY TO THERANOS AFTER THAT REPORT?
10:46AM	20	A. NOT THAT I WAS AWARE OF.
10:46AM	21	Q. TO YOUR KNOWLEDGE, DID PFIZER EVER ENTER INTO ANY REVENUE
10:46AM	22	GENERATING ARRANGEMENTS WITH THERANOS?
10:46AM	23	A. NOT THAT I WAS AWARE OF.
10:46AM	24	Q. DID YOU EVER TELL ANYONE AT THERANOS THAT PFIZER VALIDATED
10:46AM	25	THERANOS'S TECHNOLOGY?

10:46AM	1	A. NO, I DID NOT.
10:46AM	2	Q. DO YOU AGREE WITH THE STATEMENT THAT PFIZER VALIDATED
10:46AM	3	THERANOS'S TECHNOLOGY?
10:46AM	4	A. NO, I DO NOT.
10:46AM	5	Q. OKAY. IN FACT, DID YOU COME TO THE OPPOSITE CONCLUSION?
10:46AM	6	A. I CONCLUDED THE OPPOSITE.
10:47AM	7	MR. LEACH: YOUR HONOR, MAY I HAVE A MOMENT?
10:47AM	8	THE COURT: YES.
10:47AM	9	(DISCUSSION AMONGST GOVERNMENT COUNSEL OFF THE RECORD.)
10:47AM	10	MR. LEACH: I HAVE NO FURTHER QUESTIONS.
10:47AM	11	THANK YOU, MR. WEBER.
10:47AM	12	THE COURT: CROSS-EXAMINATION?
10:47AM	13	MR. CAZARES: YES, YOUR HONOR.
		YOUR HONOR, MAY I REMOVE MY MASK?
10:47AM	14	TOUR HONOR, MAI I REMOVE MI MASA:
10:47AM		THE COURT: YES.
	15	
10:47AM	15	THE COURT: YES.
10:47AM 10:48AM	15 16 17	THE COURT: YES. MR. CAZARES: THANK YOU.
10:47AM 10:48AM 10:48AM	15 16 17 18	THE COURT: YES. MR. CAZARES: THANK YOU. CROSS-EXAMINATION
10:47AM 10:48AM 10:48AM 10:48AM	15 16 17 18 19	THE COURT: YES. MR. CAZARES: THANK YOU. CROSS-EXAMINATION BY MR. CAZARES:
10:47AM 10:48AM 10:48AM 10:48AM	15 16 17 18 19 20	THE COURT: YES. MR. CAZARES: THANK YOU. CROSS-EXAMINATION BY MR. CAZARES: Q. GOOD MORNING, MR. WEBER. MY NAME IS STEPHEN CAZARES AND I
10:47AM 10:48AM 10:48AM 10:48AM 10:48AM	15 16 17 18 19 20 21	THE COURT: YES. MR. CAZARES: THANK YOU. CROSS-EXAMINATION BY MR. CAZARES: Q. GOOD MORNING, MR. WEBER. MY NAME IS STEPHEN CAZARES AND I REPRESENT MR. BALWANI. I JUST HAVE A FEW QUESTIONS FOR YOU
10:47AM 10:48AM 10:48AM 10:48AM 10:48AM 10:48AM	15 16 17 18 19 20 21	THE COURT: YES. MR. CAZARES: THANK YOU. CROSS-EXAMINATION BY MR. CAZARES: Q. GOOD MORNING, MR. WEBER. MY NAME IS STEPHEN CAZARES AND I REPRESENT MR. BALWANI. I JUST HAVE A FEW QUESTIONS FOR YOU THIS MORNING. WOULD THAT BE OKAY?
10:47AM 10:48AM 10:48AM 10:48AM 10:48AM 10:48AM 10:48AM	15 16 17 18 19 20 21 22	THE COURT: YES. MR. CAZARES: THANK YOU. CROSS-EXAMINATION BY MR. CAZARES: Q. GOOD MORNING, MR. WEBER. MY NAME IS STEPHEN CAZARES AND I REPRESENT MR. BALWANI. I JUST HAVE A FEW QUESTIONS FOR YOU THIS MORNING. WOULD THAT BE OKAY? A. THAT WOULD BE OKAY.
10:47AM 10:48AM 10:48AM 10:48AM 10:48AM 10:48AM 10:48AM	15 16 17 18 19 20 21 22 23 24	THE COURT: YES. MR. CAZARES: THANK YOU. CROSS-EXAMINATION BY MR. CAZARES: Q. GOOD MORNING, MR. WEBER. MY NAME IS STEPHEN CAZARES AND I REPRESENT MR. BALWANI. I JUST HAVE A FEW QUESTIONS FOR YOU THIS MORNING. WOULD THAT BE OKAY? A. THAT WOULD BE OKAY. GOOD MORNING, STEVE.

10:48AM	1	YOU INDICATED THAT YOU JOINED PFIZER IN MID-2008 OR SO;
10:48AM	2	CORRECT?
10:48AM	3	A. YES.
10:48AM	4	Q. OKAY. AND AT THE TIME THAT YOU JOINED PFIZER, WAS IT
10:48AM	5	ALREADY IN THE PROCESS OF THIS KIND OF REORGANIZATION THAT I
10:48AM	6	THINK YOU DESCRIBED ALREADY?
10:48AM	7	A. IT WAS JUST INITIATING.
10:48AM	8	Q. SO IT WAS JUST STARTING AT THAT POINT?
10:48AM	9	A. YES.
10:48AM	10	Q. SO YOU WERE KIND OF PART OF THIS REORGANIZATION; IS THAT
10:48AM	11	RIGHT?
10:48AM	12	A. YES.
10:48AM	13	Q. OKAY. AND THIS REORGANIZATION DIRECTLY RELATED TO I GUESS
10:48AM	14	SOME OF THE CLINICAL STUDY WORK THAT PFIZER ENGAGED IN ON A
10:49AM	15	KIND OF REGULAR BASIS; CORRECT?
10:49AM	16	A. YES.
10:49AM	17	Q. AND WHEN YOU JOINED THE COMPANY, YOU CAME AS THE DIRECTOR
10:49AM	18	OF DIAGNOSTICS; IS THAT RIGHT?
10:49AM	19	A. I CAME AS THE DIRECTOR OF DIAGNOSTICS TO A DIAGNOSTIC
10:49AM	20	GROUP.
10:49AM	21	Q. OKAY. AND AT THE TIME THAT YOU JOINED, YOU REPORTED TO
10:49AM	22	MR. SAKUL?
10:49AM	23	A. I DID.
10:49AM	24	Q. OKAY. AND JUST SO I'M RIGHT, MR. SAKUL REPORTED TO
10:49AM	25	MR. LIPSET?

10:49AM	1	A. NO. HE REPORTED TO AIDAN POWER. SO HAKAN SAKUL WAS A
10:49AM	2	PEER OF CRAIG LIPSET.
10:49AM	3	Q. GOT IT. GOT IT.
10:49AM	4	NOW, WHEN YOU JOINED PFIZER, AS YOU CAME TO UNDERSTAND THE
10:49AM	5	RELATIONSHIP WITH THERANOS, THE WORK THAT THERANOS DID WITH
10:49AM	6	PFIZER TOOK PLACE A COUPLE OF YEARS BEFORE YOU JOINED; CORRECT?
10:49AM	7	A. YES.
10:49AM	8	Q. AND IN THE PROCESS OF DOING THAT WORK BETWEEN THERANOS AND
10:50AM	9	PFIZER, THERE WERE OTHER PFIZER SCIENTISTS AND DIRECTORS THAT
10:50AM	10	WERE INVOLVED IN THAT WORK; CORRECT?
10:50AM	11	A. YES.
10:50AM	12	Q. AND SO THOSE PERSONS ENGAGED IN CONTRACTS WITH THERANOS,
10:50AM	13	TO RETAIN THERANOS FOR THE PURPOSES OF PERFORMING THIS STUDY;
10:50AM	14	IS THAT CORRECT?
10:50AM	15	A. YES, AS I UNDERSTOOD IT. AS I REMEMBER IT.
10:50AM	16	Q. I'M SORRY TO STEP OVER YOUR WORDS, SIR. I'LL TRY NOT TO
10:50AM	17	DO IT.
10:50AM	18	A. THAT'S FINE.
10:50AM	19	Q. AND THE PURPOSE FOR THE PFIZER'S PERSPECTIVE WAS TO
10:50AM	20	DETERMINE WHETHER THERANOS TECHNOLOGY MIGHT BE USEFUL TO PFIZER
10:50AM	21	GOING FORWARD IN SOME OF ITS CLINICAL STUDY WORK; CORRECT?
10:50AM	22	A. YES, AS I UNDERSTAND IT, YES.
10:50AM	23	Q. AND TO THE EXTENT THAT SOMETHING WAS DISCOVERED DURING THE
10:50AM	24	COURSE OF THAT WORK AND PFIZER DEEMED THERANOS HAVING A
10:50AM	25	TECHNOLOGY THAT WAS USEFUL TO PFIZER, PFIZER MAY HAVE ENGAGED

10:50AM	1	IN FURTHER WORK WITH THERANOS; IS THAT FAIR?
10:50AM	2	A. IN TERMS OF SOMETHING BEING DISCOVERED AS USEFUL, I'M NOT
10:51AM	3	SURE.
10:51AM	4	I DON'T REMEMBER ANYTHING ABOUT THE INTELLECTUAL PROPERTY
10:51AM	5	RIGHTS ARRANGEMENTS THAT WOULD HAVE BEEN SET UP.
10:51AM	6	Q. OKAY. THE POINT OF THE WORK WITH THERANOS, FROM PFIZER'S
10:51AM	7	PERSPECTIVE, WAS TO DETERMINE WHETHER THERANOS TECHNOLOGY MIGHT
10:51AM	8	BE USEFUL TO PFIZER GOING FORWARD; CORRECT?
10:51AM	9	A. YES, AS I UNDERSTAND THE STUDY DESIGN FROM MY MEMORY.
10:51AM	10	Q. AND IS THAT A, IS THAT A KIND OF CORPORATE RELATIONSHIP,
10:51AM	11	BUSINESS RELATIONSHIP THAT PFIZER WOULD HAVE ENGAGED WITH AT
10:51AM	12	THAT TIME ON A REGULAR BASIS, MEANING PFIZER, A LARGE
10:51AM	13	INTERNATIONAL PHARMACEUTICAL COMPANY, I THINK YOU MENTIONED
10:51AM	14	IT'S NOT UNCOMMON FOR SMALLER DIAGNOSTIC COMPANIES WHO ARE
10:51AM	15	DEVELOPING NEW TECHNOLOGY TO ENGAGE WITH COMPANIES LIKE PFIZER
10:52AM	16	TO TRY AND GENERATE BUSINESS AND TRY TO FIND OUT IF THEY CAN
10:52AM	17	WORK TOGETHER?
10:52AM	18	A. YES, I THINK THAT WOULD BE A FAIR SUMMARY.
10:52AM	19	Q. AND I THINK YOU DESCRIBED HAVING SOME SYMPATHY FOR THESE
10:52AM	20	SMALLER PLAYERS IN THEIR WORK WITH A LARGE COMPANY, YOU KNOW,
10:52AM	21	ONE, TO GET THE WORK, AND TWO, TO GET PAID; RIGHT?
10:52AM	22	A. AND TO KEEP THE CONTACTS GOING. YOU KNOW, I WAS, YOU
10:52AM	23	KNOW, THE FIRST EMPLOYEE OF A SMALL COMPANY AT ONE TIME, A
10:52AM	24	STARTUP.
10:52AM	25	Q. FAIR ENOUGH.

10:52AM	1	AND SO YOU LEARNED ABOUT THIS RELATIONSHIP WITH THERANOS
10:52AM	2	FROM MR. LIPSET; IS THAT RIGHT?
10:52AM	3	A. YES.
10:52AM	4	Q. OKAY. AND I GUESS MR. LIPSET'S REQUEST WAS THAT YOU
10:52AM	5	REVIEW SOME OF MATERIALS, ENGAGE IN DISCUSSION WITH THERANOS TO
10:52AM	6	COME TO SOME SORT OF A DETERMINATION AS TO WHETHER THERE WAS A
10:52AM	7	BUSINESS USE FOR PFIZER TO CONTINUE THIS RELATIONSHIP WITH
10:52AM	8	THERANOS; CORRECT?
10:52AM	9	A. YES, AS I UNDERSTAND IT, YES.
10:52AM	10	Q. OKAY. AND THEN I THINK YOU DESCRIBED THAT JUST A COUPLE
10:53AM	11	OF MINUTES AGO, THIS KIND OF REORGANIZATION AT PFIZER INCLUDED
10:53AM	12	SOME BUDGETARY CONSTRAINTS AS WELL; CORRECT?
10:53AM	13	A. YES. IT WAS JUST THE BEGINNING.
10:53AM	14	Q. UNDERSTOOD. AND BUDGETARY CONSTRAINTS IN A LARGE
10:53AM	15	CORPORATION CAN INFLUENCE BUSINESS DECISIONS, WHETHER TO ENGAGE
10:53AM	16	WITH COUNTER-PARTIES BECAUSE, YOU KNOW, MONEY MAY NOT BE AS
10:53AM	17	AVAILABLE AS IT WAS AT OTHER TIMES; CORRECT?
10:53AM	18	A. CORRECT.
10:53AM	19	Q. AND THIS TIME PERIOD THAT WE'LL RECALL, 2008 LEADING INTO
10:53AM	20	2009, THIS WAS KIND OF A ROCKY TIME IN CORPORATE AMERICA.
10:53AM	21	DO YOU RECALL THAT?
10:53AM	22	A. I DO.
10:53AM	23	Q. AND THIS IS
10:53AM	24	A. THE CONTAINED DEPRESSION.
10:53AM	25	Q. YES. AND LIKE MANY IN CORPORATE AMERICA, PFIZER WAS

10:53AM	1	FEELING A LITTLE PRESSURE AS A RESULT OF THE FINANCIAL CRISIS
10:53AM	2	AS WELL; CORRECT?
10:53AM	3	A. CORRECT.
10:53AM	4	Q. AND BECAUSE OF THAT, THESE BUDGETARY ISSUES WERE IMPORTANT
10:54AM	5	TO PFIZER; CORRECT?
10:54AM	6	MR. LEACH: OBJECTION. SPECULATION.
10:54AM	7	THE COURT: WITHIN YOUR PERSONAL KNOWLEDGE, YOU CAN
10:54AM	8	ANSWER THAT QUESTION, SIR.
10:54AM	9	THE WITNESS: IN TERMS OF A TECHNOLOGY ASSESSMENT
10:54AM	10	LIKE THIS, I WAS NOT PRIVY TO ANY FINANCIAL DOCUMENTATION OF
10:54AM	11	WHAT WAS BEING PAID AND SO FORTH.
10:54AM	12	SO ACTUALLY FOR MY ASSESSMENT, FINANCES, MONEY WAS NOT A
10:54AM	13	RELEVANT INPUT.
10:54AM	14	IT WAS WHETHER THE TECHNOLOGY WORKED AND WHETHER THE
10:54AM	15	TECHNOLOGY COULD BE UTILIZED, CONVERTED TO AN APPROVED
10:54AM	16	DIAGNOSTIC, AND THEN COULD IT ACTUALLY PLAY A ROLE IN ANY
10:54AM	17	CLINICAL TRIAL THAT WE NEEDED THAT KIND OF HELP.
10:54AM	18	SO THE MONETARY ISSUE IS MOOT FOR ME.
10:54AM	19	BY MR. CAZARES:
10:54AM	20	Q. FAIR ENOUGH.
10:54AM	21	BUT AT THAT TIME I THINK YOU'VE DESCRIBED PFIZER'S NEED
10:55AM	22	WAS RELATING TO MOLECULAR NUCLEIC TESTING? IS THAT
10:55AM	23	A. YES.
10:55AM	24	Q. AND THAT'S A PARTICULAR CATEGORY OF TESTING; CORRECT?
10:55AM	25	A. YES.

1	Q. NUCLEIC ACID AMPLIFICATION, IS THAT THE CORRECT
2	DESCRIPTION?
3	A. THERE'S A MULTITUDE OF PLATFORM TECHNOLOGIES, POLYMERASE
4	CHAIN REACTION, SMALL NUCLEOTIDE POLYMORPHISM SO POLYMERASE
5	CHAIN REACTION, ALSO KNOWN AS PCR, AND THEN SMALL NUCLEOTIDE
6	POLYMORPHISMS, ALSO KNOWN AS SNP'S, SO THESE ARE SEVERAL
7	DIFFERENT WAYS TO MEASURE GENETIC VARIATION AND THEN DETERMINE
8	IF IT'S CORRELATED WITH A CLINICAL OUTCOME.
9	Q. AND SO THAT'S REALLY THE SCIENCE WITH RESPECT TO THIS KIND
10	OF TESTING THAT PFIZER WAS INTERESTED IN AT THE TIME?
11	A. YES.
12	Q. OKAY. AND AS YOU MENTIONED ALREADY, THAT WASN'T THE TYPE
13	OF TESTING THAT THE THERANOS DEVICE WAS PERFORMING AT THE TIME;
14	CORRECT?
15	A. YES. AS I MENTIONED, AT THE TIME THAT WAS NOT THE IT'S
16	AN IMMUNOASSAY AT HOME PLATFORM, BUT THAT'S WHY I HAD ASKED THE
17	BROADER QUESTION OF, WHERE ARE YOU GOING?
18	Q. BECAUSE THAT WAS ALWAYS OF INTEREST IF ULTIMATELY THE
19	TECHNOLOGY WAS CAPABLE OF PERFORMING THIS NUCLEIC ACID
20	AMPLIFICATION TESTING; CORRECT?
21	A. BROADLY SO, YES.
22	Q. AND THERANOS WERE ABLE TO ACHIEVE THAT, THERE MAY HAVE
23	BEEN A REASON FOR PFIZER TO BE INTERESTED IN THERANOS?
24	A. IT WOULD HAVE AT LEAST STARTED THE CONVERSATION OF, DO YOU
25	HAVE A TECHNOLOGY THAT WORKS? IS IT ACCURATE? IS IT PRECISE?
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

10:56AM	1	AND MANY OF THESE TECHNOLOGIES HAVE SIGNIFICANT
10:56AM	2	INTELLECTUAL PROPERTY LANDSCAPES AROUND THEM, AND SO THERANOS
10:56AM	3	WOULD ACTUALLY HAVE HAD TO ACCESS ALL OF THAT AS WELL.
10:56AM	4	Q. NOW, IN THE COURSE OF DOING THIS EVALUATION, YOU'VE
10:57AM	5	DESCRIBED USING SOME MATERIALS, AND I THINK ONE WAS THE
10:57AM	6	ANGIOGENESIS REPORT OR REPORTS; CORRECT?
10:57AM	7	A. YES.
10:57AM	8	Q. AND THE OTHER WAS WAS IT KIND OF LIKE A PRESENTATION OR
10:57AM	9	A POWERPOINT TYPE OF DECK?
10:57AM	10	A. AS I REMEMBER IT, THERE WAS THIS LARGE, ONGOING VOLUMINOUS
10:57AM	11	REPORT AND SLIDE DECK.
10:57AM	12	Q. OKAY.
10:57AM	13	A. MAYBE 100 PAGES.
10:57AM	14	Q. AND THAT WAS PROVIDED BY PERSONS AT THERANOS AT THE TIME?
10:57AM	15	A. YES, AFTER CRAIG HAD INTRODUCED ME TO THEM.
10:57AM	16	Q. OKAY. AND THE PERSONS YOU WERE INTRODUCED OH, GO
10:57AM	17	AHEAD.
10:57AM	18	A. YEAH, THAT WAS THE REPORT THAT WAS SENT TO ME INITIALLY BY
10:57AM	19	CRAIG AS I REMEMBER IT.
10:57AM	20	Q. SO YOU LOOKED AT THE ANGIOGENESIS REPORT, THIS
10:57AM	21	PRESENTATION DECK I'LL CALL IT.
10:57AM	22	ANY OTHER DOCUMENTATION?
10:57AM	23	A. IRB, WHICH IS THE INSTITUTIONAL REVIEW BOARD DOCUMENT THAT
10:58AM	24	ALLOWS AN INSTITUTE, ALLOWS AN ENTITY TO TAKE PATIENTS INTO A
10:58AM	25	STUDY.

10:58AM	1	AND THEN THERE WAS THE CLINICAL STUDY PROTOCOL AT THE TIME
10:58AM	2	THAT HAD BEEN WRITTEN BEFORE I ARRIVED.
10:58AM	3	Q. AND YOU ALSO SPOKE TO MR. FRENZEL?
10:58AM	4	A. I DID, YES.
10:58AM	5	Q. AND THEN YOU HAD THIS CONFERENCE CALL, I THINK YOU
10:58AM	6	DESCRIBED IT AS BEING ALMOST AN HOUR
10:58AM	7	A. YES.
10:58AM	8	Q WITH PERSONS AT THERANOS, AS WELL AS MS. HOLMES?
10:58AM	9	A. YES.
10:58AM	10	Q. OKAY. BUT YOU AGREE, I THINK YOU'VE CONCEDED, YOU'VE
10:58AM	11	NEVER SPOKEN TO MR. BALWANI; CORRECT?
10:58AM	12	A. AS FAR AS I KNOW, NO, I HAVE NOT SPOKEN WITH MR. BALWANI.
10:58AM	13	Q. NOW, IN ALL OF THE WORK THAT THERANOS PERFORMED WITH
10:58AM	14	PFIZER, THIS STUDY, THE ANGIOGENESIS STUDY I'LL CALL IT, AGAIN,
10:59AM	15	THAT WAS PERFORMED BEFORE YOU JOINED PFIZER; CORRECT?
10:59AM	16	A. YES.
10:59AM	17	Q. AND IT INVOLVED OTHERS AT PFIZER, NOT YOURSELF?
10:59AM	18	A. YES.
10:59AM	19	Q. OKAY. AND AS YOU MENTIONED, YOU CONFIRMED IN YOUR
10:59AM	20	CONVERSATION WITH MS. HOLMES WHEN YOU WERE LETTING HER KNOW
10:59AM	21	THAT PFIZER HAD NO FURTHER KIND OF BUSINESS NEED TO WORK WITH
10:59AM	22	THERANOS, THAT YOU CONFIRMED THAT THERANOS WAS PAID FOR ITS
10:59AM	23	PRIOR WORK; CORRECT?
10:59AM	24	A. YES, I CONFIRMED THAT, AS I REMEMBER IT, TO HER, AND THEN
10:59AM	25	ALSO TO AIDAN POWER AND HIS TEAM.

BECAUSE LIKE YOU SAID, YOU WERE SYMPATHETIC TO SMALL 1 Q. 10:59AM COMPANIES. YOU WANTED TO MAKE SURE THAT THEY GOT PAID FOR THE 2 10:59AM WORK THAT THEY DID, AT LEAST UP UNTIL THAT TIME? 3 10:59AM 4 Α. YES. 10:59AM AND ULTIMATELY YOU LEARNED THAT THE AMOUNT OF MONEY 10:59AM Q. OKAY. THAT PFIZER PAID TO THERANOS WAS \$900,000; CORRECT? 6 11:00AM I LEARNED THAT LATER FROM THE INTERACTION WITH THE FEDERAL 11:00AM GOVERNMENT HERE. 8 11:00AM BUT AT SOME POINT IN TIME YOU DID CONFIRM THAT? 9 Q. 11:00AM I DIDN'T CONFIRM THE DOLLAR AMOUNT, BUT I CONFIRMED THAT 10 11:00AM Α. 11:00AM 11 IT HAD BEEN PAID. 12 AIDAN POWER AND THE MOLECULAR MEDICINE GROUP, BECAUSE IT'S 11:00AM 11:00AM 13 SUCH A LARGE ORGANIZATION, 140 PEOPLE, WE HAVE AN EXTENSIVE 14 MULTIMILLION DOLLAR BUDGET. WE HAD AN IN-HOUSE, OR 11:00AM IN-DEPARTMENT PROJECT MANAGER WHO KEPT TRACK OF ALL OF OUR 15 11:00AM FUNDING AND STUDIES SO THAT WE DIDN'T GET CROSS BILLED BY OTHER 16 11:00AM 17 PARTS OF THE COMPANY ACCIDENTALLY, WHICH CAN HAPPEN. 11:00AM 18 I DON'T REMEMBER HER NAME, BUT SHE CONFIRMED, YEP, IT'S 11:00AM 11:00AM 19 ALL TAKEN CARE OF, IT'S NOT ON OUR BUDGET, IT CAME FROM THAT 20 POOL OF MONEY. 11:01AM 21 BUT I NEVER KNEW THE DOLLAR AMOUNT INVOLVED. 11:01AM 22 VERY GOOD. 11:01AM Ο. NOW, YOUR ULTIMATE CONCLUSION, THOUGH, WAS THAT AT THE 23 11:01AM 24 TIME WHEN YOU WROTE THE REPORT, YOU DIDN'T BELIEVE THAT THERE 11:01AM 25 WAS ANY FURTHER KIND OF REASON FOR PFIZER TO ENGAGE WITH 11:01AM

THERANOS BASED ON THE CURRENT, THEN-CURRENT STATUS OF ITS 1 11:01AM TECHNOLOGY; CORRECT? 2 11:01AM I DID BASED ON MY DIAGNOSTIC EXPERTISE. 3 11:01AM Α. 4 BUT I ALSO SPOKE WITH MY PEERS IN MOLECULAR MEDICINE, THE 11:01AM SO-CALLED TAMMLS WHO ARE OUR MOLECULAR MEDICINE PEOPLE WHO SIT 11:01AM 6 ON EACH OF THE CLINICAL TEAMS WORLDWIDE FOR EVERY DISEASE AREA 11:01AM AND WHO ARE INJECTING TECHNOLOGY INTO THE CLINICAL TRIALS AND 11:01AM WOULD BE AWARE OF WHAT THE CLINICAL TRIAL NEEDS WERE, NOT ONLY 8 11:01AM 9 EXISTING, BUT GOING FORWARD, AND THERE WAS NO INTEREST IN THE 11:01AM ONCOLOGY TAMMLS FOR THIS TYPE OF APPROACH. 10 11:01AM 11:02AM 11 Q. FOR IMMUNOASSAYS? 12 Α. FOR IMMUNOASSAYS. 11:02AM 13 0. BUT AS YOU MENTIONED THIS MORNING, IN YOUR DISCUSSION WITH 11:02AM 14 MS. HOLMES, YOU LEFT OPEN THE POSSIBILITY OF MAINTAINING 11:02AM COMMUNICATIONS IN THE EVENT THAT THERANOS FURTHER DEVELOPED ITS 15 11:02AM 16 TECHNOLOGY TO A POINT WHERE IT MIGHT BE USEFUL TO PFIZER; 11:02AM 17 CORRECT? 11:02AM YES. I LEFT OPEN THAT DOOR, BUT IT WAS A TWO-WAY DOOR. 18 11:02AM 11:02AM 19 MS. ELIZABETH HOLMES COULD REACH OUT TO ME AT SIX MONTH INTERVALS, OR IF THINGS CHANGED I COULD REACH OUT TO HER AT SIX 11:02AM 20 21 MONTH INTERVALS. 11:02AM 22 NOW, THE SUMMARY THAT YOU WROTE AT EXHIBIT 167 THAT WAS 11:02AM DISCUSSED THIS MORNING -- WE DON'T NEED TO PUT IT UP ON THE 23 11:02AM 24 SCREEN -- THAT WAS SOMETHING PUT TOGETHER BY YOURSELF; CORRECT? 11:02AM 25 YES. 11:02AM Α.

11:02AM	1	Q. OKAY. BASED ON THE INPUTS THAT WE HAVE ALREADY DESCRIBED,
11:03AM	2	YOUR REVIEW OF THE REPORT, THIS PRESENTATION DECK,
11:03AM	3	CONVERSATIONS WITH THERANOS PERSONNEL, AND THEN YOUR OWN KIND
11:03AM	4	OF REVIEW AND ANALYSIS?
11:03AM	5	A. AND MY, YOU KNOW, OBTAINING PUBLIC INFORMATION, YOU KNOW,
11:03AM	6	NOT ONLY ON THE INTERNET, BUT ISSUED PATENTS OR PATENT
11:03AM	7	APPLICATIONS BY THERANOS.
11:03AM	8	Q. AND THERE WERE PUBLICLY PUBLISHED PATENTS THAT THERANOS
11:03AM	9	HAD AT THE TIME; CORRECT?
11:03AM	10	A. THERE WAS ONE AT THE TIME, AND I DOCUMENTED THAT IN MY
11:03AM	11	REPORT.
11:03AM	12	Q. OKAY. NOW, AND YOU TESTIFIED THAT THE REPORT WAS SHARED
11:03AM	13	WITH MR. SAKUL, MR. LIPSET, AND MR. POWER; CORRECT?
11:03AM	14	A. YES.
11:03AM	15	Q. AND THE REPORT, THE SUMMARY WHERE YOU ESSENTIALLY STATE
11:03AM	16	OUT YOUR OPINIONS REGARDING THERANOS AND ITS USEFULNESS TO
11:03AM	17	PFIZER, WAS NOT SHARED WITH MS. HOLMES?
11:03AM	18	A. NO, IT WAS NOT SHARED WITH MS. HOLMES.
11:03AM	19	Q. IT WAS NOT SHARED WITH ANYONE ELSE AT THERANOS; CORRECT?
11:03AM	20	A. NO, IT WAS NOT.
11:04AM	21	Q. AND IT WAS NOT SHARED WITH MR. BALWANI; CORRECT?
11:04AM	22	A. NO, IT WAS NOT.
11:04AM	23	WELL, I HAD NEVER KNOWN MR. BALWANI AS FAR AS I'M AWARE
11:04AM	24	OF, AND FOR MY INTERACTIONS I DON'T REMEMBER SEEING HIS NAME.
11:04AM	25	SO AS FAR AS I KNOW IT WAS NOT SHARED WITH HIM. I

CERTAINLY DIDN'T. 1 11:04AM FAIR ENOUGH. 2 Q. 11:04AM AND IN THAT PHONE CALL THAT YOU HAD WITH MS. HOLMES THAT 3 11:04AM 4 IS REPORTED BY YOURSELF TO YOUR COLLEAGUES, IN THAT PHONE CALL, 11:04AM YOU DIDN'T READ OR SUMMARIZE THE REPORT THAT YOU WROTE FOR YOUR 11:04AM SUPERVISORS TO MS. HOLMES; CORRECT? 11:04AM NO, I DID NOT, BECAUSE THE REPORT ACTUALLY DIDN'T EXIST 11:04AM 8 YET. 11:04AM SO IS IT CORRECT THEN THAT YOU ADVISED MS. HOLMES THAT 9 Ο. 11:04AM PFIZER HAD NO KIND OF CURRENT NEED OR USE FOR THERANOS 10 11:04AM TECHNOLOGY PRIOR TO YOUR DRAFTING UP THE REPORT; CORRECT? 11:04AM 11 12 PRIOR TO DRAFTING THE REPORT, I DID NOT COMMUNICATE ANY 11:05AM 13 LACK OF INTEREST BY PFIZER TO MS. ELIZABETH HOLMES BECAUSE I 11:05AM 14 WOULD NOT HAVE MADE THAT CONCLUSION UNTIL I GATHERED ALL OF THE 11:05AM INFORMATION, INCLUDING THE ONE HOUR INTERACTION WITH HER. 15 11:05AM 16 YOU KNOW, UNTIL I HAVE ALL OF MY INTAKE, I HAVE A VERY 11:05AM 17 OPEN MIND ON THESE MATTERS. 11:05AM 18 I GUESS I MISUNDERSTOOD YOUR TESTIMONY. 11:05AM 11:05AM 19 SO YOU COMPLETED YOUR REPORT FIRST, AND THEN YOU SPOKE TO MS. HOLMES ON THE PHONE; CORRECT? 11:05AM 20 21 NO. I SPOKE TO MS. HOLMES FIRST IN THAT HOUR, AND THEN 11:05AM 22 AFTER I RECEIVED -- I SPOKE WITH HER IN THAT ONE HOUR; THEN 11:05AM LATER I RECEIVED, AS I REMEMBER IT THEN, THE ANSWERS TO THE 23 11:05AM WRITTEN QUESTIONS THAT I HAD SENT DURING THE ONE HOUR THAT I 24 11:05AM 25 PROBED FOR THE ANSWERS FOR THE SIX QUESTIONS THAT I LISTED IN 11:05AM

11:05AM	1	MY REPORT.
11:05AM	2	AND THEN AFTER REVIEWING ALL INFORMATION THAT I HAD
11:06AM	3	GATHERED OVER A PERIOD OF A COUPLE OF WEEKS AFTER THAT ONE
11:06AM	4	HOUR, THEN TOWARDS THE END OF DECEMBER THEN I WOULD HAVE
11:06AM	5	DRAFTED THAT REPORT ONCE I HAD ALL INPUT.
11:06AM	6	Q. AND THEN LATER I GUESS I'M NOT STATING MY QUESTION VERY
11:06AM	7	CLEARLY.
11:06AM	8	THEN IN JANUARY OF 2009 YOU HAD THIS ULTIMATE CONVERSATION
11:06AM	9	WITH MS. HOLMES WHERE YOU ADVISED HER THAT PFIZER HAD NO NEED
11:06AM	10	FOR THERANOS'S TECHNOLOGY AT THAT TIME; CORRECT?
11:06AM	11	A. YES, AS I UNDERSTOOD YES.
11:06AM	12	Q. AND IN THAT CONVERSATION, THAT LAST CONVERSATION WITH
11:06AM	13	MS. HOLMES
11:06AM	14	A. UH-HUH.
11:06AM	15	Q YOU DID NOT READ OR RECITE THE CONCLUSIONS FROM YOUR
11:06AM	16	REPORT TO MS. HOLMES; CORRECT?
11:06AM	17	A. NO, I DID NOT.
11:06AM	18	Q. NOW, ONE OF YOUR I GUESS YOUR ULTIMATE CONCLUSION, I
11:06AM	19	GUESS AT THE TIME YOU DIDN'T BELIEVE THAT PFIZER HAD ANY NEED
11:06AM	20	FOR THERANOS'S TECHNOLOGY AS OF THAT MOMENT IN LATE 2008, EARLY
11:07AM	21	2009.
11:07AM	22	WERE YOU AWARE OF SUBSEQUENT CONTACTS, COMMUNICATIONS BY
11:07AM	23	YOUR SUPERVISORS, MR. SAKUL, MR. LIPSET, WITH MS. HOLMES AND
11:07AM	24	THERANOS SUBSEQUENT TO YOUR RECOMMENDATION?
11:07AM	25	A. SUBSEQUENT? NO, I'M NOT AWARE OF ANY CONTACTS.

11:07AM	1	Q. WOULD YOU HAVE EXPECTED TO BE NOTIFIED OF ANY CONTACTS?
11:07AM	2	A. OFTEN, BUT NOT ALWAYS.
11:07AM	3	IN AN ASSESSMENT LIKE THIS, OFTEN I WOULD BE INFORMED.
11:07AM	4	BUT IF THERE'S ALSO, YOU KNOW, A NEED TO KNOW BASIS OF
11:07AM	5	DOING BUSINESS INTERACTIONS, AT TIMES I MIGHT HAVE BEEN
11:07AM	6	BLINDED. BUT I WAS NOT SURPRISED THAT I WAS NOT CONTACTED
11:07AM	7	FURTHER.
11:07AM	8	THIS WAS MY FINAL SUMMARY RECOMMENDATION THAT BECAME THE
11:07AM	9	PFIZER POSITION AT THAT POINT, AND
11:08AM	10	Q. FAIR ENOUGH.
11:08AM	11	YOUR HONOR, MAY I HAVE A MOMENT TO GET SOME BINDERS?
11:08AM	12	THE COURT: YES.
11:08AM	13	MR. CAZARES: (HANDING.)
11:08AM	14	Q. MR. WEBER, I'VE JUST HANDED YOU A BINDER WITH SOME
11:08AM	15	DOCUMENTS IN THERE.
11:08AM	16	I WOULD ASK YOU TO TURN TO THE TAB THAT IS MARKED 10561.
11:08AM	17	A. 10561?
11:08AM	18	Q. YES.
11:08AM	19	A. OKAY. YES, I SEE 10561.
11:09AM	20	Q. AND 10561 APPEARS TO BE AN EMAIL CHAIN, THE LATTER OF
11:09AM	21	WHICH LOOKS LIKE IT'S FEBRUARY 21, 2009.
11:09AM	22	DO YOU SEE THAT?
11:09AM	23	A. YES.
11:09AM	24	Q. NOW, THAT ONE DOESN'T INVOLVE YOURSELF, BUT BELOW THAT
11:09AM	25	THERE'S AN EXCHANGE OF EMAILS BETWEEN YOURSELF AND MR. FRENZEL.

11:09AM	1	DO YOU SEE THAT?
11:09AM	2	A. I DO.
11:09AM	3	Q. AND IT RELATES TO MR. FRENZEL REACHING OUT TO YOU ABOUT I
11:09AM	4	GUESS AN OPPORTUNITY FROM THERANOS'S PERSPECTIVE.
11:09AM	5	DO YOU SEE THAT?
11:09AM	6	A. YES, I DO.
11:09AM	7	MR. CAZARES: YOUR HONOR, MOVE TO ADMIT
11:09AM	8	EXHIBIT 10561.
11:09AM	9	MR. LEACH: NO OBJECTION, YOUR HONOR.
11:09AM	10	THE COURT: IT'S ADMITTED. IT MAY BE PUBLISHED.
11:09AM	11	(DEFENDANT'S EXHIBIT 10561 WAS RECEIVED IN EVIDENCE.)
11:09AM	12	BY MR. CAZARES:
11:09AM	13	Q. AND IF YOU FOCUS ON THE LOWER PORTION OF THE MESSAGE, AT
11:09AM	14	LEAST AT THIS TIME YOU'LL SEE THE MESSAGE FROM MR. FRENZEL TO
11:10AM	15	YOURSELF DATED FEBRUARY 20TH.
11:10AM	16	DO YOU SEE THAT?
11:10AM	17	A. I DO.
11:10AM	18	Q. AND THE SUBJECT SAYS FERTILITY ASSAYS.
11:10AM	19	DO YOU SEE THAT?
11:10AM	20	A. I DO.
11:10AM	21	Q. AND IN THE MESSAGE MR. FRENZEL WRITES, "HELLO SHANE,
11:10AM	22	"WE ARE IN THE PROCESS OF RELEASING OUR FERTILITY PANELS
11:10AM	23	AND RECALLED OUR DISCUSSION ON PRE-ECLAMPSIA. ARE YOU STILL
11:10AM	24	INTERESTED IN PURSUING THIS? IF YOU HAVE ANY FURTHER THOUGHTS
11:10AM	25	AND WOULD LIKE TO DISCUSS, PLEASE LET ME KNOW. THANKS, GARY."

11:10AM	1	DO YOU SEE THAT?
11:10AM	2	A. I DO.
11:10AM	3	Q. AND I APOLOGIZE. LET ME SLOW DOWN.
11:10AM	4	MR. FRENZEL IS REACHING OUT TO YOU TO INQUIRE ABOUT
11:10AM	5	WHETHER OR NOT THERE'S ANY INTEREST IN PFIZER; CORRECT?
11:10AM	6	A. I.
11:10AM	7	Q. AND THEN YOU RESPOND "HI GARY,
11:10AM	8	"THANKS FOR CONTACTING ME.
11:10AM	9	"PFIZER HAS NO INTEREST IN PREECLAMPSIA.
11:10AM	10	"BEST OF LUCK, YOU ARE ON TO SOMETHING GOOD."
11:11AM	11	DO YOU SEE THAT?
11:11AM	12	A. YES.
11:11AM	13	Q. AND YOU WERE SINCERE IN THAT?
11:11AM	14	A. I DO. I WAS.
11:11AM	15	Q. AND I'M NOT QUESTIONING THAT. I'M JUST CONFIRMING.
11:11AM	16	THE, I GUESS, VISION FOR THERANOS'S TECHNOLOGY, A SMALL
11:11AM	17	DEVICE, THE IN VITRO DEVICE THAT COULD TEST BLOOD SAMPLES IN A
11:11AM	18	REMOTE LOCATION, WHETHER IT'S A HOME, WHETHER IT'S A DOCTOR'S
11:11AM	19	OFFICE, A PHYSICIAN'S OFFICE, A CLINIC, MAYBE EVEN A, YOU KNOW,
11:11AM	20	A PHARMACY, THAT COULD HAVE SOME USE IN KIND OF CLINICAL
11:11AM	21	STUDIES IF THE TECHNOLOGY ACTUALLY WORKED; CORRECT?
11:11AM	22	A. IT COULD.
11:11AM	23	Q. OKAY. AND TECHNOLOGY LIKE THAT THAT COULD BE USED
11:11AM	24	REMOTELY COULD HAVE SOME ADVANTAGES IN CLINICAL STUDIES AND
11:11AM	25	RECRUITING PATIENTS FOR CLINICAL STUDIES TO MAKE THE PROCESS

KIND OF EASIER FOR THEM? 1 11:11AM A. FOR THIS PARTICULAR DISEASE OF PREECLAMPSIA. 2 11:11AM I AM A WORLDWIDE EXPERT IN DIAGNOSTICS FOR PREECLAMPSIA, 3 11:11AM 4 AND HERE I'M SIGNALLING THAT THEY HAD AN OPPORTUNITY, BUT NOT 11:12AM 11:12AM WITH PFIZER. WHEN I WAS WITH ORTHO CLINICAL DIAGNOSTICS, I WAS INVOLVED 11:12AM IN THE IDENTIFICATION OF THE KEY BREAKING BIOMARKER ANALYTES 11:12AM FOR PREECLAMPSIA, WHICH ARE PLGF, VEGF AND SFLIP1 AND WAS 8 11:12AM INVOLVED IN THE LICENSING AND THE TECHNOLOGY ASSESSMENT FOR 9 11:12AM 10 THAT, AND AT THIS TIME I WAS UNDER A CONFIDENTIALITY WITH 11:12AM JOHNSON & JOHNSON, SO I COULD NOT SPEAK FURTHER ON POINTING 11:12AM 11 12 THEM TO WHERE THE WATER WAS. 11:12AM 13 BUT THIS HAD NO INTEREST AND NO CLINICAL UTILITY FOR 11:12AM 14 PFIZER, BUT THERE COULD HAVE BEEN AN OPPORTUNITY, BUT I WAS NOT 11:12AM ALLOWED -- MY HANDS WERE BOUND. I COULD NOT TELL THEM WHO TO 15 11:12AM 16 TALK TO. 11:13AM 17 BUT IF THEY WERE WORKING IN FERTILITY, THEY KNEW WHO THEY 11:13AM 18 SHOULD BE TALKING TO. 11:13AM 19 Q. UNDERSTOOD. 11:13AM SO YOU WERE AWARE OF WHERE THE UTILITY MIGHT RESIDE, BUT 11:13AM 20 21 IT WASN'T WITH PFIZER? 11:13AM 22 YES. Α. 11:13AM Q. AND AGAIN, MR. FRENZEL WASN'T PROVIDED WITH A COPY OF THE 23 11:13AM 24 REPORT THAT YOU SHARED WITH YOUR COLLEAGUES WITHIN PFIZER WHERE 11:13AM YOU REACHED YOUR CONCLUSIONS ABOUT THE IMMUNOASSAY DEVICE THAT 25 11:13AM

PFIZER WAS INTRODUCED TO BACK IN 2006 AND 2007; CORRECT? 1 11:13AM NO, I DID NOT COMMUNICATE MY DUE DILIGENCE REPORT TO GARY. 2 11:13AM Α. WITHIN THAT BINDER, IF YOU COULD TAKE A LOOK AT 15041? 3 Q. 11:13AM 4 Α. OKAY. 15041. YES, I SEE THIS. 11:14AM MAYBE YOU COULD TAKE A LOOK AT THE MESSAGES FOR A MOMENT 11:14AM TO FAMILIARIZE YOURSELF WITH THE CHAIN. 11:14AM OKAY. I'VE SCANNED THIS. Α. 11:14AM AND OBVIOUSLY YOU'RE FAMILIAR WITH MR. LIPSET, AND YOU'VE 8 Q. 11:14AM 9 ALREADY DESCRIBED HIM? 11:14AM 10 YES. 11:14AM Α. 11:14AM 11 Q. HE WAS BY HIS NEW YORK OFFICE; CORRECT? 11:14AM 12 Α. YES. 13 Q. AND ROOP UNNIKRISHNAN, DID I SAY THAT RIGHT? DO YOU KNOW 11:14AM 14 WHO THAT IS? 11:14AM NO, I DON'T. I'M NOT ON THESE EMAILS, SO I'M NOT AWARE OF 15 11:14AM ANY OF THIS. 16 11:14AM 17 OKAY. WERE YOU AWARE OF THE FACT, JUST TO CONFIRM, IN Q. 11:14AM 18 AUGUST OF 2009, MR. LIPSET PUTTING PERSONS WITHIN PFIZER IN 11:15AM 11:15AM 19 CONNECTION WITH SETH MICHELSON AT THERANOS RELATING TO SOME 20 STUDY WORK? 11:15AM 21 NO, I WAS NOT AWARE OF THIS. 11:15AM Α. 22 NOW, MR. LIPSET, JUST TO CONFIRM, IS A PARALLEL OF 0. 11:15AM MR. SAKUL? 23 11:15AM 24 YES. Α. 11:15AM SO THEY'RE LIKE ON THE SAME CORPORATE LEVEL? 25 Q. 11:15AM

11:15AM	1	A. YES.
11:15AM	2	Q. OKAY. AND I DON'T SAY THIS IN ANY WAY TO INSULT YOU, BUT
11:15AM	3	MR. LIPSET WASN'T REQUIRED TO GET YOUR PERMISSION IN ORDER TO
11:15AM	4	REACH OUT TO COUNTER-PARTIES ABOUT POTENTIAL BUSINESS
11:15AM	5	OPPORTUNITIES.
11:15AM	6	WOULD THAT BE FAIR?
11:15AM	7	A. YES, THAT WOULD BE FAIR.
11:15AM	8	Q. OKAY. IF YOU COULD STAY WITHIN THAT SAME BINDER, I
11:16AM	9	APOLOGIZE, TAKE A LOOK AT THE TAB THAT IS MARKED 4018.
11:16AM	10	ACTUALLY, 4018, YOUR HONOR, I BELIEVE IS ALREADY IN
11:16AM	11	EVIDENCE.
11:16AM	12	THE COURT: IT IS, AND IT MAY BE PUBLISHED.
11:16AM	13	THE WITNESS: 4018.
11:16AM	14	BY MR. CAZARES:
11:16AM	15	Q. 4018. IT WILL ALSO BE UP ON THE SCREEN.
11:16AM	16	A. OH, OKAY.
11:16AM	17	Q. SO YOU SEE 4018 IS A SHORT I'LL CALL IT AN OUTLOOK
11:16AM	18	INVITE FOR AN APPOINTMENT DATED OCTOBER 23TH, 2013.
11:17AM	19	DO YOU SEE THAT AT THE TOP?
11:17AM	20	A. I DO, YES.
11:17AM	21	Q. AND THE SUBJECT LINE SAYS THERANOS SITE VISIT.
11:17AM	22	DO YOU SEE THAT?
11:17AM	23	A. YES, I SEE THAT.
11:17AM	24	Q. AND THEN FOR THE APPOINTMENT THAT IS BEING SCHEDULED, IT'S
11:17AM	25	INDICATED IT AS OCTOBER 28TH, 2013.

11:17AM	1	DO YOU SEE THAT?
11:17AM	2	A. YES, I DO.
11:17AM	3	Q. AND THE MESSAGE IS TO, ON THE TO LIST IS MORTEN SOGAARD.
11:17AM	4	DO YOU SEE THAT?
11:17AM	5	A. I DO.
11:17AM	6	Q. AND WHO IS MR. SOGAARD?
11:17AM	7	A. I DON'T REMEMBER AT THIS TIME. HE WAS SOME NEW VICE
11:17AM	8	PRESIDENT THAT HAD COME INTO NEW YORK CITY' PFIZER OFFICE, BUT
11:17AM	9	I DON'T REMEMBER. THE NAME IS VAGUELY FAMILIAR.
11:17AM	10	Q. AND WHAT ABOUT GREGORY NAEVE OR NAEVE?
11:17AM	11	A. I HAVE NO IDEA WHO THIS IS.
11:18AM	12	Q. AND CRAIG LIPSET WE'VE SPOKEN ABOUT IN NEW YORK.
11:18AM	13	AND THEN CHRISTIAN HOLMES, HAD YOU EVER SPOKEN TO
11:18AM	14	CHRISTIAN HOLMES?
11:18AM	15	A. NOT THAT I'M AWARE OF.
11:18AM	16	Q. AND THEN THERE'S A LEONA GARRIOTT.
11:18AM	17	DO YOU SEE THAT?
11:18AM	18	A. YES, I SEE THAT.
11:18AM	19	Q. AND HAVE YOU EVER SPOKEN WITH GARRIOTT?
11:18AM	20	A. NOT THAT I'M AWARE OF.
11:18AM	21	Q. AND THEN FURTHER DOWN IN THE APPOINTMENT MESSAGE, IT SAYS
11:18AM	22	"PLEASE CONTACT HAKAN IF YOU NEED FURTHER ASSISTANCE. HIS
11:18AM	23	CELL," AND THEN THERE'S A PHONE NUMBER.
11:18AM	24	AND THEN FOR THERANOS REPRESENTATIVES, IT'S
11:18AM	25	ELIZABETH HOLMES, CHRISTIAN HOLMES, AND DAN EDLIN.

11:18AM	1	DO YOU SEE THAT?
11:18AM	2	A. I DO.
11:18AM	3	Q. AND THEN THE PFIZER PERSON, MR. SAKUL, WHO WE JUST TALKED
11:18AM	4	ABOUT; THIS MORTEN SOGAARD WHO YOU JUST MENTIONED SOME
11:18AM	5	FAMILIARITY WITH; AND THEN GREGORY NAEVE.
11:18AM	6	DO YOU SEE THAT?
11:18AM	7	A. I DO.
11:18AM	8	Q. AND THEN CRAIG LIPSET WAS GOING TO PARTICIPATE BY
11:18AM	9	TELEPHONE CALL.
11:18AM	10	DO YOU SEE THAT?
11:18AM	11	A. I SEE THAT.
11:18AM	12	Q. WERE YOU AWARE OF THIS KIND OF MEETING BETWEEN THERANOS
11:19AM	13	AND PFIZER IN 2013?
11:19AM	14	A. NO, I WAS NOT.
11:19AM	15	Q. BUT YOU WERE STILL AT PFIZER AT THE TIME; RIGHT?
11:19AM	16	A. YES.
11:19AM	17	Q. AND SO MR. SAKUL AND MR. LIPSET, IT APPEARS, HAVE
11:19AM	18	REENGAGED WITH THERANOS, AT LEAST TO TALK, IN LATE 2013, BUT
11:19AM	19	DIDN'T APPEAR NOT TO HAVE INCLUDED YOU IN THOSE
11:19AM	20	CONVERSATIONS; CORRECT?
11:19AM	21	A. I'M NOT INCLUDED IN THE CONVERSATION. BUT I ACTUALLY
11:19AM	22	DON'T KNOW IF THEY ENGAGED WITH THERANOS, IF THERANOS ENGAGED
11:19AM	23	WITH THEM.
11:19AM	24	THE PURPOSE OF MY REPORT WAS TO CLOSE OFF THESE REPEATED
11:19AM	25	DISTRACTIVE BUSINESS INEFFICIENCIES.

11:19AM	1	Q. AND THAT WAS INQUIRIES BY SMALL COMPANIES TO PFIZER. WAS
11:19AM	2	THAT THE GIST, SIR?
11:19AM	3	A. NO, IT'S NOT BY SMALL COMPANIES. IT WAS REPEATED,
11:19AM	4	REPEATED CONTACTS LOOKING FOR A DOOR THAT IS WILLING TO PAY
11:19AM	5	MONEY.
11:19AM	6	Q. YOU CAN TAKE THAT DOWN.
11:20AM	7	I THINK THIS IS ALREADY IN EVIDENCE. THIS IS 20546.
11:20AM	8	MAY I PUBLISH, YOUR HONOR?
11:20AM	9	THE COURT: YES.
11:20AM	10	BY MR. CAZARES:
11:20AM	11	Q. YOU'LL SEE IT UP ON THE SCREEN, MR. WEBER, AN EMAIL CHAIN,
11:20AM	12	THE LATTER AT THE TOP WHICH IS NOVEMBER 25TH, 2013. THAT'S NOT
11:20AM	13	A MESSAGE THAT ANYONE FROM PFIZER IS ON.
11:20AM	14	YOU SEE THE SUBJECT LINE IS PFIZER/THERANOS DISCUSSIONS.
11:20AM	15	BUT IF WE MAYBE FOCUS AT THE START OF THE CHAIN IN THE
11:20AM	16	LOWER PORTION.
11:21AM	17	DO YOU SEE THERE'S A MESSAGE FROM CHRISTIAN HOLMES TO
11:21AM	18	MORTEN SOGAARD, COPYING MR. SAKUL AND MS. HOLMES?
11:21AM	19	DO YOU SEE THAT?
11:21AM	20	A. I DO.
11:21AM	21	Q. AND IN THE MESSAGE FROM MR. HOLMES TO MR. SOGAARD, HE
11:21AM	22	WRITES, "MORTEN,
11:21AM	23	"THANK YOU FOR THIS NOTE. WE CERTAINLY REMAIN VERY
11:21AM	24	INTERESTED IN MOVING FORWARD WITH OUR WORK TOGETHER.
11:21AM	25	"I SENT SOME PROPOSED EDITS ON THE PFIZER CDA BACK TO TINA

11:21AM	1	EARLY IN THE WEEK OF NOVEMBER 11TH, AND I JUST RESENT THAT NOTE
11:21AM	2	(ATTACHED) TO ENSURE IT DIDN'T GET HELD UP FOR SOME REASON."
11:21AM	3	DO YOU SEE THAT?
11:21AM	4	A. I DO.
11:21AM	5	Q. AND YOU UNDERSTOOD THAT A CDA REFERS TO A CONFIDENTIALITY
11:21AM	6	AGREEMENT; CORRECT?
11:21AM	7	A. YES, CONFIDENTIALITY, CDA, NDA.
11:21AM	8	Q. COMMONLY USED?
11:21AM	9	A. COMMONLY USED.
11:21AM	10	Q. AND THE REFERENCE IS TO A PFIZER CDA.
11:21AM	11	DO YOU SEE THAT?
11:21AM	12	A. YES, I SEE THAT.
11:21AM	13	Q. OKAY. AND THEN THE MESSAGE IS, "I CHECKED THROUGH MY
11:22AM	14	INBOX AGAIN AND HAVE NOT SEEN A RESPONSE. IN PARALLEL TO
11:22AM	15	EXECUTING THIS CDA, PERHAPS WE CAN LOOK TO SCHEDULE A
11:22AM	16	DISCUSSION REGARDING NEXT STEPS AND OUTLINING A PROCESS TO MOVE
11:22AM	17	FORWARD."
11:22AM	18	DO YOU SEE THAT?
11:22AM	19	A. I DO.
11:22AM	20	Q. AND AGAIN, AT THE TIME IN NOVEMBER OF 2013, WERE YOU AWARE
11:22AM	21	THAT PFIZER WAS ENGAGING WITH THERANOS TO ENTER INTO A
11:22AM	22	CONFIDENTIALITY AGREEMENT TO FACILITATE FURTHER DISCUSSIONS?
11:22AM	23	A. NO, I WAS NOT.
11:22AM	24	Q. AND IF WE CAN MOVE UP IN THE MESSAGE CHAIN.
11:22AM	25	IT APPEARS MR. SOGAARD RESPONDED TO MR. HOLMES, COPYING

11:22AM	1	MR. SAKUL AND MS. HOLMES.
11:22AM	2	"CHRISTIAN,
11:22AM	3	"MY SINCERE APOLOGIES. I SHOULD HAVE CHECKED ON OUR SIDE
11:22AM	4	FIRST. I WILL FOLLOW UP TO MOVE THINGS ALONG ON OUR SIDE.
11:22AM	5	"PLEASE TAKE MY EMAIL AS AN EXPRESSION OF INTEREST AND
11:22AM	6	EXCITEMENT WITH YOUR TECHNOLOGY AND ASPIRATIONS THAT WE CAN
11:22AM	7	MOVE FORWARD WITH DISCUSSIONS AND HOPEFULLY A PARTNERSHIP."
11:22AM	8	DO YOU SEE THAT?
11:22AM	9	A. I DO.
11:22AM	10	Q. OKAY. IN THE COURSE OF YOUR EVALUATION OF THERANOS
11:23AM	11	TECHNOLOGY AND ITS USEFULNESS TO PFIZER, YOU DIDN'T ACTUALLY
11:23AM	12	RECEIVE OR EXAMINE THERANOS TESTING TECHNOLOGY IN PERSON;
11:23AM	13	CORRECT?
11:23AM	14	A. I DID NOT PHYSICALLY TOUCH A TESTING BOX, BUT IT'S
11:23AM	15	ACTUALLY ONLY THE DATA SET THAT I NEED TO SEE.
11:23AM	16	Q. OKAY. AND YOU NEVER ACTUALLY AND I GUESS BY THAT YOU
11:24AM	17	MEAN YOU NEVER ACTUALLY USED THE DEVICE; CORRECT?
11:24AM	18	A. NO, I HAVE NOT.
11:24AM	19	Q. BUT YOU ARE AWARE OF THE FACT THAT THE UNDERLYING CLINICAL
11:24AM	20	STUDIES AND DATA THAT YOU EVALUATED, THERANOS'S DEVICE WAS
11:24AM	21	ACTUALLY PLACED IN CLINICAL PATIENTS' HOMES TO DO THE TESTING;
11:24AM	22	CORRECT?
11:24AM	23	A. THAT IS MY UNDERSTANDING FROM THE STUDY REPORTS SENT TO
11:24AM	24	ME.
11:24AM	25	Q. AND YOU HAVE NO REASON TO DISBELIEVE THAT THAT ACTUALLY

11:24AM	1	TOOK PLACE; CORRECT?
11:24AM	2	A. NO, I DO NOT.
11:24AM	3	Q. OKAY.
11:24AM	4	YOUR HONOR, MAY I HAVE A MOMENT?
11:24AM	5	THE COURT: YES.
11:24AM	6	(DISCUSSION AMONGST DEFENSE COUNSEL OFF THE RECORD.)
11:26AM	7	MR. CAZARES: I APOLOGIZE, YOUR HONOR. I WILL BE
11:26AM	8	DONE VERY SOON.
11:26AM	9	THE COURT: OF COURSE.
11:26AM	10	(PAUSE IN PROCEEDINGS.)
11:26AM	11	MR. CAZARES: I APOLOGIZE, YOUR HONOR.
11:26AM	12	THE COURT: WE CAN STAND UP AND STRETCH FOR A
11:26AM	13	MOMENT, FOLKS.
11:26AM	14	YOU AS WELL, YES.
11:26AM	15	(STRETCHING.)
11:27AM	16	MR. CAZARES: THANK YOU, YOUR HONOR.
11:27AM	17	Q. MR. WEBER, IF YOU COULD TAKE A LOOK WITHIN THE BINDER THAT
11:27AM	18	YOU HAVE, THERE'S AN EMAIL CHAIN AT EXHIBIT 15048, 15048. TAKE
11:27AM	19	A LOOK AT IT AND TAKE A LOOK AT THE ATTACHMENT.
11:27AM	20	A. 15048.
11:27AM	21	Q. YES.
11:27AM	22	A. 15048.
11:27AM	23	Q. YES. AND DO YOU SEE THE EMAIL CHAIN, THE LATTER WHICH
11:27AM	24	LOOKS TO BE JANUARY 9, 2014.
11:27AM	25	DO YOU SEE THAT?

11:27AM	1	A. I DO.
11:27AM	2	Q. AND JANUARY 2014 YOU WERE STILL EMPLOYED AT PFIZER;
11:27AM	3	CORRECT?
11:27AM	4	A. YES.
11:27AM	5	Q. AND I THINK YOU TESTIFIED CAN YOU TAKE A LOOK AT THE
11:28AM	6	ATTACHMENT AS WELL.
11:28AM	7	DO YOU SEE THAT?
11:28AM	8	A. I DO.
11:28AM	9	Q. NOW, YOU'VE TESTIFIED THAT YOU, I GUESS YOURSELF, DIDN'T
11:28AM	10	AUTHORIZE THERANOS TO IN ANY WAY PLACE A PFIZER LOGO ON ANY
11:28AM	11	SORT OF DOCUMENTATION; CORRECT?
11:28AM	12	A. CORRECT. IT WOULD ONLY REALLY BE PFIZER LEGAL AND PFIZER
11:28AM	13	COMMERCIAL WHO COULD DO THAT.
11:28AM	14	Q. OKAY. AND YOU SEE IN THIS EXCHANGE AT 15048, MR. SOGAARD
11:28AM	15	AND MR. SAKUL ARE ENGAGED IN AN EMAIL EXCHANGE?
11:28AM	16	DO YOU SEE MR. SAKUL'S NAME AT THE TOP?
11:29AM	17	A. THERE ARE THREE TO FOUR PAGES HERE OF EMAIL. WHERE?
11:29AM	18	Q. AT THE TOP OF THE FIRST PAGE.
11:29AM	19	A. THE TOP OF THE FIRST PAGE.
11:29AM	20	Q. THE CC LINE.
11:29AM	21	A. THE CC LINE IS ELIZABETH HOLMES AND HAKAN SAKUL.
11:29AM	22	Q. AND YOU SEE, WITH THE ATTACHMENT, IT LOOKS LIKE MR. SAKUL
11:29AM	23	RECEIVED A COPY OF THE THERANOS STUDY REPORT WITH BOTH PFIZER'S
11:29AM	24	LOGO AND THERANOS'S LOGO; CORRECT?
11:29AM	25	A. IT APPEARS TO BE SO FROM THIS DOCUMENT.

11:29AM	1	MR. CAZARES: NOTHING FURTHER, YOUR HONOR.
11:29AM	2	THE COURT: REDIRECT?
11:30AM	3	MR. LEACH: THANK YOU, YOUR HONOR.
11:30AM	4	REDIRECT EXAMINATION
11:30AM	5	BY MR. LEACH:
11:30AM	6	Q. GOOD MORNING AGAIN, MR. WEBER. I JUST HAVE A FEW
11:30AM	7	FOLLOW-UP QUESTIONS.
11:30AM	8	YOU TESTIFIED ON EXAMINATION BY MR. CAZARES THAT MONEY
11:30AM	9	DIDN'T PLAY A ROLE IN YOUR EVALUATION OF THERANOS'S TECHNOLOGY.
11:30AM	10	DO YOU RECALL THAT TESTIMONY?
11:30AM	11	A. YES.
11:30AM	12	Q. WHAT DID YOU MEAN BY THAT?
11:30AM	13	A. I MEANT THAT MY ASSESSMENT IS ALWAYS ABOUT THE ACTUAL
11:30AM	14	TECHNICAL CAPABILITY AND ITS UTILITY, AND THAT IF THERE WERE
11:30AM	15	LARGER OR SMALLER AMOUNTS OF MONEY, THAT THAT DID NOT SWAY MY
11:30AM	16	JUDGMENT IN ANY WAY.
11:30AM	17	Q. MR. CAZARES ALSO ASKED YOU QUESTIONS ABOUT 15041.
11:30AM	18	I DON'T BELIEVE HE OFFERED IT INTO EVIDENCE. I WOULD LIKE
11:30AM	19	TO OFFER IT INTO EVIDENCE.
11:31AM	20	THE COURT: ANY OBJECTION?
11:31AM	21	MR. CAZARES: NO, YOUR HONOR.
11:31AM	22	THE COURT: IT'S ADMITTED. IT MAY BE PUBLISHED.
11:31AM	23	(DEFENDANT'S EXHIBIT 15041 WAS RECEIVED IN EVIDENCE.)
11:31AM	24	BY MR. LEACH:
11:31AM	25	Q. MR. WEBER, DO YOU SEE AT THE TOP THERE'S AN EMAIL FROM

11:31AM	1	ELIZABETH HOLMES TO MR. LIPSET, A DAVID LESTER AT THERANOS,
11:31AM	2	SETH MICHELSON AT THERANOS, AND ANOTHER ONE OF YOUR COLLEAGUES
11:31AM	3	AT PFIZER.
11:31AM	4	DO YOU SEE THAT?
11:31AM	5	A. I DO.
11:31AM	6	Q. OKAY. AND THIS RELATES TO SOMETHING CALLED MOMENTUM IL-6.
11:31AM	7	DO YOU SEE THAT?
11:31AM	8	A. I DO.
11:31AM	9	Q. OKAY. AND THERE'S REFERENCE IN HERE TO SETTING UP A PHONE
11:31AM	10	CALL.
11:31AM	11	DO YOU SEE THAT?
11:31AM	12	A. OH, IT'S ON THE SCREEN. YES, I SEE THAT. I APOLOGIZE.
11:32AM	13	Q. OKAY. DO YOU KNOW WHETHER ANYTHING EVER CAME OF THIS
11:32AM	14	PHONE CALL?
11:32AM	15	A. I HAVE NO AWARENESS.
11:32AM	16	Q. OKAY. AND YOU WERE ALSO SHOWN EXHIBITS 4018 AND 20546
11:32AM	17	FROM SOME POINT AFTER OCTOBER 28TH, 2013.
11:32AM	18	AND THESE WERE EMAILS THAT YOU WEREN'T ON.
11:32AM	19	DO YOU RECALL QUESTIONS ABOUT THOSE?
11:32AM	20	A. I DO.
11:32AM	21	Q. OKAY. AND DO YOU KNOW WHETHER, IN SEPTEMBER OF 2013,
11:32AM	22	THERANOS ANNOUNCED A PARTNERSHIP WITH WALGREENS?
11:32AM	23	A. I HAVE A VAGUE AWARENESS OF THIS HAPPENING IN THE OUTSIDE
11:32AM	24	WORLD.
11:32AM	25	Q. OKAY. DO YOU KNOW IF IN THE FALL AND WINTER OF 2013 THERE

11:32AM	1	WERE PRESS ARTICLES ABOUT THERANOS AND ITS TECHNOLOGY?
11:32AM	2	A. I'M NOT AWARE OF THOSE.
11:32AM	3	Q. OKAY. DO YOU KNOW WHETHER ANYTHING CAME FROM THOSE EMAILS
11:32AM	4	SETTING UP DISCUSSIONS?
11:32AM	5	A. NO, I'M NOT AWARE OF ANYTHING HAPPENING.
11:32AM	6	Q. OKAY.
11:33AM	7	IF WE COULD DISPLAY, YOUR HONOR, WHAT IS IN EVIDENCE AS
11:33AM	8	EXHIBIT 7753.
11:33AM	9	THE COURT: ALL RIGHT.
11:33AM	10	MR. LEACH: I BELIEVE IT'S ATTACHMENT 2, MS. WACHS.
11:33AM	11	Q. ARE YOU ABLE TO SEE THE SPREADSHEET ON YOUR SCREEN,
11:33AM	12	MR. WEBER?
11:33AM	13	A. YES, I DO.
11:33AM	14	Q. AND DO YOU SEE A REFERENCE TO PFIZER IN LINE 12?
11:33AM	15	A. I DO.
11:33AM	16	Q. AND DO YOU SEE, AS YOU MOVE TO THE RIGHT, THERE'S TWO
11:33AM	17	AMOUNTS, 500,000 AND 400,000, WITH THE 400,000 NUMBER BEING IN
11:33AM	18	NOVEMBER OF 2008?
11:33AM	19	A. YES.
11:33AM	20	Q. OKAY. AND YOU RECALL VERIFYING BEFORE YOUR PHONE CALL
11:33AM	21	WITH MS. HOLMES THAT PFIZER HAD PAID THERANOS FOR THE
11:33AM	22	ANGIOGENESIS STUDY?
11:33AM	23	A. YES, I RECALL THAT PFIZER YOU KNOW, WE HAD CONFIRMED
11:33AM	24	THAT PFIZER HAD PAID FOR THE STUDY, BUT I WAS NOT EVER INFORMED
11:33AM	25	OF THE DOLLAR AMOUNT INVOLVED.

2	YOUR REVIEW AND THE ULTIMATE PHONE CALL WITH MS. HOLMES?
3	A. YES.
4	Q. OKAY.
5	A. IT'S CONSISTENT TIME-WISE.
6	Q. OKAY. AND IF WE CAN MOVE FORWARD TO THE RIGHT, MS. WACHS,
7	THROUGH 2009, 2010, 2011, ALL OF THE WAY THROUGH 2014.
8	YOU DON'T SEE ANY OTHER AMOUNTS RELATING TO PFIZER, DO
9	YOU?
10	A. I DO NOT.
11	Q. OKAY. AND YOU, SITTING HERE TODAY, YOU HAVE NO KNOWLEDGE
12	OF ANY REVENUE GENERATING CONTRACTS BETWEEN PFIZER AND THERANOS
13	AFTER YOUR REVIEW?
14	A. I'M NOT AWARE OF ANY FURTHER CONTRACTS.
15	Q. OKAY. AND YOU'VE SEEN SOME EMAILS ABOUT DISCUSSIONS,
16	POSSIBILITIES. YOU HAVE NO REASON, SITTING HERE TODAY, TO
17	THINK THAT ANYTHING EVER CAME OF THOSE?
18	A. NO, I DO NOT THINK I'M NOT AWARE OF ANYTHING THAT CAME
19	FROM ANY OF THOSE DISCUSSIONS.
20	Q. OKAY.
21	NO FURTHER QUESTIONS, YOUR HONOR.
22	THE COURT: RECROSS?
23	MR. CAZARES: ACTUALLY, NO FURTHER QUESTIONS,
24	YOUR HONOR.
25	THE COURT: ALL RIGHT. THANK YOU.
	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

11:35AM	1	MAY THIS WITNESS BE EXCUSED?
11:35AM	2	MR. LEACH: YES, YOUR HONOR.
11:35AM	3	MR. CAZARES: YES, YOUR HONOR.
11:35AM	4	THE COURT: YOU'RE EXCUSED, SIR. YOU CAN JUST LEAVE
11:35AM	5	THOSE BINDERS THERE. THANK YOU SO MUCH.
11:35AM	6	THE WITNESS: THANK YOU.
11:35AM	7	THE COURT: YOU'RE WELCOME.
11:35AM	8	DOES THE GOVERNMENT HAVE ANOTHER WITNESS TO CALL?
11:35AM	9	MR. LEACH: YES, YOUR HONOR.
11:35AM	10	THE UNITED STATES CALLED SARAH BENNETT.
11:35AM	11	THE COURT: LADIES AND GENTLEMEN, WE'LL TAKE OUR
11:35AM	12	BREAK AROUND NOON, MAYBE A LITTLE THEREAFTER. I'D LIKE TO GET
11:35AM	13	THE WITNESS STARTED.
11:36AM	14	GOOD MORNING. COME FORWARD, PLEASE.
11:36AM	15	I'LL ASK YOU TO STAND OVER HERE WHILE YOU FACE OUR
11:36AM	16	COURTROOM DEPUTY. AND IF YOU RAISE YOUR RIGHT HAND, SHE HAS A
11:36AM	4.0	
	Ι/	QUESTION FOR YOU.
11:36AM		QUESTION FOR YOU. (GOVERNMENT'S WITNESS, SARAH BENNETT, WAS SWORN.)
11:36AM 11:36AM	18	
	18	(GOVERNMENT'S WITNESS, SARAH BENNETT, WAS SWORN.)
11:36AM	18 19 20	(GOVERNMENT'S WITNESS, SARAH BENNETT, WAS SWORN.) THE WITNESS: I DO.
11:36AM 11:36AM	18 19 20 21	(GOVERNMENT'S WITNESS, SARAH BENNETT, WAS SWORN.) THE WITNESS: I DO. THE COURT: PLEASE HAVE A SEAT UP HERE.
11:36AM 11:36AM 11:36AM	18 19 20 21 22	(GOVERNMENT'S WITNESS, SARAH BENNETT, WAS SWORN.) THE WITNESS: I DO. THE COURT: PLEASE HAVE A SEAT UP HERE. PLEASE ADJUST THE CHAIR AND MICROPHONE AS YOU NEED.
11:36AM 11:36AM 11:36AM 11:36AM	18 19 20 21 22 23	(GOVERNMENT'S WITNESS, SARAH BENNETT, WAS SWORN.) THE WITNESS: I DO. THE COURT: PLEASE HAVE A SEAT UP HERE. PLEASE ADJUST THE CHAIR AND MICROPHONE AS YOU NEED. WHEN YOU ARE COMFORTABLE, WOULD YOU PLEASE STATE YOUR NAME
11:36AM 11:36AM 11:36AM 11:36AM 11:36AM	18 19 20 21 22 23 24	(GOVERNMENT'S WITNESS, SARAH BENNETT, WAS SWORN.) THE WITNESS: I DO. THE COURT: PLEASE HAVE A SEAT UP HERE. PLEASE ADJUST THE CHAIR AND MICROPHONE AS YOU NEED. WHEN YOU ARE COMFORTABLE, WOULD YOU PLEASE STATE YOUR NAME AND SPELL IT.

11:36AM	1	THE COURT: THANK YOU.
11:36AM	2	COUNSEL.
11:36AM	3	MR. LEACH: THANK YOU, YOUR HONOR.
11:36AM	4	MAY I APPROACH THE COURTROOM DEPUTY?
11:37AM	5	THE COURT: YES.
11:37AM	6	MR. LEACH: (HANDING.)
11:37AM	7	DIRECT EXAMINATION
11:37AM	8	BY MR. LEACH:
11:37AM	9	Q. GOOD MORNING, MS. BENNETT. HOW ARE YOU?
11:37AM	10	A. I'M GOOD.
11:37AM	11	Q. AND IF YOU ARE FULLY VACCINATED AND COMFORTABLE, YOU CAN
11:37AM	12	TAKE OFF YOUR MASK. YOU CAN TAKE IT OFF.
11:37AM	13	AND I HAVE TAKEN OFF MINE AS WELL.
11:37AM	14	WHERE DO YOU WORK?
11:37AM	15	A. I WORK FOR CMS, WHICH IS THE CENTER FOR MEDICARE AND
11:37AM	16	MEDICAID SERVICES.
11:37AM	17	Q. AND WHAT IS CMS?
11:37AM	18	A. CMS IS THE CENTER FOR MEDICARE AND MEDICAID SERVICES,
11:37AM	19	WHICH IS A DEPARTMENT UNDER THE DEPARTMENT OF HEALTH, AN AGENCY
11:37AM	20	UNDER THE DEPARTMENT OF HEALTH AND HUMAN SERVICES.
11:37AM	21	Q. OKAY. DO YOU WORK WITHIN A PARTICULAR DIVISION OF CMS?
11:37AM	22	A. YES. I WORK IN THE DIVISION OF CLINICAL LABORATORY
11:37AM	23	IMPROVEMENT AND QUALITY.
11:37AM	24	Q. AND CAN YOU SAY THAT ONE MORE TIME SLOWLY, PLEASE?
11:37AM	25	A. SURE. DCLIQ, THE DIVISION OF CLINICAL LABORATORY

11:38AM	1	IMPROVEMENT AND QUALITY.
11:38AM	2	Q. AND WHAT ARE THE RESPONSIBILITIES OF THAT DIVISION WITHIN
11:38AM	3	CMS?
11:38AM	4	A. THAT DIVISION WITHIN CMS IS RESPONSIBLE FOR DETERMINING
11:38AM	5	NATIONAL POLICY RELATED TO CLINICAL LABORATORIES AND THE
11:38AM	6	OVERSIGHT OF LABORATORIES.
11:38AM	7	Q. WHEN YOU SAY THE OVERSIGHT OF LABORATORIES, WHAT DO YOU
11:38AM	8	MEAN?
11:38AM	9	A. WE SET NATIONAL POLICY FOR HOW LABORATORIES SHOULD BE
11:38AM	10	SURVEYED AND INTERPRET THE REGULATIONS.
11:38AM	11	WE ENSURE THAT THERE IS SURVEYOR CONSISTENCY AMONG OUR
11:38AM	12	SURVEYORS AS THEY'RE GOING INTO CLINICAL LABORATORIES.
11:38AM	13	Q. WHEN DID YOU START WORKING FOR CMS?
11:38AM	14	A. I STARTED WORKING FOR CMS IN 2011.
11:38AM	15	Q. OKAY. WE'LL FOLLOW UP ON THAT.
11:38AM	16	BUT FOR NOW, CAN YOU BRIEFLY DESCRIBE YOUR EDUCATIONAL
11:38AM	17	BACKGROUND.
11:38AM	18	A. SURE.
11:38AM	19	I HAVE A BACHELOR'S DEGREE FROM THE MEDICAL COLLEGE OF
11:38AM	20	VIRGINIA, VIRGINIA COMMONWEALTH UNIVERSITY.
11:38AM	21	Q. OKAY. AND WOULD YOU BRIEFLY DESCRIBE YOUR PROFESSIONAL
11:39AM	22	BACKGROUND AFTER OBTAINING YOUR DEGREE.
11:39AM	23	A. SURE.
11:39AM	24	I AFTER I GRADUATED FROM COLLEGE, I STARTED WORKING AT
11:39AM	25	HOSPITAL LABORATORIES.

11:39AM	1	AFTER I WORKED IN HOSPITAL LABORATORIES, I WENT TO WORK AT
11:39AM	2	DOCTOR AT PHYSICIAN OFFICE LABORATORIES WHERE I OVERSAW THE
11:39AM	3	LABORATORY TESTING IN THOSE LABORATORIES.
11:39AM	4	in 2007 i went to the maryland state agency where i was
11:39AM	5	THE SUPERVISOR OF THE IMPLEMENTATION OF THE CLIA PROGRAM AND
11:39AM	6	THE STATE LICENSURE PROGRAM, AND I ALSO AND THE OVERSIGHT OF
11:39AM	7	THE LABORATORIES IN THE STATE OF MARYLAND, AND I ALSO SURVEYED
11:39AM	8	LABORATORIES IN THAT CAPACITY.
11:39AM	9	Q. SO YOU WERE WORKING FOR THE STATE OF MARYLAND BETWEEN 2007
11:39AM	10	AND 2011?
11:39AM	11	A. YES.
11:39AM	12	Q. AND YOU SAID YOU HAD SOME RESPONSIBILITIES FOR SURVEYS?
11:39AM	13	A. YES.
11:39AM	14	Q. AND WHAT IS A SURVEY?
11:39AM	15	A. A SURVEY IS WHERE WHEN WE TALK ABOUT SURVEY, WE USE
11:39AM	16	THAT WORD INTERCHANGEABLY WITH INSPECTION. TO US IT MEANS THE
11:40AM	17	SAME THING.
11:40AM	18	AND WHAT WE DO IS WE GO INTO LABORATORIES AND WE LOOK AT
11:40AM	19	HOW THE LABORATORY IS PERFORMING TESTING, WHETHER THEY'RE
11:40AM	20	FOLLOWING THE MINIMAL STANDARDS THAT THEY'RE REQUIRED TO FOLLOW
11:40AM	21	TO ENSURE ACCURACY AND RELIABILITY AND TIMELINESS OF TEST
11:40AM	22	RESULTS.
11:40AM	23	Q. YOU JOINED CMS IN 2011?
11:40AM	24	A. YES.
11:40AM	25	Q. AND WHAT WERE YOU HIRED TO DO?

11:40AM	1	A. I WAS HIRED TO BE A MEDICAL TECHNOLOGIST, OR CLINICAL
11:40AM	2	LABORATORY SCIENTIST, AND I HAD CERTAIN AREAS OF EXPERTISE THAT
11:40AM	3	I WAS CONSIDERING A SUBJECT MATTER EXPERT IN.
11:40AM	4	Q. AND WHAT AREAS WERE YOU CONSIDERED A SUBJECT MATTER EXPERT
11:40AM	5	IN?
11:40AM	6	A. SURVEY, TRAINING, SURVEYOR TRAINING, ENFORCEMENT,
11:40AM	7	REVIEWING THE STATE AGENCY'S PERFORMANCE, PROFICIENCY TESTING,
11:40AM	8	PERSONNEL REQUIREMENTS.
11:40AM	9	Q. HOW LONG DID YOU SERVE AS A MEDICAL TECHNOLOGIST?
11:40AM	10	A. I WAS A MEDICAL TECHNOLOGIST AT CMS UNTIL 2018 WHEN I
11:41AM	11	BECAME A TECHNICAL DIRECTOR.
11:41AM	12	Q. OKAY. AND ARE YOU STILL AN EMPLOYEE OF CMS TODAY?
11:41AM	13	A. I AM.
11:41AM	14	Q. AND AT CMS, HAVE YOU PARTICIPATED IN SURVEYS OF
11:41AM	15	LABORATORIES THAT ARE REGISTERED OR CERTIFIED BY CMS?
11:41AM	16	A. YES, I HAVE.
11:41AM	17	Q. OKAY. I'D LIKE TO TALK TO YOU A LITTLE BIT ABOUT THE ROLE
11:41AM	18	OF CMS AND WHAT IT DOES VIS-A-VIS LABORATORIES.
11:41AM	19	CAN YOU DESCRIBE TO ME WHAT CMS RESPONSIBILITIES ARE
11:41AM	20	RELATING TO LABORATORIES?
11:41AM	21	A. CMS IS RESPONSIBLE FOR THE OVERSIGHT OF LABORATORIES.
11:41AM	22	WE'RE RESPONSIBLE OUR DIVISION AND THE SURVEYORS IN OUR
11:41AM	23	DIVISION AND THE STATE AGENCIES ARE RESPONSIBLE FOR ENSURING
11:41AM	24	THAT LABORATORIES FOLLOW THE STANDARD AND CONDITION LEVEL
11:41AM	25	REQUIREMENTS FOR COMPLIANCE.

11:41AM	1	Q. APPROXIMATELY HOW MANY LABORATORIES DOES CMS REGULATE?
11:41AM	2	A. APPROXIMATELY 323,000 LABORATORIES.
11:42AM	3	Q. ARE YOU FAMILIAR WITH THE TERM "CLIA"?
11:42AM	4	A. I AM.
11:42AM	5	Q. WHAT DOES CLIA STAND FOR?
11:42AM	6	A. THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS. THAT'S
11:42AM	7	THE LAW AND THE REGULATIONS THAT SET THE MINIMAL STANDARDS FOR
11:42AM	8	LABORATORIES.
11:42AM	9	Q. OKAY. AND DO YOU HAVE FAMILIARITY WITH CMS'S CLIA
11:42AM	10	PROGRAM?
11:42AM	11	A. I DO. THAT'S WHERE I WORK.
11:42AM	12	Q. OKAY. WHAT IS THE OBJECTIVE OF CMS'S CLIA PROGRAM?
11:42AM	13	MR. CAZARES: OBJECTION. 702 AND FOUNDATION.
11:42AM	14	THE COURT: WELL, YOU CAN LAY A FOUNDATION FOR THAT
11:42AM	15	QUESTION.
11:42AM	16	BY MR. LEACH:
11:42AM	17	Q. THROUGH YOUR RESPONSIBILITIES AS MEDICAL TECHNOLOGIST AND
11:42AM	18	NOW TECHNICAL DIRECTOR AT CMS, ARE YOU RESPONSIBLE FOR
11:42AM	19	IMPLEMENTING THE CLIA PROGRAM? DO YOU HAVE RESPONSIBILITIES IN
11:42AM	20	THAT REGARD?
11:42AM	21	A. YES, I DO.
11:42AM	22	Q. OKAY. AND DOES PART OF THAT INVOLVE TEACHING SURVEYORS
11:42AM	23	WHAT TO LOOK FOR IN INSPECTIONS?
11:42AM	24	A. YES.
11:42AM	25	Q. AND DOES PART OF THAT ACTUALLY INVOLVE DOING SURVEYS OF

LABORATORIES? 1 11:42AM YES. 2 11:42AM Α. AND BY VIRTUE OF YOUR WORK IN YOUR JOB, RELATING TO 3 11:42AM SURVEYS, DO YOU HAVE SOME UNDERSTANDING OF WHAT THE GOAL OF THE 4 11:43AM CLIA PROGRAM IS? 11:43AM 5 6 Α. YES. 11:43AM WHAT IS THAT UNDERSTANDING? 0. 11:43AM MR. CAZARES: OBJECTION. 702 AND CALLS FOR A LEGAL 8 11:43AM 9 CONCLUSION. 11:43AM 10 THE COURT: OVERRULED. 11:43AM YOU CAN ANSWER THE QUESTION. 11:43AM 11 12 THE WITNESS: OKAY. SO THE CLIA PROGRAM IS THE 11:43AM 13 PROGRAM IN THE FEDERAL GOVERNMENT THAT IS RESPONSIBLE FOR THE 11:43AM 14 OVERSIGHT OF LABORATORIES TO ENSURE THAT THEY ARE FOLLOWING THE 11:43AM STANDARDS AND CONDITIONS THAT THEY ARE SUPPOSED TO FOLLOW IN 15 11:43AM 16 ORDER TO ALLOW LABORATORIES TO REPORT ACCURATE, RELIABLE, AND 11:43AM 17 TIMELY PATIENT TEST RESULTS. 11:43AM 18 BY MR. LEACH: 11:43AM 11:43AM 19 ARE THERE DIFFERENT LICENSES THAT LABORATORIES CAN OBTAIN 20 AS PART OF THE CLIA PROGRAM? 11:43AM 21 THERE ARE DIFFERENT TYPES OF CLIA CERTIFICATES, YES. 11:43AM Α. 22 WHAT ARE THE DIFFERENT TYPES OF CLIA CERTIFICATES? 0. 11:43AM THERE ARE FOUR TYPES OF CLIA CERTIFICATES. THERE'S A 23 Α. 11:43AM 24 CERTIFICATE OF A WAIVER; CERTIFICATE FOR PROVIDER PERFORMED 11:43AM 25 MICROSCOPY; CERTIFICATE OF COMPLIANCE; AND A CERTIFICATE OF 11:44AM

ACCREDITATION. 1 11:44AM A CERTIFICATE OF WAIVER, WHAT IS THAT? 2 Q. 11:44AM THAT IS A CERTIFICATE THAT ALLOWS A LABORATORY TO PERFORM 3 11:44AM 4 ONLY WAIVED TESTS THAT THE FDA CATEGORIZES TESTS, AND THOSE 11:44AM CERTIFICATES -- THOSE LABORATORIES CAN ONLY PERFORM THOSE TESTS 11:44AM 5 CLIA APPROVED AS WAIVED BY THE FDA. 11:44AM AND WHEN YOU SAY A "WAIVED" TEST, CAN YOU GIVE US AN 11:44AM EXAMPLE OF ONE OF THOSE? 8 11:44AM 9 LIKE A BLOOD GLUCOSE METER THAT YOU WOULD USE, OR A URINE 11:44AM PREGNANCY TEST, THINGS THAT YOU CAN BUY -- AND ONE OF THE WAYS 10 11:44AM 11:44AM 11 THE TESTS CAN BE BECOME WAIVED IS BY BEING SOLD OVER THE 12 COUNTER. 11:44AM 13 AND YOU ALSO MENTIONED SOMETHING CALLED A CERTIFICATE OF 11:44AM 14 PROVIDER MICROSCOPY PROCEDURE? 11:44AM THAT'S A VERY LIMITED CERTIFICATE WHERE THERE ARE --15 11:44AM THEY CAN PERFORM NINE TESTS THAT ARE CONSIDERED PROVIDER 16 11:44AM 17 PERFORMED MICROSCOPY AND WAIVED TESTS, AND THOSE ARE TESTS LIKE 11:45AM YOU TAKE URINE AND YOU SPIN IT DOWN AND YOU GET SOME SEDIMENT 11:45AM 18 IN THE BOTTOM, AND THEN YOU LOOK AT IT UNDER A MICROSCOPE. 19 11:45AM 20 THOSE ARE TESTS THAT ARE USUALLY PERFORMED VERY CLOSE TO 11:45AM 21 THE PATIENT BEDSIDE, AND YOU NEED TO PERFORM THEM RIGHT AWAY OR 11:45AM THE TESTS MAY NOT NECESSARILY GIVE YOU RESULTS. 22 11:45AM YOU ALSO MENTIONED TWO CERTIFICATES CALLED A CERTIFICATE 23 Q. 11:45AM OF COMPLIANCE AND A CERTIFICATE OF ACCREDITATION. 24 11:45AM WHAT ARE THOSE? 25 11:45AM

1 11:45AM 2 11:45AM 3 11:45AM 4 11:45AM 11:45AM 11:45AM 11:45AM 8 11:45AM 9 11:46AM 10 11:46AM 11:46AM 11 12 11:46AM 13 11:46AM 14 11:46AM 15 11:46AM 16 11:46AM 17 11:46AM 18 11:46AM 19 11:46AM 20 11:46AM 21 11:46AM 22 11:46AM 23 11:46AM 24 11:46AM 25 11:47AM

A. CERTIFICATE OF COMPLIANCE AND CERTIFICATE OF ACCREDITATION

ALLOW LABORATORIES TO PERFORM WAIVED, MODERATE, AND HIGH

COMPLEXITY TESTING AS LONG AS THEY MEET THE REQUIREMENTS FOR

THOSE, WHATEVER COMPLEXITY THEY'RE TESTING.

THE CERTIFICATE OF COMPLIANCE LABORATORY IS TYPICALLY SURVEYED BY THE STATE AGENCY, BUT MAY ALSO BE INSPECTED BY FEDERAL SURVEYORS.

AND THE CERTIFICATE OF ACCREDITATION, THE SURVEYS ARE NORMALLY PERFORMED BY AN HHS APPROVED ACCREDITED ORGANIZATION.

Q. YOU MENTIONED SOMETHING CALLED HIGH COMPLEXITY AND MODERATE COMPLEXITY TESTS, AND I THINK YOU EARLIER MENTIONED WAIVED TESTS.

CAN YOU EXPLAIN WHAT THOSE ARE?

A. SURE. WAIVED TESTS ARE TESTS THAT ARE GENERALLY EASY TO PERFORM, AND IF THERE'S AN ERRONEOUS RESULT, THERE'S NOT NECESSARILY A HIGH RISK TO THE PATIENT IF THE RESULT IS INCORRECT.

MODERATE AND HIGH ARE CONSIDERED NON-WAIVED TESTS, AND THE DIFFERENCE BETWEEN MODERATE AND HIGH IS THAT HIGH COMPLEXITY TESTS USUALLY REQUIRE HIGHER QUALIFICATIONS FOR PERSONNEL IN THE LABORATORY. THEY REQUIRE ADDITIONAL STEPS TO BE ABLE TO PERFORM THOSE TESTS. THEY'RE USUALLY MORE COMPLICATED AND MAY HAVE MORE STEPS THAN A MODERATE COMPLEXITY TEST.

Q. YOU -- ARE YOU FAMILIAR WITH THE TERM LDT, OR LABORATORY DEVELOPED TEST?

11:47AM	1	A. I AM.
11:47AM	2	Q. IS THAT A TERM OF ART IN THE CMS WORLD?
11:47AM	3	A. IT IS NOT. WE
11:47AM	4	Q. IS THAT A TERM OF ART IN THE FDA WORLD?
11:47AM	5	A. YES, IT IS. BUT MOST PEOPLE UNDERSTAND, WHEN WE SAY LDT,
11:47AM	6	OR LABORATORY DEVELOPED TESTS, WHEN WE TALK ABOUT THOSE.
11:47AM	7	IN THE CLIA WORLD WE HAVE TESTS THAT ARE APPROVED.
11:47AM	8	THEY'RE CLEARED BY THE FDA OR THEY'RE NOT. THOSE THAT ARE NOT
11:47AM	9	APPROVED BY THE FDA, WE GENERALLY CONSIDER THOSE TO BE LDT'S.
11:47AM	10	Q. AND WHAT TYPES OF LABS ARE PERMITTED TO PERFORM LDT'S?
11:47AM	11	A. HIGH COMPLEXITY LABORATORIES THAT HAVE QUALIFIED PERSONNEL
11:47AM	12	TO PERFORM HIGH COMPLEXITY TESTS.
11:47AM	13	Q. CAN LDT'S BE PERFORMED IN A MODERATE COMPLEXITY LAB?
11:47AM	14	A. THEY CANNOT.
11:47AM	15	Q. YOU MENTIONED SOMETHING CALLED FDA CLEARANCE.
11:47AM	16	WHAT IS THAT?
11:47AM	17	A. TESTS THAT ARE PUT OUT INTO THE MARKET ARE THEY HAVE
11:47AM	18	SEVERAL PROCESSES THEY CAN GO THROUGH THE FDA, WHETHER THEY'RE
11:48AM	19	CLEAR OR APPROVED, AND THEN THE FDA IS THE ONE THAT ASSIGNS THE
11:48AM	20	CLIA COMPLEXITY SO WE KNOW WHETHER IT'S HIGH, MODERATE, OR
11:48AM	21	WAIVED.
11:48AM	22	Q. AND FDA IS THE U.S. FOOD AND DRUG ADMINISTRATION?
11:48AM	23	A. YES.
11:48AM	24	Q. AND DOES THEIR AUTHORITY OVERLAP WITH CMS'S IN TERMS OF
11:48AM	25	LAB REGULATION?

11:48AM	1	A. THEY HAVE A DIFFERENT FOCUS THAN WHAT CLIA HAS.
11:48AM	2	THE CLIA PROGRAM IS ACTUALLY IMPLEMENTED BY THREE
11:48AM	3	DIFFERENT AGENCIES, CMS, THE FDA, AND THE CDC.
11:48AM	4	CMS IS RESPONSIBLE FOR THE OVERSIGHT OF THE LABORATORIES.
11:48AM	5	WE WRITE THE REGULATIONS, WE COLLECT ALL OF THE FEES.
11:48AM	6	THE FDA CATEGORIZES TESTS FOR US, AND THE CDC ARE OUR
11:48AM	7	TECHNICAL THEY GIVE US TECHNICAL ADVICE.
11:48AM	8	BUT FOR LABORATORIES, CMS USUALLY DEALS SPECIFICALLY WITH
11:48AM	9	LABORATORIES. THE FDA DEALS MORE WITH MANUFACTURERS.
11:49AM	10	Q. WHEN YOU SAY CMS DEALS WITH LABORATORIES AND THE FDA DEALS
11:49AM	11	WITH MANUFACTURERS, WHAT DO YOU MEAN BY THAT?
11:49AM	12	A. CLIA DEALS CLIA IS LOOKING AT SPECIFIC LABORATORIES AND
11:49AM	13	THE PRACTICES WITHIN A SPECIFIC LABORATORY WHEN WE GO IN TO
11:49AM	14	INSPECT OR SURVEY A LABORATORY.
11:49AM	15	THE FDA IS
11:49AM	16	MR. CAZARES: OBJECTION. FOUNDATION AS TO THE FDA.
11:49AM	17	THE COURT: IS THIS BASED ON THIS WITNESS'S
11:49AM	18	KNOWLEDGE?
11:49AM	19	MR. LEACH: YES, YOUR HONOR. I CAN ASK SOME MORE
11:49AM	20	QUESTIONS ON THIS.
11:49AM	21	THE COURT: SURE.
11:49AM	22	BY MR. LEACH:
11:49AM	23	Q. IN THE COURSE OF YOUR CAREER WITHIN THE MY APOLOGIES,
11:49AM	24	MS. RODRIGUEZ. I'LL GO SLOWER.
11:49AM	25	IN YOUR EXPERIENCE AS A MEDICAL TECHNOLOGIST AT CMS, HAVE

11:49AM	1	YOU HAD MEETINGS WITH THE FDA?
11:49AM	2	A. YES.
11:49AM	3	Q. HAVE YOU HAD MEETINGS WITH THE FDA DIRECTLY RELATED TO
11:49AM	4	THERANOS?
11:49AM	5	A. NO.
11:49AM	6	Q. DID YOU PARTICIPATE IN A MEETING WITH THE FDA WHERE
11:50AM	7	WITH THERANOS WHERE THE FDA WAS ON THE PHONE?
11:50AM	8	A. OH, YES, SORRY. I DID, YES.
11:50AM	9	Q. AND PUTTING ASIDE THAT INTERACTION, IN THE COURSE, HAVE
11:50AM	10	YOU HAD CONVERSATIONS WITH THE FDA ABOUT HOW CMS REGULATES
11:50AM	11	LABORATORIES AND THE FDA REGULATES MEDICAL DEVICE
11:50AM	12	MANUFACTURERS?
11:50AM	13	A. YES.
11:50AM	14	Q. AND WHAT IS THAT DISTINCTION? CAN YOU EXPLAIN WHAT YOU
11:50AM	15	MEAN BY THAT?
11:50AM	16	MR. CAZARES: SAME OBJECTION.
11:50AM	17	THE COURT: OVERRULED.
11:50AM	18	YOU CAN ANSWER THE QUESTION.
11:50AM	19	THE WITNESS: OKAY. SO CMS, LIKE I SAID, WE DEAL
11:50AM	20	SPECIFICALLY WITH LABORATORIES AND OVERSIGHT AND IMPLEMENTING
11:50AM	21	AND MAKING SURE THAT LABORATORIES ARE FOLLOWING THE CLIA
11:50AM	22	REQUIREMENTS, THE STANDARDS AND CONDITIONS OF THE CLIA
11:50AM	23	REQUIREMENTS.
11:50AM	24	THE FDA DEALS WITH MANUFACTURERS WHO ARE TRYING TO
11:50AM	25	MANUFACTURE THE PRODUCTS TO OTHER LABORATORIES OR TO ANY

11:50AM	1	LABORATORY.
11:50AM	2	BY MR. LEACH:
11:50AM	3	Q. WHEN YOU SAY "MARKET TO OTHERS," WHAT DO YOU MEAN BY THAT?
11:50AM	4	A. ONCE THE ONCE A TEST GOES THROUGH THE FDA PROCESS, THEN
11:51AM	5	THEY'RE ABLE TO MARKET THAT TO WHICHEVER LABORATORY THAT THE
11:51AM	6	MANUFACTURER OR DISTRIBUTOR IS ALLOWED TO DISTRIBUTE THAT TEST
11:51AM	7	OR SELL THAT TEST TO ANY LABORATORY THAT WANTS IT.
11:51AM	8	THE COURT: MS. BENNETT, I'M GOING TO ASK YOU TO
11:51AM	9	SLOW DOWN JUST A LITTLE BIT.
11:51AM	10	THE WITNESS: THANK YOU.
11:51AM	11	BY MR. LEACH:
11:51AM	12	Q. WE NEED TO MAKE SURE WE'RE SPEAKING ONE AT A TIME,
11:51AM	13	MS. BENNETT, AND ALSO MAKE SURE THAT THE COURT REPORTER IS ABLE
11:51AM	14	TO GET ALL OF OUR DIALOGUE.
11:51AM	15	YOU TALKED EARLIER ABOUT SURVEYS THAT CMS CONDUCTS.
11:51AM	16	WHAT IS INVOLVED IN A SURVEY?
11:51AM	17	A. PRIOR TO GOING ON THE SURVEY, WE DO A LITTLE BIT OF LEG
11:51AM	18	WORK. WE LOOK AT SOME REPORTS. WE LOOK AT, LIKE, A PREVIOUS
11:51AM	19	REPORT FROM THE LAST SURVEY TO SEE WHAT THE ISSUES WERE,
11:51AM	20	BECAUSE WE WANT TO MAKE SURE THAT WHEN WE GO ONSITE TO DO A
11:51AM	21	SURVEY THAT THEY ACTUALLY CORRECTED WHAT THEY WHAT WAS FOUND
11:51AM	22	IN A PREVIOUS SURVEY IF THERE IS ONE.
11:51AM	23	WHAT I DO IS THAT I PULL PROFICIENCY TESTING RECORDS AND
11:52AM	24	REPORTS TO SEE HOW THEIR PROFICIENCY TESTING LOOKS.
11:52AM	25	AND WE CAN ALSO PULL A SUMMARY REPORT SO THAT WE KNOW

11:52AM	1	APPROXIMATELY WHAT TYPES OF TESTING, NOT SPECIFIC TESTS, BUT IN
11:52AM	2	WHAT AREAS THEY'RE TESTING.
11:52AM	3	Q. AND WHEN YOU GO ONSITE FOR A SURVEY, DO YOU REQUEST
11:52AM	4	DOCUMENTS?
11:52AM	5	A. WE DO.
11:52AM	6	Q. IS THE LABORATORY REQUIRED TO PROVIDE DOCUMENTS TO YOU?
11:52AM	7	A. THEY ARE REQUIRED TO SUPPLY TO US WHATEVER DOCUMENTS WE
11:52AM	8	REQUEST.
11:52AM	9	Q. AND DO YOU ALSO CONDUCT INTERVIEWS?
11:52AM	10	A. YES.
11:52AM	11	Q. AND WHY DO YOU CONDUCT INTERVIEWS?
11:52AM	12	A. WE HAVE THREE MECHANISMS BY WHICH WE COLLECT INFORMATION.
11:52AM	13	ONE IS BY RECORDS REVIEW OR DOCUMENTS, AND THE SECOND IS
11:52AM	14	INTERVIEW, AND THE THIRD IS OBSERVATION.
11:52AM	15	SO IT'S A WAY FOR US TO COLLECT INFORMATION, AND ALSO
11:52AM	16	VERIFY INFORMATION THAT WE FIND OR ARE TOLD.
11:52AM	17	Q. ARE YOU FAMILIAR WITH A COMPANY CALLED THERANOS?
11:52AM	18	A. YES, I AM.
11:52AM	19	Q. AND HOW DID YOU BECOME FAMILIAR WITH THERANOS?
11:52AM	20	A. THERANOS CAME TO CMS I BELIEVE IN JANUARY OF 2014 TO SHOW
11:53AM	21	US AND TALK TO US ABOUT THEIR TECHNOLOGY.
11:53AM	22	AND THEN I WAS ASKED TO PARTICIPATE IN A SURVEY OF THE
11:53AM	23	CALIFORNIA AND THE ARIZONA FACILITIES.
11:53AM	24	Q. I'D LIKE TO FOCUS ON THE MEETING THAT YOU JUST DESCRIBED
11:53AM	25	AND TALK ABOUT THE SURVEY A LITTLE BIT LATER.

11:53AM	1	A. SURE.
11:53AM	2	Q. SO FOCUSSING ON THE MEETING THAT YOU JUST DESCRIBED, YOU
11:53AM	3	SAID THAT WAS AT SOME POINT IN 2014?
11:53AM	4	A. I BELIEVE IT WAS JANUARY OF 2014.
11:53AM	5	Q. OKAY. AND WHERE WAS THIS MEETING?
11:53AM	6	A. IT WAS AT CMS.
11:53AM	7	Q. OKAY. WHO ATTENDED FROM CMS TO THE BEST OF YOUR
11:53AM	8	KNOWLEDGE?
11:53AM	9	A. AS BEST I CAN RECALL, KAREN DYER, PENNY FULLER,
11:53AM	10	PENNY MYERS, MYSELF, I BELIEVE JUDY YOST WAS THERE.
11:53AM	11	Q. AND WHO IS KAREN DYER?
11:54AM	12	A. KAREN DYER WAS THE PREVIOUS DIRECTOR OF THE CLIA PROGRAM.
11:54AM	13	Q. SOMEONE YOU REPORTED TO?
11:54AM	14	A. YES.
11:54AM	15	Q. AND KAREN FULLER, WHO IS THAT?
11:54AM	16	A. KAREN FULLER WAS THE MANAGER IN THE SAN FRANCISCO REGIONAL
11:54AM	17	OFFICE.
11:54AM	18	Q. AND WHAT ARE THE RESPONSIBILITIES OF THE SAN FRANCISCO
11:54AM	19	REGIONAL OFFICE?
11:54AM	20	A. THE WHAT WE CALL THE CENTRAL OFFICE, OR CMS BALTIMORE,
11:54AM	21	IS THE AREA OF THE CLIA PROGRAM WE USUALLY DEVELOP POLICY FOR
11:54AM	22	LABORATORIES AND FOR OUR SURVEYORS.
11:54AM	23	THE REGIONAL OFFICE, LIKE CMS SAN FRANCISCO, THEY'RE
11:54AM	24	USUALLY RESPONSIBLE FOR PERFORMING SURVEYS AND THE DIRECT
11:54AM	25	OVERSIGHT OF LABORATORIES IN THE STATES.

11:54AM	1	Q. AND ARE THERE OTHER OFFICES BESIDES THE SAN FRANCISCO ONE
11:54AM	2	THAT DO THE SURVEYS, OR IS THAT JUST THE ONE THAT HAPPENS TO BE
11:54AM	3	HERE IN OUR NECK OF THE WOODS?
11:54AM	4	A. THAT'S HERE IN YOUR NECK OF THE WOODS.
11:54AM	5	Q. OKAY.
11:54AM	6	A. WE HAVE TEN REGIONAL OFFICES AROUND THE UNITED STATES.
11:54AM	7	Q. SO MS. DYER WAS THERE, MS. FULLER WAS THERE?
11:55AM	8	A. I DON'T KNOW WHETHER MS. FULLER WAS AT THAT MEETING.
11:55AM	9	Q. OKAY. WHO FROM THERANOS WAS THERE?
11:55AM	10	A. I BELIEVE MS. HOLMES AND MR. BALWANI WERE THERE.
11:55AM	11	Q. OKAY. AND DID ANY INDIVIDUALS FROM THE FDA PARTICIPATE?
11:55AM	12	A. I BELIEVE THEY WERE ON THE PHONE.
11:55AM	13	Q. OKAY. AND WHAT WAS THE PURPOSE OF THE MEETING?
11:55AM	14	A. MY UNDERSTANDING OF THE PURPOSE OF THE MEETING WAS THAT
11:55AM	15	THERANOS WAS COMING TO SHOW US THEIR TECHNOLOGY. THEY WANTED
11:55AM	16	TO TRY TO PUT THE DEVICES IN A LOT OF IN MULTIPLE FACILITIES
11:55AM	17	WITHOUT A CLIA CERTIFICATE, AND WE TOLD THEM THAT THEY WOULD
11:55AM	18	NEED CLIA CERTIFICATES AT EACH OF THE FACILITIES.
11:55AM	19	Q. AND WHEN YOU SAY "PUT THE DEVICES IN A LOT OF FACILITIES,"
11:55AM	20	WHAT DO YOU MEAN BY "DEVICES"?
11:55AM	21	A. THE LITTLE BLACK BOX.
11:55AM	22	Q. AND DID THEY BRING A BLACK BOX WITH THEM?
11:55AM	23	A. NOT THAT I RECALL.
11:55AM	24	Q. BUT WHAT WERE THEY TELLING YOU THAT THEY WANTED TO DO WITH
11:55AM	25	THE BLACK BOX?

11:55AM	1	A. THEY WANTED TO BE ABLE TO PUT THE PATIENT SPECIMEN INTO
11:56AM	2	THE BOX, AND THEN THE INFORMATION WOULD GO BACK TO CALIFORNIA,
11:56AM	3	AND THEN THE RESULTS WOULD BE LOOKED AT AND REPORTED OUT FROM
11:56AM	4	CALIFORNIA.
11:56AM	5	Q. AND WHAT DID CMS TELL THERANOS AT THIS MEETING?
11:56AM	6	A. WE TOLD THEM THAT THEY WOULD NEED TO HAVE A CLIA
11:56AM	7	CERTIFICATE AT EACH PLACE THAT THE BLACK BOX WAS
11:56AM	8	Q. OKAY.
11:56AM	9	A LOCATED.
11:56AM	10	Q. AND BY "CLIA CERTIFICATE," IS THAT A CERTIFICATE OF
11:56AM	11	COMPLIANCE? A CERTIFICATE OF WAIVER? WHAT TYPE OF CERTIFICATE
11:56AM	12	WOULD BE REQUIRED?
11:56AM	13	A. IN THIS PARTICULAR INSTANCE, IT WOULD HAVE BEEN A
11:56AM	14	CERTIFICATE OF COMPLIANCE OR A CERTIFICATE OF ACCREDITATION
11:56AM	15	BECAUSE IT WAS NOT FDA APPROVED OR CLEARED, SO IT WOULD BE HIGH
11:56AM	16	COMPLEXITY.
11:56AM	17	Q. OKAY. AND WHEN YOU SAY "NOT FDA APPROVED OR CLEARED,"
11:56AM	18	WHAT IS THE DIFFERENCE BETWEEN APPROVAL AND CLEARANCE?
11:56AM	19	A. THERE'S A DIFFERENCE IN THE PROCESS DEPENDING ON THE TEST.
11:56AM	20	THE FDA HAS SEVERAL PATHWAYS THAT TESTS CAN BE APPROVED OR
11:56AM	21	CLEARED, AND DEPENDING ON THE PATHWAY, IT'S EITHER APPROVED OR
11:56AM	22	CLEARED.
11:56AM	23	Q. AND IS ONE OF THEM MORE RIGOROUS THAN THE OTHER?
11:57AM	24	A. I DON'T KNOW.
11:57AM	25	Q. AND IS YOUR NEXT INTERACTION WITH THERANOS AT SOME POINT

11:57AM	1	IN CONNECTION WITH A SURVEY THAT YOU CONDUCTED?
11:57AM	2	A. YES.
11:57AM	3	Q. WAS THAT IN 2015?
11:57AM	4	A. YES.
11:57AM	5	MR. LEACH: YOUR HONOR, I'M ABOUT TO MOVE INTO
11:57AM	6	ANOTHER TOPIC. THIS MIGHT BE A CONVENIENT TIME TO BREAK.
11:57AM	7	THE COURT: ALL RIGHT. LET'S DO THAT THEN.
11:57AM	8	WE'LL TAKE OUR NOON BREAK. IT'S 30 MINUTES, 30 MINUTES.
11:57AM	9	AND WE'LL COME BACK AND FINISH YOUR TESTIMONY.
11:57AM	10	THANK YOU.
11:57AM	11	MR. LEACH: THANK YOU.
12:12PM	12	(RECESS FROM 12:12 P.M. UNTIL 12:33 P.M.)
12:34PM	13	(JURY IN AT 12:34 P.M.)
12:34PM	14	THE COURT: ALL RIGHT. WE'RE BACK ON THE RECORD.
12:34PM	15	OUR JURY IS PRESENT. ALL PARTIES PREVIOUSLY PRESENT ARE
12:34PM	16	PRESENT AGAIN.
12:35PM	17	MR. LEACH, YOU'D LIKE TO CONTINUE?
12:35PM	18	MR. LEACH: I WOULD, YOUR HONOR. THANK YOU.
12:35PM	19	Q. MS. BENNETT, BEFORE WE BROKE, WE WERE ABOUT TO GET INTO A
12:35PM	20	SURVEY THAT YOU PERFORMED OR PARTICIPATED IN WITH RESPECT TO
12:35PM	21	THERANOS IN 2015.
12:35PM	22	DO YOU RECALL STARTING TO TALK ABOUT THAT?
12:35PM	23	A. YES.
12:35PM	24	Q. OKAY. HOW DID YOU FIRST LEARN THAT HOW DID IT COME
12:35PM	25	ABOUT THAT YOU WERE TO PARTICIPATE IN A SURVEY OF THERANOS?

12:35PM	1	A. MY SUPERVISOR, KAREN DYER, ASKED ME IF I WOULD
12:35PM	2	PARTICIPATE.
12:35PM	3	Q. AND YOU WORK IN THE HOME OFFICE, OR THE CENTRAL OFFICE OF
12:35PM	4	CMS?
12:35PM	5	A. YES.
12:35PM	6	Q. WAS IT COMMON OR UNUSUAL FOR YOU TO PARTICIPATE IN SURVEYS
12:35PM	7	IN YOUR ROLE?
12:35PM	8	A. I PARTICIPATED IN SEVERAL SURVEYS SINCE I CAME TO THE
12:35PM	9	CENTRAL OFFICE IN BALTIMORE.
12:35PM	10	Q. AND WERE YOU ASKED TO PARTNER WITH ANY PARTICULAR PERSON
12:36PM	11	ON THIS SURVEY?
12:36PM	12	A. YES.
12:36PM	13	Q. WHO WAS THAT?
12:36PM	14	A. GARY YAMAMOTO.
12:36PM	15	Q. AND MR. YAMAMOTO WORKS IN SAN FRANCISCO OFFICE?
12:36PM	16	A. HE DOES.
12:36PM	17	Q. AND WHAT WAS YOUR UNDERSTANDING OF WHY YOU WERE CONDUCTING
12:36PM	18	A SURVEY OF THERANOS?
12:36PM	19	A. MY UNDERSTANDING, BECAUSE OF MY SURVEY BACKGROUND, I WAS
12:36PM	20	ASKED TO PARTICIPATE AND HELP OUT.
12:36PM	21	Q. LET ME ASK A DIFFERENT QUESTION. WHY WAS CMS SURVEYING
12:36PM	22	THERANOS AT SOME POINT IN 2015?
12:36PM	23	A. I DON'T KNOW THE EXACT REASON. IT COULD HAVE BEEN THAT
12:36PM	24	THEY WERE SHORT OF SURVEYORS IN CALIFORNIA, OR IT WAS JUST THAT
12:36PM	25	THEY WANTED US TO PERFORM THAT SURVEY.

AT THE TIME THAT YOU -- WHEN DID YOU ACTUALLY CONDUCT THE 1 Q. 12:36PM SURVEY? 2 12:36PM THE FIRST VISIT WAS SEPTEMBER OF 2015, AND THEN WE WENT 3 12:36PM 4 BACK TO COMPLETE THE SURVEY IN NOVEMBER OF 2015. 12:36PM PRIOR TO SEPTEMBER OF 2015, DID YOU HAVE AN UNDERSTANDING 12:37PM 5 OF WHEN IN THE SURVEY CYCLE THERANOS WOULD FALL? 6 12:37PM YES. Α. 12:37PM AND WHEN WAS THAT? 8 Q. 12:37PM 9 WE KNEW THAT THE SURVEY NEEDED TO BE PERFORMED LATE Α. 12:37PM 10 SUMMER, EARLY FALL BECAUSE WE NEEDED TO PERFORM THE 12:37PM RECERTIFICATION SURVEY, AND WE RECEIVED A COMPLAINT, AND SO 12:37PM 11 12:37PM 12 WE -- THE DECISION WAS MADE TO PERFORM THOSE TWO SURVEYS 13 TOGETHER AS ONE. 12:37PM 14 OKAY. THE RECERTIFICATION SURVEY, WHAT DO YOU MEAN BY 12:37PM Ο. THAT? 15 12:37PM EVERY LABORATORY THAT HAS A CERTIFICATE OF COMPLIANCE 16 12:37PM 17 EVERY OTHER YEAR HAS TO BE SURVEYED FOR -- TO MAKE SURE THAT 12:37PM 18 THEY'RE FOLLOWING THE STANDARDS AND CONDITIONS THAT THEY ARE 12:37PM 12:37PM 19 REQUIRED TO FOLLOW. 20 AND THERANOS WAS DUE FOR THAT AT SOME POINT AT THE END OF 12:37PM 21 2015? 12:37PM 22 YES. Α. 12:37PM OKAY. YOU ALSO MENTIONED THAT IT CAME TO YOUR ATTENTION 23 Q. 12:37PM 24 THAT THERE HAD BEEN A COMPLAINT ABOUT THERANOS? 12:37PM 25 YES. 12:38PM Α.

12:38PM	1	Q. OKAY. WITHOUT TALKING ABOUT THE SUBSTANCE OF THE
12:38PM	2	COMPLAINT, DID THAT INFORM SOME OF THE TOPIC AREAS THAT YOU
12:38PM	3	ELECTED TO FOCUS ON IN YOUR SURVEY?
12:38PM	4	A. IT DID.
12:38PM	5	Q. OKAY. AND WHAT TOPIC AREAS WERE THOSE?
12:38PM	6	A. IT WAS THAT THIS PARTICULAR COMPLAINT WAS RELATED TO
12:38PM	7	MR. CAZARES: OBJECTION. HEARSAY AND 403.
12:38PM	8	THE COURT: SUSTAINED.
12:38PM	9	IF YOU COULD JUST GET THE, I THINK, THE AREAS.
12:38PM	10	BY MR. LEACH:
12:38PM	11	Q. OKAY. AS A RESULT OF THE COMPLAINT, MS. BENNETT, DID YOU
12:38PM	12	MAKE A DECISION TO FOCUS ON PARTICULAR AREAS WITHIN THE CMS
12:38PM	13	SURVEY?
12:38PM	14	A. YES.
12:38PM	15	Q. AND WHAT AREAS DID YOU ELECT TO FOCUS ON?
12:38PM	16	A. PROFICIENCY TESTING.
12:38PM	17	Q. OKAY. DID YOU ALSO ELECT TO FOCUS ON QUALITY CONTROL?
12:38PM	18	A. WE DID.
12:38PM	19	Q. OKAY. WITHOUT DESCRIBING THE SUBSTANCE OF THE COMPLAINTS,
12:38PM	20	DID YOU HAVE AN UNDERSTANDING OF WHERE THE COMPLAINTS WERE
12:38PM	21	COMING FROM?
12:38PM	22	A. WE, WE KNEW THAT THE COMPLAINTS HAD COME FROM INDIVIDUALS.
12:39PM	23	Q. OKAY. INDIVIDUALS OUTSIDE OF THE COMPANY OR INSIDE OF THE
12:39PM	24	COMPANY?
12:39PM	25	A. ONE COMPLAINT WE KNEW WAS INSIDE OF THE COMPANY. THE

12:39PM	1	OTHER ONE WE DID NOT KNOW I DID NOT KNOW.
12:39PM	2	Q. OKAY. AT SOME POINT IN TIME DID YOU BECOME AWARE THAT A
12:39PM	3	REPORTER FROM "THE WALL STREET JOURNAL" WAS ASKING CMS
12:39PM	4	QUESTIONS ABOUT THERANOS?
12:39PM	5	A. I DID.
12:39PM	6	Q. OKAY. AND DID THAT HAPPEN BEFORE YOUR SURVEY IN SEPTEMBER
12:39PM	7	OF 2015?
12:39PM	8	A. IT DID.
12:39PM	9	Q. DID THAT IN ANY WAY AFFECT HOW YOU WENT ABOUT CONDUCTING
12:39PM	10	THE SURVEY?
12:39PM	11	A. IT DID NOT.
12:39PM	12	Q. PRIOR TO CONDUCTING THE SURVEY BEGINNING AT THE END OF
12:39PM	13	SEPTEMBER 2015, WHAT DID YOU DO? HOW DID YOU PREPARE FOR THE
12:39PM	14	SURVEY?
12:39PM	15	A. I REQUESTED THE PREVIOUS SURVEY REPORT FROM THE LAST
12:39PM	16	SURVEY THAT HAD BEEN PERFORMED ON THERANOS; I LOOKED AT THE
12:40PM	17	PROFICIENCY TESTING INFORMATION; AND I ALSO PULLED A REPORT
12:40PM	18	THAT SUMMARIZED INFORMATION ABOUT THE LABORATORY.
12:40PM	19	Q. OKAY. DID YOU LOOK AT THE RESULTS OF PRIOR INSPECTIONS OF
12:40PM	20	THERANOS?
12:40PM	21	A. I DID.
12:40PM	22	Q. OKAY. AND WHEN YOU SAY YOU PULLED PROFICIENCY TESTING,
12:40PM	23	HOW DID YOU DO THAT? WHAT DID YOU DO?
12:40PM	24	A. WE HAVE AN INTERNAL REPORT WHERE WE CAN PUT IN THE
12:40PM	25	LABORATORY NAME OR CLIA NUMBER, AND IT PULLS UP THEIR

12:40PM	1	PROFICIENCY TESTING HISTORY.
12:40PM	2	Q. AND THE PROFICIENCY TESTING THAT YOU REVIEWED, WAS THIS
12:40PM	3	WERE THESE RESULTS PROVIDED BY A THIRD PARTY PROVIDER, OR WERE
12:40PM	4	THEY SOME OTHER FORM OF PROFICIENCY TESTING?
12:40PM	5	A. THE INFORMATION IS PUT INTO OUR SYSTEM BY THE PT PROGRAMS.
12:40PM	6	WHEN THEY GRADE THE RESULTS, THEY ENTER IT INTO THE SYSTEM, AND
12:40PM	7	THEN WE CAN PULL THE REPORT.
12:40PM	8	Q. SO IF A LAB IS PERFORMING ALTERNATE ASSESSMENT OF
12:41PM	9	PROFICIENCIES, IS THAT SOMETHING THAT IS AVAILABLE TO YOU
12:41PM	10	BEFORE YOU GO IN TO DO YOUR SURVEY?
12:41PM	11	A. NO.
12:41PM	12	Q. DO YOU KNOW THE NAME ERIKA CHEUNG?
12:41PM	13	A. I DO.
12:41PM	14	Q. AND WHO IS ERIKA CHEUNG?
12:41PM	15	A. SHE WAS A COMPLAINANT. SHE WAS ONE OF THE COMPLAINTS THAT
12:41PM	16	WE RECEIVED.
12:41PM	17	Q. AND PRIOR TO GOING IN TO CONDUCT YOUR SURVEY, DID YOU HAVE
12:41PM	18	AN UNDERSTANDING OF SOME OF THE THINGS THAT MS. CHEUNG WAS
12:41PM	19	ALLEGING?
12:41PM	20	A. I DID.
12:41PM	21	Q. AND DID YOU CONDUCT THE SURVEY WITH AN EYE TOWARDS SOME OF
12:41PM	22	THOSE ALLEGATIONS?
12:41PM	23	A. YES.
12:41PM	24	Q. LET ME PLEASE DRAW YOUR ATTENTION TO EXHIBIT 5831.
12:41PM	25	BEFORE I DO THAT, MAY I APPROACH, YOUR HONOR?

12:41PM	1	THE COURT: YES.
12:42PM	2	MR. LEACH: (HANDING.)
12:42PM	3	Q. MS. BENNETT, I'VE PLACED BEFORE YOU A BINDER OF DOCUMENTS.
12:42PM	4	IF YOU COULD TURN TO THE LAST TAB, EXHIBIT 5831?
12:42PM	5	A. OKAY.
12:42PM	6	Q. OKAY. DO YOU SEE AT THE TOP THERE APPEARS TO BE AN EMAIL
12:42PM	7	FROM LANGLY GEE?
12:42PM	8	A. I DO.
12:42PM	9	Q. OKAY. DO YOU KNOW MR. GEE?
12:42PM	10	A. I DO.
12:42PM	11	Q. OKAY. IS HE SOMEONE THAT YOU INTERACTED WITH IN THE
12:42PM	12	SURVEY?
12:42PM	13	A. YES.
12:42PM	14	Q. AND DID YOU UNDERSTAND THAT HE HAD RESPONSIBILITY FOR
12:42PM	15	QUALITY CONTROL AT THERANOS?
12:42PM	16	A. YES.
12:42PM	17	Q. AND THIS APPEARS TO BE AN EMAIL FROM MR. GEE TO
12:42PM	18	SUNNY BALWANI AND SOMEONE NAMED BRAD ARINGTON.
12:43PM	19	DO YOU SEE THAT?
12:43PM	20	A. YES.
12:43PM	21	Q. AND THE DATE OF THIS EMAIL IS JUNE 13TH, 2015.
12:43PM	22	DO YOU SEE THAT?
12:43PM	23	A. I DO.
12:43PM	24	Q. AND IS THAT BEFORE YOU ACTUALLY WENT IN TO CONDUCT THE
12:43PM	25	SURVEY?

12:43PM	1	A. YES.
12:43PM	2	Q. OKAY. THERE'S AN ATTACHMENT TO THIS EMAIL TO MR. BALWANI
12:43PM	3	BEGINNING ON PAGE 2.
12:43PM	4	DO YOU SEE THAT?
12:43PM	5	A. YES.
12:43PM	6	Q. AND YOU SEE THERE APPEARS TO BE A LETTER WITH A FORM
12:43PM	7	BEGINNING ON PAGE 5?
12:43PM	8	A. YES.
12:43PM	9	Q. DOWN AT THE BOTTOM OF PAGE 5 IS A LINE FORM CMS-2567.
12:43PM	10	DO YOU SEE THAT?
12:43PM	11	A. YES.
12:43PM	12	Q. AND ARE YOU FAMILIAR WITH THAT TYPE OF FORM?
12:43PM	13	A. YES.
12:43PM	14	Q. AND WHAT IS THAT FORM?
12:43PM	15	A. FORM CMS-2567, IT IS THE STATEMENT OF DEFICIENCIES FORM.
12:44PM	16	Q. IS THIS SOMETHING THAT YOU IS THE STATEMENT OF
12:44PM	17	DEFICIENCIES ATTACHED TO EXHIBIT 5831 SOMETHING THAT YOU
12:44PM	18	REVIEWED PRIOR TO YOUR SURVEY?
12:44PM	19	A. IT IS.
12:44PM	20	MR. LEACH: YOUR HONOR, THE GOVERNMENT OFFERS 5831.
12:44PM	21	MR. CAZARES: OBJECTION. HEARSAY AS TO THE EMAIL,
12:44PM	22	AS TO THE LETTER; DOUBLE HEARSAY AND FOUNDATION ON THE
12:44PM	23	ATTACHMENT TO THE LETTER, ATTACHMENTS; ALSO 403.
12:44PM	24	MR. LEACH: I'M OFFERING THIS FOR THE PURPOSE OF
12:44PM	25	NOTICE TO MR. BALWANI.

12:44PM	1	THE COURT: AND NOT FOR THE TRUTH OF THE MATTER
12:44PM	2	ASSERTED?
12:44PM	3	MR. LEACH: CORRECT.
12:44PM	4	THE COURT: IN ANY OF THESE DOCUMENTS, INCLUDING THE
12:44PM	5	ATTACHMENT?
12:44PM	6	MR. LEACH: CORRECT.
12:44PM	7	THE COURT: ALL RIGHT. THANK YOU.
12:44PM	8	LADIES AND GENTLEMEN, THE OBJECTION IS OVERRULED. THIS
12:45PM	9	WILL BE ADMITTED NOT FOR THE TRUTH OF THE MATTER ASSERTED IN
12:45PM	10	THE EMAILS NOR THE ATTACHMENTS, BUT ONLY AS TO THE ISSUE OF
12:45PM	11	NOTICE, NOTICE AS TO MR. BALWANI, AND FOR THAT PURPOSE THE
12:45PM	12	PROBATIVE VALUE OUTWEIGHS ANY PREJUDICIAL EFFECT.
12:45PM	13	SO IT CAN BE ADMITTED, AND IT MAY BE PUBLISHED FOR THAT
12:45PM	14	LIMITED PURPOSE.
12:45PM	15	MR. LEACH: THANK YOU, YOUR HONOR.
12:45PM	16	(GOVERNMENT'S EXHIBIT 5831 WAS RECEIVED IN EVIDENCE.)
12:45PM	17	BY MR. LEACH:
12:45PM	18	Q. IF WE CAN PLEASE ZOOM IN ON THE BOTTOM PORTION OF THIS
12:45PM	19	EMAIL, MS. WACHS.
12:45PM	20	MS. BENNETT, DO YOU SEE AT THE BOTTOM WHERE MR. BALWANI IS
12:45PM	21	EMAILING LANGLY GEE AND BRAD ARINGTON, "LANGLY.
12:45PM	22	"CAN YOU PLEASE EMAIL ME A COPY OF ALL OF OUR AUDIT
12:45PM	23	REPORTS."
12:45PM	24	DO YOU SEE THAT?
12:45PM	25	A. I DO.

12:45PM	1	Q. OKAY. AND IF WE CAN GO TO THE TOP, DO YOU SEE WHERE
12:45PM	2	MR. GEE WRITES, "SUNNY:
12:45PM	3	"ATTACHED ARE THE CLIA INSPECTION REPORT FOR 2013 AND THE
12:46PM	4	CORRECTIVE ACTIONS."
12:46PM	5	DO YOU SEE THAT?
12:46PM	6	A. I DO.
12:46PM	7	Q. AND PRIOR INSPECTION REPORTS ARE SOMETHING THAT YOU WOULD
12:46PM	8	REVIEW TO INFORM THE SURVEY THAT YOU WERE ABOUT TO CONDUCT IN
12:46PM	9	2015?
12:46PM	10	A. YES.
12:46PM	11	Q. LET'S LOOK AT PAGE 2.
12:46PM	12	DO YOU SEE ON PAGE 2 THERE'S A LETTER DATED DECEMBER 10TH,
12:46PM	13	2013?
12:46PM	14	A. YES.
12:46PM	15	Q. IF YOU WERE CONDUCTING YOUR SURVEY AT THE END OF 2015, IS
12:46PM	16	THAT CONSISTENT WITH THE TIME PERIOD WHEN THERANOS WOULD HAVE
12:46PM	17	BEEN HAD ITS MOST RECENT RECERTIFICATION INSPECTION?
12:46PM	18	A. YES.
12:46PM	19	Q. AND DID CMS CONDUCT THAT 2013 INSPECTION?
12:46PM	20	A. I BELIEVE THAT THE STATE AGENCY PERFORMED THAT SURVEY.
12:46PM	21	Q. OKAY. IS ARE THERE OCCASIONS WHEN THE STATE WILL
12:46PM	22	PERFORM INSPECTIONS RATHER THAN CMS?
12:46PM	23	A. YES.
12:46PM	24	Q. CAN YOU EXPLAIN THAT?
12:46PM	25	A. GENERALLY LABORATORIES THAT DON'T HAVE ANY CONFLICT OF

12:47PM	1	INTEREST OR ARE NOT FEDERAL LABORATORIES WOULD BE INSPECTED BY
12:47PM	2	THE STATE.
12:47PM	3	IT'S JUST IT'S DONE ON A CASE-BY-CASE BASIS. THERE ARE
12:47PM	4	SITUATIONS WHERE WE WOULD GO IN AND PERFORM A SURVEY, OR GO IN
12:47PM	5	JOINTLY WITH THE STATE TO PERFORM A SURVEY.
12:47PM	6	Q. OKAY. SO THERE ARE TIMES WHEN CMS WILL DO AN INSPECTION
12:47PM	7	ON ITS OWN?
12:47PM	8	A. YES.
12:47PM	9	Q. AND THERE ARE TIMES WHEN THE STATE MIGHT DO AN INSPECTION?
12:47PM	10	A. YES.
12:47PM	11	Q. AND THERE ARE TIMES WHEN THE STATE AND CMS MIGHT DO IT
12:47PM	12	TOGETHER?
12:47PM	13	A. YES.
12:47PM	14	Q. OKAY. DO YOU SEE THAT THIS LETTER IS ADDRESSED TO
12:47PM	15	DR. ROSENDORFF?
12:47PM	16	A. I DO.
12:47PM	17	Q. DO YOU KNOW SOMEONE NAMED ADAM ROSENDORFF?
12:47PM	18	A. I DO NOT.
12:47PM	19	Q. OKAY. AND IF WE COULD IF I COULD DRAW YOUR ATTENTION
12:47PM	20	TO PAGE 4, DO YOU SEE THAT THERE'S A SIGNATURE FROM SOMEONE
12:48PM	21	NAMED EILEEN NORKIN?
12:48PM	22	A. I DO.
12:48PM	23	Q. OKAY. DID SHE PARTICIPATE IN THE 2015 INSPECTION?
12:48PM	24	A. SHE DID NOT.
12:48PM	25	Q. AND THERE'S AN ENCLOSURE TO THIS LETTER "CMS-2567,

12:48PM	1	STATEMENT OF DEFICIENCIES."
12:48PM	2	IS THAT A FORM THAT YOU USE REGULARLY IN SURVEYS?
12:48PM	3	A. YES.
12:48PM	4	Q. AND LET'S LOOK AT THE NEXT PAGE OF 5831.
12:48PM	5	DO YOU SEE IN THE UPPER RIGHT CORNER THERE'S DATE SURVEY
12:48PM	6	COMPLETED, DECEMBER 3RD, 2013?
12:48PM	7	A. I DO.
12:48PM	8	Q. AND IS THAT CONSISTENT WITH THE TIME PERIOD WHEN
12:48PM	9	THERANOS'S RECERTIFICATION WOULD HAVE OCCURRED BACK THEN?
12:48PM	10	A. YES.
12:48PM	11	Q. AND TO THE RIGHT THERE'S A NUMBER OF TO THE RIGHT
12:48PM	12	THERE'S SOMETHING CALLED AN I.D. PREFIX TAG AND D5215.
12:49PM	13	DO YOU SEE THAT?
12:49PM	14	A. I DO.
12:49PM	15	Q. AND ARE YOU FAMILIAR WITH SOMETHING CALLED AN I.D. PREFIX
12:49PM	16	TAG?
12:49PM	17	A. YES. WE CALL THEM D-TAGS.
12:49PM	18	Q. AND WHAT IS A D-TAG?
12:49PM	19	A. THE D-TAG IS THE DEFICIENCY TAG, AND THE DEFICIENCY TAG IS
12:49PM	20	SPECIFICALLY ASSIGNED TO A REGULATION.
12:49PM	21	Q. AND WHAT IS THE PURPOSE OF THE 2567?
12:49PM	22	A. THE PURPOSE OF THE 2567 IS TO ALLOW THE LABORATORY TO KNOW
12:49PM	23	WHAT STANDARDS AND/OR CONDITIONS HAVE NOT BEEN MET SO THEY CAN
12:49PM	24	CORRECT THE DEFICIENCIES THAT WERE CITED.
12:49PM	25	Q. AND THE DEFICIENCY THAT IS LISTED HERE IS EVALUATION OF

12:49PM	1	PROFICIENCY PERFORMANCE.
12:49PM	2	DO YOU SEE THAT?
12:49PM	3	A. I DO.
12:49PM	4	Q. AND IS THIS SOMETHING THAT YOU REVIEWED PRIOR TO GOING
12:49PM	5	INTO THE LAB IN GOING INTO THERANOS'S LAB IN 2015?
12:49PM	6	A. IT IS.
12:49PM	7	THE COURT: AND, MR. LEACH, THIS IS PAGE 5 OF THE
12:49PM	8	EXHIBIT?
12:50PM	9	MR. LEACH: YES, YOUR HONOR.
12:50PM	10	THE COURT: OKAY. THANK YOU.
12:50PM	11	BY MR. LEACH:
12:50PM	12	Q. OKAY. WE CAN PUT THAT TO THE SIDE.
12:50PM	13	AND LET ME ASK YOU ABOUT, I WANT TO FOCUS ON THE TIME
12:50PM	14	PERIOD AT THE END OF SEPTEMBER OF 2015 WHEN YOU TRAVELLED TO
12:50PM	15	CALIFORNIA FOR THE INSPECTION.
12:50PM	16	DO YOU HAVE THAT TIME PERIOD IN MIND?
12:50PM	17	A. I DO.
12:50PM	18	Q. OKAY. HOW DID THE INSPECTION START? TELL US WHAT
12:50PM	19	HAPPENED.
12:50PM	20	A. WHEN WE GO IN TO DO AN INSPECTION, WE GENERALLY MEET WITH
12:50PM	21	THE REPRESENTATIVES OF THE LABORATORY THAT ARE INVOLVED WITH
12:50PM	22	THE SURVEY. WE CALL THAT THE ENTRANCE CONFERENCE.
12:50PM	23	TYPICALLY AFTER THAT TYPICALLY AFTER THAT WE ASK TO
12:50PM	24	TOUR THE LABORATORY.
12:50PM	25	AND ONCE WE TOUR THE LABORATORY, WE COME BACK AND WE START

12:50PM	1	LOOKING AT THE LABORATORY'S DOCUMENTS AND INTERVIEW STAFF AND
12:51PM	2	OBSERVE HOW TESTING IS OCCURRING, OR HOW EMPLOYEES ARE
12:51PM	3	PERFORMING TESTING.
12:51PM	4	AND WE THEN WILL, YOU KNOW, JUST ASSESS WHETHER THEY'VE
12:51PM	5	MET THE MINIMUM STANDARDS AND CONDITIONS THAT THEY'RE REQUIRED
12:51PM	6	TO MEET.
12:51PM	7	Q. AND ON THIS OCCASION WITH THERANOS, WAS THERE AN ENTRANCE
12:51PM	8	INTERVIEW?
12:51PM	9	A. THERE WAS.
12:51PM	10	Q. OKAY. WHO WAS PRESENT FOR THAT?
12:51PM	11	A. MR. BALWANI WAS THERE, DR. YOUNG WAS THERE, MR. SAKSENA.
12:51PM	12	I CAN'T REMEMBER HOW TO SAY IT. MS THERE WAS SEVERAL OTHER
12:51PM	13	STAFF. LANGLY GEE WAS THERE. THE GENERAL SUPERVISOR, GURBIR;
12:51PM	14	THE TECHNICAL CONSULTANT, HODA I'M SORRY I DON'T REMEMBER
12:52PM	15	THEIR LAST NAMES AND SEVERAL OTHER STAFF.
12:52PM	16	AND THERE WERE TWO ATTORNEYS THERE, HEATHER KING, AND I
12:52PM	17	DON'T REMEMBER THE NAME OF THE OTHER ATTORNEY.
12:52PM	18	Q. AND WHO WAS LEADING FROM THE THERANOS SIDE?
12:52PM	19	A. MR. BALWANI.
12:52PM	20	Q. AND WHY DO YOU SAY THAT?
12:52PM	21	A. BECAUSE HE TOOK CHARGE OF THE CONFERENCE, HE PRESENTED THE
12:52PM	22	POWERPOINT, THE STAFF DEFERRED TO HIM AND ALLOWED HIM TO TAKE
12:52PM	23	THE LEAD.
12:52PM	24	Q. WERE THERE OCCASIONS WHERE MR. BALWANI DIRECTED THERANOS
12:52PM	25	STAFF IN FRONT OF YOU TO PROVIDE DOCUMENTS?

12:52PM	1	A. YES.
12:52PM	2	Q. OKAY. WHAT DID HE SAY?
12:52PM	3	A. HE ASKED THEM TO GO FIND DOCUMENTS THAT WE WERE
12:52PM	4	REQUESTING.
12:52PM	5	Q. OKAY. AND YOU MENTIONED A POWERPOINT. WHAT DO YOU MEAN
12:52PM	6	BY THAT?
12:52PM	7	A. AS PART OF THE ENTRANCE, MR. BALWANI GAVE US A POWERPOINT
12:52PM	8	THAT WAS AN OVERVIEW OF THERANOS AND THE STAFF, THE TECHNICAL
12:53PM	9	STAFF, LIKE THE DIRECTOR OF ASSAYS, THE TECHNICAL CONSULT AT
12:53PM	10	ANY TIME, THE QA/QC QUALITY CONTROL MANAGER.
12:53PM	11	Q. LET ME PLEASE DIRECT YOUR ATTENTION TO TAB 5830.
12:53PM	12	DOES THIS APPEAR TO BE AN EMAIL FROM SUNNY BALWANI TO
12:53PM	13	OTHERS AT THERANOS DATED SEPTEMBER 22ND, 2015?
12:53PM	14	A. IT DOES.
12:53PM	15	Q. AND SEPTEMBER 22ND, 2015, IS THAT THE FIRST DAY OF YOUR
12:53PM	16	SURVEY?
12:53PM	17	A. YES.
12:53PM	18	Q. THERE'S AN ATTACHMENT TO THIS. IF I COULD DRAW YOUR
12:53PM	19	ATTENTION TO PAGE 2.
12:53PM	20	DO YOU SEE THAT?
12:53PM	21	A. YES.
12:53PM	22	Q. AND DOES THIS APPEAR TO BE A POWERPOINT?
12:53PM	23	A. YES.
12:54PM	24	Q. DOES THIS APPEAR TO BE A COPY OF THE POWERPOINT
12:54PM	25	PRESENTATION THAT MR. BALWANI MADE TO YOU AT THE OUTSET OF THE

12:54PM	1	SURVEY?
12:54PM	2	A. IT DOES.
12:54PM	3	MR. LEACH: YOUR HONOR, THE GOVERNMENT OFFERS
12:54PM	4	EXHIBIT 5830.
12:54PM	5	MR. CAZARES: OBJECTION. HEARSAY AND FOUNDATION AS
12:54PM	6	TO THE EMAIL.
12:54PM	7	MR. LEACH: 901 IS SATISFIED BY THE BATES NUMBER.
12:54PM	8	IT'S NOT HEARSAY BECAUSE IT'S A STATEMENT BY A PARTY
12:54PM	9	OPPONENT, AND THE WITNESS HAS JUST TESTIFIED THAT SHE RECEIVED
12:54PM	10	AN ITERATION OF THIS DIRECTLY FROM THE DEFENDANT.
12:54PM	11	THE COURT: THIS IS SUBJECT TO THE STIPULATION OF
12:54PM	12	THE PARTIES AS TO THE BATES NUMBERS?
12:54PM	13	MR. LEACH: YES.
12:55PM	14	THE COURT: ALL RIGHT. THANK YOU.
12:55PM	15	THE OBJECTION IS OVERRULED. AND THIS MAY BE ADMITTED AND
12:55PM	16	PUBLISHED.
12:55PM	17	(GOVERNMENT'S EXHIBIT 5830 WAS RECEIVED IN EVIDENCE.)
12:56PM	18	MR. LEACH: THERE WE GO. THANK YOU, MS. WACHS.
12:56PM	19	IF WE CAN ZOOM IN AT THE TOP BRIEFLY, MS. WACHS.
12:56PM	20	Q. DO YOU SEE AT THE TOP IN THE FROM LINE MR. BALWANI'S NAME?
12:56PM	21	A. I DO.
12:56PM	22	Q. AND IN THE TO LINE, THERE'S SOMEONE NAMED HEATHER KING.
12:56PM	23	DO YOU SEE THAT?
12:56PM	24	A. YES.
12:56PM	25	Q. AND DO YOU KNOW WHO MS. KING WAS?

12:56PM	1	A. I DO.
12:56PM	2	Q. AND WHO IS SHE?
12:56PM	3	A. SHE WAS AN ATTORNEY WHO WAS PRESENT AT THE SURVEY.
12:56PM	4	Q. LET ME DRAW YOUR ATTENTION TO PAGE 2.
12:56PM	5	DO YOU SEE THE HEADING THERANOS CLIA LABORATORY OVERVIEW,
12:56PM	6	9-22-15?
12:56PM	7	A. I DO.
12:56PM	8	Q. OKAY. LET'S GO TO PAGE 3, PLEASE.
12:56PM	9	DO YOU SEE THE HEADING NEWARK, CA, CLIA LABORATORY?
12:56PM	10	A. I DO.
12:56PM	11	Q. AND THIS SAYS, "THERANOS'S NEWARK CLIA LABORATORY
12:56PM	12	PROCESSES AN AVERAGE OF" 2,000 "PATIENT SAMPLES PER DAY."
12:56PM	13	IS THAT CONSISTENT WITH STATEMENTS THAT MR. BALWANI MADE
12:57PM	14	TO YOU DURING THE INSPECTION?
12:57PM	15	A. I SEE 200.
12:57PM	16	Q. 200, EXCUSE ME. I MISSPOKE.
12:57PM	17	IS THE 200 PATIENT SAMPLES PER DAY CONSISTENT WITH WHAT
12:57PM	18	MR. BALWANI TOLD YOU DURING THE INSPECTION?
12:57PM	19	A. I WOULD SAY, YES, IT'S IN THE POWERPOINT. THAT'S HOW IT
12:57PM	20	WAS PRESENTED.
12:57PM	21	Q. OKAY. TO THE RIGHT THERE'S A COPY OF A STATE OF
12:57PM	22	CALIFORNIA DEPARTMENT OF PUBLIC HEALTH CLINICAL LABORATORY
12:57PM	23	LICENSE.
12:57PM	24	DO YOU SEE THAT?
12:57PM	25	A. I DO.

12:57PM	1	Q. AND THERE'S TWO DIRECTORS LISTED, SUNIL DHAWAN AND
12:57PM	2	LYNETTE SAWYER.
12:57PM	3	DO YOU SEE THAT?
12:57PM	4	A. I DO.
12:57PM	5	Q. AND HAVE YOU EVER MET LYNETTE SAWYER?
12:57PM	6	A. I HAVE NOT.
12:57PM	7	Q. AND WAS SUNIL DHAWAN PRESENT FOR THE SURVEY?
12:57PM	8	A. FOR A SHORT PERIOD OF TIME.
12:57PM	9	Q. WHAT DO YOU MEAN, "A SHORT PERIOD OF TIME"?
12:57PM	10	A. HE WAS THERE I WOULD SAY AN HOUR OR TWO ONE OF THE DAYS.
12:57PM	11	Q. OKAY. DID HE SAY ANYTHING?
12:57PM	12	A. NO.
12:57PM	13	Q. OKAY. LET'S LOOK AT THE NEXT PAGE, PLEASE.
12:58PM	14	DO YOU SEE THE HEADING CLIA LABORATORY NEWARK, CA?
12:58PM	15	A. I DO.
12:58PM	16	Q. AND IN THE LAST TWO BULLET POINTS IT SAYS, "HIGH
12:58PM	17	COMPLEXITY LABORATORY.
12:58PM	18	"ALL TESTS PROCESSED ON FDA-CLEARED AND APPROVED ANALYZERS
12:58PM	19	AND VALIDATED LDT'S."
12:58PM	20	DO YOU SEE THAT LANGUAGE?
12:58PM	21	A. I DO.
12:58PM	22	Q. AND WHAT DID YOU UNDERSTAND THAT TO MEAN?
12:58PM	23	A. I UNDERSTOOD THAT TO MEAN THAT THE LABORATORY WAS USING
12:58PM	24	ANY THE TESTS THAT THEY WERE USING WERE BEING USED ON
12:58PM	25	COMMERCIAL INSTRUMENTS, AND THAT THEY ALSO HAD LDT'S.

12:58PM	1	Q. AND THE REFERENCE TO "HIGH COMPLEXITY LABORATORY," DID YOU
12:58PM	2	UNDERSTAND THAT THE NEWARK LABORATORY WAS PERFORMING LDT'S?
12:58PM	3	A. I DID.
12:58PM	4	Q. OKAY. WERE YOU ALSO AWARE THAT THERANOS HAD ANOTHER
12:58PM	5	LABORATORY IN ARIZONA?
12:59PM	6	A. I WAS.
12:59PM	7	Q. OKAY. AND WAS THAT LABORATORY HIGH COMPLEXITY? MODERATE
12:59PM	8	COMPLEXITY? OR SOMETHING ELSE?
12:59PM	9	A. MY UNDERSTANDING WAS THAT THEY ONLY PERFORMED UP TO
12:59PM	10	MODERATE COMPLEXITY TESTS, NO HIGH COMPLEXITY TESTS.
12:59PM	11	Q. AND WHAT DOES THAT MEAN?
12:59PM	12	A. THAT MEANS THAT THEY WERE PERFORMING NON-WAIVED TESTS THAT
12:59PM	13	WERE MODERATE COMPLEXITY AND WAIVED TESTS.
12:59PM	14	Q. OKAY. DID YOU HAVE AN UNDERSTANDING THAT LDT'S WERE BEING
12:59PM	15	PERFORMED IN THE ARIZONA LAB?
12:59PM	16	A. I DID NOT.
12:59PM	17	Q. AND AN LDT IS IF YOU'RE USING YOUR OWN NON-FDA APPROVED
12:59PM	18	DEVICE, LIKE THE EDISON, OR MODIFYING AN FDA APPROVED DEVICE,
12:59PM	19	LIKE A SIEMENS ANALYZER?
12:59PM	20	A. YES.
12:59PM	21	Q. OKAY. LET ME DRAW YOUR ATTENTION TO PAGE 10.
01:00PM	22	DO YOU SEE THE HEAD CLIA LABORATORY NEWARK, CALIFORNIA.
01:00PM	23	"ANALYZERS WE USE"?
01:00PM	24	A. YES.
01:00PM	25	Q. OKAY. AND ARE YOU GENERALLY FAMILIAR WITH THE ANALYZERS

01:00PM	1	THAT ARE LISTED ON THIS PAGE?
01:00PM	2	A. YES.
01:00PM	3	Q. ARE THESE ANALYZERS THAT ARE APPROVED BY THE FDA?
01:00PM	4	A. YES.
01:00PM	5	Q. AND DO YOU SEE ANY REFERENCE TO THE EDISON OR A DEVICE
01:00PM	6	MANUFACTURED BY THERANOS?
01:00PM	7	A. I DO NOT.
01:00PM	8	Q. LET ME DRAW YOUR ATTENTION TO PAGE 20.
01:00PM	9	DO YOU SEE THE NAME LANGLY GEE WITH A TITLE TO THE LEFT
01:00PM	10	AND A DESCRIPTION TO THE RIGHT?
01:00PM	11	A. I DO.
01:00PM	12	Q. AND MR. GEE, THAT'S SOMEONE THAT YOU INTERACTED WITH
01:01PM	13	DURING THE SURVEY?
01:01PM	14	A. YES.
01:01PM	15	Q. YOU HAD A NUMBER OF REQUESTS OF DOCUMENTS FOR HIM?
01:01PM	16	A. YES, I DID.
01:01PM	17	Q. WAS IT EASY TO GET INFORMATION FROM MR. GEE?
01:01PM	18	A. IT WAS NOT.
01:01PM	19	Q. WHAT DO YOU MEAN BY THAT?
01:01PM	20	A. MR. GEE DID NOT APPEAR TO BE ABLE TO ANSWER THE QUESTIONS
01:01PM	21	THAT I ASKED. HE WAS NOT ABLE TO BRING US DOCUMENTS IN A
01:01PM	22	TIMELY MANNER. AND WHEN THE DOCUMENTS WERE GIVEN TO US, OFTEN
01:01PM	23	THEY WERE NOT WHAT WE HAD REQUESTED.
01:01PM	24	Q. OKAY. AND IF WE COULD GO TO THE NEXT PAGE, PLEASE,
01:01PM	25	THERE'S A BIOGRAPHY FOR MR. BALWANI.

01:01PM	1	DO YOU SEE THAT?
01:01PM	2	A. IS I DO.
01:01PM	3	Q. AND DO YOU SEE THAT HE'S LISTED AS PRESIDENT AND COO OF
01:01PM	4	THERANOS, INC.?
01:01PM	5	A. I DO.
01:01PM	6	Q. AND DO YOU SEE IN THE UPPER RIGHT-HAND CORNER WHERE IT
01:01PM	7	SAYS, "RESPONSIBLE FOR ALL CLIA LAB BUSINESS OPERATIONS."
01:02PM	8	DO YOU SEE THAT?
01:02PM	9	A. I DO.
01:02PM	10	Q. AND WHAT DID YOU UNDERSTAND THAT TO MEAN?
01:02PM	11	A. I UNDERSTOOD THAT TO MEAN THAT MR. BALWANI WAS RESPONSIBLE
01:02PM	12	FOR ALL OF THE BUSINESS THAT THE THAT THERANOS DID,
01:02PM	13	INCLUDING THE LABORATORY.
01:02PM	14	Q. AND WAS THAT CONSISTENT WITH THE ROLE THAT MR. BALWANI WAS
01:02PM	15	PLAYING IN THIS ENTRANCE INTERVIEW THAT YOU WERE PARTICIPATING
01:02PM	16	IN?
01:02PM	17	A. IT WAS.
01:02PM	18	Q. OKAY. AND LET'S ALSO LOOK BRIEFLY AT PAGE 12.
01:02PM	19	DOES THIS APPEAR TO BE AN ORG CHART FOR THE CLIA
01:02PM	20	LABORATORIES?
01:02PM	21	A. YES.
01:02PM	22	Q. AND DO YOU SEE MR. BALWANI AS PRESIDENT AND COO AT THE TOP
01:02PM	23	ON THE RIGHT?
01:02PM	24	A. I DO.
01:02PM	25	Q. OKAY. AND THEN BENEATH HIM IS DR. DHAWAN?

01:02PM	1	A. YES.
01:02PM	2	Q. AND THEN TO THE RIGHT DO YOU SEE LANGLY GEE'S NAME?
01:02PM	3	A. YES.
01:02PM	4	Q. AND THERE'S A BOX FOR CLINICAL LABORATORY ASSISTANTS, BUT
01:03PM	5	THERE'S NOBODY'S NAME IS LISTED THERE.
01:03PM	6	DO YOU SEE THAT?
01:03PM	7	A. YES.
01:03PM	8	Q. LET ME NEXT DRAW YOUR ATTENTION TO EXHIBIT 5450.
01:03PM	9	DO YOU RECOGNIZE THIS DOCUMENT?
01:03PM	10	A. YES.
01:03PM	11	Q. AND WHAT IS THIS?
01:03PM	12	A. THIS IS A FORM CMS 116, WHICH IS THE CLIA APPLICATION.
01:03PM	13	Q. AND HOW DID YOU GET THIS?
01:03PM	14	A. EVERY TIME A SURVEYOR GOES ON AN INSPECTION, THE
01:03PM	15	LABORATORY NEEDS TO FILL OUT THIS DOCUMENT SO THAT WE HAVE
01:03PM	16	UPDATED INFORMATION FOR THE LABORATORY.
01:03PM	17	Q. OKAY. SO IS THIS SOMETHING THAT YOU RECEIVED AT OR AROUND
01:03PM	18	THE TIME OF THE INSPECTION?
01:03PM	19	A. YES.
01:03PM	20	Q. OKAY. LET ME DRAW YOUR ATTENTION TO PAGE 7.
01:04PM	21	DO YOU SEE A SIGNATURE IN THE LINE FOR SIGNATURE OF
01:04PM	22	OWNER/DIRECTOR OF LABORATORY?
01:04PM	23	A. I DO.
01:04PM	24	Q. AND DO YOU SEE A DATE OF SEPTEMBER 22ND, 2015?
01:04PM	25	A. YES.

01:04PM	1	Q. AND YOU BELIEVE THIS WAS PROVIDED TO YOU AT OR AROUND THE
01:04PM	2	START OF THE INSPECTION?
01:04PM	3	A. YES.
01:04PM	4	Q. OKAY.
01:04PM	5	YOUR HONOR, THE GOVERNMENT
01:04PM	6	AND IS THIS SOMETHING THAT YOU CONSIDERED IN THE COURSE OF
01:04PM	7	YOUR INSPECTION?
01:04PM	8	A. YES.
01:04PM	9	MR. LEACH: YOUR HONOR, THE GOVERNMENT OFFERS
01:04PM	10	EXHIBIT 5450.
01:04PM	11	MR. CAZARES: NO OBJECTION.
01:04PM	12	THE COURT: IT'S ADMITTED. IT MAY BE PUBLISHED.
01:04PM	13	(GOVERNMENT'S EXHIBIT 5450 WAS RECEIVED IN EVIDENCE.)
01:04PM	14	BY MR. LEACH:
01:04PM	15	Q. IF WE COULD PLEASE ZOOM IN ON THE TOP HALF, MS. WACHS.
01:04PM	16	DO YOU SEE THE HEADING CLINICAL LABORATORY IMPROVEMENT
01:04PM	17	AMENDMENTS APPLICATION FOR CERTIFICATION?
01:04PM	18	A. YES.
01:04PM	19	Q. AND NUMBER 1, GENERAL INFORMATION, THERE'S A NUMBER OF
01:05PM	20	BOXES: INITIAL APPLICATION, SURVEY, CHANGE INSERT TYPE.
01:05PM	21	WHAT IS THIS FORM GETTING AT THERE?
01:05PM	22	A. THIS FORM INDICATES THAT THIS WAS FILLED THAT THIS
01:05PM	23	PARTICULAR APPLICATION WAS FILLED OUT AS A RESULT OF A SURVEY.
01:05PM	24	Q. AS OPPOSED TO THE INITIAL APPLICATION TO BE A LABORATORY?
01:05PM	25	A. YES.

01:05PM	1	Q. OKAY. AND IF WE COULD ZOOM DOWN.
01:05PM	2	DO YOU SEE THE NAME OF THE DIRECTOR AS SUNIL DHAWAN?
01:05PM	3	A. I DO.
01:05PM	4	Q. OKAY. IF WE CAN GO DOWN FURTHER TO THE TYPE OF
01:05PM	5	CERTIFICATE REQUESTED.
01:05PM	6	DO YOU SEE THERE'S FOUR BOXES, BEGINNING CERTIFICATE OF
01:05PM	7	WAIVER AND ENDING INSERT OF ACCREDITATION?
01:05PM	8	A. YES.
01:05PM	9	Q. AND THOSE ARE THE CERTIFICATES THAT YOU TALKED ABOUT
01:05PM	10	EARLIER?
01:05PM	11	A. YES.
01:05PM	12	Q. OKAY. AND IN THIS CASE THERANOS WAS APPLYING, OR
01:05PM	13	RECERTIFYING A CERTIFICATE OF COMPLIANCE?
01:05PM	14	A. CORRECT.
01:05PM	15	Q. OKAY. LET'S GO TO PAGE 5.
01:06PM	16	UP AT THE TOP THERE'S A PROVISION FOR WAIVED TESTING.
01:06PM	17	DO YOU SEE THAT?
01:06PM	18	A. I DO.
01:06PM	19	Q. AND IF WE COULD ACTUALLY, MS. WACHS, IF WE CAN CAPTURE
01:06PM	20	THE WHOLE PART OF SECTION 6. PERFECT. THANK YOU.
01:06PM	21	WHAT IS WAIVED TESTING?
01:06PM	22	A. THOSE WAIVED TESTS ARE TESTS THAT ARE EASY TO PERFORM AND
01:06PM	23	THERE'S A LOW RISK, IF THERE'S AN ERRONEOUS RESULT, IN PATIENT
01:06PM	24	HARM.
01:06PM	25	Q. AND THERE'S AN EXAMPLE, ACME HOME GLUCOSE METER.

1	DO YOU SEE THAT?
2	A. YES.
3	Q. AND IS THAT INDICATIVE OF WHAT A WAIVED TEST IS?
4	A. YES.
5	Q. AND THERE'S A LINE, "INDICATE THE ESTIMATED TOTAL ANNUAL
6	TEST VOLUME OF ALL WAIVED TESTS PERFORMED."
7	THERE'S THE NUMBER 776.
8	DO YOU SEE THAT?
9	A. I DO.
10	Q. AND WHAT DID YOU UNDERSTAND THAT TO MEAN?
11	A. THAT THERANOS WAS PERFORMING 776 TOTAL TEST VOLUME OF ALL
12	WAIVED TESTS.
13	Q. IF WE CAN NOW PLEASE ZOOM DOWN TO SECTION 8, THERE'S A
14	HEADING, NON-WAIVED TESTING. IF WE CAN GET THE ENTIRE PORTION
15	DOWN TO THE BOTTOM.
16	AND IT SAYS WHAT IS A NON-WAIVED TEST?
17	A. IT'S A TEST THAT IS EITHER MODERATE OR HIGH COMPLEXITY.
18	IT IS NOT WAIVED.
19	Q. OKAY. AND THERE ARE SOME NUMBERS LISTED ON THIS CHART.
20	17,170 FOR MICROBIOLOGY; 280,763 DIAGNOSTIC IMMUNOLOGY; 683,939
21	FOR CHEMISTRY.
22	DO YOU SEE THOSE NUMBERS?
23	A. I DO.
24	Q. AND WHAT DO YOU UNDERSTAND THOSE TO REPRESENT?
25	A. THAT IS THE NUMBER THAT IS THE LABORATORY'S ANNUAL TEST
	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

01:08PM	1	VOLUME.
01:08PM	2	SO THEY'RE PERFORMING IF YOU LOOK AT MICROBIOLOGY,
01:08PM	3	THEIR ANNUAL TEST VOLUME FOR MICROBIOLOGY IS 17,170 TESTS.
01:08PM	4	IF YOU LOOK AT MICROBIOLOGY, THE TOTAL TEST VOLUME, NUMBER
01:08PM	5	OF MICROBIOLOGY TESTS THAT THEY PERFORM IN A YEAR IS 17,170.
01:08PM	6	THAT'S A SELF-REPORTED NUMBER.
01:08PM	7	Q. SO THAT'S A NUMBER THAT THERANOS GIVES YOU?
01:08PM	8	A. YES.
01:08PM	9	Q. OKAY. AND IF WE LOOK IN THE BOTTOM RIGHT CORNER, IT SAYS,
01:08PM	10	"TOTAL ESTIMATE ANNUAL TEST VOLUME," AND THERE'S A NUMBER
01:08PM	11	894,782.
01:08PM	12	DO YOU SEE THAT NUMBER?
01:08PM	13	A. I DO.
01:08PM	14	Q. AND WHAT DID YOU UNDERSTAND THAT TO BE?
01:08PM	15	A. THAT IS THE TOTAL NUMBER OF TESTS ACROSS ALL OF THE
01:08PM	16	SPECIALTIES AND SUBSPECIALTIES THAT THERANOS PERFORMED IN A
01:09PM	17	YEAR, ONE YEAR.
01:09PM	18	Q. LET ME NEXT DRAW YOUR ATTENTION TO EXHIBIT 5451.
01:09PM	19	ARE YOU FAMILIAR WITH THIS DOCUMENT?
01:09PM	20	A. YES.
01:09PM	21	Q. AND WHAT IS THIS?
01:09PM	22	A. THIS IS A LIST OF THE TESTS THAT THERANOS PERFORMED AND
01:09PM	23	THE NAME OF THE INSTRUMENT OR DEVICE "INSTRUMENT" AND
01:09PM	24	"DEVICE" WE USE INTERCHANGEABLY ON WHICH THEY PERFORM THOSE
01:09PM	25	TESTS.

01:09PM	1	Q. AND IS THIS SOMETHING THAT WAS PROVIDED TO YOU DURING THE
01:09PM	2	INSPECTION?
01:09PM	3	A. YES.
01:09PM	4	Q. OKAY. AND WAS THIS SOMETHING THAT YOU RELIED ON IN THE
01:09PM	5	COURSE OF CONDUCTING YOUR WORK?
01:09PM	6	A. WE DID.
01:09PM	7	Q. OKAY.
01:09PM	8	YOUR HONOR, THE GOVERNMENT OFFERS EXHIBIT 5451.
01:09PM	9	MR. CAZARES: NO OBJECTION.
01:09PM	10	THE COURT: IT'S ADMITTED. IT MAY BE PUBLISHED.
01:09PM	11	(GOVERNMENT'S EXHIBIT 5451 WAS RECEIVED IN EVIDENCE.)
01:10PM	12	BY MR. LEACH:
01:10PM	13	Q. MS. BENNETT, I DRAW YOUR ATTENTION TO THE LEFT COLUMN.
01:10PM	14	THERE'S A HEADING DEVICE NAMES.
01:10PM	15	DO YOU SEE THAT?
01:10PM	16	A. I DO.
01:10PM	17	Q. AND TO THE RIGHT THERE'S A COLUMN ASSAY NAME.
01:10PM	18	DO YOU SEE THAT?
01:10PM	19	A. YES.
01:10PM	20	Q. AND UNDER THE COLUMN DEVICE NAMES, THERE'S SOMETHING
01:10PM	21	CALLED ABBOTT M2000, CARDTEST, EVOLVIS, VITEK MASS SPEC,
01:10PM	22	SIEMENS ADVIA XPT.
01:10PM	23	DO YOU SEE THAT?
01:10PM	24	A. YES.
01:10PM	25	Q. ARE THOSE FDA APPROVED DEVICES?

01:10PM	1	A. YES, THOSE ARE COMMERCIAL DEVICES.
01:10PM	2	Q. LET ME DRAW YOUR ATTENTION TO PAGE 3.
01:10PM	3	THERE'S AN ADDITIONAL LISTING OF SIEMENS ADVIA AND BCSXP
01:10PM	4	DEVICES.
01:10PM	5	DO YOU SEE THAT?
01:10PM	6	A. I DO, THE BCSXP.
01:10PM	7	Q. OKAY. ARE THOSE COMMERCIALLY AVAILABLE DEVICES?
01:10PM	8	A. YES.
01:10PM	9	Q. AND LET'S LOOK AT PAGE 5, PLEASE.
01:11PM	10	DO YOU SEE AN ADDITIONAL LISTING OF COMMERCIALLY AVAILABLE
01:11PM	11	DEVICES IN THE LEFT-HAND CORNER UNDER DEVICE NAME?
01:11PM	12	A. YES.
01:11PM	13	Q. AND SAME QUESTION ON PAGE 7.
01:11PM	14	A. YES.
01:11PM	15	Q. SAME QUESTION ON PAGE 9.
01:11PM	16	A. YES.
01:11PM	17	Q. THANK YOU. WE CAN TAKE THAT DOWN, MS. WACHS.
01:11PM	18	AND LET ME DRAW YOUR ATTENTION TO EXHIBIT 5453.
01:11PM	19	ARE YOU FAMILIAR WITH THIS DOCUMENT?
01:11PM	20	A. YES.
01:11PM	21	Q. AND WHAT IS IT?
01:11PM	22	A. THIS IS ALSO A LIST OF TESTS THAT WERE PROVIDED TO US AT
01:12PM	23	THE SURVEY OF THE LAB, TESTS THAT THERANOS WAS PERFORMING AS OF
01:12PM	24	JUNE 12TH, 2015.
01:12PM	25	Q. AND WAS THIS SOMETHING THAT WAS PROVIDED TO YOU DURING THE

01:12PM	1	INSPECTION?
01:12PM	2	A. YES.
01:12PM	3	Q. IS IT SOMETHING THAT YOU RELIED ON?
01:12PM	4	A. YES.
01:12PM	5	MR. LEACH: YOUR HONOR, THE GOVERNMENT OFFERS
01:12PM	6	EXHIBIT 5453.
01:12PM	7	MR. CAZARES: NO OBJECTION.
01:12PM	8	THE COURT: IT'S ADMITTED. IT MAY BE PUBLISHED.
01:12PM	9	(GOVERNMENT'S EXHIBIT 5453 WAS RECEIVED IN EVIDENCE.)
01:12PM	10	BY MR. LEACH:
01:12PM	11	Q. MS. BENNETT, DO YOU SEE THE HEADING THERANOS CLINICAL LAB
01:12PM	12	TESTS AS OF JUNE 12TH, 2015?
01:12PM	13	A. YES.
01:12PM	14	Q. OKAY. AND THIS WAS SOMETHING THAT THERANOS PROVIDED
01:12PM	15	PREPARED AND PROVIDED TO YOU; CORRECT?
01:12PM	16	A. YES.
01:12PM	17	Q. OKAY. AND THERE'S A COLUMN CALLED ASSAY NAME.
01:12PM	18	DO YOU SEE THAT?
01:12PM	19	A. I DO.
01:12PM	20	Q. AND DO YOU HAVE HIGH LEVEL FAMILIARITY WITH THE ASSAYS
01:12PM	21	THAT ARE LISTED HERE?
01:12PM	22	A. THE MAJORITY OF THEM, YES.
01:12PM	23	Q. AND TO THE RIGHT THERE'S A COLUMN TEST CLASSIFICATION.
01:12PM	24	DO YOU SEE THAT?
01:12PM	25	A. I DO.

01:12PM	1	Q. AND THE FIRST FOUR LINES, OR THREE LINES, SAY FDA CLEARED
01:12PM	2	OR APPROVED.
01:12PM	3	DO YOU SEE THAT?
01:13PM	4	A. I DO.
01:13PM	5	Q. AND WHAT DID YOU UNDERSTAND THAT TO MEAN?
01:13PM	6	A. I UNDERSTOOD THAT TO MEAN THAT THESE WERE BEING PERFORMED
01:13PM	7	ON COMMERCIALLY AVAILABLE DEVICES.
01:13PM	8	Q. THAT HAD NO MODIFICATIONS?
01:13PM	9	A. NO MODIFICATIONS.
01:13PM	10	Q. OKAY. THAT WERE BEING RUN THE WAY THE MANUFACTURER HAD
01:13PM	11	PROVIDED FOR?
01:13PM	12	A. YES, THAT THE LABORATORY WAS FOLLOWING THE MANUFACTURER'S
01:13PM	13	INSTRUCTIONS.
01:13PM	14	Q. OKAY. IN THE FOURTH ROW TO THE RIGHT OF ALANINE AMINO, IT
01:13PM	15	SAYS LDT.
01:13PM	16	DO YOU SEE THAT?
01:13PM	17	A. I DO.
01:13PM	18	Q. AND WHAT DID YOU UNDERSTAND THAT TO MEAN?
01:13PM	19	A. I UNDERSTOOD THAT TO MEAN THAT IF THEY WERE USING AN FDA
01:13PM	20	CLEARED OR APPROVED DEVICE, THAT IT HAD BEEN MODIFIED.
01:13PM	21	Q. AND IF WE COUNT UP THE NUMBER OF LDT'S IN THE ROWS, BY MY
01:13PM	22	COUNT I GET ABOUT EIGHT. AM I COUNTING THOSE RIGHT?
01:13PM	23	A. I GET EIGHT AS WELL.
01:13PM	24	Q. OKAY. AND THE MAJORITY ON THIS PAGE ARE FDA CLEARED OR
01:14PM	25	APPROVED TESTS?

01:14PM	1	A. YES.
01:14PM	2	Q. OKAY. LET'S LOOK AT THE NEXT PAGE, PLEASE. THIS IS
01:14PM	3	PAGE 2.
01:14PM	4	DO YOU SEE ADDITIONAL LISTING OF TESTS TO THE LEFT AND THE
01:14PM	5	FDA CLEARED OR APPROVED LDT ON THE RIGHT?
01:14PM	6	A. YES.
01:14PM	7	Q. AND IF I COUNT THE NUMBER OF LDT'S, I'M ALSO GETTING EIGHT
01:14PM	8	ON THIS PAGE.
01:14PM	9	AM I COUNTING THAT CORRECTLY?
01:14PM	10	A. YES.
01:14PM	11	Q. SO A TOTAL OF 16 SO FAR?
01:14PM	12	A. YES.
01:14PM	13	Q. AND THE MAJORITY OF THE TESTS ON THIS PAGE ARE BEING
01:14PM	14	LISTED AS BEING FDA CLEARED OR APPROVED; IS THAT CORRECT?
01:14PM	15	A. YES.
01:14PM	16	Q. LET'S LOOK AT PAGE 3, PLEASE. DO YOU SEE THAT THERE ARE
01:14PM	17	TWO LDT'S ON THIS PAGE?
01:14PM	18	A. I DO.
01:14PM	19	Q. AND SO NOW WE'RE UP TO 18 TOTAL ON THE THREE PAGES?
01:14PM	20	A. YES.
01:14PM	21	Q. AND THE MAJORITY ON THIS PAGE ARE LISTED AS BEING FDA
01:15PM	22	CLEARED OR APPROVED TESTS?
01:15PM	23	A. YES.
01:15PM	24	Q. IF WE CAN LOOK AT PAGE 4.
01:15PM	25	DO YOU SEE AN ADDITIONAL LISTING OF ASSAYS AND A COLUMN

01:15PM	1	FOR FDA CLEARED OR APPROVED FOR LDT'S?
01:15PM	2	A. YES.
01:15PM	3	Q. AND BY MY COUNT I HAVE 12 LDT'S ON THIS PAGE.
01:15PM	4	A. YES.
01:15PM	5	Q. AND ARE THE MAJORITY ON THIS PAGE FDA CLEARED OR APPROVED
01:15PM	6	ASSAYS?
01:15PM	7	A. YES.
01:15PM	8	Q. AND BY MY COUNT WE'RE UP TO 28.
01:16PM	9	A. YES.
01:16PM	10	Q. LET'S LOOK AT PAGE 5, PLEASE.
01:16PM	11	DO YOU SEE SEVEN LDT'S LISTED ON THIS PAGE?
01:16PM	12	A. I DO.
01:16PM	13	Q. AND ARE THE MAJORITY FDA CLEARED OR APPROVED ASSAYS?
01:16PM	14	A. YES.
01:16PM	15	Q. AND ARE WE UP TO 35 LDT'S?
01:16PM	16	A. YES.
01:16PM	17	Q. LET'S LOOK AT PAGE 6.
01:16PM	18	DO YOU SEE FOUR ADDITIONAL LDT'S?
01:16PM	19	A. I DO.
01:16PM	20	Q. AND THE MAJORITY ON THIS PAGE ARE FDA CLEARED OR APPROVED
01:16PM	21	ASSAYS?
01:16PM	22	A. YES.
01:16PM	23	Q. AND SO NOW WE'RE UP TO 39 LDT'S AS OF JUNE 12TH, 2015?
01:16PM	24	A. YES.
01:16PM	25	Q. THANK YOU. WE CAN TAKE THAT DOWN, MS. WACHS.

01:21PM	1	IN YOUR ENTRANCE INTERVIEW WITH MR. BALWANI, DID YOU ASK
01:21PM	2	QUESTIONS AROUND OR DID MR. BALWANI MAKE STATEMENTS ABOUT WHAT
01:21PM	3	ASSAYS THERANOS WAS PERFORMING IN ITS LAB?
01:21PM	4	A. I DON'T RECALL IF HE MADE A SPECIFIC STATEMENT.
01:21PM	5	Q. OKAY. AT THE START OF THE ENTRANCE EXAM, DID MR. BALWANI
01:21PM	6	VOLUNTEER THE FACT THAT THERANOS HAD BEEN USING AN FDA APPROVED
01:21PM	7	DEVICE THAT IT HAD MANUFACTURED?
01:21PM	8	A. YES.
01:21PM	9	Q. AND HOW DID THAT COME UP?
01:21PM	10	A. AS A RESULT OF ONE OF THE COMPLAINTS, IT WAS RELATED TO
01:21PM	11	THE EDISON DEVICE, AND SO I ASKED FOR A LIST OF THE TESTS THAT
01:21PM	12	WERE BEING RUN ON THE EDISON DEVICE.
01:21PM	13	Q. OKAY. WAS THAT SOMETHING THAT YOU SPECIFICALLY HAD TO ASK
01:21PM	14	MR. BALWANI FOR?
01:21PM	15	A. YES.
01:21PM	16	Q. AND WHAT DO YOU MEAN BY THAT? LIKE HOW DID IT COME ABOUT?
01:21PM	17	A. AS A RESULT OF THE COMPLAINT, WE HAD TO LOOK INTO TESTING
01:21PM	18	ON THE EDISON AND WHETHER IT WAS ACCURATE OR RELIABLE.
01:21PM	19	SO I ASKED FOR A LIST, AND MR. BALWANI TOLD ME THAT THEY
01:21PM	20	WERE NO LONGER USING THE EDISON DEVICE.
01:21PM	21	Q. AND WAS THAT EXPLANATION SATISFACTORY TO YOU?
01:21PM	22	A. NO.
01:21PM	23	Q. WHY NOT?
01:21PM	24	A. I NEEDED TO KNOW, BECAUSE OF THE COMPLAINT, WHEN THEY
01:21PM	25	STARTED USING THE EDISON DEVICE AND WHEN THEY STOPPED USING THE

01:21PM	1	EDISON DEVICE, SO I REQUESTED THAT INFORMATION.
01:21PM	2	Q. AND DID MR. BALWANI ULTIMATELY PROVIDE YOU A LIST OF WHAT
01:21PM	3	HAD BEEN TESTED ON THE EDISON DEVICE?
01:21PM	4	A. HE DID.
01:21PM	5	Q. OKAY. LET ME DRAW YOUR ATTENTION TO EXHIBIT 4533.
01:21PM	6	DO YOU RECOGNIZE THIS DOCUMENT?
01:21PM	7	A. I DO.
01:21PM	8	Q. AND WHAT IS THIS?
01:21PM	9	A. THIS IS THE DOCUMENT THAT MR. BALWANI PROVIDED ME AS A
01:21PM	10	RESULT OF MY REQUEST.
01:21PM	11	Q. AND THERE'S A DATE, SEPTEMBER 23RD, 2015.
01:21PM	12	DO YOU SEE THAT?
01:21PM	13	A. I DO.
01:21PM	14	Q. WAS THAT THE SECOND DAY OF YOUR SURVEY?
01:21PM	15	A. IT WAS.
01:21PM	16	Q. AND WAS THIS SOMETHING THAT YOU HAD TO SPECIFICALLY ASK
01:21PM	17	FOR?
01:21PM	18	A. YES.
01:21PM	19	Q. OKAY.
01:21PM	20	MR. LEACH: YOUR HONOR, THE GOVERNMENT OFFERS
01:21PM	21	EXHIBIT 4533.
01:21PM	22	MR. CAZARES: NO OBJECTION.
01:21PM	23	THE COURT: IT'S ADMITTED. IT MAY BE PUBLISHED.
01:21PM	24	(GOVERNMENT'S EXHIBIT 4533 WAS RECEIVED IN EVIDENCE.)
01:21PM	25	MR. LEACH: IF WE COULD PLEASE ZOOM IN ON THE TOP

01:21PM	1	HALF OF THIS, MS. WACHS.
01:21PM	2	Q. DO YOU SEE THE DATE SEPTEMBER 23RD, 2015?
01:21PM	3	A. YES.
01:21PM	4	Q. AND THIS SAYS "TO WHOM IT MAY CONCERN"?
01:21PM	5	A. YES.
01:21PM	6	Q. "YOU REQUESTED A CURRENT LIST OF THE PLATFORMS ON WHICH
01:21PM	7	ALL OF OUR TESTS ARE RUNNING AS OF SEPTEMBER 22ND, 2015. WE
01:21PM	8	ARE PROVIDING THAT INFORMATION TO YOU UNDER SEPARATE COVER."
01:21PM	9	HAD YOU ASKED FOR A CURRENT LIST OF ALL OF THE PLATFORMS
01:21PM	10	UNDER WHICH TESTS WERE BEING RUN?
01:21PM	11	A. YES.
01:21PM	12	Q. AND YOU ALSO SPECIFICALLY ASKED FOR HISTORICAL INFORMATION
01:21PM	13	ABOUT THE EDISON?
01:21PM	14	A. YES.
01:21PM	15	Q. OKAY. BECAUSE THAT WAS INFORMATION THAT WASN'T
01:21PM	16	VOLUNTEERED TO YOU?
01:21PM	17	A. CORRECT.
01:21PM	18	Q. IT THEN READS, "ADDITIONALLY, THE FOLLOWING IS THE LIST OF
01:21PM	19	LABORATORY DEVELOPED TESTS (LDT'S) THAT THERANOS TESTED ON
01:21PM	20	THERANOS DEVICES, ALSO CALLED THERANOS SAMPLE PROCESSING UNITS,
01:21PM	21	(TSPU'S) ALONG WITH THE TIME PERIODS WHEN THOSE TESTS WERE
01:21PM	22	RUN."
01:21PM	23	DO YOU SEE THAT LANGUAGE?
01:21PM	24	A. I DO.
01:21PM	25	Q. AND IT THEN SAYS, "THERANOS RECENTLY RECEIVED FDA

01:21PM	1	CLEARANCE FOR ITS THERANOS SYSTEM INCLUDING THE DEVICE, THE
01:21PM	2	THERANOS SAMPLE COLLECTION DEVICE (INCLUDING THE NANOTAINERS)
01:21PM	3	AND OTHER COMPONENTS OF THE SYSTEM."
01:21PM	4	DID YOU HAVE AN UNDERSTANDING OF WHAT THAT WAS REFERRING
01:21PM	5	TO?
01:21PM	6	A. YES.
01:21PM	7	Q. AND WHAT WAS YOUR UNDERSTANDING?
01:21PM	8	A. SO THEY HAD A SEPARATE DEVICE THAT THEY ACTUALLY COLLECTED
01:21PM	9	THE FINGERSTICK SPECIMEN IN. IT WAS PART OF THE WHOLE TEST
01:21PM	10	SYSTEM.
01:21PM	11	Q. BUT THE FDA CLEARANCE THAT WAS BEING REFERRED TO THERE,
01:21PM	12	WERE YOU FAMILIAR WITH THAT?
01:21PM	13	A. I WAS FAMILIAR THAT THE FDA HAD CLEARED, I BELIEVE, A
01:21PM	14	STREP TEST, I BELIEVE IT WAS STREP, BUT I WAS NOT SURE IF THE
01:21PM	15	COLLECTION DEVICE HAD ALSO BEEN CLEARED.
01:21PM	16	Q. OKAY. DID YOU HAVE AN UNDERSTANDING WHETHER IT WAS
01:21PM	17	CLEARED FOR ONE ASSAY OR MORE THAN ONE ASSAY?
01:21PM	18	MR. CAZARES: OBJECTION. LEADING.
01:21PM	19	THE COURT: WHY DON'T YOU ASK IT IN A DIFFERENT
01:21PM	20	FORM?
01:21PM	21	BY MR. LEACH:
01:21PM	22	Q. DID YOU HAVE AN UNDERSTANDING OF HOW MANY ASSAYS THE FDA
01:21PM	23	CLEARANCE RELATED TO?
01:21PM	24	A. YES. ONE.
01:21PM	25	Q. LET'S ZOOM OUT, PLEASE.

01:21PM	1	THERE'S A TABLE AT THE BOTTOM OF THIS WITH THREE COLUMNS:
01:21PM	2	TEST, INITIAL, AND END.
01:21PM	3	DO YOU SEE THAT?
01:21PM	4	A. I DO.
01:21PM	5	Q. AND THERE ARE 12 ASSAYS HERE, BEGINNING WITH VIT D AND
01:21PM	6	ENDING WITH PROLACTIN.
01:21PM	7	DO YOU SEE THAT?
01:21PM	8	A. I DO.
01:21PM	9	Q. AND WHAT DO YOU UNDERSTAND THOSE TO BE?
01:21PM	10	A. THOSE WERE THE TESTS THAT THERANOS USED THE EDISON TO
01:22PM	11	PERFORM.
01:22PM	12	FOR EXAMPLE, THE VITAMIN D, THEY STARTED USING THE EDISON
01:22PM	13	DEVICE TO TEST VITAMIN D ON NOVEMBER 6TH, 2013, AND STOPPED
01:22PM	14	USING IT ON MARCH 10TH, 2015.
01:22PM	15	Q. AND DOES IT APPEAR FROM THIS LISTING THAT MR. BALWANI
01:22PM	16	PROVIDED YOU THAT THE LAST EDISON TEST FOR ANY OF THESE ASSAYS
01:22PM	17	WAS JUNE 25TH, 2015?
01:22PM	18	AND I DRAW YOUR ATTENTION TO TPSA AND HCG.
01:22PM	19	A. YES.
01:22PM	20	Q. AND WITH RESPECT TO ESTRADIOL AND PROLACTIN, DO YOU SEE
01:22PM	21	THAT AT THE BOTTOM?
01:22PM	22	A. I DO.
01:22PM	23	Q. AND DOES IT APPEAR THAT THOSE ASSAYS WERE IN USE ON THE
01:22PM	24	THERANOS DEVICE FOR A COUPLE OF MONTHS BETWEEN SEPTEMBER OF
01:22PM	25	2014 AND DECEMBER OF 2014?

01:22PM	1	A. YES.
01:23PM	2	Q. OKAY. DURING YOUR SURVEY, DID YOU MAKE DOCUMENT
01:23PM	3	REQUESTS FIRST OF ALL, LET ME BACK UP.
01:23PM	4	FOR THE ENTRANCE INTERVIEW THAT MR. BALWANI WAS LEADING,
01:23PM	5	DID THAT EVOLVE INTO YOU ACTUALLY REVIEWING DOCUMENTS AND
01:23PM	6	CONDUCTING THE SURVEY?
01:23PM	7	A. YES.
01:23PM	8	Q. AND WHERE DID THAT TAKE PLACE?
01:23PM	9	A. IT WAS IN A CONFERENCE ROOM OFF THE MAIN LOBBY.
01:23PM	10	Q. WHO WAS IN THAT CONFERENCE ROOM?
01:23PM	11	A. GARY AND I WERE IN THERE, VARIOUS OTHER STAFF, MR. GEE WAS
01:23PM	12	THERE, SUNNY WAS THERE, MR. BALWANI WAS THERE, THE TECHNICAL
01:23PM	13	CONSULTANTS, TECHNICAL SUPERVISORS, HEATHER KING, AND ANOTHER
01:23PM	14	ATTORNEY.
01:23PM	15	Q. AND DURING THE COURSE OF YOUR SURVEY, DID YOU REQUEST
01:24PM	16	DOCUMENTS OF MR. BALWANI AND MR. GEE AND OTHERS?
01:24PM	17	A. YES.
01:24PM	18	Q. AND WAS IT EASY TO GET DOCUMENTS DURING THE SURVEY?
01:24PM	19	A. IT WAS NOT.
01:24PM	20	Q. WHY DO YOU SAY THAT?
01:24PM	21	A. WE WOULD REQUEST DOCUMENTS AND THEY WOULD GO AND TRY OR
01:24PM	22	GO LOOK FOR THE DOCUMENTS OR FIND THE DOCUMENTS, AND IT WOULD
01:24PM	23	BE SEVERAL HOURS BEFORE WE WOULD GET THE DOCUMENTS, OR WE WOULD
01:24PM	24	NEVER GET THE DOCUMENTS BECAUSE THEY COULDN'T FIND THEM, OR
01:24PM	25	THEY WOULD BRING DOCUMENTS BACK THAT WERE NOT WHAT WE ASKED

01:24PM	1	FOR.
01:24PM	2	Q. OKAY. WERE THERE ALSO OCCASIONS WHERE YOU REQUESTED
01:24PM	3	INTERVIEWS OF EMPLOYEES?
01:24PM	4	A. YES.
01:24PM	5	Q. AND DID YOU REQUEST TO INTERVIEW EMPLOYEES CONFIDENTIALLY?
01:24PM	6	A. YES.
01:24PM	7	Q. AND WHAT HAPPENED WHEN YOU DID THAT?
01:24PM	8	A. I WAS TOLD THAT I COULD NOT CONFIDENTIALLY INTERVIEW
01:24PM	9	STAFF, THAT THERE HAD TO BE AN ATTORNEY PRESENT.
01:24PM	10	AND WHEN I SAID THAT I COULD INTERVIEW STAFF
01:25PM	11	CONFIDENTIALLY, I WAS PUT INTO A ROOM TO WAIT UNTIL THEY WORKED
01:25PM	12	OUT THE LOGISTICS OF THAT.
01:25PM	13	AND THEY CAME AND GOT ME SOME TIME LATER AND BROUGHT ME UP
01:25PM	14	TO AN OFFICE WHERE THIS EMPLOYEE WAS, AND BOTH ATTORNEYS WERE
01:25PM	15	IN THE ROOM, AND BEFORE I COULD GET STARTED, THE EMPLOYEE SAID
01:25PM	16	THAT SHE WANTED THE ATTORNEYS PRESENT.
01:25PM	17	Q. HOW LONG WERE YOU WAITING BEFORE YOU GOT TO MEET WITH THE
01:25PM	18	EMPLOYEE?
01:25PM	19	A. I WOULD SAY PROBABLY AN HOUR OR TWO.
01:25PM	20	Q. AND WHERE WERE YOU WAITING?
01:25PM	21	A. I WAS IN A SMALL ROOM WITH NO WINDOWS.
01:25PM	22	Q. YOU MENTIONED THAT HEATHER KING WAS INVOLVED IN RESPONDING
01:25PM	23	TO SOME INFORMATION IN THE SURVEY.
01:25PM	24	A. SHE WAS.
01:25PM	25	Q. AND SHE'S A LAWYER?

01:25PM	1	A. YES.
01:25PM	2	Q. OKAY. AND IN YOUR EXPERIENCE THROUGH SURVEYS, HOW DO YOU
01:25PM	3	COMPARE THE LEVEL OF LAWYER INVOLVEMENT IN THIS SURVEY?
01:26PM	4	MR. CAZARES: OBJECTION. RELEVANCE.
01:26PM	5	THE COURT: OVERRULED.
01:26PM	6	THE WITNESS: THE AMOUNT AND INTERACTION WITH
01:26PM	7	ATTORNEYS ON THEIR SURVEY WAS VERY UNUSUAL. I HAD NEVER
01:26PM	8	EXPERIENCED IT BEFORE.
01:26PM	9	BY MR. LEACH:
01:26PM	10	Q. DURING THE FIRST PART OF HOW LONG DID THE SURVEY LAST
01:26PM	11	IN SEPTEMBER?
01:26PM	12	A. I BELIEVE WE WERE THERE FOR THREE DAYS.
01:26PM	13	Q. OKAY. AND WHAT TYPES OF DOCUMENTS DID YOU REQUEST AND
01:26PM	14	REVIEW?
01:26PM	15	A. PROFICIENCY TESTING DOCUMENTATION, DOCUMENT RELATED TO
01:26PM	16	COAGULATION TESTING, PT INR, WHICH IS THE COAGULATION TEST.
01:26PM	17	I BELIEVE I ALSO ASKED FOR PERSONNEL FOLDERS, BUT I'M NOT
01:27PM	18	SURE IF THAT WAS SEPTEMBER OR NOVEMBER.
01:27PM	19	Q. YOU SAY YOU'RE NOT SURE WHETHER IT WAS SEPTEMBER OR
01:27PM	20	NOVEMBER.
01:27PM	21	WERE YOU ABLE TO FINISH YOUR SURVEY IN SEPTEMBER?
01:27PM	22	A. WE WERE NOT.
01:27PM	23	Q. WHY WERE YOU UNABLE TO FINISH?
01:27PM	24	A. ONCE WE STARTED THE SURVEY, WE REALIZED THAT WE WERE GOING
01:27PM	25	TO NEED MORE THAN THE ALLOTTED THREE DAYS, AND THE DELAY IN

01:27PM	1	GETTING US THE DOCUMENTATION THAT WE ASKED FOR CREATED PROBLEMS
01:27PM	2	FOR US TO BE ABLE TO COMPLETE THE SURVEY.
01:27PM	3	Q. AND DID YOU ULTIMATELY COME BACK IN NOVEMBER?
01:27PM	4	A. WE DID.
01:27PM	5	Q. AND HOW MANY DAYS AND YOU WERE OUT HERE IN CALIFORNIA
01:27PM	6	FOR THAT?
01:27PM	7	A. YES.
01:27PM	8	Q. AND AT A HIGH LEVEL, DESCRIBE FOR US WHAT YOU DID IN
01:27PM	9	CONNECTION WITH YOUR SURVEY.
01:27PM	10	A. WE CONTINUED THE SURVEY, INVESTIGATING THE COMPLAINTS, AND
01:28PM	11	PERFORMING THE RECERTIFICATION SURVEY.
01:28PM	12	WE LOOKED AT THE EDISON INFORMATION, OR REQUESTED THE
01:28PM	13	EDISON INFORMATION.
01:28PM	14	Q. WHEN YOU SAY YOU REQUESTED THE EDISON INFORMATION, WHAT DO
01:28PM	15	YOU MEAN?
01:28PM	16	A. THE QUALITY CONTROL INFORMATION AND THE VALIDATION OF THE
01:28PM	17	TESTS.
01:28PM	18	Q. WHY WERE YOU ASKED FOR QUALITY CONTROL INFORMATION?
01:28PM	19	A. WELL, WE WOULD NORMALLY ASK FOR QUALITY CONTROL
01:28PM	20	INFORMATION.
01:28PM	21	IN THIS PARTICULAR CASE, IT WAS PART OF A SPECIFIC IT
01:28PM	22	WAS A SPECIFIC AREA THAT WE HAD RECEIVED A COMPLAINT ABOUT.
01:28PM	23	Q. OKAY. AND WHY DID YOU ASK FOR VALIDATION REPORTS?
01:28PM	24	A. WE RECEIVED THE SAME IT WAS PART OF THE SAME COMPLAINT,
01:28PM	25	BUT WE ALSO ALWAYS LOOK AT THOSE, THAT TYPE OF INFORMATION WHEN

01:28PM	1	WE SURVEY LABORATORIES.
01:28PM	2	Q. AT THE END OF NOVEMBER OF 2015, AT THE END OF YOUR ONSITE
01:28PM	3	SURVEY, DID MS. HOLMES AND MR. BALWANI REQUEST TO MEET WITH
01:29PM	4	YOU?
01:29PM	5	A. THEY DID.
01:29PM	6	Q. OKAY. DID THEY ASK TO DO THAT EVERY DAY OF THE
01:29PM	7	INSPECTION?
01:29PM	8	A. THEY DID.
01:29PM	9	Q. AND WOULD YOU DESCRIBE TO THEM WHAT YOU WERE FINDING IN
01:29PM	10	TERMS OF YOUR INSPECTION?
01:29PM	11	A. YES. MR. BALWANI REQUESTED THAT WE MEET WITH THEM EVERY
01:29PM	12	DAY AT THE END OF THE SURVEY FOR THAT PARTICULAR DAY SO WE
01:29PM	13	COULD LET THEM KNOW WHAT KIND OF DEFICIENT PRACTICES THAT WE
01:29PM	14	HAD FOUND, SO WE DID THAT EVERY SINGLE DAY.
01:29PM	15	Q. I WANT TO DRAW YOUR ATTENTION TO THE END OF THE ONSITE
01:29PM	16	SURVEY IN NOVEMBER OF 2015.
01:29PM	17	WHAT DID YOU TELL MS. HOLMES AND MR. BALWANI?
01:29PM	18	A. WE SUMMARIZED OUR FINDINGS FROM BOTH SEPTEMBER AND
01:29PM	19	NOVEMBER, AND SO THEY WERE AWARE OF THE DEFICIENCIES THAT WE
01:29PM	20	HAD FOUND.
01:29PM	21	WE TOLD THEM WHAT WOULD COME NEXT, THAT THEY WOULD BE
01:29PM	22	RECEIVING A LETTER AND A STATEMENT OF DEFICIENCIES THAT THEY
01:29PM	23	WOULD HAVE TO RESPOND TO.
01:29PM	24	WE TOLD THEM AT THE TIME THAT WE WERE CONSIDERING
01:30PM	25	IMMEDIATE JEOPARDY, BUT WE HADN'T MADE A DECISION ABOUT THAT

01:30PM	1	YET.
01:30PM	2	BUT WE WANTED TO MAKE SURE THAT THEY WERE AWARE THAT THAT
01:30PM	3	COULD HAPPEN.
01:30PM	4	AND THEN WHAT THEY WOULD NEED TO DO SPECIFICALLY TO
01:30PM	5	RESPOND TO THE DEFICIENCIES.
01:30PM	6	Q. AND WHAT DO YOU MEAN BY "IMMEDIATE JEOPARDY"?
01:30PM	7	A. IMMEDIATE JEOPARDY IS A SITUATION WHERE THE LAB PRACTICES
01:30PM	8	HAVE THE POTENTIAL TO CAUSE HARM, OR HAVE CAUSED HARM, OR COULD
01:30PM	9	CAUSE DEATH TO PATIENTS.
01:30PM	10	Q. AND DID MS. HOLMES OR MR. BALWANI ATTEMPT TO DISSUADE YOU
01:30PM	11	FROM MAKING THAT FINDING?
01:30PM	12	A. THEY DID.
01:30PM	13	Q. AND TELL US WHAT WAS SAID.
01:30PM	14	A. THEY WERE TRYING TO CONVINCE US THAT, YOU KNOW, PERHAPS WE
01:30PM	15	DIDN'T NEED TO CITE THIS, OR COULD WE DO THIS ANOTHER WAY SO
01:31PM	16	THAT IT DIDN'T LOOK QUITE SO BAD. BUT WE CITE WHAT WE SEE THE
01:31PM	17	WAY WE SEE IT.
01:31PM	18	Q. AND AT SOME POINT IN TIME, DID YOU DELIVER A 2567
01:31PM	19	STATEMENT OF DEFICIENCIES TO THERANOS SUMMARIZING THE RESULTS
01:31PM	20	OF YOUR SURVEY?
01:31PM	21	A. WE DID.
01:31PM	22	Q. LET ME DRAW YOUR ATTENTION TO WHAT HAS BEEN MARKED AS
01:31PM	23	EXHIBIT 4621.
01:31PM	24	DO YOU RECOGNIZE THIS DOCUMENT?
01:31PM	25	A. YES.

01:31PM	1	Q. THE FIRST FOUR PAGES OF EXHIBIT 4621 APPEAR TO BE A LETTER
01:31PM	2	DATED JANUARY 25TH, 2006.
01:31PM	3	DO YOU SEE THAT?
01:31PM	4	A. I DO.
01:31PM	5	Q. AND DID YOU HAVE A HAND IN DRAFTING THIS LETTER?
01:31PM	6	A. I REVIEWED IT.
01:31PM	7	Q. YOU REVIEWED IT.
01:32PM	8	AND BEGINNING ON PAGE 5 THERE IS A FORM WITH THE NUMBER
01:32PM	9	FORM 2567 DOWN IN THE BOTTOM LEFT.
01:32PM	10	DO YOU SEE THAT?
01:32PM	11	A. I DO.
01:32PM	12	Q. AND DO YOU SEE TO THE RIGHT THAT THIS IS 121 PAGES?
01:32PM	13	A. YES.
01:32PM	14	Q. WITH RESPECT TO THE FORM BEGINNING ON PAGE 5 AND
01:32PM	15	CONTINUING TO PAGE 125 OF THE TRIAL EXHIBIT, IS THIS SOMETHING
01:32PM	16	THAT YOU HAD A HAND IN PREPARING?
01:32PM	17	A. YES.
01:32PM	18	Q. AND WHAT WAS YOUR ROLE IN PREPARING THIS?
01:32PM	19	A. MY ROLE WAS TO WRITE UP THE CITATIONS BASED ON THE AREAS
01:32PM	20	THAT I HAD LOOKED AT AND FOUND DEFICIENT PRACTICES.
01:32PM	21	Q. OKAY. AND IS THIS A REPORT OF MATTERS THAT YOU AND
01:32PM	22	MR. YAMAMOTO OBSERVED WHILE UNDER A LEGAL DUTY TO REPORT?
01:33PM	23	A. YES.
01:33PM	24	Q. DOES IT ACCURATELY DESCRIBE THE OBSERVATIONS YOU AND
01:33PM	25	MR. YAMAMOTO MADE DURING THE INSPECTION?

01:33PM	1	A. YES, IT DOES.
01:33PM	2	Q. WAS THIS PREPARED IN THE ORDINARY COURSE OF CMS'S
01:33PM	3	BUSINESS?
01:33PM	4	A. YES.
01:33PM	5	Q. OKAY. AND WAS IT PREPARED AT OR AROUND THE TIME OF THE
01:33PM	6	MATTERS THAT YOU INSPECTED?
01:33PM	7	A. YES.
01:33PM	8	Q. AND WITH RESPECT TO THE LETTER, IS THE PURPOSE OF THIS
01:33PM	9	LETTER TO PROVIDE NOTICE TO THERANOS OF WHAT YOU HAVE FOUND?
01:33PM	10	A. YES.
01:33PM	11	Q. OKAY.
01:33PM	12	YOUR HONOR, THE GOVERNMENT OFFERS EXHIBIT 4621.
01:33PM	13	MR. CAZARES: OBJECTION, YOUR HONOR. HEARSAY, 403,
01:33PM	14	702, AND I REFERENCE OUR MOTIONS IN LIMINE.
01:33PM	15	THE COURT: ALL RIGHT. THANK YOU.
01:33PM	16	ANYTHING FURTHER ON THIS, MR. LEACH?
01:33PM	17	MR. LEACH: NO, YOUR HONOR.
01:33PM	18	THE COURT: ALL RIGHT. THANK YOU.
01:33PM	19	THE OBJECTION IS OVERRULED. THIS WILL BE ADMITTED, AND IT
01:33PM	20	MAY BE PUBLISHED.
01:33PM	21	(GOVERNMENT'S EXHIBIT 4621 WAS RECEIVED IN EVIDENCE.)
01:34PM	22	BY MR. LEACH:
01:34PM	23	Q. MR. BALWANI, I WANT TO DRAW YOUR ATTENTION TO THE TOP
01:34PM	24	PORTION OF THE LETTER.
01:34PM	25	DO YOU SEE THE DATE JANUARY 25TH, 2016?

01:34PM	1	A. YES.
01:34PM	2	Q. AND THIS IS ADDRESSED TO SUNIL DHAWAN, M.D., DIRECTOR.
01:34PM	3	DO YOU SEE THAT?
01:34PM	4	A. I DO.
01:34PM	5	Q. WHY IS THIS ADDRESSED TO DR. DHAWAN?
01:34PM	6	A. IT'S USUALLY THESE ENFORCEMENT LETTERS ARE USUALLY SENT
01:34PM	7	TO THE LABORATORY DIRECTOR.
01:34PM	8	Q. THE SUBJECT LINE IS RE: CONDITION LEVEL DEFICIENCIES
01:34PM	9	IMMEDIATE JEOPARDY.
01:34PM	10	DO YOU SEE THAT?
01:34PM	11	A. I DO.
01:34PM	12	Q. AND IS THAT A REFERENCE TO THE TERMINOLOGY THAT YOU WERE
01:34PM	13	EXPRESSING TO MS. HOLMES AND MR. BALWANI IN THE EXIT INTERVIEW?
01:34PM	14	A. YES.
01:34PM	15	Q. LET'S LOOK AT THE FIRST PARAGRAPH.
01:34PM	16	THE LAST SENTENCE SAYS, "FEDERAL REGULATIONS REQUIRE
01:34PM	17	ONSITE SURVEYS TO DETERMINE WHETHER OR NOT A LABORATORY IS IN
01:34PM	18	COMPLIANCE WITH THE APPLICABLE REGULATIONS. COMPLIANCE WITH
01:34PM	19	THESE REGULATIONS IS A CONDITION OF CERTIFICATION OF THE CLIA
01:34PM	20	PROGRAM."
01:34PM	21	DO YOU SEE THAT?
01:34PM	22	A. I DO.
01:34PM	23	Q. AND IS THAT A FAIR SUMMARY OF WHAT YOU DID IN YOUR WORK AS
01:35PM	24	A SURVEYOR?
01:35PM	25	A. IT IS.

01:35PM	1	Q. OKAY. THIS SAYS, "THE" IN THE NEXT PARAGRAPH IT SAYS,
01:35PM	2	"THE CENTERS FOR MEDICARE AND MEDICAID SERVICE (CMS) CONDUCTED
01:35PM	3	A CLIA RECERTIFICATION AND COMPLAINT SURVEY OF THE LABORATORY."
01:35PM	4	IS THAT ACCURATE?
01:35PM	5	A. YES.
01:35PM	6	Q. "THE ONSITE SURVEY WAS COMPLETED ON NOVEMBER 20TH, 2015."
01:35PM	7	IS THAT CORRECT?
01:35PM	8	A. YES.
01:35PM	9	Q. AND IT THEN SAYS, "AS A RESULT OF THE SURVEY, IT WAS
01:35PM	10	DETERMINED THAT YOUR FACILITY IS NOT IN COMPLIANCE WITH ALL OF
01:35PM	11	THE CONDITIONS REQUIRED FOR CERTIFICATION IN THE CLIA PROGRAM."
01:35PM	12	DO YOU SEE THAT?
01:35PM	13	A. I DO.
01:35PM	14	Q. AND CONDITIONS IS CAPITALIZED THERE. IS THAT A TERM OF
01:35PM	15	ART?
01:35PM	16	A. YES.
01:35PM	17	Q. OKAY. WHAT IS A CONDITION?
01:35PM	18	A. CLIA REQUIREMENTS ARE DIVIDED INTO TWO LEVELS, STANDARD
01:35PM	19	LEVEL AND CONDITION LEVEL.
01:35PM	20	CONDITION LEVEL NONCOMPLIANCE IS MORE SERIOUS THAN A
01:36PM	21	DEFICIENCY FOUND AT THE STANDARD LEVEL.
01:36PM	22	Q. OKAY. AND THIS SAYS, "IN ADDITION, BASED ON THE
01:36PM	23	CONDITION-LEVEL REQUIREMENT, HEMATOLOGY, IT WAS DETERMINED THAT
01:36PM	24	THE DEFICIENT PRACTICES OF THE LABORATORY POSE IMMEDIATE
01:36PM	25	JEOPARDY TO PATIENT HEALTH AND SAFETY."

01:36PM	1	DO YOU SEE THAT LANGUAGE?
01:36PM	2	A. I DO.
01:36PM	3	Q. AND THAT'S WHAT YOU WERE EXPRESSING TO MS. HOLMES AND
01:36PM	4	MR. BALWANI IN YOUR NOVEMBER EXIT INTERVIEW?
01:36PM	5	A. YES.
01:36PM	6	Q. OKAY. LET'S GO TO PAGE 2, PLEASE.
01:36PM	7	DO YOU SEE AT THE TOP WHERE IT SAYS, "ENCLOSED IS FORM
01:36PM	8	CMS-2567, STATEMENT OF DEFICIENCIES, LISTING ALL DEFICIENCIES
01:36PM	9	FOUND DURING THE SURVEY"?
01:36PM	10	A. YES.
01:36PM	11	Q. AND THAT'S THE FORM THAT IS ATTACHED TO THIS DOCUMENT?
01:36PM	12	A. YES.
01:36PM	13	Q. OKAY. LET'S LOOK AT THE FORM, PLEASE, PAGE 5.
01:37PM	14	AND IF WE CAN ZOOM IN ON THE TOP, MS. WACHS, ALL OF THE
01:37PM	15	WAY TO THE LINE WHERE IT SAYS, "THIS STANDARD IS NOT MET."
01:37PM	16	THANK YOU.
01:37PM	17	I JUST WANT TO ORIENT US ON THE FORM, MS. BENNETT. DO YOU
01:37PM	18	SEE THERE'S A BOX FOR A PROVIDER NUMBER AND IT BEGINS 05D?
01:37PM	19	A. YES.
01:37PM	20	Q. IS THAT THE PROVIDER NUMBER THAT IS ASSIGNED TO THERANOS?
01:37PM	21	A. YES, THAT'S THE CLIA NUMBER.
01:37PM	22	Q. OKAY. AND THEN TO THE FAR RIGHT DO YOU LIST THE DATE THAT
01:37PM	23	THE SURVEY WAS COMPLETED?
01:37PM	24	A. YES.
01:37PM	25	Q. AND THEN THERE'S AN ADDRESS 7333 GATEWAY BOULEVARD.

01:37PM	1		IS THAT WHERE THE LAB WAS LOCATED?
01:37PM	2	Α.	YES.
01:37PM	3	Q.	AND THEN YOU MENTION THAT THERE'S BELOW THAT TO THE
01:37PM	4	LEFT	THERE'S D2094.
01:37PM	5		DO YOU SEE THAT?
01:37PM	6	Α.	I DO.
01:37PM	7	Q.	AND YOU MENTIONED SOMETHING CALLED D-TAGS EARLIER?
01:38PM	8	А.	WE CALL THEM D-TAGS, DEFICIENCY TAGS.
01:38PM	9	Q.	OKAY. AND IT THEN HAS SOME LANGUAGE RELATING TO ROUTINE
01:38PM	10	CHEM	ISTRY, 1, 2.
01:38PM	11		DO YOU SEE THAT?
01:38PM	12	Α.	I DO.
01:38PM	13	Q.	IS THAT A DESCRIPTION OF THE STANDARD OR THE CONDITION
01:38PM	14	THAT	YOU'RE CONSIDERING WHEN DOING THE SURVEY?
01:38PM	15	Α.	NO. THAT IS THE ACTUAL REGULATORY LANGUAGE.
01:38PM	16	Q.	OKAY. AND THEN IT SAYS, "THIS STANDARD IS NOT MET AS
01:38PM	17	EVID	ENCED BY."
01:38PM	18		AND DOES IT LIST WHAT YOU SAW IN THE SURVEY?
01:38PM	19	Α.	IT DOES.
01:38PM	20	Q.	AND DO YOU USE THIS FORMAT THROUGHOUT 2567?
01:38PM	21	Α.	YES.
01:38PM	22	Q.	AND THEN THERE'S SPACE FOR THE RIGHT.
01:38PM	23		DO YOU SEE WHERE IT SAYS PROVIDER'S PLAN OF CORRECTION?
01:38PM	24	Α.	YES.
01:38PM	25	Q.	AND IS THIS THE SPACE THAT THE LABORATORY IS SUPPOSED TO

01:39PM	1	USE TO DESCRIBE TO YOU WHAT IT'S DOING TO ADDRESS THE
01:39PM	2	DEFICIENCIES?
01:39PM	3	A. THEY CAN PUT IT IN THAT RIGHT-HAND COLUMN OR THEY CAN
01:39PM	4	ATTACH DOCUMENTS.
01:39PM	5	Q. OKAY.
01:39PM	6	LET ME PLEASE DRAW YOUR ATTENTION TO PAGE 47 OR EXCUSE
01:39PM	7	ME, 51 OF THE TRIAL EXHIBIT.
01:39PM	8	DO YOU HAVE PAGE 51 IN FRONT OF YOU?
01:39PM	9	A. I DO.
01:39PM	10	Q. AND ARE YOU ABLE TO SEE IT ON THE SCREEN AS WELL?
01:40PM	11	A. YES.
01:40PM	12	Q. OKAY. DOWN TOWARDS THE BOTTOM THERE'S THE NUMBER D5791.
01:40PM	13	DO YOU SEE THAT?
01:40PM	14	A. I DO.
01:40PM	15	Q. IS THAT A REFERENCE TO A PARTICULAR DEFICIENCY RELATING TO
01:40PM	16	ANALYTICAL SYSTEMS QUALITY ASSESSMENT?
01:40PM	17	A. IT IS.
01:40PM	18	Q. AND WHAT IS ANALYTICAL SYSTEMS QUALITY ASSESSMENT?
01:40PM	19	A. SO TESTING IS DIVIDED INTO THREE AREAS: PRE-ANALYTIC,
01:40PM	20	WHICH IS WHEN YOU RECEIVE THE SPECIMEN AND YOU'RE LOOKING AT
01:40PM	21	THE SPECIMEN BEFORE YOU BEGIN TESTING; THE ANALYTIC PORTION IS
01:40PM	22	THE ACTUAL TESTING OF THE SPECIMEN; AND THEN POST-ANALYTIC IS
01:40PM	23	WHERE YOU'RE ACTUALLY REPORTING OUT THE PATIENT RESULT.
01:40PM	24	Q. SO ANALYTIC SYSTEMS QUALITY WOULD RELATE TO THE ACTUAL
01:40PM	25	PERFORMANCE OF THE DEVICE?

01:40PM	1	A. YES.
01:40PM	2	Q. OKAY. AND YOU FOUND THAT THIS STANDARD WAS NOT BEING MET;
01:41PM	3	IS THAT CORRECT?
01:41PM	4	A. YES.
01:41PM	5	Q. AND LET ME LOOK AT SOME OF YOUR OBSERVATIONS BEGINNING ON
01:41PM	6	PAGE 53.
01:41PM	7	DO YOU SEE AT THE BOTTOM NUMBER 2, "BASED ON REVIEW OF
01:41PM	8	QUALITY CONTROL (QC) DATA AND MONTHLY QC REPORTS, THE
01:41PM	9	LABORATORY FAILED TO HAVE A QUALITY ASSESSMENT (QA) PROCEDURE
01:41PM	10	TO IDENTIFY AND CORRECT PROBLEM WITH THE QC VALUES FOR THE
01:41PM	11	THERANOS PROPRIETARY SYSTEM (TPS) WHEN PRECISION DID NOT MEET
01:41PM	12	THE LABORATORY'S REQUIREMENT FOR PRECISION."
01:41PM	13	DO YOU SEE THAT LANGUAGE?
01:41PM	14	A. I DO.
01:41PM	15	Q. AND WHAT DID YOU MEAN BY THAT?
01:41PM	16	A. WHAT I MEANT WAS THAT THERANOS HAD A PROCEDURE THAT THEY
01:41PM	17	WERE SUPPOSED TO BE FOLLOWING.
01:41PM	18	ACTUALLY, THEY DIDN'T HAVE A PROCEDURE, I APOLOGIZE, TO
01:42PM	19	IDENTIFY AND CORRECT PROBLEMS THAT I HAD OBSERVED THAT THE
01:42PM	20	PRECISION FOR THE THERANOS PROPRIETARY SYSTEM OR EDISON DID NOT
01:42PM	21	MEET WHAT THEY HAD SAID HOW PRECISE IT SHOULD BE.
01:42PM	22	Q. AND WHAT IS PRECISION?
01:42PM	23	A. PRECISION IS THE ABILITY TO TEST THE SAME SPECIMEN FROM
01:42PM	24	WITHIN ONE TEST, TESTING TIME, AND AS WELL AS ON DIFFERENT RUNS
01:42PM	25	OF THE TESTS, AS WELL AS FROM DIFFERENT DAYS AND DIFFERENT

01:42PM	1	OPERATORS, AND YOU SHOULD BE ABLE TO RUN THE SPECIMEN AND GET
01:42PM	2	THE SAME RESULT EVERY SINGLE TIME, OR WITHIN A CERTAIN
01:42FM		
01:42PM	3	PERCENTAGE YOU SHOULD BE ABLE TO DO THAT.
01:42PM	4	Q. OKAY. AND THEN FURTHER BELOW IN BENEATH 2, YOU WROTE
01:42PM	5	A, "CL PLN-14003 REVISION A: MASTER VALIDATION PLAN FOR
01:42PM	6	ROUTINE CHEMISTRY ASSAYS FOR THERANOS."
01:43PM	7	AND THEN IT CONTINUES ON THE NEXT PAGE.
01:43PM	8	"DEVICES IN SECTION 13.4.5 REQUIRES THE PERCENTAGE CV OF
01:43PM	9	THE REPLICATES TO BE NOT MORE THAN 15 PERCENT (20 PERCENT AT
01:43PM	10	THE LOWER AND UPPER LIMITS OF DETECTION)."
01:43PM	11	WHAT WERE YOU GETTING AT THERE?
01:43PM	12	A. THE SMALL A COEFFICIENT OF VARIATION IS A RELATIONSHIP
01:43PM	13	BETWEEN THE MEAN, THE KNOWN MEAN, AND HOW FAR A STANDARD
01:43PM	14	DEVIATION FOR THAT MEAN IS. AND IT'S A WAY TO EVALUATE THE
01:43PM	15	ACCURACY AND PRECISION OF A TEST. YOU WANT A LOWER IN MOST
01:43PM	16	CASES YOU WANT A LOWER CV. IT MEANS THE TEST IS MORE ACCURATE
01:43PM	17	AND PRECISE.
01:43PM	18	Q. AND IS THIS SAYING THAT THERANOS'S MASTER VALIDATION PLAN
01:43PM	19	REQUIRED THAT THE PERCENTAGE OF CV'S BE NOT MORE THAN
01:43PM	20	15 PERCENT FOR CERTAIN ASSAYS?
01:44PM	21	A. THAT'S CORRECT.
01:44PM	22	Q. AND DID YOU OBSERVE THROUGH YOUR REVIEW OF DOCUMENTS THAT
01:44PM	23	IT WAS GREATER THAN THAT IN CERTAIN CIRCUMSTANCES?
01:44PM	24	A. I DID.
01:44PM	25	Q. LET'S ZOOM OUT, MS. WACHS, AND IF WE CAN CAPTURE B

01:44PM	1	THROUGH E.
01:44PM	2	YOU WROTE, "QC RESULTS WERE REVIEWED FROM JUNE 2014
01:44PM	3	THROUGH NOVEMBER 2014 AND JANUARY THROUGH FEBRUARY 2015 FOR
01:44PM	4	VITAMIN B12, VITAMIN D, AND SEX HORMONE BINDING GLOBULIN, WHICH
01:44PM	5	WERE USED FOR PATIENT TESTING ON TPS DEVICES."
01:44PM	6	DO YOU SEE THAT?
01:44PM	7	A. I DO.
01:44PM	8	Q. AND SO YOU UNDERSTOOD THOSE TO BE EDISON DEVICES?
01:44PM	9	A. YES.
01:44PM	10	Q. AND HOW DID YOU GO ABOUT PICKING THESE TIME PERIODS FOR
01:44PM	11	REVIEWING QC RESULTS?
01:44PM	12	A. IT WAS JUST A RANDOM SELECTION, EXCEPT FOR THE VITAMIN D
01:44PM	13	WHICH WAS TARGETED BECAUSE OF A COMPLAINT.
01:44PM	14	Q. SO THIS IS A SUMMARY OF THE QC RESULTS THAT YOU WERE
01:45PM	15	REVIEWING?
01:45PM	16	A. YES.
01:45PM	17	Q. AND COMPARING THOSE AGAINST THE VALIDATION PLAN?
01:45PM	18	A. YES.
01:45PM	19	Q. YOU THEN WRITE IN C, "VB12 QC LEVEL 1 AND LEVEL 3."
01:45PM	20	WHAT ARE LEVEL 1 AND LEVEL 3?
01:45PM	21	A. QUALITY CONTROL HAS DIFFERENT LEVELS. IT COULD BE
01:45PM	22	LEVEL 1, LEVEL 2, LEVEL 3.
01:45PM	23	IN THIS PARTICULAR CASE THEY WERE USING LEVEL 1 AND
01:45PM	24	LEVEL 3.
01:45PM	25	Q. ON DEVICE E00110, IS THAT A REFERENCE TO A PARTICULAR

01:45PM	1	EDISON DEVICE?
01:45PM	2	A. IT IS.
01:45PM	3	Q. THAT WAS BEING USED IN THE CLIA LAB?
01:45PM	4	A. IT IS.
01:45PM	5	Q. "REVEALED THE FOLLOWING PERCENTAGE CV (COEFFICIENT OF
01:45PM	6	VARIATION): 34.3 PERCENT AND 48.5 PERCENT RESPECTIVELY FROM
01:46PM	7	JANUARY 5TH, 2015 THROUGH JANUARY 30TH, 2015."
01:46PM	8	DO YOU SEE THAT LANGUAGE?
01:46PM	9	A. I DO.
01:46PM	10	Q. AND THAT WAS OUTSIDE OF WHAT WAS PROVIDED FOR IN THE
01:46PM	11	VALIDATION REPORT? WHY DO YOU HIGHLIGHT THOSE NUMBERS?
01:46PM	12	A. BECAUSE THEY WERE MORE THAN THE 15 AND THE 20 PERCENT.
01:46PM	13	Q. OKAY. ARE THOSE DESIRABLE RESULTS FOR A LABORATORY?
01:46PM	14	A. THEY ARE NOT.
01:46PM	15	Q. THERE'S AN ADDITIONAL ENTRY IN D FOR "VITAMIN B12 QC 1 AND
01:46PM	16	QC 3 ON DEVICE E001085."
01:46PM	17	DO YOU SEE THAT?
01:46PM	18	A. YES.
01:46PM	19	Q. AND IS THAT ANOTHER EDISON DEVICE?
01:46PM	20	A. IT IS.
01:46PM	21	Q. AND "REVEALED FOLLOWING CV'S: 52.5 PERCENT AND
01:46PM	22	35.2 PERCENT."
01:46PM	23	DO YOU SEE THAT?
01:46PM	24	A. I DO.
01:46PM	25	Q. AND ARE THOSE DESIRABLE CV'S?

01:46PM	1	A. THEY ARE NOT.
01:46PM	2	Q. AND WHY ARE YOU CALLING OUT THE INFORMATION?
01:46PM	3	A. I AM CALLING OUT THE INFORMATION BECAUSE IT DID NOT MEET
01:46PM	4	THEIR APPROVED PROCEDURE OF 15 PERCENT AND 20 PERCENT AT THE
01:47PM	5	HIGH/LOW END.
01:47PM	6	Q. THERE'S AN ADDITIONAL ENTRY IN E FOR "VITAMIN B12 QC 1 AND
01:47PM	7	QC 3 ON DEVICE E001102."
01:47PM	8	DO YOU SEE THAT?
01:47PM	9	A. I DO.
01:47PM	10	Q. IS THAT A REFERENCE TO ANOTHER EDISON DEVICE?
01:47PM	11	A. YES.
01:47PM	12	Q. AND THIS IS DESCRIBING PERCENTAGE CV'S OF 39 PERCENT AND
01:47PM	13	20 PERCENT FOR A TIME PERIOD IN FEBRUARY OF 2015.
01:47PM	14	DO YOU SEE THAT?
01:47PM	15	A. I DO.
01:47PM	16	Q. ARE THOSE DESIRABLE CV'S FOR A LAB?
01:47PM	17	A. THEY ARE NOT.
01:47PM	18	Q. OKAY. WE CAN ZOOM OUT, MS. WACHS.
01:48PM	19	COULD WE GO TO THE BOTTOM PORTION FOR F, G, H AND I.
01:48PM	20	DOES THIS RELATE TO CV'S RELATING TO VITAMIN B12 AND
01:48PM	21	VITAMIN D?
01:48PM	22	A. YES.
01:48PM	23	Q. AND ARE THESE DESIRABLE CV'S OR UNDESIRABLE CV'S?
01:48PM	24	A. THEY ARE UNDESIRABLE.
01:48PM	25	Q. LET'S ZOOM OUT, MS. WACHS, AND GO TO PAGE 55.

01:48PM	1	AND IF WE CAN ZOOM OUT TO THE TOP PORTION UNTIL NUMBER 3.
01:48PM	2	WHAT IS BEING SUMMARIZED HERE ON J, K, AND L, MS. BENNETT?
01:48PM	3	A. I'M POINTING OUT THAT THEY THE CV'S ARE HIGHER THAN ARE
01:49PM	4	ACCEPTABLE FOR THESE TESTS ON THESE DEVICES.
01:49PM	5	Q. OKAY. AND THESE ASSAYS ARE VITAMIN D AND SHBG?
01:49PM	6	A. YES.
01:49PM	7	Q. AND THOSE ARE ASSAYS RUN ON EDISON?
01:49PM	8	A. YES.
01:49PM	9	Q. AND THIS IS INFORMATION FOR THE TIME PERIOD JUNE 2014 TO
01:49PM	10	JULY 2015, SEPTEMBER 30TH THROUGH NOVEMBER 2014, AND JULY
01:49PM	11	THROUGH AUGUST OF 2014?
01:49PM	12	A. WITH THE EXCEPTION OF THE FIRST ONE, IT WAS JUNE OF '14
01:49PM	13	THROUGH JULY OF 2014.
01:49PM	14	Q. THANK YOU. MY APOLOGIZE.
01:49PM	15	LET'S ZOOM OUT, MS. WACHS.
01:49PM	16	THOSE CV'S THAT WE WERE LOOKING AT, WERE THOSE DESIRABLE
01:49PM	17	OR UNDESIRABLE?
01:49PM	18	A. UNDESIRABLE.
01:49PM	19	Q. LET'S ZOOM IN ON NUMBER 3.
01:49PM	20	YOU WROTE IN 3, "BASED ON REVIEW OF QUALITY ASSESSMENT
01:50PM	21	(QA) DOCUMENTATION AND QA PROCEDURES, THE LABORATORY FAILED TO
01:50PM	22	HAVE A QUALITY ASSESSMENT (QA) PROCEDURE ESTABLISHED TO
01:50PM	23	IDENTIFY AND CORRECT PROBLEMS WITH THE QUALITY CONTROL PROGRAM
01:50PM	24	FOR THE THERANOS PROPRIETARY SYSTEM (TPS)."
01:50PM	25	DO YOU SEE THAT?

01:50PM	1	A. I DO.
01:50PM	2	Q. AND WHEN YOU'RE USING TPS, IS THAT A REFERENCE TO THE
01:50PM	3	EDISON?
01:50PM	4	A. IT IS.
01:50PM	5	Q. OR THE TSPU?
01:50PM	6	A. WE CALLED IN OUR SURVEY REPORT, WE CALLED THE EDISON
01:50PM	7	THE TPS.
01:50PM	8	Q. OKAY. AND THIS SAYS WHAT IS A QUALITY ASSESSMENT
01:50PM	9	PROCEDURE?
01:50PM	10	A. QUALITY ASSESSMENT PROCEDURE DESCRIBES HOW THE LABORATORY
01:50PM	11	LOOKS AT THE OVERALL FUNCTIONING OF THE LABORATORY TO IDENTIFY
01:50PM	12	ANY ISSUES WITH TESTING, AND THEN THEY HAVE TO CORRECT, FIND
01:50PM	13	THEY HAVE TO BE ABLE TO IDENTIFY AND CORRECT PROBLEMS WITH THE
01:51PM	14	TESTING SO THAT IT DOESN'T KEEP GOING ON AND ON AND ON.
01:51PM	15	Q. BENEATH THE 3 YOU WROTE, "MONTHLY QC REPORTS WERE REVIEWED
01:51PM	16	FOR JULY 2014, OCTOBER 2014, AND FEBRUARY THROUGH JUNE OF
01:51PM	17	2015."
01:51PM	18	DO YOU SEE THAT?
01:51PM	19	A. I DO.
01:51PM	20	Q. AND WHAT ARE MONTHLY QC REPORTS?
01:51PM	21	A. THOSE WERE REPORTS THAT THERANOS PROVIDED US THAT
01:51PM	22	SHOWED THAT THEY WERE LIKE SUMMARY REPORTS OF THE QUALITY
01:51PM	23	CONTROL WHERE YOU COULD SEE IF THEY MET THEIR CV'S THAT THEY
01:51PM	24	WERE SUPPOSED TO. IT INCLUDED ALL OF THEIR STATISTICS ABOUT
01:51PM	25	THE TESTING.

AND IN PARAGRAPH C YOU WROTE, "THE TOTAL PERCENTAGE OF QC 1 01:51PM VALUES GREATER THAN 2 STANDARD DEVIATIONS (SD'S) WAS REVIEWED 2 01:51PM BY THE SURVEYOR." 3 01:51PM 01:51PM 4 DO YOU SEE THAT? I DO. 01:51PM 5 Α. AND WHY WERE YOU LOOKING FOR THAT INFORMATION? 6 0. 01:51PM I WAS LOOKING FOR THAT INFORMATION BECAUSE THE PROCEDURE 01:52PM TALKED ABOUT USING TWO STANDARD DEVIATIONS -- PART OF THEIR 8 01:52PM PROCEDURE TALKED ABOUT USING TWO STANDARD DEVIATIONS AS A WAY 9 01:52PM TO EVALUATE WHETHER THE QUALITY CONTROL WAS ACCEPTABLE OR NOT. 10 01:52PM IT WAS ONE OF THE MEASURES THAT THEY USED. 01:52PM 11 12 AND THAT WAS THERANOS'S OWN METRIC? THAT WAS THERANOS'S 01:52PM 13 OWN METRIC? 01:52PM 14 Α. YES. 01:52PM AND WHAT IS A STANDARD DEVIATION? 15 Ο. OKAY. 01:52PM THAT EVERY TEST HAS A MEAN, WHICH IS THE AVERAGE NUMBER, 16 01:52PM 17 AVERAGE VALUE OF THAT TEST. 01:52PM 18 AND THEN BASED ON THE RESULTS THAT YOU GET FROM RUNNING 01:52PM 01:52PM 19 THE QUALITY CONTROL, YOU HAVE TO DETERMINE HOW FAR YOU DEVIATE 20 FROM THE MEAN. 01:52PM 21 SO ONE DEVIATION, THE STATISTICS OF ONE DEVIATION WOULD BE 01:52PM 22 THAT WHATEVER VALUE DETERMINED IT CAN BE AWAY FROM THE MEAN, 01:53PM ONE IS ONE STANDARD DEVIATION, TWO IS JUST ONE STANDARD 23 01:53PM 24 DEVIATION DOUBLED. 01:53PM SO YOU'RE LOOKING FOR INFORMATION OUTSIDE OF TWO STANDARD 25 01:53PM Q.

01:53PM	1	DEVIATIONS?
01:53PM	2	A. YES.
01:53PM	3	Q. OKAY. AND THAT WAS THE STANDARD THAT THERANOS WAS
01:53PM	4	EMPLOYING?
01:53PM	5	A. YES.
01:53PM	6	Q. LET'S GO TO THE NEXT PAGE, PAGE 56.
01:53PM	7	YOU WROTE IN AND IF WE CAN ZOOM IN ON E AND F,
01:53PM	8	MS. WACHS.
01:53PM	9	YOU WROTE, "IN JULY 2014, THE DATA REVEALED THE FOLLOWING
01:53PM	10	TESTS SHOWED PERCENTAGE OF QC SAMPLES WITH MORE THAN 15 PERCENT
01:53PM	11	OF VALUES GREATER THAN 2 SD."
01:53PM	12	AND THEN YOU LIST NUMBERS FOR TESTOSTERONE, TOTAL T4, AND
01:53PM	13	VITAMIN D.
01:53PM	14	DO YOU SEE THAT?
01:53PM	15	A. I DO.
01:53PM	16	Q. AND THOSE WERE ASSAYS RUN ON THE EDISON?
01:54PM	17	A. YES.
01:54PM	18	Q. AND ARE THESE NUMBERS DESIRABLE OR UNDESIRABLE?
01:54PM	19	A. THEY ARE UNDESIRABLE.
01:54PM	20	Q. "OVERALL 16 PERCENT OF QC SAMPLES ON ALL TESTS ON ALL
01:54PM	21	DEVICES HAD VALUES GREATER THAN 2 SD'S."
01:54PM	22	WHY ARE YOU CALLING THAT INFORMATION OUT?
01:54PM	23	A. I CALLED THAT INFORMATION OUT BECAUSE I GAVE SOME SPECIFIC
01:54PM	24	EXAMPLES WITH TESTOSTERONE, TOTAL T4, AND VITAMIN D TO SHOW
01:54PM	25	THAT THEY WERE OVER THE 15 PERCENT.

01:54PM	1	BUT I ALSO INCLUDED THIS INFORMATION SO THERANOS WOULD
01:54PM	2	KNOW THAT EVEN THOUGH I HAD SAMPLED SOME TESTS, I WAS REFERRING
01:54PM	3	TO ALL OF THE TESTS AS WELL.
01:54PM	4	Q. IN F YOU WROTE, "IN OCTOBER 2014, THE DATA REVEALED THE
01:54PM	5	FOLLOWING TESTS SHOWED PERCENTAGE OF QC SAMPLES WITH MORE THAN
01:54PM	6	15 PERCENT OF VALUES GREATER THAN 2 SD."
01:55PM	7	AND YOU LIST "ESTRADIOL, FREE T4, PROLACTIN, SHBG, TSH,
01:55PM	8	TST, TOTAL T3, TT4, AND VITAMIN D, AND VITAMIN B12."
01:55PM	9	DO YOU SEE THAT?
01:55PM	10	A. I DO.
01:55PM	11	Q. ARE THESE NUMBERS DESIRABLE OR UNDESIRABLE?
01:55PM	12	A. THEY ARE UNDESIRABLE.
01:55PM	13	Q. YOU THEN WROTE, "OVERALL 29 PERCENT OF QC SAMPLES ON ALL
01:55PM	14	TESTS ON ALL DEVICES HAD VALUES GREATER THAN 2 SD'S."
01:55PM	15	DO YOU SEE THAT LANGUAGE?
01:55PM	16	A. I DO.
01:55PM	17	Q. AND THAT WAS BASED ON YOUR REVIEW OF THERANOS'S OWN
01:55PM	18	DOCUMENTS?
01:55PM	19	A. YES.
01:55PM	20	Q. AND WHY WERE YOU CALLING OUT THIS 29 PERCENT FIGURE?
01:55PM	21	A. FOR THE SAME REASON I DID IN E. IT'S JUST A DIFFERENT
01:55PM	22	TIMEFRAME. ONE WAS JULY OF 2014 AND THE OTHER IS OCTOBER OF
01:55PM	23	2014.
01:55PM	24	SO IT SHOWS THAT THE QUALITY ASSURANCE PROGRAM WAS NOT
01:55PM	25	IDENTIFYING THE ISSUES AND THE ISSUES CONTINUED TO EXIST.

01:56PM	1	Q. THE ISSUES THAT YOU OBSERVED, WERE THEY ISOLATED?
01:56PM	2	A. THEY WERE NOT.
01:56PM	3	Q. OKAY. WERE THEY SYSTEMIC?
01:56PM	4	A. THEY WERE SYSTEMIC ISSUES.
01:56PM	5	Q. AND IF WE CAN ZOOM OUT, MS. WACHS, AND LOOK AT G
01:56PM	6	THROUGH I.
01:56PM	7	ARE THESE ADDITIONAL EXAMPLES WHERE YOU'RE SUMMARIZING QC
01:56PM	8	DATA FOR DIFFERENT PERIODS RELATING TO EDISON ASSAYS WHERE THE
01:56PM	9	STANDARD DEVIATION IS MORE THAN 15 PERCENT?
01:56PM	10	A. YES.
01:56PM	11	Q. AND IT APPEARS THAT THIS IS CONTINUED OR YOUR
01:56PM	12	OBSERVATIONS CONTINUE THROUGH APRIL OF 2015 ON THIS PAGE?
01:56PM	13	A. YES.
01:56PM	14	Q. OKAY. LET'S GO TO THE NEXT PAGE, PLEASE.
01:56PM	15	THEN IF WE CAN ZOOM IN ON EVERYTHING DOWN THROUGH K.
01:57PM	16	ARE YOU REPORTING HERE QC SAMPLING FOR MAY AND JUNE OF
01:57PM	17	2015 FOR PARTICULAR EDISON ASSAYS?
01:57PM	18	A. YES.
01:57PM	19	Q. AND IS THIS SIMILAR DATA TO WHAT WE SAW IN THE PRIOR PAGE?
01:57PM	20	A. IT IS.
01:57PM	21	Q. OKAY. LET ME NEXT I WANT TO MOVE TO A DIFFERENT
01:57PM	22	PORTION OF THE 2567.
01:57PM	23	AND IF I COULD DRAW YOUR ATTENTION, PLEASE, TO PAGE 58.
01:57PM	24	DO YOU SEE THAT THERE'S A D-TAG, D5793?
01:57PM	25	A. YES.

DO YOU SEE THAT? 1 01:59PM Α. I DO. 2 01:59PM AND WHAT IS THAT GETTING AT? 3 Q. 01:59PM 4 THE LABORATORY DID NOT HAVE A MECHANISM IN THEIR QUALITY 01:59PM ASSESSMENT PROGRAM THAT ALLOWED THEM TO IDENTIFY ISSUES IN A 01:59PM 5 TIMELY MANNER, AND THEY COULD NOT THEN IDENTIFY THOSE ISSUES IN 01:59PM A TIMELY MANNER SO THAT THEY COULD NOT CORRECT THEM IN A TIMELY 01:59PM 8 MANNER. 02:00PM 9 Q. OKAY. WHAT IS MEANT BY ALTERNATIVE ASSESSMENT PROGRAM? 02:00PM SO FOR PROFICIENCY TESTING, WE HAVE A SECTION IN OUR 10 02:00PM Α. REGULATIONS THAT, WITH CERTAIN ANALYTES, THAT THE LABORATORY 02:00PM 11 12 HAS TO ENROLL AND PARTICIPATE IN PROFICIENCY TESTING. 02:00PM 13 IF THE ANALYTE OR THE TEST IS NOT IN THAT SECTION, THEN 02:00PM 14 THEY HAVE TO DO SOMETHING CALLED ALTERNATIVE PT, PROFICIENCY 02:00PM 15 TESTING, WHERE THEY HAVE TO EVALUATE THE ACCURACY OF TESTS 02:00PM 16 TWICE A YEAR. 02:00PM 17 IT'S COMMONLY KNOWN AS ALTERNATIVE PT. 02:00PM 18 AND DID CMS REVIEW THERANOS'S ALTERNATIVE PT RECORDS? 02:00PM Q. 02:00PM 19 YES. MR. YAMAMOTO DID THOSE FOR THE CHEMISTRY AND I DID 20 THEM FOR THE EDISON. 02:00PM 21 AND WHAT DID YOU OBSERVE WITH RESPECT TO THE EDISON? 02:00PM Ο. 22 I OBSERVED THAT THEY HAD NOT DONE THEM ACCORDING TO THEIR 02:00PM PROCEDURE. THEY HAD NOT DONE THEM IN THE INTERVAL THAT THEY 23 02:01PM 24 SAID THEY WOULD DO THEM, THAT THEY HAD IN SOME CASES NOT BEEN 02:01PM REVIEWED, AND IN OTHER CASES THEY HAD BEEN REVIEWED RIGHT 25 02:01PM

02:01PM	1	BEFORE WE GOT THERE IN SEPTEMBER, EVEN THOUGH SOME OF THE
02:01PM	2	TESTING WAS DONE MONTHS TO A YEAR BEFORE WE WERE THERE.
02:01PM	3	Q. AND THAT WAS BASED ON YOUR REVIEW OF RECORDS PROVIDED BY
02:01PM	4	THERANOS?
02:01PM	5	A. YES.
02:01PM	6	Q. LET ME DRAW YOUR ATTENTION TO PAGE 79.
02:02PM	7	IF WE CAN ZOOM IN ON THE D-TAG, D6085, ALL OF THE WAY AT
02:02PM	8	THE BOTTOM.
02:02PM	9	THIS IS A D-TAG RELATING TO LABORATORY DIRECTOR
02:02PM	10	RESPONSIBILITIES.
02:02PM	11	DO YOU SEE THAT?
02:02PM	12	A. I DO.
02:02PM	13	Q. AND DO YOU SEE THE PARAGRAPH WHERE IT SAYS, "BASED ON
02:02PM	14	REVIEW OF VALIDATION DOCUMENTS ON THE THERANOS PROPRIETARY
02:02PM	15	SYSTEM, THE LABORATORY DIRECTOR FAILED TO ENSURE THAT THE
02:02PM	16	QUALITY OF RESULTS ON THE TPS; FAILED TO ENSURE THE
02:02PM	17	ESTABLISHMENT OF PERFORMANCE SPECIFICATIONS FOLLOWED THE
02:02PM	18	LABORATORY'S PROCEDURES TO ESTABLISH ACCURACY, PRECISION,
02:02PM	19	REPORTABLE RANGE AND/OR REFERENCE RANGE."
02:02PM	20	DO YOU SEE THAT?
02:02PM	21	A. I DO.
02:02PM	22	Q. WHAT DID YOU MEAN BY THAT?
02:02PM	23	A. WHAT I HAD MEANT BY THAT IS THAT THE LABORATORY DIRECTOR
02:02PM	24	DID NOT FULFILL HIS RESPONSIBILITIES TO ENSURE THAT THE RESULTS
02:03PM	25	ON THE EDISON WERE ACCURATE AND RELIABLE.

THE LABORATORY DIRECTOR DID NOT ENSURE THAT THE 1 02:03PM PERFORMANCE SPECIFICATIONS WERE -- THE ESTABLISHMENT OF THE 2 02:03PM PERFORMANCE SPECIFICATIONS, THEY DID NOT FOLLOW THE 3 02:03PM 4 LABORATORY'S PROCEDURE ON HOW TO DO THAT FOR ALL OF THE AREAS 02:03PM THAT THEY HAD TO ESTABLISH THOSE PERFORMANCE SPECIFICATIONS 02:03PM FOR. 02:03PM WHEN YOU SAY "ESTABLISHMENT OF PERFORMANCE 02:03PM SPECIFICATIONS," WHAT DOES THAT MEAN? 8 02:03PM 9 SO LABORATORIES THAT PERFORM NON-WAIVED TESTING, MODERATE 02:03PM Α. OR HIGH COMPLEXITY TESTING, EITHER HAVE TO VERIFY THEIR 10 02:03PM PERFORMANCE SPECIFICATIONS OR THEY HAVE TO ESTABLISH 02:03PM 11 12 PERFORMANCE SPECIFICATIONS. 02:03PM 02:03PM 13 SO IF A TEST IS FDA CLEARED OR APPROVED, THE MANUFACTURER 14 PROVIDES VALUES FOR ACCURACY AND PRECISION OF THE TESTS, THE 02:03PM REPORTABLE RANGE, WHICH IS THE HIGHEST NUMBER THAT THE TEST CAN 15 02:04PM 16 MEASURE, AND THE LOWEST NUMBER. 02:04PM 17 THESE ARE ALL INFORMATION THAT ARE PUBLISHED IN AND 02:04PM 18 APPROVED BY THE FDA. 02:04PM 19 SO THE LABORATORY SIMPLY HAS TO VERIFY THE NUMBERS THAT 02:04PM THE MANUFACTURER PROVIDES. 02:04PM 20 21 BUT IF YOU HAVE A TEST THAT IS NOT APPROVED OR CLEARED BY 02:04PM THE FDA, OR IT'S A LABORATORY DEVELOPED TEST BECAUSE THERE'S NO 22 02:04PM MANUFACTURER GIVING YOU THESE VALUES, THEN THE LABORATORY HAS 23 02:04PM 24 TO ESTABLISH THEIR OWN. THEY HAVE TO SHOW THAT THE TEST IS 02:04PM ACCURATE, PRECISE, THE HIGHEST AND LOWEST NUMBER THAT THEY CAN 25 02:04PM

02:04PM	1	REPORT OUT FOR THAT TEST, WHAT THE NORMAL VALUE IS, THE
02:04PM	2	REFERENCE RANGE.
02:04PM	3	AND THEY ALSO HAVE TO DO TWO ADDITIONAL STEPS IN
02:05PM	4	ESTABLISHING. THEY HAVE TO DO DETERMINE THE ANALYTIC
02:05PM	5	SENSITIVITY AND THE ANALYTIC SPECIFICITY.
02:05PM	6	AND WHAT THE SENSITIVITY IS, IS BASICALLY HOW LOW CAN YOU
02:05PM	7	GO. HOW WHAT IS THE LOWEST AMOUNT THAT YOU CAN FIND OF WHAT
02:05PM	8	YOU'RE LOOKING FOR.
02:05PM	9	THE ANALYTIC SPECIFICITY IS, IS THE TEST ACTUALLY
02:05PM	10	MEASURING WHAT YOU'RE LOOKING FOR AND IS THERE ANYTHING THAT IS
02:05PM	11	GOING TO INTERFERE WITH THAT? IN OTHER WORDS, IF AN INDIVIDUAL
02:05PM	12	IS TAKING A SPECIFIC MEDICATION, IS THE MEDICATION GOING TO
02:05PM	13	INTERFERE WITH THE RESULTS AND MAKE THE RESULT APPEARING HIGHER
02:05PM	14	OR LOWER?
02:05PM	15	Q. ARE YOU FAMILIAR WITH THE TERM "VALIDATION REPORT"?
02:05PM	16	A. YES.
02:05PM	17	Q. AND HOW DOES ESTABLISHMENT OF PERFORMANCE SPECIFICATIONS
02:05PM	18	RELATE TO A VALIDATION REPORT?
02:05PM	19	A. WHEN WE'RE TALKING ABOUT VERIFYING OR ESTABLISHING
02:06PM	20	PERFORMANCE SPECIFICATIONS, THAT'S WHAT MOST PEOPLE CALL THE
02:06PM	21	VALIDATION, SO IT'S KIND OF AN INTERCHANGEABLE TERM.
02:06PM	22	AGAIN, VALIDATION IS NOT REALLY A CLIA TERM. WE TALK
02:06PM	23	ABOUT PERFORMANCE SPECIFICATIONS.
02:06PM	24	Q. OKAY. AND IN A IT SAYS, "VALIDATIONS REPORTS FOR
02:06PM	25	VITAMIN D, TOTAL T3, HUMAN CHORIONIC GONADOTROPIN, AND SEX

02:06PM	1	HORMONE BINDING GLOBULIN WERE REVIEWED."
02:06PM	2	DO YOU SEE THAT LANGUAGE?
02:06PM	3	A. I DO.
02:06PM	4	Q. AND THOSE ARE VALIDATION REPORTS THAT YOU REVIEWED?
02:06PM	5	A. I DID.
02:06PM	6	Q. AND THEN IN D, DOES THIS REFLECT THAT YOU ALSO REVIEWED
02:06PM	7	THE MASTER VALIDATION PLAN FOR ROUTINE CHEMISTRY ASSAY?
02:06PM	8	A. I DID.
02:06PM	9	Q. AND IF WE CAN CONTINUE, MS. WACHS, ON TO PAGE 80.
02:06PM	10	DO YOU SEE WHERE IT SAYS, "ACCURACY FOR VITAMIN D, TT3,
02:06PM	11	HCG, AND SHBG WAS NOT DETERMINED FOLLOWING CL PLN-14003."
02:07PM	12	DO YOU SEE THAT LANGUAGE?
02:07PM	13	A. I DO.
02:07PM	14	Q. AND THERE'S PRECISION AND REPORTABLE RANGE.
02:07PM	15	WHAT ARE YOU GETTING AT HERE?
02:07PM	16	A. WHAT I'M REPORTING HERE IS THAT THE LABORATORY HAD A
02:07PM	17	PROCEDURE THAT THEY WERE SUPPOSED TO FOLLOW, AND THEY DID NOT.
02:07PM	18	Q. OKAY. DOES MORE DETAIL ABOUT THIS DEFICIENCY CONTINUE IN
02:07PM	19	ANOTHER D-TAG IF WE CAN ZOOM OUT, MS. WACHS IT SAYS
02:07PM	20	D60 LET ME START OVER.
02:07PM	21	IT SAYS REFER TO D6115.
02:07PM	22	IS THAT A REFERENCE TO ANOTHER DEFICIENCY TAG?
02:07PM	23	A. YES.
02:07PM	24	Q. DURING YOUR SURVEY, DID YOU ALSO OBSERVE INSTANCES WHERE
02:08PM	25	THERANOS REPORTED PATIENT RESULTS AFTER FAILING QUALITY

02:08PM	1	CONTROL?
02:08PM	2	A. YES, I DID.
02:08PM	3	Q. WHAT DID YOU OBSERVE?
02:08PM	4	A. BASED ON THE INFORMATION AND THE PRINTOUTS THAT THEY GAVE
02:08PM	5	ME FOR QUALITY CONTROL, THERE WERE AFTER QUALITY CONTROL ON
02:08PM	6	ONE DEVICE FAILED, THEY, PERHAPS THE NEXT DAY OR A DAY LATER,
02:08PM	7	RAN IT ON THAT SAME DEVICE, AND THE CONTROL WAS IN, BUT IN
02:08PM	8	BETWEEN THAT TIME, THERE WERE PATIENTS RUNNING REPORTED AFTER
02:08PM	9	THE QUALITY CONTROL WAS UNACCEPTABLE AND BEFORE THE QUALITY
02:08PM	10	CONTROL WAS ACCEPTABLE.
02:08PM	11	IN OTHER INSTANCES THEY WOULD IF THE QUALITY CONTROL
02:08PM	12	WAS NOT ACCEPTABLE ON ONE DEVICE, THEY WOULD SIMPLY RUN IT ON
02:08PM	13	ANOTHER DEVICE.
02:08PM	14	Q. AND WAS THAT AN ISSUE?
02:08PM	15	A. IT WAS AN ISSUE, YES.
02:08PM	16	Q. WHY?
02:09PM	17	A. QUALITY CONTROL IS REQUIRED TO BE ACCEPTABLE BEFORE YOU
02:09PM	18	REPORT PATIENT TEST RESULTS.
02:09PM	19	Q. DID YOU ALSO OBSERVE ISSUES WITH THERANOS'S TESTING OF
02:09PM	20	SOMETHING CALLED PT INR?
02:09PM	21	A. YES.
02:09PM	22	Q. AND WHAT IS PT INR?
02:09PM	23	A. PT INR IS A TEST THAT IS USED FOR COAGULATION. IT'S
02:09PM	24	USUALLY USED ON PATIENTS WHO ARE ON WARFARIN, AND WARFARIN IS
02:09PM	25	ALSO KNOWN AS COUMADIN THERAPY, WHICH IS A BLOOD THINNER.

- Q. AND WHAT DID YOU OBSERVE IN YOUR SURVEY?
- A. WHEN I WENT TO LOOK AT THE REAGENTS, THERE WERE SEVERAL THINGS. IN THE REAGENT BOX WHERE ALL OF THE CHEMICALS ARE TO PERFORM THE TESTS, THERE WAS A PINK STUFFER.

NORMALLY THE PACKAGE INSERTS ARE WHITE, AND IN THIS

PARTICULAR CASE, THE LOT NUMBER THAT I WAS LOOKING AT THAT THEY

WERE USING WAS PINK, AND THERE WAS A NOTIFICATION FROM THE

MANUFACTURER THAT THE STABILITY OF THE REAGENT, INSTEAD OF

BEING TEN DAYS, WAS TWO DAYS.

THEY -- THEIR PROCEDURE REQUIRED THAT THEY LOOK FOR THIS.

THEY DID NOT LOOK FOR THIS. THEY DID NOT FIND IT.

AND THEY WERE DATING THE REAGENT FOR FIVE DAYS, SO WHEN IT ONLY SHOULD HAVE BEEN USED IT FOR TWO, THEY WERE USING IT FOR FIVE.

THE OTHER ISSUE, WHEN YOU'RE RUNNING PT INR, YOU HAVE TO HAVE -- IN ORDER TO CALCULATE THE INR, YOU HAVE TO MAKE SURE THAT ALL OF THE NUMBERS USED TO CALCULATE IT ARE ACCURATE, AND ACCURATE FOR A SPECIFIC LOT NUMBER OF REAGENT.

- Q. DID YOU ALERT MR. BALWANI TO THE PROBLEMS WITH PT INR IN THE SEPTEMBER PORTION OF THE EXAM?
- A. YES.
- Q. AND WHEN YOU CAME BACK IN NOVEMBER, WHAT HAD HAPPENED?
- A. NOTHING.

WELL, THEY HAD NOTIFIED -- EVEN THOUGH WE HAD NOTIFIED

THEM THAT THERE WAS A PROBLEM WITH THE PT INR, THEY HAD WAITED

02:11PM	1	TO NOTIFY PATIENTS OF CORRECTED RESULTS UNTIL RIGHT BEFORE WHEN
02:11PM	2	WE RETURNED IN NOVEMBER.
02:11PM	3	Q. DID YOU ALSO OBSERVE INSTANCES IN YOUR SURVEY WHERE
02:11PM	4	THERANOS FAILED TO HAVE A QUALITY CONTROL PROCEDURE AT ALL
02:11PM	5	PRIOR TO A PARTICULAR DATE THAT YOU WERE LOOKING FOR?
02:11PM	6	A. YES.
02:11PM	7	Q. IS THAT AN ISSUE?
02:11PM	8	A. THAT'S AN ISSUE, YES.
02:11PM	9	Q. HOW SO?
02:11PM	10	A. THE PEOPLE WHO ARE PERFORMING THE TESTING NEED TO KNOW
02:12PM	11	WHAT THE PROCEDURE IS THAT HAS BEEN APPROVED BY THE LABORATORY
02:12PM	12	DIRECTOR SO THEY CAN PERFORM THE TEST.
02:12PM	13	THEY NEED TO BE ABLE TO KNOW WHAT AN ACCEPTABLE QUALITY
02:12PM	14	CONTROL VALUE IS TO MAKE A DETERMINATION WHETHER THE PARTICULAR
02:12PM	15	RUN OF PATIENT TESTING IS ACCEPTABLE OR NOT BEFORE THEY REPORT
02:12PM	16	OUT PATIENT RESULTS.
02:12PM	17	Q. MS. BENNETT, THE DATE OF THE STATEMENT OF DEFICIENCIES,
02:12PM	18	THE FORM 2567, IS JANUARY 25TH, 2016. WAS THERANOS EVER ABLE
02:12PM	19	TO RESOLVE THE DEFICIENCIES TO YOUR SATISFACTION?
02:12PM	20	A. THEY WERE NOT.
02:12PM	21	Q. DO YOU KNOW WHETHER THE NEWARK LAB ULTIMATELY CLOSED?
02:12PM	22	A. THEY DID.
02:12PM	23	Q. I'D LIKE TO DRAW YOUR ATTENTION, PLEASE, TO WHAT IS
02:12PM	24	ALREADY AS EXHIBIT 5387H.
02:12PM	25	MAY WE DISPLAY, YOUR HONOR?

02:12PM	1	THE COURT: YES.
02:13PM	2	BY MR. LEACH:
02:13PM	3	Q. AND I'M DISPLAYING, MS. BENNETT, A SERIES OF TEXT MESSAGES
02:13PM	4	BETWEEN ELIZABETH HOLMES AND SUNNY BALWANI.
02:13PM	5	PLEASE DON'T TRY TO READ THIS PAGE QUITE YET.
02:13PM	6	BUT YOU'VE NEVER SEEN THESE BEFORE; CORRECT?
02:13PM	7	A. I HAVE NOT.
02:13PM	8	Q. OKAY. I'D LIKE TO GO TO PAGE 26, PLEASE.
02:13PM	9	ONE MOMENT, YOUR HONOR.
02:13PM	10	IF WE CAN PLEASE ZOOM IN ON THE TOP HALF ALL OF THE WAY
02:13PM	11	DOWN TO THE TEXT READING "NEED PROFESSIONALS ACROSS THE BOARD,"
02:14PM	12	MS. WACHS.
02:14PM	13	I'M SORRY, ARE WE ON PAGE 26? YEAH. OKAY. MY APOLOGIES.
02:14PM	14	ALL OF THE WAY DOWN TO "WE CAN'T SCALE WITH WAG."
02:14PM	15	DO YOU SEE THE DATE OF THESE MESSAGES, MS. BENNETT,
02:14PM	16	NOVEMBER 19TH, 2014, IN THE LEFT COLUMN?
02:14PM	17	A. I DO.
02:14PM	18	Q. OKAY. THAT'S ALMOST YOUR SURVEY WAS IN SEPTEMBER OF
02:15PM	19	2015?
02:15PM	20	A. YES.
02:15PM	21	Q. OKAY. SO A NUMBER OF MONTHS AFTER THESE TEXT EXCHANGES?
02:15PM	22	A. YES.
02:15PM	23	Q. OKAY. AND DO YOU SEE WHERE MR. BALWANI WROTE,
02:15PM	24	"FUNDAMENTALLY, WE NEED TO STOP FIGHTING FIRES BY NOT CREATING
02:15PM	25	THEM"?

02:15PM	1	A. I DO.
02:15PM	2	Q. OKAY. DO YOU SEE FURTHER DOWN HE WROTE, "REBUILD"?
02:15PM	3	A. YES.
02:15PM	4	Q. DO YOU SEE WHERE HE WROTE, "NEW LAB DIRS"?
02:15PM	5	A. YES.
02:15PM	6	Q. AND DO YOU SEE WHERE MS. HOLMES WROTE, "NEED TO FIX ROOT
02:15PM	7	CAUSE HERE"?
02:15PM	8	A. YES.
02:15PM	9	Q. AND THEN IT ENDS WITH, "WE CAN'T SCALE WITH WAG"?
02:15PM	10	A. YES.
02:15PM	11	Q. IN THE COURSE OF YOUR INSPECTION, DID YOU EVER SPEAK TO
02:15PM	12	ANYBODY FROM WALGREENS?
02:15PM	13	A. NO.
02:15PM	14	Q. OKAY. THAT WASN'T PART OF YOUR RESPONSIBILITIES?
02:15PM	15	A. NO.
02:15PM	16	Q. OKAY. LET'S GO TO PAGE 31.
02:16PM	17	DO YOU SEE THE DATE OF NOVEMBER 28TH, 2014
02:16PM	18	A. I DO.
02:16PM	19	Q FOR THESE MESSAGES?
02:16PM	20	A. I DO.
02:16PM	21	Q. AND DO YOU SEE THE TOP TEXT SAYS, "NORMANDY LAB IS A," AND
02:16PM	22	THEN THERE'S AN EXPLETIVE. "GLAD I CAME HERE. WILL WORK ON
02:16PM	23	FIXING THIS."
02:16PM	24	DO YOU SEE THAT?
02:16PM	25	A. I DO.

02:16PM	1	Q. DO YOU KNOW WHAT NORMANDY IS?
02:16PM	2	A. I'M TRYING TO REMEMBER. THE LABS HAD DIFFERENT NAMES
02:16PM	3	DEPENDING ON WHAT TYPE OF TESTING WAS BEING DONE. I'M
02:16PM	4	TRYING I DON'T REMEMBER IF NORMANDY WAS ONE OF THE NAMES.
02:16PM	5	Q. OKAY. THAT'S NOT A TERM THAT MR. BALWANI USED WITH YOU?
02:16PM	6	A. HE DID USE THE NAMES OF THE LABS, THE DIFFERENT LABS, BUT
02:17PM	7	I DON'T REMEMBER WHAT THEY ARE.
02:17PM	8	Q. WAS IT SOMETHING WITHIN NEWARK OR WAS IT SOMETHING
02:17PM	9	ELSEWHERE?
02:17PM	10	A. NEWARK.
02:17PM	11	Q. AND THIS IS FROM NOVEMBER 28TH, 2014, SEVERAL MONTHS
02:17PM	12	BEFORE YOUR INSPECTION?
02:17PM	13	A. YES.
02:17PM	14	Q. OKAY. IF WE CAN PLEASE GO TO PAGE 106.
02:17PM	15	AND IF WE CAN ZOOM IN ON THE TOP HALF, MS. WACHS, ALL OF
02:17PM	16	THE WAY DOWN TO THE TEXT, "WE CAN DEFINITELY RUN CIRCLES."
02:17PM	17	DO YOU SEE UP AT THE TOP THERE'S A DATE SEPTEMBER 2ND,
02:17PM	18	2015?
02:17PM	19	A. YES.
02:17PM	20	Q. AND THIS IS A FEW WEEKS BEFORE THE CMS INSPECTION?
02:17PM	21	A. YES.
02:17PM	22	Q. WHEN YOU CONDUCTED THE CMS INSPECTION, WERE YOU AWARE THAT
02:18PM	23	THE FDA HAD CONDUCTED AN INSPECTION OF THERANOS?
02:18PM	24	A. I WAS.
02:18PM	25	Q. OKAY. AND THAT WAS BEFORE YOUR INSPECTION?

02:18PM	1	A. YES.
02:18PM	2	Q. AND DO YOU SEE DOWN TOWARDS THE BOTTOM MR. BALWANI WROTE,
02:18PM	3	"WE CAN BUILD THIS BUSINESS THEY SOFTWARE AND JP AND RUN
02:18PM	4	CIRCLES AROUND OTHERS AND FDA BY MANIPULATING THEIR GAME"?
02:18PM	5	DO YOU SEE THAT LANGUAGE?
02:18PM	6	A. I DO.
02:18PM	7	Q. AND DO YOU SEE WHERE MS. HOLMES RESPONDS, "WE CAN
02:18PM	8	DEFINITELY RUN CIRCLES"?
02:18PM	9	A. I DO.
02:18PM	10	Q. AND LAST, IF WE COULD PLEASE LOOK AT PAGE 111.
02:18PM	11	DO YOU SEE THE DATE SEPTEMBER 22ND, 2015?
02:18PM	12	A. I DO.
02:18PM	13	Q. THAT'S THE DATE THAT YOUR SURVEY STARTED?
02:18PM	14	A. YES.
02:18PM	15	Q. AND MR. BALWANI WROTE, "VERY HOSTILE SO FAR. THEY HAVE
02:19PM	16	COMPLAINTS"?
02:19PM	17	A. YES.
02:19PM	18	Q. WERE YOU BEING HOSTILE?
02:19PM	19	A. NO, I WOULDN'T HAVE CHARACTERIZED IT AS HOSTILE.
02:19PM	20	Q. YOU WERE DOING YOUR JOB?
02:19PM	21	A. I WAS DOING MY JOB. I DIDN'T THINK THE OVERALL WHOLE
02:19PM	22	PROCESS WAS HOSTILE.
02:19PM	23	Q. AND THEN FURTHER DOWN MS. HOLMES WRITES THERE'S A
02:19PM	24	REFERENCE BY MS. HOLMES, "JC HIMSELF PLAYING LITERALLY OFF LAB
02:19PM	25	COMMENTS IS LIKELY THE OTHER."

02:19PM	1	DO YOU SEE THAT?
02:19PM	2	A. I DO.
02:19PM	3	Q. AND ARE YOU FAMILIAR WITH SOMEONE NAMED JOHN CARREYROU?
02:19PM	4	A. I AM.
02:19PM	5	Q. AND WHO IS?
02:19PM	6	A. HE'S A REPORTER FROM "THE WALL STREET JOURNAL."
02:19PM	7	Q. AND THEN DO YOU SEE MS. HOLMES, "PRAYING LITERALLY
02:19PM	8	NONSTOP"?
02:19PM	9	A. I DO.
02:19PM	10	MR. LEACH: MAY I HAVE A MOMENT, YOUR HONOR?
02:19PM	11	THE COURT: YES.
02:20PM	12	(DISCUSSION AMONGST GOVERNMENT COUNSEL OFF THE RECORD.)
02:20PM	13	MR. LEACH: MS. WACHS, IF WE CAN PLEASE GO TO PAGE
02:20PM	14	65.
02:21PM	15	I'M SORRY, PAGE 61. MY APOLOGIES.
02:21PM	16	Q. DO YOU SEE SOME ADDITIONAL TEXTS, MS. BENNETT, FROM THE
02:21PM	17	TIME PERIOD APRIL 28TH, 2015?
02:21PM	18	A. YES.
02:21PM	19	Q. AND DO YOU SEE MR. BALWANI WRITING, "IT IS MOST MADDENING
02:21PM	20	THERE IS NO FOCUS IN ANY CHEM TEAMS AND NO PRODUCT COMING OUT"?
02:21PM	21	A. I DO.
02:21PM	22	Q. AND DO YOU SEE AT THE BOTTOM HE WROTE, "MOST DISAPPOINTING
02:21PM	23	HOW BAD THESE PEOPLE ARE"?
02:21PM	24	A. I DO.
02:21PM	25	MR. LEACH: THANK YOU, YOUR HONOR.

02:21PM	1	I HAVE NO FURTHER QUESTIONS.
02:21PM	2	THANK YOU, MS. BENNETT.
02:21PM	3	THE COURT: WILL THERE BE CROSS-EXAMINATION?
02:21PM	4	MR. CAZARES: THERE WILL BE, YOUR HONOR.
02:21PM	5	THE COURT: ALL RIGHT. LET'S TAKE OUR BREAK RIGHT
02:21PM	6	NOW, LADIES AND GENTLEMEN. WE'LL TAKE ABOUT 25 MINUTES, AND
02:22PM	7	THEN WE'LL DO CROSS-EXAMINATION.
02:22PM	8	(RECESS FROM 2:22 P.M. UNTIL 2:49 P.M.)
02:50PM	9	THE COURT: ALL RIGHT. WE'RE BACK ON THE RECORD.
02:50PM	10	ALL PARTIES PREVIOUSLY PRESENT ARE PRESENT AGAIN.
02:50PM	11	AND COUNSEL, DO YOU HAVE CROSS-EXAMINATION?
02:50PM	12	MR. CAZARES: YES, YOUR HONOR. THANK YOU,
02:50PM	13	YOUR HONOR.
02:50PM	14	YOUR HONOR, MAY I REMOVE MY MASK?
02:50PM 02:50PM		YOUR HONOR, MAY I REMOVE MY MASK? THE COURT: YES. YES.
	15	
02:50PM 02:50PM	15 16	THE COURT: YES. YES.
02:50PM 02:50PM	15 16	THE COURT: YES. YES. CROSS-EXAMINATION
02:50PM 02:50PM 02:50PM	15 16 17 18	THE COURT: YES. YES. CROSS-EXAMINATION BY MR. CAZARES:
02:50PM 02:50PM 02:50PM 02:50PM	15 16 17 18	THE COURT: YES. YES. CROSS-EXAMINATION BY MR. CAZARES: Q. GOOD AFTERNOON, MS. BENNETT.
02:50PM 02:50PM 02:50PM 02:50PM 02:50PM	15 16 17 18 19	THE COURT: YES. YES. CROSS-EXAMINATION BY MR. CAZARES: Q. GOOD AFTERNOON, MS. BENNETT. A. GOOD AFTERNOON.
02:50PM 02:50PM 02:50PM 02:50PM 02:50PM 02:50PM	15 16 17 18 19 20	THE COURT: YES. YES. CROSS-EXAMINATION BY MR. CAZARES: Q. GOOD AFTERNOON, MS. BENNETT. A. GOOD AFTERNOON. Q. I'M STEVE CAZARES, AND I REPRESENT MR. BALWANI IN THIS
02:50PM 02:50PM 02:50PM 02:50PM 02:50PM 02:50PM	15 16 17 18 19 20 21	THE COURT: YES. YES. CROSS-EXAMINATION BY MR. CAZARES: Q. GOOD AFTERNOON, MS. BENNETT. A. GOOD AFTERNOON. Q. I'M STEVE CAZARES, AND I REPRESENT MR. BALWANI IN THIS CASE. I HAVE A FEW QUESTIONS ABOUT YOUR TESTIMONY TODAY.
02:50PM 02:50PM 02:50PM 02:50PM 02:50PM 02:50PM 02:50PM	15 16 17 18 19 20 21 22 23	THE COURT: YES. YES. CROSS-EXAMINATION BY MR. CAZARES: Q. GOOD AFTERNOON, MS. BENNETT. A. GOOD AFTERNOON. Q. I'M STEVE CAZARES, AND I REPRESENT MR. BALWANI IN THIS CASE. I HAVE A FEW QUESTIONS ABOUT YOUR TESTIMONY TODAY. WOULD THAT BE OKAY?
02:50PM 02:50PM 02:50PM 02:50PM 02:50PM 02:50PM 02:50PM 02:50PM	15 16 17 18 19 20 21 22 23 24	THE COURT: YES. YES. CROSS-EXAMINATION BY MR. CAZARES: Q. GOOD AFTERNOON, MS. BENNETT. A. GOOD AFTERNOON. Q. I'M STEVE CAZARES, AND I REPRESENT MR. BALWANI IN THIS CASE. I HAVE A FEW QUESTIONS ABOUT YOUR TESTIMONY TODAY. WOULD THAT BE OKAY? A. SURE.

02:51PM	1	FAMILIAR WITH THERANOS.
02:51PM	2	AND I THINK YOU TESTIFIED THAT THERE WERE SOME MEETINGS IN
02:51PM	3	LATE '13 AND EARLY '14 BETWEEN AND AMONGST THERANOS, CMS, AND
02:51PM	4	THE FDA; IS THAT RIGHT?
02:51PM	5	A. I CAN SAY THAT I WAS INVOLVED IN JANUARY 2014. I WASN'T
02:51PM	6	AWARE OF ANY OTHER MEETINGS THAT OCCURRED.
02:51PM	7	Q. OKAY. SO YOU DIDN'T ATTEND AN EARLIER MEETING
02:51PM	8	A. I DID NOT.
02:51PM	9	Q PRIOR TO JANUARY 2014?
02:51PM	10	BUT YOU DID PARTICIPATE IN THE JANUARY 2014 MEETING; IS
02:51PM	11	THAT RIGHT?
02:51PM	12	A. I ATTENDED IT, YES.
02:51PM	13	Q. IF YOU COULD TAKE A LOOK OH, ACTUALLY, I HAVE BINDERS
02:51PM	14	FIRST.
02:51PM	15	YOUR HONOR, MAY I HAVE A MOMENT? I HAVE BINDERS.
02:51PM	16	THE COURT: YES.
02:51PM	17	MR. CAZARES: (HANDING.)
02:52PM	18	Q. MS. BENNETT, I'VE JUST HANDED YOU A BINDER, AND I WOULD
02:52PM	19	ASK IF YOU COULD TAKE A LOOK AT THE TAB MARKED 7350, 7350.
02:52PM	20	ARE YOU THERE AT 7350?
02:52PM	21	A. I AM, YES.
02:52PM	22	Q. OKAY. AND 7350 APPEARS TO BE AN EMAIL CHAIN, THE LATTER
02:52PM	23	OF WHICH AT THE TOP OF THE FIRST PAGE LOOKS TO BE FROM A
02:53PM	24	PENNY KELLER TO YOURSELF, SOME OTHER INDIVIDUALS, ON
02:53PM	25	OCTOBER 25, 2013.

02:53PM	1	DO YOU SEE THAT?
02:53PM	2	A. I SEE THE DATE, YES.
02:53PM	3	Q. AND THERE'S A REFERENCE TO BACKGROUND INFORMATION AND
02:53PM	4	DISCUSSION REGARDING THERANOS.
02:53PM	5	DO YOU SEE THAT AS WELL?
02:53PM	6	A. YEAH, THAT'S THE ATTACHMENT, YEP, AND THE SUBJECT.
02:53PM	7	Q. OKAY. AND THEN BENEATH THAT LAST MESSAGE, THERE'S A TWO
02:53PM	8	EMAIL CHAIN STARTING WITH SOME INDIVIDUALS FROM THE FDA, AND
02:53PM	9	THEN A MESSAGE FROM FDA TO A PENNY KELLER AT CMS.
02:53PM	10	DO YOU SEE THAT?
02:53PM	11	A. I DO.
02:53PM	12	Q. AND THEN MS. KELLER APPEARS TO HAVE FORWARDED THE MESSAGE
02:53PM	13	AND DOCUMENTS TO YOURSELF; CORRECT?
02:53PM	14	A. YES, I APPEAR TO BE ON THE TO LINE.
02:53PM	15	Q. OKAY. AND I THINK YOU DESCRIBED PREVIOUSLY THAT IN THE
02:53PM	16	COURSE OF YOUR WORK AND IN RELATION TO THERANOS, IT WAS YOU
02:54PM	17	KNOW, EMAIL WAS USED TO COMMUNICATE AMONGST YOURSELVES AT CMS,
02:54PM	18	AS WELL AS COMMUNICATION WITH FDA PERSONNEL; CORRECT?
02:54PM	19	A. I DON'T BELIEVE I SAID THAT, BUT EMAIL WAS ONE OF THE
02:54PM	20	MECHANISMS THAT WE USED, YES.
02:54PM	21	Q. OKAY. WITHIN CMS?
02:54PM	22	A. WITHIN CMS.
02:54PM	23	Q. AND WHEN YOU USED EMAIL TO COMMUNICATE ABOUT BUSINESS
02:54PM	24	MATTERS, YOU MAKE WHATEVER EFFORTS YOU CAN TO BE ACCURATE AND
02:54PM	25	PRECISE IN YOUR EXCHANGES; CORRECT?

02:54PM	1	A. WE DO.
02:54PM	2	Q. AND IT WAS THE PRACTICE AT CMS TO PRESERVE THOSE MESSAGES;
02:54PM	3	CORRECT?
02:54PM	4	A. YES. AS LONG AS THEY WERE CONSIDERED RECORDS, THEY ARE
02:54PM	5	PRESERVED, YES.
02:54PM	6	Q. BECAUSE THERE ARE CERTAIN REQUIREMENTS TO MAINTAIN RECORDS
02:54PM	7	AT CMS; RIGHT?
02:54PM	8	A. YES. WE HAVE RECORDS RETENTION REQUIREMENTS.
02:54PM	9	Q. AND IT WAS YOUR REGULAR PRACTICE TO REVIEW EMAIL MESSAGES
02:54PM	10	RECEIVED WHEN THE MESSAGES CONCERN CMS BUSINESS; CORRECT?
02:55PM	11	A. IF THE EMAIL WAS ADDRESSED TO ME, YES.
02:55PM	12	MR. CAZARES: YOUR HONOR, MOVE TO ADMIT 7350.
02:55PM	13	THE COURT: INCLUDING THE ATTACHMENT?
02:55PM	14	MR. CAZARES: YES, YOUR HONOR.
02:55PM	15	MR. LEACH: YOUR HONOR, HEARSAY AS TO THE
02:55PM	16	ATTACHMENTS.
02:55PM	17	IF THE PROFFER FOR THE EMAIL ITSELF IS 803(6), I HAVE NO
02:55PM	18	OBJECTION TO THAT.
02:55PM	19	THE COURT: IS THE ATTACHMENT BEING OFFERED FOR A
02:55PM	20	PURPOSE OTHER THAN ITS TRUTH?
02:55PM	21	MR. CAZARES: NO. I THINK IT'S BACKGROUND FOR THIS
02:55PM	22	INDIVIDUAL WHO HAS ALREADY NOW TESTIFIED ABOUT A SERIES OF
02:55PM	23	ENGAGEMENTS IN THE ULTIMATE INSPECTION OF THERANOS.
02:55PM	24	SO IT'S NOTICE TO THIS WITNESS OF THERANOS MATTERS,
02:55PM	25	CORRECT.

02:55PM	1	THE COURT: TO MS. BENNETT.
02:55PM	2	MR. CAZARES: CORRECT.
02:56PM	3	THE COURT: ALL RIGHT. I WILL ADMIT THE EMAIL CHAIN
02:56PM	4	PURSUANT TO 803(6).
02:56PM	5	THE ATTACHMENTS WILL BE ADMITTED NOT FOR THE TRUTH OF THE
02:56PM	6	MATTER ASSERTED IN THE ATTACHMENTS THAT YOU'LL SEE, LADIES AND
02:56PM	7	GENTLEMEN, BUT THEY WILL BE ADMITTED ONLY AS TO NOTICE AND
02:56PM	8	BACKGROUND FOR THIS WITNESS'S PARTICIPATION, IF ANY, IN REGARDS
02:56PM	9	TO THE ATTACHMENTS AND HER WORK DONE.
02:56PM	10	SO FOR THAT LIMITED PURPOSE, THEY'RE ADMITTED AND MAY BE
02:56PM	11	PUBLISHED.
02:56PM	12	MR. CAZARES: THANK YOU, YOUR HONOR.
02:56PM	13	(DEFENDANT'S EXHIBIT 7350 WAS RECEIVED IN EVIDENCE.)
02:56PM	14	MR. CAZARES: IF WE CAN PUBLISH THE BOTTOM HALF OF
02:56PM	15	THE EMAIL FOR NOW AND THE LOWER HALF OF THE MESSAGE.
02:56PM	16	Q. MS. BENNETT, DO YOU SEE UP ON THE SCREEN THERE'S THE LOWER
02:56PM	17	HALF OF EXHIBIT 7350.
02:56PM	18	DO YOU SEE THAT?
02:56PM	19	A. I DO.
02:56PM	20	Q. AND IT APPEARS TO BE A MESSAGE FROM JOHN HOBSON TO
02:56PM	21	JUDITH YOST, ALBERTO GUTIERREZ, WITH A COPY TO A SALLY HOJVAT.
02:57PM	22	DO YOU SEE THAT?
02:57PM	23	A. I DO.
02:57PM	24	Q. AND ARE YOU FAMILIAR WITH MR. HOBSON?
02:57PM	25	A. NO.

02:57PM	1	Q. AND HOW ABOUT MS. YOST AND MR. GUTIERREZ?
02:57PM	2	A. JUDY YOST IN 2013 WAS THE DIRECTOR OF THE CLIA PROGRAM AND
02:57PM	3	ALBERT GUTIERREZ WAS HER COUNTERPART AT THE FDA.
02:57PM	4	Q. SO THESE WERE PEOPLE WHO YOU INTERACTED WITH IN YOUR
02:57PM	5	PROFESSIONAL CAPACITY?
02:57PM	6	A. YES.
02:57PM	7	Q. AND HOW ABOUT MS. HOJVAT?
02:57PM	8	A. I DON'T KNOW HER.
02:57PM	9	Q. OKAY. AND MS. YOST'S POSITION AT THAT TIME, WAS SHE
02:57PM	10	WHERE WAS SHE IN THE CMS HIERARCHY RELATIVE TO YOU?
02:57PM	11	A. SHE WAS THE DIRECTOR OF THE CLIA PROGRAM, AND I WAS A
02:57PM	12	TECHNOLOGIST IN THE CLIA PROGRAM.
02:57PM	13	Q. OKAY. AND SO MR. HOBSON IS SENDING TO MS. YOST A MESSAGE
02:57PM	14	AND HE WRITES, "ATTACHED TO THIS EMAIL ARE DOCUMENTS THAT
02:57PM	15	OUTLINE THE PROPOSED BUSINESS MODEL OF THERANOS."
02:57PM	16	DO YOU SEE THAT?
02:57PM	17	A. I DO.
02:57PM	18	Q. AND THEN HE CONTINUES.
02:57PM	19	"PLEASE FIND A SET OF SLIDES DEPICTING THE PROPOSED
02:57PM	20	PHASE I AND PHASE II PROPOSALS AS WELL AS A DESCRIPTION OF THE
02:58PM	21	TSPU AND THE TLAS?"
02:58PM	22	DID I READ THAT RIGHT?
02:58PM	23	A. YES.
02:58PM	24	Q. OKAY. AND THEN HE CONTINUES.
02:58PM	25	"IN ADDITION THERE IS A SHORT NARRATIVE DESCRIBING THE

02:58PM	1	PROPOSED PHASES. IN PREPARATION FOR THE MEETING ON
02:58PM	2	NOVEMBER 4TH, I WOULD LIKE TO REQUEST A BRIEF TELECONFERENCE
02:58PM	3	WITH YOU AND ALBERTO TO GO OVER THE SALIENT POINTS OF THE
02:58PM	4	SUBMISSION, ANSWER ANY QUESTIONS THAT YOU MAY HAVE, AS WELL AS
02:58PM	5	GET YOUR FEEDBACK REGARDING THE THERANOS PHASE II MODEL?"
02:58PM	6	DO YOU SEE THAT?
02:58PM	7	A. I DO.
02:58PM	8	Q. AND THEN MR. HOBSON CONTINUES.
02:58PM	9	"SPECIFICALLY WHAT ARE ANY OF THE CONCERNS OR REGULATORY
02:58PM	10	HURDLES WITH REGARD TO PLACING AN INSTRUMENT INTO PATIENT
02:58PM	11	SERVICE CENTER."
02:58PM	12	DO YOU SEE THAT?
02:58PM	13	A. I DO.
02:58PM	14	Q. AND THEN THE MESSAGE GETS FORWARDED FROM MR. GUTIERREZ TO
02:58PM	15	MS. KELLER AND THEN FROM MS. KELLER TO YOURSELF IN THE LATTER
02:58PM	16	THREE MESSAGES.
02:58PM	17	DO YOU SEE THAT?
02:58PM	18	A. I DO.
02:58PM	19	Q. NOW, IF WE CAN TURN TO THE NEXT PAGE OF THE EXHIBIT. IT'S
02:58PM	20	ACTUALLY 7357A, THE ATTACHMENT, PAGE 1 OF THE ATTACHMENT.
02:59PM	21	AT THE TOP IT APPEARS TO BE A TYPEWRITTEN KIND OF SUMMARY.
02:59PM	22	DO YOU SEE THAT?
02:59PM	23	A. I DO.
02:59PM	24	Q. AND THEN IT DESCRIBES THERANOS BACKGROUND.
02:59PM	25	AGAIN, WOULD IT HAVE BEEN YOUR PRACTICE AT THE TIME TO

REVIEW THE MESSAGE AND THE ATTACHMENTS? 1 02:59PM I MAY HAVE. I DON'T REMEMBER IN THIS PARTICULAR CASE OR 2 02:59PM NOT. 3 02:59PM 02:59PM 4 OKAY. WHEN YOU HAD THE MEETING IN JANUARY OF 2014, WOULD YOU HAVE DONE A LITTLE BIT OF DUE DILIGENCE OR INVESTIGATION TO 02:59PM 5 PREP FOR THE MEETING? 6 02:59PM IF ANY DOCUMENTS HAD BEEN GIVEN TO ME TO PREPARE FOR THE 02:59PM MEETING, I WOULD HAVE LOOKED AT THOSE DOCUMENTS, YES. 8 02:59PM 9 FAIR ENOUGH. THANK YOU. Q. 02:59PM NOW, GETTING BACK TO THIS 7350A AT THE TOP. THE DOCUMENT 10 02:59PM STARTS, "PHASE I: CURRENT MODEL. 02:59PM 11 12 "THERANOS IS CURRENTLY OPERATING A CLIA CERTIFIED HIGH 02:59PM 13 COMPLEXITY LABORATORY IN PALO ALTO, CALIFORNIA AND IS USING FDA 03:00PM 14 CLEARED/APPROVED COMMERCIAL PLATFORMS, AND A THERANOS DEVELOPED 03:00PM DIAGNOSTIC SYSTEM THAT INCLUDES A UNIT TO PROCESS THE SPECIMEN 15 03:00PM AND GENERATE THE TEST SIGNALS." 16 03:00PM 17 DO YOU SEE THAT? 03:00PM Α. 18 I DO. 03:00PM 03:00PM 19 Ο. AND DO YOU UNDERSTAND THAT LATTER REFERENCE TO BE TO 20 THERANOS'S PROPRIETARY ANALYZER, SOME OF WHICH YOU REVIEWED 03:00PM DOCUMENTATION FOR IN YOUR 2013 SURVEY OF THERANOS? 21 03:00PM 22 I DO. Α. 03:00PM AND THEN, OF COURSE, YOU AND MR. YAMAMOTO REVIEWED RECORDS 23 Q. 03:00PM 24 RELATING TO THERANOS'S USE OF FDA CLEARED MACHINES IN 2015 AS 03:00PM 25 WELL; CORRECT? 03:00PM

YES. 1 Α. 03:00PM 2 Q. WE WON'T REVIEW THIS WHOLE THING BUT CONTINUING OKAY. 03:00PM TOWARD THE BOTTOM QUARTILE OF THAT PARAGRAPH BEGINNING, 3 03:00PM "THERANOS HAS EXPRESSED." 03:00PM 4 THE SUMMARY CONTINUES, "THERANOS HAS EXPRESSED ITS 03:00PM 5 INTENTION TO PURSUE FDA REGULATORY APPROVAL OR CLEARANCE OF ALL 6 03:01PM ASSAYS RUN AT THE THERANOS CLIA CERTIFIED LABORATORY ON THE 03:01PM THERANOS DEVICE SYSTEM AND HAS SENT IN THEIR FIRST 8 03:01PM PRE-SUBMISSION FOR REVIEW OF THEIR TSPU/TLAS PLUS A PANEL OF 9 03:01PM MOLECULAR AND SEROLOGICAL INFLUENZA ASSAYS." 10 03:01PM DO YOU SEE THAT? 03:01PM 11 03:01PM 12 Α. I DO. NOW, THAT ISSUE OF OBTAINING FDA REGULATORY APPROVAL OR 13 0. 03:01PM 14 CLEARANCE FOR ALL ASSAYS, WOULD THERANOS REQUIRE OR NEED FDA 03:01PM 15 APPROVAL OR CLEARANCE OF ITS TECHNOLOGY TO USE THE DEVICE IN 03:01PM 16 ITS CLIA LAB? 03:01PM 17 FROM A CLIA PERSPECTIVE, NO. 03:01PM Α. 18 OKAY. SO LONG AS THEY PERFORM THIS VALIDATION WORK AND 03:01PM STUDIES I THINK THAT YOU DISCUSSED ALREADY A LITTLE BIT TODAY; 03:01PM 19 20 CORRECT? 03:02PM 21 AS LONG AS THEY MEET THE REQUIREMENTS FOR THOSE TYPES OF 03:02PM 22 TESTS LIKE VALIDATION AND APPROPRIATE PERSONNEL. 03:02PM OKAY. NOW, THE DOCUMENT CONTINUES. 23 Q. 03:02PM 24 "IN PHASE I THERANOS IS USING EITHER THEIR OWN 03:02PM 25 MANUFACTURED CAPILLARY COLLECTION TUBES OR OTHERS THAT ARE 03:02PM

03:02PM	1	COMMERCIALLY AVAILABLE."
03:02PM	2	AND THEN THERE'S A DESCRIPTION OF THE BLOOD COLLECTION
03:02PM	3	PROCESS.
03:02PM	4	DO YOU SEE THAT?
03:02PM	5	A. I DO.
03:02PM	6	Q. AND AT THIS TIME PERIOD IN LATE 2013, EARLY 2014, YOU AT
03:02PM	7	LEAST CAME TO LEARN BY JANUARY OF 2014 THAT THERANOS HAD A CLIA
03:02PM	8	CERTIFIED LAB IN CALIFORNIA; CORRECT?
03:02PM	9	A. CERTAINLY BY JANUARY OF 2014, YES.
03:02PM	10	Q. OKAY. AND BY THAT TIME THEY WERE RUNNING OR USING FDA
03:02PM	11	APPROVED MACHINES AS WELL AS SOME OF THEIR PROPRIETARY
03:02PM	12	EQUIPMENT; CORRECT?
03:02PM	13	A. I WAS AWARE THAT THEY HAD A LABORATORY. I WAS NOT AWARE
03:03PM	14	OF THE SPECIFICS OF EXACTLY WHAT TESTING THEY WERE DOING.
03:03PM	15	Q. NOW, THE SUMMARY, THE BACKGROUND SUMMARY THAT YOU RECEIVED
03:03PM	16	CONTINUES AT THE BOTTOM OF PAGE 1.
03:03PM	17	IT SAYS, "PHASE II: PROPOSED MODEL AFTER 510(K)
03:03PM	18	CLEARANCE."
03:03PM	19	DO YOU SEE THAT?
03:03PM	20	A. I DO.
03:03PM	21	Q. AND 510(K) CLEARANCE IS ONE OF THE METHODS TO OBTAIN SOME
03:03PM	22	SORT OF FDA APPROVAL OF YOUR TECHNOLOGY; IS THAT RIGHT?
03:03PM	23	A. NOT OF MY TECHNOLOGY, BUT OF DEVICES.
03:03PM	24	Q. OF A MANUFACTURER'S TECHNOLOGY?
03:03PM	25	A. YES.

03:03PM	1	Q. 510(K) IS ONE PATH?
03:03PM	2	A. YES.
03:03PM	3	Q. THERE'S ANOTHER PATH AS WELL?
03:03PM	4	A. YES.
03:03PM	5	Q. OKAY. NOW, AT THE TOP OF PAGE 2 OF 7350A, THE BACKGROUND
03:03PM	6	SUMMARY CONTINUES.
03:03PM	7	"THE THERANOS PROPOSED MODEL IS BASED ON PLACING TSPU IN
03:04PM	8	DEDICATED SPACES IN CONVENIENT SERVICE CENTERS (SUCH AS
03:04PM	9	SELECTED WALGREENS), WHICH THERANOS HAS CALLED WELLNESS CENTERS
03:04PM	10	OR PATIENT SERVICE CENTERS, WITH TESTING OPERATED UNDER THE
03:04PM	11	DIRECT OVERSIGHT OF THE PALO ALTO LABORATORY."
03:04PM	12	DO YOU SEE THAT?
03:04PM	13	A. I DO.
03:04PM	14	Q. AND THEN IT DESCRIBES, "ONE OF THESE SITES HAS ALREADY
03:04PM	15	BEEN SET UP AS A SPECIMEN COLLECTION CENTER WITH SAMPLES BEING
03:04PM	16	SENT BACK TO THE CLIA CERTIFIED THERANOS LABORATORY."
03:04PM	17	DO YOU SEE THAT AS WELL?
03:04PM	18	A. I DO.
03:04PM	19	Q. SO IT WOULD BE FAIR TO SAY THAT AT LEAST BY THIS TIME, AND
03:04PM	20	I UNDERSTAND YOU DON'T RECALL NECESSARILY REVIEWING THIS
03:04PM	21	BACKGROUND SUMMARY IN OCTOBER OF 2013, BUT THERE WERE OTHER CMS
03:04PM	22	COLLEAGUES ON THE EXCHANGE, MS. KELLER.
03:04PM	23	SO AT LEAST SOME INFORMATION RELATING TO THERANOS'S USE OF
03:04PM	24	ITS PROPRIETARY EQUIPMENT, AS WELL AS FDA APPROVED EQUIPMENT,
03:04PM	25	HAD BEEN SOMEHOW REPORTED TO THE FDA AND CMS; CORRECT?

I CAN ONLY SPEAK TO WHAT I LOOKED AT. I CAN'T SPEAK TO 1 03:04PM WHETHER THEY LOOKED AT THE INFORMATION AND WHAT THEY DID WITH 2 03:05PM THAT INFORMATION. 3 03:05PM 03:05PM 4 OKAY. BUT THE DOCUMENT 7350 REFLECTS A BACKGROUND MATERIAL PROVIDED TO YOU BY YOUR COLLEAGUE AT CMS; CORRECT? 03:05PM 5 6 Α. IT DOES. 03:05PM OKAY. AND PAGE 2 ALSO CONTINUES IN THE MIDDLE OF THAT TOP 0. 03:05PM PARAGRAPH. 8 03:05PM "UPON REGULATORY CLEARANCE OR APPROVAL OF THEIR DEVICE, 9 03:05PM AND ASSAYS, THERANOS WOULD LIKE TO PLACE THE DEVICE IN THE 10 03:05PM WELLNESS CENTERS FOR DIAGNOSTIC USE. THIS SETTING COULD ALSO 03:05PM 11 12 BE USED TO CONDUCT CLINICAL STUDIES OF THEIR INVESTIGATIONAL 03:05PM 13 USE ONLY LABELLED DEVICES." 03:05PM 14 DO YOU SEE THAT? 03:05PM 15 Α. I DO. 03:05PM 16 Q. AND I THINK YOU TOUCHED UPON THIS A LITTLE BIT. 03:05PM 17 IN ORDER TO USE THERANOS'S PROPRIETARY TECHNOLOGY, FOR 03:05PM 18 EXAMPLE, AT A WALGREENS PHARMACY OF SOME SORT, SOME SORT OF 03:05PM 03:05PM 19 REGULATORY APPROVAL OF THE USE OF THE DEVICE AT THAT LOCATION 20 WAS REQUIRED; CORRECT? 03:05PM 21 WE DON'T GIVE PERMISSION FOR REGULATORY USE OF A DEVICE. 03:06PM Α. 22 WHAT WE DO IS WE DETERMINE WHETHER CLIA IS APPLICABLE FOR 03:06PM A CERTAIN FACILITY AND IF IT IS APPLICABLE, IF THE CLIA 23 03:06PM 24 REGULATIONS COVER WHAT THAT TESTING IS BEING USED FOR, THEN 03:06PM 25 THEY WOULD BE REQUIRED TO HAVE A CLIA CERTIFICATE. 03:06PM

AND YOU TOUCHED UPON THAT A LITTLE BIT, ABOUT THAT 1 Q. 03:06PM JANUARY 2014 MEETING. 2 03:06PM YES, I DID. 3 03:06PM Α. 03:06PM 4 Q. I APOLOGIZE. I WON'T TALK OVER YOUR WORDS. Α. 03:06PM 5 SORRY. YOU TOUCHED UPON THAT ISSUE OF NEEDING A CLIA CERTIFICATE 6 0. 03:06PM TO USE THE THERANOS TECHNOLOGY IN SOME SORT OF DISTRIBUTED 03:06PM ENVIRONMENT, FOR EXAMPLE, IN A WALGREENS STORE? 8 03:06PM YES. IF THE DEVICES WERE GOING TO BE USED IN A FACILITY, 9 03:06PM THEY NEEDED TO HAVE A CLIA CERTIFICATE. 10 03:06PM HOWEVER, IF THE DEVICE WAS FDA APPROVED, WHETHER 03:06PM 11 OKAY. 12 510(K) OR PREMARKET APPROVAL, THE DEVICE COULD ALSO BE USED IN 03:06PM 13 A WALGREENS STORE FOR WHATEVER THE APPROVED TEST OR ASSAY WAS; 03:07PM 14 CORRECT? 03:07PM A. YES. BUT FDA APPROVAL IS NOT REQUIRED UNDER CLIA. 15 03:07PM SO REGARDLESS OF WHETHER IT WAS FDA APPROVED OR CLEARED, 16 03:07PM 17 OR NOT, THEY WOULD HAVE REQUIRED TO HAVE A CLIA CERTIFICATE. 03:07PM 18 AND WHAT IF AN FDA CLEARANCE -- OR AN FDA WAIVER WAS 03:07PM 03:07PM 19 **OBTAINED?** 20 I'M NOT FAMILIAR WITH WHAT YOU'RE TALKING ABOUT AN "FDA 03:07PM 21 WAIVER." 03:07PM 22 ARE YOU FAMILIAR WITH THE FACT THAT SOMETIMES TESTS IN 03:07PM MEDICAL DEVICES CAN BE WAIVED BY THE FDA? 23 03:07PM 24 I NEED YOU TO CLARIFY BECAUSE THEY CATEGORIZE TESTS AS 03:07PM Α. 25 WAIVED FOR CLIA PURPOSES. 03:07PM

03:07PM	1	ARE YOU TALKING ABOUT A DIFFERENT PROCESS?
03:07PM	2	Q. NO. I'M TALKING ABOUT WAIVED FOR CLIA PURPOSES.
03:07PM	3	A. OKAY. YES, THE FDA IS RESPONSIBLE FOR CATEGORIZING THE
03:07PM	4	TEST AS WAIVED, MODERATE OR HIGH COMPLEXITY.
03:08PM	5	Q. AND A WAIVED TEST COULD BE USED OUTSIDE OF A CLIA LAB;
03:08PM	6	CORRECT?
03:08PM	7	A. NO, IT CANNOT.
03:08PM	8	IF THE TEST IF A TEST IS DETERMINED BY THE FDA TO BE A
03:08PM	9	WAIVED TEST, AND THE FACILITY THAT IS PERFORMING THE TEST MEETS
03:08PM	10	THE DEFINITION OF A LABORATORY UNDER CLIA, THEN THEY'RE
03:08PM	11	REQUIRED TO HAVE A CLIA CERTIFICATE.
03:08PM	12	Q. OKAY. YOU CAN RETURN BACK TO 7350A.
03:08PM	13	NOW, WITHIN ACTUALLY, LET'S GO TO 7350C, THE DECK. IT
03:08PM	14	STARTS OFF, "THERANOS OVERVIEW OF SAMPLE PROCESSING WORKFLOW
03:08PM	15	PREPARED FOR FDA:
03:08PM	16	"PHASE I AND PHASE II OF THERANOS BUSINESS OPERATIONS."
03:08PM	17	DO YOU SEE THAT?
03:08PM	18	A. I DO.
03:08PM	19	Q. AND THEN PAGE 2 AND 3 KIND OF DESCRIBE WORKFLOW FOR THE
03:09PM	20	PROPOSED BUSINESS MODEL.
03:09PM	21	DO YOU SEE THAT?
03:09PM	22	A. I DO.
03:09PM	23	Q. AND THE PHASE I WITH A THERANOS SITE OPERATED BY THERANOS
03:09PM	24	CLIA LAB. A THERANOS PSC OPERATED BY THERANOS'S CLIA LAB.
03:09PM	25	DO YOU SEE THAT?

03:09PM	1	A. I DO.
03:09PM	2	Q. AND THEN WITH SAMPLES BEING COURIERED TO THE HIGH
03:09PM	3	COMPLEXITY LAB FOR PROCESSING.
03:09PM	4	DO YOU SEE THAT?
03:09PM	5	A. YEAH, I SEE THAT.
03:09PM	6	Q. OKAY. AND THEN THE PHASE II THAT WAS AT LEAST DESCRIBED
03:09PM	7	IN THE BACKGROUND MATERIAL SHARED WITH YOU DESCRIBES THERANOS
03:09PM	8	PSC, THERANOS SITE OPERATED BY THERANOS CLIA LAB.
03:10PM	9	"WITH SAMPLE COLLECTION PERFORMED IN A DEDICATED THERANOS
03:10PM	10	PATIENT SERVICE CENTER."
03:10PM	11	DO YOU SEE THAT?
03:10PM	12	A. YES.
03:10PM	13	Q. "AND COLLECTION AND PROCESSING PERFORMED BY THERANOS
03:10PM	14	LICENSED PHLEBOTOMISTS."
03:10PM	15	DO YOU SEE THAT?
03:10PM	16	A. YEAH.
03:10PM	17	Q. AND THEN AGAIN, THERE'S A DESCRIPTION OF THERANOS COURIER
03:10PM	18	PHYSICALLY TRANSPORTS SAMPLE TO THE LAB FOR ANALYSIS.
03:10PM	19	DO YOU SEE THAT?
03:10PM	20	A. I DO.
03:10PM	21	Q. OKAY. AND THIS IS ASSUMING A POST-FDA CLEARANCE.
03:10PM	22	DO YOU SEE THAT?
03:10PM	23	A. YES.
03:10PM	24	Q. YOU CAN SET THAT ASIDE.
03:10PM	25	SO THE MEETING THAT TOOK PLACE IN JANUARY OF 2014,

03:10PM	1	MR. BALWANI WAS PRESENT?
03:10PM	2	A. YES.
03:10PM	3	Q. AND MS. HOLMES WAS PRESENT?
03:10PM	4	A. YES.
03:10PM	5	Q. AND YOU DESCRIBED YOU WERE THERE?
03:10PM	6	A. I WAS.
03:10PM	7	Q. THE FDA WAS ON THE PHONE?
03:11PM	8	A. I BELIEVE SO.
03:11PM	9	Q. OKAY. TO THE BEST OF YOUR RECOLLECTION?
03:11PM	10	A. TO THE BEST OF MY RECOLLECTION, YES.
03:11PM	11	Q. AND WAS MS. KELLER OR YOST THERE?
03:11PM	12	A. I BELIEVE THAT THEY WERE BOTH THERE.
03:11PM	13	Q. AND THEN MS. DYER?
03:11PM	14	A. YES, TO THE BEST OF MY RECOLLECTION, YES.
03:11PM	15	Q. NOW, THIS MEETING WAS REQUESTED BY THERANOS; CORRECT?
03:11PM	16	A. THAT'S MY UNDERSTANDING.
03:11PM	17	Q. OKAY. AND THAT'S UNUSUAL THAT A SMALL CLINICAL LABORATORY
03:11PM	18	AT THE TIME WOULD REQUEST A MEETING WITH CMS TO DISCUSS ITS
03:11PM	19	BUSINESS MODEL; CORRECT?
03:11PM	20	A. IT IS NOT UNUSUAL.
03:11PM	21	Q. IT'S NOT UNUSUAL?
03:11PM	22	A. IT IS NOT.
03:11PM	23	Q. YOU HAVE EXPERIENCED THAT BEFORE IN YOUR CAREER?
03:11PM	24	A. WE HAVE.
03:11PM	25	Q. AND WHAT ABOUT WITH A MANUFACTURER OF A TESTING DEVICE,

03:11PM	1	WAS IT UNUSUAL FOR A MANUFACTURER TO BE REQUESTING MEETINGS
03:11PM	2	WITH CMS?
03:11PM	3	A. I DON'T KNOW IF IT'S UNUSUAL, BUT WE HAVE HAD OTHER
03:11PM	4	MEETINGS WITH OTHER MANUFACTURERS OF NEW TECHNOLOGY.
03:12PM	5	Q. OKAY. AND THEN YOU HAD ONE WITH THERANOS; CORRECT?
03:12PM	6	A. WE DID.
03:12PM	7	Q. NOW, AT SOME POINT IN TIME YOU DESCRIBED LEARNING THAT
03:12PM	8	WELL, NOT LEARNING YOU WERE REQUESTED BY MS. DYER TO
03:12PM	9	PARTICIPATE IN THE THERANOS SURVEY THAT TOOK PLACE IN 2013;
03:12PM	10	CORRECT?
03:12PM	11	A. I WAS.
03:12PM	12	Q. OKAY. BUT THAT WASN'T THE NORMAL PROCESS.
03:12PM	13	THE NORMAL PROCESS WAS FOR STATE REGULATORS TO PERFORM
03:12PM	14	THESE TWICE OR BIANNUAL RECERTIFICATION SURVEYS; CORRECT?
03:12PM	15	A. IN A LOT OF CASES THE STATE DOES THEM.
03:12PM	16	BUT DEPENDING ON THE ACTUAL SPECIFICS OR THE RESOURCES
03:12PM	17	THAT THE STATE HAVE, WE MAY PERFORM THE SURVEYS, CMS MAY
03:13PM	18	PERFORM THEM IN CONJUNCTION WITH THE STATE OR BY JUST THE
03:13PM	19	FEDERAL SURVEYORS.
03:13PM	20	Q. OKAY. AND PRIOR TO 2015, THERANOS HAD BEEN SURVEYED BY
03:13PM	21	STATE REGULATORS ON AT LEAST TWO OCCASIONS; CORRECT?
03:13PM	22	A. I KNOW THEY HAD BEEN INSPECTED IN 2013.
03:13PM	23	I DON'T KNOW IF THEY HAD BEEN OFFICIALLY INSPECTED PRIOR
03:13PM	24	TO 2013.
03:13PM	25	Q. OKAY. BUT IN ORDER TO OBTAIN THE CERTIFICATE THAT THEY

03:13PM	1	OBTAINED, THEY WOULD HAVE HAD TO HAVE BEEN INSPECTED AT SOME
03:13PM	2	POINT IN TIME?
03:13PM	3	A. YES. BUT THE CLIA CERTIFICATE IS ISSUED BEFORE WE INSPECT
03:13PM	4	THE LABORATORY.
03:13PM	5	Q. UNDERSTOOD.
03:13PM	6	WOULD YOU TAKE A LOOK AT WITHIN THE GOVERNMENT'S EXHIBIT
03:14PM	7	BINDER THAT I THINK YOU STILL HAVE, ALTHOUGH IT IS ALSO IN
03:14PM	8	EVIDENCE.
03:14PM	9	IF WE CAN PUT UP ON THE SCREEN, EXHIBIT 5831.
03:14PM	10	AND YOU'LL RECALL THAT 5831, YOU WERE ASKED SOME QUESTIONS
03:14PM	11	ABOUT THE BACKGROUND, THE DOCUMENTS BEHIND THE EMAIL THAT IS
03:14PM	12	DATED 6-13-2015 FROM LANGLY GEE TO MR. BALWANI AND OTHERS
03:14PM	13	RELATING TO SUBJECT AUDIT REPORTS.
03:14PM	14	DO YOU SEE THAT?
03:14PM	15	A. I DO.
03:14PM	16	Q. OKAY. AND MR. GEE WAS THE QUALITY ASSURANCE/QUALITY
03:14PM	17	CONTROL MANAGER AT THERANOS THAT YOU ENGAGED WITH AND MENTIONED
03:14PM	18	IN YOUR TESTIMONY ALREADY TODAY; CORRECT?
03:14PM	19	A. HE WAS.
03:14PM	20	Q. OKAY. AND AT PAGE 2 OF THE EXHIBIT IS THAT COVER LETTER
03:14PM	21	THAT YOU WERE ASKED SOME QUESTIONS ABOUT BY MR. LEACH DATED
03:15PM	22	DECEMBER 10TH, 2013 ADDRESSED TO DR. ROSENDORFF REGARDING
03:15PM	23	STANDARD-LEVEL DEFICIENCIES.
03:15PM	24	DO YOU SEE THAT?
03:15PM	25	A. I DO.

03:15PM	1	Q. AND THIS IS ATTACHED IS A LETTER AND A SURVEY REPORT
03:15PM	2	FROM THE CALIFORNIA DEPARTMENT OF PUBLIC HEALTH; IS THAT RIGHT?
03:15PM	3	A. YES. THIS IS THE COVER LETTER THAT GOES WITH THE SURVEY
03:15PM	4	THAT WAS PERFORMED IN DECEMBER OF 2013.
03:15PM	5	Q. AND I THINK YOU DESCRIBED IN YOUR TESTIMONY THAT UNDER
03:15PM	6	CLIA, THERE ARE DIFFERENT LEVELS OF DEFICIENCIES.
03:15PM	7	STANDARD IS ONE AND CONDITION IS ANOTHER; CORRECT?
03:15PM	8	A. YES.
03:15PM	9	Q. AND STANDARD IS A LESS SERIOUS LEVEL OF DEFICIENCY, AND
03:15PM	10	CONDITION LEVEL IS A MORE SERIOUS DEFICIENCY?
03:15PM	11	A. THAT'S CORRECT.
03:15PM	12	Q. OKAY. AND IS IT ACCURATE THAT SOMETIMES AN ACCUMULATION
03:15PM	13	OF MULTIPLE STANDARD LEVEL DEFICIENCIES CAN CONTRIBUTE OR
03:15PM	14	SUPPORT A CONDITION LEVEL DEFICIENCY?
03:15PM	15	A. YES. BUT THE NUMBER OF STANDARDS, THERE DOES NOT HAVE TO
03:16PM	16	BE A LEVEL OF STANDARD IN ORDER TO CALL IT A CONDITION LEVEL.
03:16PM	17	Q. AND JUST SO I UNDERSTAND THAT RIGHT, JUST BECAUSE THERE
03:16PM	18	MAY BE, LET'S SAY HYPOTHETICALLY, NUMEROUS STANDARD LEVEL
03:16PM	19	DEFICIENCIES, WOULDN'T NECESSARILY MEAN THAT THAT WOULD RISE TO
03:16PM	20	THE LEVEL OF CONDITION LEVEL DEFICIENCIES; IS THAT RIGHT?
03:16PM	21	A. THAT'S CORRECT.
03:16PM	22	BUT THAT ALSO MEANS THAT YOU COULD HAVE ONE STANDARD THAT
03:16PM	23	WOULD RISE TO THE CONDITION LEVEL AS WELL.
03:16PM	24	Q. BECAUSE IT MAY BE A REALLY SERIOUS SPECIFIC STANDARD?
03:16PM	25	A. YES.

03:16PM	1	Q. OKAY. OR THE FINDINGS THAT SUPPORT THE STANDARD LEVEL
03:16PM	2	VIOLATION MAY BE SERIOUS?
03:16PM	3	A. YES.
03:16PM	4	Q. OKAY. AND IF WE CAN TAKE A LOOK AT PAGE 2 OF THE COVER
03:16PM	5	LETTER ANYWAY. NEAR THE BOTTOM THERE'S A PARAGRAPH THAT SAYS
03:16PM	6	"PLEASE NOTE."
03:16PM	7	AT PAGE 2, SORRY.
03:17PM	8	AND THE LETTER READS, "PLEASE NOTE THAT THE ROUTINE SURVEY
03:17PM	9	TAKES AN OVERVIEW OF THE LABORATORY THROUGH RANDOM SAMPLING.
03:17PM	10	BY ITS NATURE, THE ROUTINE SURVEY MAY NOT FIND EVERY VIOLATION
03:17PM	11	THAT THE LABORATORY MAY HAVE COMMITTED. IT REMAINS THE
03:17PM	12	RESPONSIBILITY OF THE LABORATORY AND ITS DIRECTOR TO ENSURE
03:17PM	13	THAT THE LABORATORY IS AT ALL TIMES FOLLOWING ALL CLIA
03:17PM	14	REQUIREMENTS."
03:17PM	15	DO YOU SEE THAT?
03:17PM	16	A. I DO.
03:17PM	17	Q. OKAY. AND THE DESCRIPTION OF "RANDOM SAMPLING," THAT'S
03:17PM	18	ESSENTIALLY THE METHODS SURVEYORS USE IN ORDER TO TEST
03:17PM	19	COMPLIANCE IN A CLIA LABORATORY; CORRECT?
03:17PM	20	A. WE USE RANDOM SAMPLING, BUT WE ALSO THE OVERARCHING WAY
03:17PM	21	THAT WE SURVEY IS THE OUTCOME ORIENTED SURVEY PROCESS.
03:17PM	22	Q. OKAY. AND PART OF THE REASON THAT YOU USE THESE PROCESSES
03:17PM	23	IS BECAUSE YOU CAN'T LOOK AT EVERYTHING; IS THAT FAIR?
03:18PM	24	A. THAT DEPENDS ON THE LABORATORY.
03:18PM	25	Q. OKAY.

03:18PM	1	A. HOW MUCH WE ARE ABLE TO REVIEW.
03:18PM	2	Q. OKAY. AND BY ITS NATURE, THOUGH, TYPICALLY SURVEYS ARE
03:18PM	3	CONDUCTED ON THIS SAMPLING METHOD; CORRECT?
03:18PM	4	A. AGAIN, IT DEPENDS ON THE LABORATORY, HOW BIG THE
03:18PM	5	LABORATORY IS, AND HOW MUCH TESTING THEY'RE DOING.
03:18PM	6	Q. OKAY. AND YOUR SURVEY IN YOUR SURVEY OF THERANOS'S
03:18PM	7	LABORATORY, YOU USED BOTH A SAMPLING METHOD AND THIS OUTCOME
03:18PM	8	METHOD?
03:18PM	9	A. YES.
03:18PM	10	Q. OKAY. AND THEN THE LETTER THAT WAS SENT TO DR. ROSENDORFF
03:18PM	11	IN 2013 REFERENCED THE FACT THAT "IT IS THE RESPONSIBILITY OF
03:18PM	12	THE LABORATORY AND ITS DIRECTOR TO ENSURE THAT THE LABORATORY
03:18PM	13	IS IT AT ALL TIMES FOLLOWING ALL CLIA REQUIREMENTS."
03:18PM	14	DO YOU SEE THAT?
03:18PM	15	A. I DO.
03:18PM	16	Q. AND THAT IS ACCURATE; CORRECT?
03:18PM	17	A. THAT IS ACCURATE.
03:19PM	18	Q. NOW, CONTINUING WITH THIS EXHIBIT, YOU WERE SHOWN IT
03:19PM	19	BRIEFLY, BUT I DON'T THINK YOU DISCUSSED ANY DETAILS AT 5831.
03:19PM	20	AND I WANTED TO ASK YOU A FEW QUESTIONS ABOUT WHAT IS
03:19PM	21	REFLECTED IN THE SURVEY REPORT HERE.
03:19PM	22	SO TURNING TO PAGE 5 OF 5831, YOU WERE ASKED SOME
03:19PM	23	QUESTIONS ABOUT THE FIRST D-TAG. I THINK YOU CALLED IT D5215.
03:19PM	24	DO YOU SEE THAT?
03:19PM	25	A. I DO.

03:19PM	1	Q. AND DO I HAVE THAT RIGHT, IT'S A D-TAG?
03:19PM	2	A. YES.
03:19PM	3	Q. IS THAT HOW YOU RELATE OR REFER TO IT?
03:19PM	4	A. YES.
03:19PM	5	Q. SO I'LL USE THAT PHRASE. SO D-TAG D5215, IN THIS SURVEY
03:19PM	6	REPORT FROM DECEMBER 3RD, 2013, CONCERNS EVALUATION OF
03:19PM	7	PROFICIENCY TESTING PERFORMANCE.
03:19PM	8	DID I GET THAT RIGHT?
03:19PM	9	A. YOU DID.
03:19PM	10	Q. OKAY. AND THEN YOU DESCRIBE THERE'S A DESCRIPTION OF THE
03:19PM	11	REGULATION?
03:19PM	12	A. YES.
03:19PM	13	Q. OKAY. AND THEN BELOW THAT IS THE KIND OF SURVEYOR'S
03:19PM	14	FINDINGS.
03:20PM	15	IS THAT FAIR?
03:20PM	16	A. YES.
03:20PM	17	Q. OKAY. AND THEN HERE THE SURVEYOR WROTE, "THIS STANDARD IS
03:20PM	18	NOT MET AS EVIDENCED BY," AND THEN, "BASED ON REVIEW OF
03:20PM	19	AMERICAN PROFICIENCY INSTITUTE PROFICIENCY TESTING DOCUMENTS
03:20PM	20	(FROM THE 2ND TESTING EVENT OF 2013 TO THE 3RD TESTING EVENT OF
03:20PM	21	2013), LACK OF CORRECTIVE ACTION DOCUMENTS, AND INTERVIEW WITH
03:20PM	22	THE LABORATORY DIRECTOR, IT WAS DETERMINED THAT THE LABORATORY
03:20PM	23	DIRECTOR FAILED TO ENSURE THAT CORRECTIVE ACTIONS WERE
03:20PM	24	PERFORMED WHEN THE LABORATORY RECEIVED UNGRADED PROFICIENCY
03:20PM	25	TESTING RESULTS."

03:20PM	1	AND THEN THERE'S A DESCRIPTION OF SOME FINDINGS.
03:20PM	2	DID I READ THAT RIGHT?
03:20PM	3	A. YOU DID.
03:20PM	4	Q. NOW, "UNGRADED PROFICIENCY TESTING RESULTS," THAT MEANS
03:20PM	5	THAT THE RESULT THAT THE LAB REPORTED TO, IN THIS CASE IT WAS
03:20PM	6	API, WASN'T INACCURATE OR INCONSISTENT WITH PEERS, IT SIMPLY
03:21PM	7	WASN'T GRADED OR IT WASN'T SCORED; IS THAT RIGHT?
03:21PM	8	A. WHEN THE LABORATORY SUBMITTED THEIR RESULTS, AND THEN THE
03:21PM	9	RESULTS WERE SUBMITTED TO THE LABORATORY, THE PROFICIENCY
03:21PM	10	TESTING PROGRAM HAD NOT GRADED THE RESULTS BECAUSE THEY WERE
03:21PM	11	UNABLE TO DO SO.
03:21PM	12	Q. OKAY. AND THAT CAN HAPPEN WHEN THERE ARE NOT ENOUGH PEER
03:21PM	13	PARTICIPANTS IN A PROFICIENCY TESTING CHALLENGE; CORRECT?
03:21PM	14	A. IT CAN.
03:21PM	15	Q. OKAY. SO RESULTS GO OUT TO THE API, API MAY NOT BE IN A
03:21PM	16	SITUATION WHERE THEY DON'T HAVE ENOUGH COMPARATIVE LABS, SO
03:21PM	17	THEY SEND THE RESULT BACK UNGRADED TO THE LAB.
03:21PM	18	AT THAT POINT THE LAB ISN'T BEING TOLD THAT THE RESULT IS
03:21PM	19	WRONG.
03:21PM	20	IS THAT FAIR?
03:21PM	21	A. THEY'RE NOT BEING TOLD WHETHER IT'S RIGHT OR WRONG.
03:21PM	22	Q. OKAY. BUT AT THAT POINT THE LAB HAS SOME RESPONSIBILITIES
03:21PM	23	TO DO SOME FOLLOW-UP?
03:21PM	24	A. THEY DO.
03:21PM	25	Q. OKAY. AND IS THAT WHAT THE DEFICIENCY IS HERE, THAT THE

03:22PM	1	LAB DIRECTOR FAILED TO ENSURE THAT THE LAB FOLLOWED UP ON THIS
03:22PM	2	UNGRADED EVENT?
03:22PM	3	A. WELL, I DID NOT WRITE THIS, THIS SURVEY REPORT. IT
03:22PM	4	APPEARS THAT THEY DID NOT MEET THE REQUIREMENT TO EVALUATE
03:22PM	5	THEIR UNGRADED RESULTS.
03:22PM	6	Q. OKAY. OKAY. AND EVALUATING AN UNGRADED RESULT WOULD
03:22PM	7	INVOLVE DOING SOME INVESTIGATIVE WORK IN ORDER TO REACH SOME
03:22PM	8	ASSURANCE OR DEMONSTRATE THAT THE RESULTS THAT WERE ARRIVED AT
03:22PM	9	WERE ACCURATE; CORRECT?
03:22PM	10	A. THE LABORATORY HAS TO DETERMINE HOW THEY'RE GOING TO
03:22PM	11	FIGURE OUT THE UNGRADED RESULTS ARE ACCEPTABLE OR ACCURATE.
03:22PM	12	Q. AND IT'S UP TO THE LABORATORY TO MAKE THAT DECISION?
03:22PM	13	A. IT IS.
03:22PM	14	Q. ALL RIGHT.
03:22PM	15	A. AND THEY HAVE TO SHOW THE DOCUMENTATION OF HOW THEY DID
03:22PM	16	THAT AND HOW THEY DETERMINED THAT IT WAS AN ACCURATE RESULT.
03:22PM	17	Q. AND SOME OF THE DOCUMENTATION A LAB OR A LABORATORY
03:23PM	18	DIRECTOR MAY LOOK TO IN ORDER TO PERFORM THIS CORRECTIVE ACTION
03:23PM	19	MAY BE TO LOOK AT QUALITY CONTROL RECORDS?
03:23PM	20	A. IN MY EXPERIENCE, THAT'S ONE OF THE THINGS THAT THE
03:23PM	21	LABORATORY CAN LOOK AT WHEN THEY GET UNGRADED RESULTS TO ENSURE
03:23PM	22	THAT THE QUALITY CONTROL WAS OKAY THAT DAY.
03:23PM	23	Q. A LAB COULD ALSO LOOK AT MAYBE HISTORICAL PROFICIENCY
03:23PM	24	TESTING RESULTS? WOULD THAT HELP?
03:23PM	25	A. WE DON'T HAVE ANY REQUIREMENTS IN CLIA OF WHAT THEY HAVE

TO LOOK AT. 1 03:23PM THEY HAVE TO LOOK AT WHAT THEY NEED, THE DOCUMENTATION AND 2 03:23PM THE INFORMATION, TO DETERMINE IF THE UNGRADED RESULT MEETS THE 3 03:23PM 03:23PM 4 REQUIREMENTS. 03:23PM Q. FAIR ENOUGH. BUT YOU DO HAVE EXPERIENCE IN EVALUATING -- YOU DO HAVE 03:23PM SOME EXPERIENCE IN REVIEWING AND EVALUATING CORRECTIVE ACTION, 03:23PM RECORDS OR DOCUMENTS THAT LABS PRESENT TO CMS TO TRY TO SATISFY 8 03:24PM 9 THEIR OBLIGATIONS; CORRECT? 03:24PM 10 YES. 03:24PM Α. OKAY. AND SO SOMETIMES THEY LOOK AT QC RECORDS? 03:24PM 11 Q. 12 Α. UH-HUH, YES. 03:24PM 13 AND SOMETIMES THEY MIGHT LOOK AT MAYBE QC AND PATIENT 03:24PM Ο. 14 RECORDS TOGETHER TO FIGURE OUT WHETHER THERE MIGHT BE SOME 03:24PM INDICATIONS OF SOME ISSUES? 15 03:24PM 16 THEY CAN LOOK AT BOTH QC AND PATIENT RECORDS. Α. 03:24PM 17 AND WHAT OTHER TYPES OF RECORDS ARE YOU AWARE OF OR ARE Q. 03:24PM 18 YOU FAMILIAR WITH THAT LABS MIGHT HAVE PRESENTED IN PRIOR 03:24PM 03:24PM 19 SURVEYS THAT YOU'VE DONE TO SATISFY THIS DOCUMENTATION ISSUE 20 REGARDING UNGRADED PROFICIENCY TESTING EVENTS? 03:24PM 21 LIKE YOU SAID, THEY WILL LOOK AT QUALITY CONTROL RECORDS, 03:24PM 22 THEY WILL LOOK AT PATIENT RECORDS, THEY WOULD -- THEY COULD 03:24PM CHECK TO SEE IF THERE WERE ANY QUALITY ASSESSMENT ISSUES DURING 23 03:24PM THAT TIME, IF THEY HAD ANY ISSUES WITH THE TEST. THEY CAN 24 03:24PM REACH OUT TO THE MANUFACTURER TO SEE IF THERE WERE ANY PROBLEMS 25 03:24PM

WITH THE TESTING, THE REAGENTS. 1 03:25PM THEY CAN ALSO REACH OUT TO THE PROFICIENCY TESTING PROGRAM 2 03:25PM TO SEE IF THEY HAD IDENTIFIED ANY ISSUES WITH THE PT SAMPLES. 3 03:25PM 4 Q. THANK YOU. 03:25PM NOW, CONTINUING WITH THIS SURVEY REPORT FROM 2016 TO THE 03:25PM SECOND -- I'M SORRY, PAGE 6. PAGE 2 OF 8 OF THE REPORT ITSELF. 03:25PM AND CONTINUING ON THIS DEFICIENCY OF FAILURES TO TAKE 03:25PM CORRECTIVE ACTION REGARDING THIS PROFICIENCY TESTING 8 03:25PM 9 CHALLENGES. 03:25PM DO I HAVE IT RIGHT, THAT ON PAGE 6, EACH OF THE ISSUES 10 03:25PM RAISED BETWEEN D, E, F, G, H, AND I, THEY'RE ALL OF THESE 03:25PM 11 12 SIMILARLY UNGRADED PROFICIENCY TESTING CHALLENGES; CORRECT? 03:25PM 13 IT WOULD APPEAR THAT THE SURVEYOR CITED THERANOS FOR NOT 03:26PM 14 TAKING ANY CORRECTIVE ACTIONS WHEN THERE WERE UNGRADED RESULTS. 03:26PM ALTHOUGH IF WE GO TO PAGE 7, IT LOOKS LIKE AT ITEM K IT 15 03:26PM READS, "THERE WAS NO CORRECTIVE ACTION DOCUMENTED FOR THE 16 03:26PM 17 UNACCEPTABLE FOLATE PROFICIENCY TEST RESULT FOR 1 OF 2 03:26PM 18 PROFICIENCY TEST CHALLENGES FOR THE API 3RD TESTING EVENT OF 03:26PM 2013." 03:26PM 19 20 DO YOU SEE THAT? 03:26PM 21 A. I DO. 03:26PM 22 SO IT SEEMS LIKE WHEN THERE'S AN UNACCEPTABLE SCORE 03:26PM RETURNED TO THE LAB, THE LAB NEEDS TO TAKE CORRECTIVE ACTION 23 03:26PM 24 AND INVESTIGATE WHAT HAPPENED AND DEMONSTRATE THAT THEY HAVE 03:26PM 25 SOLVED WHATEVER ISSUE MAY HAVE ARISEN? 03:26PM

THAT'S TRUE. 1 Α. 03:27PM O. OKAY. AND THEN CONTINUING ON THAT SAME PAGE 7. I CAN'T 2 03:27PM READ -- I THINK IT'S LETTER L. "ON 12/3/13 THE LABORATORY 3 03:27PM 03:27PM 4 DIRECTOR AFFIRMED THAT NO INVESTIGATION WAS PERFORMED TO DETERMINE IF RESULTS SUCCESSFULLY DEMONSTRATED TEST ACCURACY 03:27PM USING LABORATORY OC DATA AND RESULTS DISTRIBUTION DATA SUPPLIED 03:27PM BY THE PT ORGANIZATION, AS PER THE LABORATORY'S POLICY." 03:27PM DO YOU SEE THAT? 8 03:27PM 9 I DO. Α. 03:27PM AND SO IT LOOKS LIKE THE LABORATORY DIRECTOR KIND OF 10 03:27PM Q. ADMITTED THAT THEY DIDN'T DO WHAT THEY WERE SUPPOSED TO DO AND 03:27PM 11 03:27PM 12 FOLLOWED THE LAB'S OWN PROCEDURE; CORRECT? 13 MR. LEACH: YOUR HONOR, OBJECTION. THIS DOCUMENT IS 03:27PM 14 IN FOR A LIMITED PURPOSE, NOT A HEARSAY PURPOSE. 03:27PM IF THE DEFENSE WANTS IT IN FOR ITS TRUTH, WE CAN DO THAT, 15 03:27PM 16 TOO. 03:27PM 17 THE COURT: COUNSEL, THIS WAS IN NOT FOR THE TRUTH 03:27PM 18 OF THE MATTER ASSERTED BUT TO INFORM AS TO ANY ACTION TAKEN. 03:28PM 03:28PM 19 MR. CAZARES: I UNDERSTOOD THAT, YOUR HONOR, TO 20 MR. BALWANI. 03:28PM 21 I'M ASKING THE WITNESS QUESTIONS ABOUT WHAT ACTUALLY DOES 03:28PM 22 THIS MEAN, THAT MR. BALWANI IS RECEIVING NOTICE OF, AND WHO IS 03:28PM INVOLVED IN IT, BECAUSE THE GOVERNMENT THREW THIS IN THE RECORD 23 03:28PM 24 AND KIND OF DIDN'T ASK ANY QUESTIONS ABOUT IT, AND SO I THINK 03:28PM THE JURY NEEDS TO SEE SOME DETAIL. 25 03:28PM

03:28PM	1	THE COURT: WELL, IT'S OFFERED FOR THE TRUTH OF WHAT
03:28PM	2	IS IN HERE. THIS IS BACKGROUND FOR HER CONDUCT.
03:28PM	3	MR. CAZARES: YES, YOUR HONOR. UNDERSTOOD,
03:28PM	4	YOUR HONOR.
03:28PM	5	THE COURT: YOU CAN GO THAT WAY.
03:28PM	6	MR. CAZARES: OKAY.
03:28PM	7	Q. AND THEN I WON'T BELABOR THIS TOO MUCH, BUT LOOK AT THE
03:28PM	8	NEXT D-TAG D5217.
03:28PM	9	DO YOU SEE THAT
03:28PM	10	A. I DO.
03:28PM	11	Q. ON PAGE 7?
03:28PM	12	AND THIS IS TITLED EVALUATION OF PROFICIENCY PERFORMANCE?
03:28PM	13	DO YOU SEE THAT?
03:28PM	14	A. I DO.
03:28PM	15	Q. AND THEN THE REQUIREMENT READS, "AT LEAST TWICE ANNUALLY,
03:29PM	16	THE LABORATORY MUST VERIFY THE ACCURACY OF ANY TEST OR
03:29PM	17	PROCEDURE IT PERFORMS THAT IS NOT INCLUDED IN SUBPART I OF THIS
03:29PM	18	PART."
03:29PM	19	DO YOU SEE THAT?
03:29PM	20	A. I DO.
03:29PM	21	Q. AND NOW THIS REFERENCE TO "SUBPART I OF THIS PART," THAT
03:29PM	22	IS RELATING TO CLIA; CORRECT?
03:29PM	23	A. IT IS.
03:29PM	24	Q. OKAY. AND THEN CONTINUING.
03:29PM	25	THE REPORT READS, "THIS STANDARD IS NOT MET AS EVIDENCED

BY: 1 03:29PM "BASED INTERVIEW WITH THE LABORATORY DIRECTOR AND TESTING 2 03:29PM PERSONNEL, LACK OF VERIFICATION OF ACCURACY DOCUMENTATION FOR 3 03:29PM 03:29PM 4 AMMONIA (NH3), AND REVIEW OF TESTING LOGS. IT WAS DETERMINED THAT FROM 2012 TO 2013 THE LABORATORY FAILED TO VERIFY THE 03:29PM 5 ACCURACY OF NH3 TESTING AT LEAST TWICE ANNUALLY." 6 03:29PM DO YOU SEE THAT? 03:30PM I DO. 8 Α. 03:30PM Q. AND SO SEPARATE AND ASIDE FROM THIS VALIDATION OF TESTS OR 9 03:30PM VERIFICATION OF FDA APPROVED TESTS USED IN THE LAB, IT SOUNDS 10 03:30PM LIKE THE LAB NEEDS TO TWICE ANNUALLY PERFORM THIS ADDITIONAL 03:30PM 11 03:30PM 12 ASSURANCE PROTOCOL? 13 YES. THIS IS WHAT I WAS TALKING ABOUT WHEN I SPOKE 03:30PM EARLIER TO WHAT WE WOULD CALL ALTERNATIVE PT. 14 03:30PM SUBPART I IS A LIST OF ANALYTES THAT LABORATORIES ARE 15 03:30PM 16 REQUIRED TO ENROLL AND PARTICIPATE FOR PROFICIENCY TESTING. 03:30PM 17 SO IF THEY ARE NOT IN SUBPART I OR IT'S AN ADDITIONAL 03:30PM 18 METHOD OF THE SAME, THEN THEY HAVE TO DO THIS TWICE ANNUAL 03:30PM 03:30PM 19 VERIFICATION. 20 IT'S NOT VALIDATION, IT'S NOT PERFORMING VERIFICATION OF 03:30PM PERFORMANCE SPECIFICATIONS. IT'S COMPLETELY A SEPARATE 2.1 03:30PM 22 REQUIREMENT FROM THAT. 03:31 PM IT'S A SEPARATE REQUIREMENT AND IN LIEU OF COMMERCIAL 23 Q. 03:31PM 24 PROFICIENCY TESTING; IS THAT RIGHT? 03:31PM 25 THEY MAY ENROLL IN PROFICIENCY TESTING FOR THESE, BUT 03:31PM Α.

03:31PM	1	THEY'RE NOT REQUIRED TO DO IT.
03:31PM	2	I'M NOT SURE IT WOULD REALLY BE IN LIEU OF. YOU KNOW,
03:31PM	3	THEY'RE REQUIRED TO ENROLL AND PARTICIPATE FOR THOSE TESTS IN
03:31PM	4	SUBPART I, AND THEY CAN EITHER ENROLL OR DO THE TWICE ANNUAL
03:31PM	5	ACCURACY INSTEAD OF ENROLLING.
03:31PM	6	Q. FAIR ENOUGH.
03:31PM	7	AND THEN CONTINUING ON WITH THE EXHIBIT ON 5831 ON
03:31PM	8	PAGE 11, THERE'S A DESCRIPTION OF A PLAN OF CORRECTION.
03:31PM	9	DO YOU SEE THAT?
03:31PM	10	A. I DO.
03:31PM	11	Q. AND THEN THERE'S A DESCRIPTION FOR SURVEY OF THERANOS
03:32PM	12	COMPLETED 12-3-2013.
03:32PM	13	DID I GET THAT RIGHT?
03:32PM	14	A. YOU DID.
03:32PM	15	Q. AND THEN THERE'S A DESCRIPTION OF RESPONSE AND PLAN TO
03:32PM	16	D-TAG 5215; 310B.
03:32PM	17	DID I GET THAT RIGHT?
03:32PM	18	A. YES.
03:32PM	19	Q. OKAY. AND THEN THE RESPONSE AND PLAN READS, "WE HAVE
03:32PM	20	COMPARED OUR REPORTED RESULT TO THAT PART OF OUR PEER GROUP
03:32PM	21	(DIASORIN, 4 PEERS) FOR THAT EVENT AND FOR THAT SPECIMEN. OUR
03:32PM	22	RESULT (POSITIVE) MATCHED THAT OF OUR ENTIRE PEER GROUP FOR
03:32PM	23	THAT CHALLENGE. COMPLETION DATE COMPLETED 12-19."
03:32PM	24	DO YOU SEE THAT?
03:32PM	25	A. I DO.

03:32PM	1	Q. NOW SO THE ISSUE HERE WAS THE RESULT MATCHED THE PEERS,
03:32PM	2	THAT'S GREAT, BUT THEY SHOULD HAVE DONE THE WORK BEFORE; IS
03:32PM	3	THAT FAIR?
03:32PM	4	A. THAT'S CORRECT.
03:32PM	5	MR. LEACH: OBJECTION, YOUR HONOR. CALLS FOR
03:32PM	6	HEARSAY.
03:33PM	7	THE COURT: THIS IS NOT IN FOR THE TRUTH OF THE
03:33PM	8	MATTER ASSERTED.
03:33PM	9	MR. CAZARES: NOTICE TO MR. BALWANI WHO THIS IS
03:33PM	10	BEING SENT TO.
03:33PM	11	THE COURT: THAT'S CORRECT.
03:33PM	12	SO YOU CAN ASK HER WHAT CONDUCT SHE ENGAGED IN. WHAT DID
03:33PM	13	SHE DO? WHAT IS HER RESPONSE TO THIS? WHAT DID SHE DO?
03:33PM	14	BUT THE DOCUMENT ITSELF IS NOT OFFERED FOR THE TRUTH OF
03:33PM	15	THE MATTER ASSERTED.
03:33PM	16	MR. CAZARES: I BELIEVE IT WAS BEING OFFERED FOR
03:33PM	17	NOTICE TO MR. BALWANI.
03:33PM	18	THE COURT: YES.
03:33PM	19	MR. CAZARES: AND I'M ASKING HER TO DESCRIBE OR
03:33PM	20	EXPLAIN WHAT THIS MEANS THAT MR. BALWANI IS RECEIVING REGARDING
03:33PM	21	THE OUTCOME OF THE INVESTIGATION.
03:33PM	22	THE COURT: WELL, I THINK YOU CAN ASK HER WHAT DOES
03:33PM	23	THIS MEAN TO HER.
03:33PM	24	MR. CAZARES: FAIR ENOUGH, YOUR HONOR. I APOLOGIZE.
03:33PM	25	I DIDN'T QUITE UNDERSTAND.

03:33PM	1	Q. SO, MS. BENNETT, LOOKING AT ITEM 1, "WE HAVE COMPARED OUR
03:33PM	2	REPORTED RESULT TO THAT OF OUR PEER GROUP FOR THAT EVENT AND
03:33PM	3	FOR THAT SPECIMEN. OUR RESULT (POSITIVE) MATCHED THAT OF OUR
03:34PM	4	ENTIRE PEER GROUP FOR THAT CHALLENGE."
03:34PM	5	AND THEN THERE'S A COMPLETION DATE.
03:34PM	6	DO YOU SEE THAT?
03:34PM	7	A. I DO.
03:34PM	8	Q. OKAY. AND IS THAT THE TYPE OF INVESTIGATIVE WORK THAT YOU
03:34PM	9	WOULD EXPECT TO SEE RELATED TO PROFICIENCY TESTING UNGRADED
03:34PM	10	CHALLENGES?
03:34PM	11	A. I WOULD EXPECT THAT TO BE PART, BUT NOT THE TOTALITY OF
03:34PM	12	WHAT THEY WOULD DO.
03:34PM	13	Q. OKAY. WHAT ELSE WOULD YOU EXPECT THEM TO DO?
03:34PM	14	A. I WOULD EXPECT THEM TO SHOW THAT THE RESULTS THAT THEY
03:34PM	15	ACTUALLY GOT WERE ACCURATE BY GIVING BY SUBMITTING
03:34PM	16	DOCUMENTATION TO SUPPORT THAT INVESTIGATION.
03:34PM	17	Q. SO JUST CAN AND JUST SO I UNDERSTAND IT, AND JUST
03:34PM	18	REPORTING A RESULT THAT MATCHED PEER GROUPS, THAT'S NOT ENOUGH?
03:35PM	19	A. IT IS NOT.
03:35PM	20	Q. OKAY. SO THE FACT THAT THERANOS'S RESULT MATCHED OTHER
03:35PM	21	LABS USING, FOR EXAMPLE, DIASORIN EQUIPMENT, IN YOUR MIND AND
03:35PM	22	EXPERIENCE, THAT'S INSUFFICIENT, YOU NEED TO DO MORE WORK?
03:35PM	23	A. I WOULD EXPECT TO SEE MORE, YES.
03:35PM	24	Q. OKAY. AND IF WE CAN TURN TO PAGE 12, THERE'S A RESPONSE
03:35PM	25	TO THE DEFICIENCY.
		1

03:35PM	1	"THERE WAS NO CORRECTIVE ACTION DOCUMENTED FOR THE
03:35PM	2	UNGRADED ANTI-RNP," I CAN'T SEE IF THAT IS AN S OR 5N,
03:35PM	3	"PROFICIENCY TEST RESULT FOR 1 OF 5 PROFICIENCY TEST CHALLENGES
03:35PM	4	FOR THE 2ND TESTING EVENT FOR 2013."
03:35PM	5	DO YOU SEE THAT?
03:35PM	6	A. I DO. AND IT'S SN.
03:35PM	7	Q. AND THEN THE RESPONSE AND PLAN STARTS, "WE HAVE COMPARED
03:36PM	8	OUR REPORTED RESULT TO THAT OF OUR PEER GROUP FOR THAT EVENT
03:36PM	9	AND FOR THAT SPECIMEN (DIASORIN, 3 PEERS). OUR RESULT
03:36PM	10	(NEGATIVE) MATCHED THAT OF OUR ENTIRE PEER GROUP FOR THAT
03:36PM	11	CHALLENGE. COMPLETION DATE 12-19."
03:36PM	12	DO YOU SEE THAT?
03:36PM	13	A. I DO.
03:36PM	14	Q. AND THE RESPONSE AND PLAN CONTINUES.
03:36PM	15	ITEM 2, "WE HAVE REVIEWED THE QC DATA FROM THE
03:36PM	16	INSTRUMENTATION?"
03:36PM	17	THAT IS SOMETHING THAT YOU WOULD EXPECT THE LAB TO DO?
03:36PM	18	A. I WOULD EXPECT THEM TO DO THAT, YES.
03:36PM	19	Q. OKAY. AND THEN ITEM 3 THERE'S A DESCRIPTION OF, "WE HAVE
03:36PM	20	REVIEWED THE FAILURE OF THE FOLLOW-UP OF THE UNGRADED RESULT
03:36PM	21	WITH SUPERVISORIAL STAFF TO REINFORCE THE NEED TO FOLLOW THE
03:36PM	22	PROTOCOL WHICH INCLUDES TO EVALUATE ALL UNGRADED PT RESULTS."
03:36PM	23	DO YOU SEE THAT?
03:36PM	24	A. I DO.
03:36PM	25	Q. AND IS THAT SOMETHING THAT YOU WOULD HAVE EXPECTED THE LAB

TO DO IN THE FIRST PLACE? 1 03:36PM A. I WOULD HAVE EXPECTED THEM TO DO THAT, BUT I WOULD HAVE 2 03:36PM ALSO EXPECTED THEM TO SHOW DOCUMENTATION THAT THAT HAD 3 03:37PM 03:37PM 4 OCCURRED. OKAY. LASTLY, ON ITEM 4 IN RESPONSE TO THIS DEFICIENCY 03:37PM 5 THE DOCUMENT READS, "THE LABORATORY HAS HIRED A QA/QC DIRECTOR 03:37PM WHOSE RESPONSIBILITIES INCLUDE REVIEWING ALL PT EVENTS AND 03:37PM GENERATING REMINDERS TO LABORATORY STAFF TO FOLLOW UP ON ALL 8 03:37PM UNGRADED PT RESPONSES." 9 03:37PM DO YOU SEE THAT? 10 03:37PM I DO. 03:37PM 11 Α. 03:37PM 12 AND WOULD YOU, AS A CLIA SURVEYOR, REQUIRE SOME SORT OF 13 DOCUMENTATION OF THAT IN ORDER TO SATISFY THIS KIND OF UNGRADED 03:37PM 14 PT CHALLENGE? 03:37PM IS JUST REPORTING THAT THE LAB HAS HIRED SOMEBODY TO 15 03:37PM 16 OVERSEE QUALITY CONTROL ENOUGH OR WOULD YOU REQUIRE SOME SORT 03:37PM 17 OF DOCUMENTATION? 03:37PM 18 I PROBABLY WOULD HAVE EXPECTED THE STATEMENT AND THEN 03:37PM 03:37PM 19 CHECKED IT ON THE NEXT SURVEY. 20 FAIR ENOUGH. 03:38PM Q. 21 AND PRIOR TO THE 2015 SURVEY OF THERANOS, YOU REVIEWED AND 03:38PM 22 LOOKED BACK AT THE SURVEY REPORT THAT WE JUST LOOKED AT FROM 03:38PM 2013; CORRECT? 23 03:38PM 24 A. I DID. 03:38PM 25 Q. AND DID YOU LOOK AT THE PLAN OF CORRECTION SUBMITTED BY 03:38PM

03:38PM	1	THE LAB?
03:38PM	2	A. I DID.
03:38PM	3	Q. AND ULTIMATELY THAT PLAN OF CORRECTION WAS ACCEPTED AND
03:38PM	4	THE CERTIFICATE WAS REISSUED; CORRECT?
03:38PM	5	A. ARE YOU ASKING ABOUT THE 23
03:38PM	6	Q. THE 2013.
03:38PM	7	A. THE 2013?
03:38PM	8	Q. YES.
03:38PM	9	A. I CAN'T SPEAK TO CALIFORNIA, BUT IT APPEARS TO ME THAT IT
03:38PM	10	WAS ACCEPTED OR THERE WOULD HAVE BEEN NO NEED FOR A 2015
03:38PM	11	SURVEY, RECERTIFICATION SURVEY.
03:38PM	12	Q. BECAUSE THEY WOULDN'T HAVE HAD A LICENSE; CORRECT?
03:38PM	13	A. YES.
03:38PM	14	Q. IS THAT RIGHT?
03:38PM	15	A. YES.
03:38PM	16	Q. OKAY.
03:39PM	17	YOUR HONOR, IF I COULD PUT UP ON THE SCREEN, I BELIEVE
03:39PM	18	IT'S ALREADY IN EVIDENCE, EXHIBIT 7386, 7386?
03:39PM	19	THE COURT: ALL RIGHT.
03:39PM	20	BY MR. CAZARES:
03:39PM	21	Q. DO YOU SEE UP ON THE SCREEN, MS. BENNETT, 7386 APPEARS TO
03:39PM	22	BE CENTERS FOR MEDICARE AND MEDICAID SERVICES CLINICAL
03:39PM	23	LABORATORY IMPROVEMENT AMENDMENTS, CERTIFICATE OF COMPLIANCE.
03:39PM	24	DO YOU SEE THAT?
03:39PM	25	A. I DO.

03:39PM	1	Q. AND YOU'RE FAMILIAR WITH THE DOCUMENT?
03:39PM	2	A. I AM.
03:39PM	3	Q. AND IT IS DATED JANUARY 9, 2014.
03:39PM	4	DO YOU SEE THAT?
03:39PM	5	A. YES, THAT'S THE EFFECTIVE DATE OF THE CERTIFICATE.
03:39PM	6	Q. AFTER THE LAB RESPONDED TO THE DEFICIENCIES CITED IN THE
03:39PM	7	REPORT THAT WE JUST TALKED ABOUT; CORRECT?
03:39PM	8	A. AFTER THE LAB IS DETERMINED TO BE IN COMPLIANCE, THEN A
03:40PM	9	NEW CERTIFICATE IS GENERATED ONCE THE LABORATORY PAYS THE
03:40PM	10	CERTIFICATE FEE.
03:40PM	11	Q. FAIR ENOUGH.
03:40PM	12	THANK YOU. YOU CAN TAKE THAT DOWN.
03:40PM	13	NOW, IN THE LEAD UP TO THE 2015 SURVEY YOU DESCRIBED
03:40PM	14	PREPARATION OR SOME WORK DONE PRIOR TO ACTUALLY GOING ON SITE
03:40PM	15	AND BEGINNING THE SURVEY; CORRECT?
03:40PM	16	A. YES.
03:40PM	17	Q. YOU REQUESTED SOME DOCUMENTS TO REVIEW SO YOU COULD BECOME
03:40PM	18	FAMILIAR WITH THE TEST MENU AND WHAT TESTING THERANOS WAS
03:40PM	19	OFFERING AT THE TIME?
03:40PM	20	A. I DON'T KNOW IF I REQUESTED THE TEST MENU, BUT I REQUESTED
03:40PM	21	THE SURVEY REPORT AND THE PLAN CORRECTION.
03:40PM	22	Q. FAIR ENOUGH.
03:40PM	23	IF YOU COULD TAKE A LOOK AT 5450. I THINK IT IS ALREADY
03:40PM	24	IN EVIDENCE. AND IT WAS USED ON DIRECT, SO YOU CAN PUT IT UP
03:41PM	25	ON THE SCREEN.

03:41PM	1	AND YOU SEE UP ON THE SCREEN IS THE CLINICAL LABORATORY
03:41PM	2	IMPROVEMENT AMENDMENTS APPLICATION FOR CERTIFICATION?
03:41PM	3	DO YOU SEE THAT?
03:41PM	4	A. I DO.
03:41PM	5	Q. AND IT'S FOR THERANOS FOR THE RECERTIFICATION SURVEY THAT
03:41PM	6	YOU ULTIMATELY PARTICIPATED IN; CORRECT?
03:41PM	7	A. YES.
03:41PM	8	Q. OKAY. AND YOU DESCRIBED PREVIOUSLY THAT THIS IS MANDATORY
03:41PM	9	EACH TIME THESE RECERTIFICATION SURVEYS COME UP?
03:41PM	10	A. THAT'S CORRECT.
03:41PM	11	Q. AND A LAB IS KIND OF TRUTHFULLY REQUIRED TO DISCLOSE ITS
03:41PM	12	TESTING DETAILS AS REQUESTED IN THE APPLICATION; IS THAT RIGHT?
03:41PM	13	A. THE INFORMATION THAT IS PUT ON THIS MUST BE ACCURATE AND
03:41PM	14	CORRECT.
03:42PM	15	Q. ON PAGE 5 OF THE APPLICATION FOR THERANOS FOR 2015 THERE'S
03:42PM	16	A DESCRIPTION AT THE KIND OF LOWER HALF OF THE PAGE OF THE
03:42PM	17	NON-WAIVED TESTING, AND THEN THERE IS IDENTIFICATION OF TESTING
03:42PM	18	THAT THE LAB ENGAGES IN.
03:42PM	19	DO YOU SEE THAT?
03:42PM	20	A. I DO.
03:42PM	21	Q. OKAY. AND YOU WENT OVER SOME OF THIS WITH THE GOVERNMENT,
03:42PM	22	BUT THERE'S A DESCRIPTION OF MICROBIOLOGY, DIAGNOSTIC
03:42PM	23	IMMUNOLOGY.
03:42PM	24	DO YOU SEE THAT?
03:42PM	25	A. YES.

03:42PM	1	Q. AND THERE'S A NUMBER OF TESTS THAT THE LAB PERFORMS UNDER
03:42PM	2	THOSE.
03:42PM	3	DO YOU SEE THAT?
03:42PM	4	A. YES.
03:42PM	5	Q. AND THEN THE TOTAL ESTIMATED ANNUAL TEST VOLUME AT THE
03:42PM	6	TIME WAS ESTIMATED AT 894,782 TESTS.
03:42PM	7	DO YOU SEE THAT?
03:42PM	8	A. I DO.
03:42PM	9	Q. NOW, THAT NUMBER, 894,000 TESTS, THAT'S LIKE A TEST WOULD
03:43PM	10	BE A COMPLETE BLOOD COUNT.
03:43PM	11	WOULD THAT BE AN EXAMPLE OF A TEST?
03:43PM	12	A. NO. A COMPLETE BLOOD COUNT ACTUALLY HAS FIVE TESTS WITHIN
03:43PM	13	IT.
03:43PM	14	Q. OKAY.
03:43PM	15	A. A CHEMISTRY PROFILE MAY HAVE 8, 12, 24 WITHIN IT. SO EACH
03:43PM	16	OF THOSE TESTS IS COUNTED INDIVIDUALLY.
03:43PM	17	Q. SO WOULD IT BE FAIR TO CALL IT COMPLETE BLOOD COUNT, THE
03:43PM	18	PANEL?
03:43PM	19	A. I GUESS IF YOU WANT TO CALL IT A PANEL, YES.
03:43PM	20	WE DON'T CALL IT A PANEL, BUT THE LABORATORY CERTAINLY
03:43PM	21	CAN.
03:43PM	22	Q. FAIR ENOUGH. FAIR ENOUGH.
03:43PM	23	AND WHEN YOU REQUEST THIS INFORMATION REGARDING THE
03:43PM	24	TESTING PROFILE OF THE LAB, WHAT DO YOU USE THAT FOR?
03:43PM	25	A. THE TOTAL TEST VOLUME IS USED TO DETERMINE THE COST FOR

03:43PM	1	THE LABORATORY FOR THEIR, FOR THEIR COMPLIANCE FEE, HOW MUCH
03:44PM	2	IT'S GOING TO COST TO PERFORM THE SURVEY.
03:44PM	3	Q. SO THE LARGER THE LAB, THE MORE HIGHER THE TESTING, THE
03:44PM	4	HIGHER THE PRICE?
03:44PM	5	A. THAT'S CORRECT.
03:44PM	6	Q. OKAY. IF WE CAN TAKE A LOOK AT EXHIBIT 5453.
03:44PM	7	AND 5453 IS UP ON THE SCREEN.
03:44PM	8	AND YOU WERE ASKED SOME QUESTIONS ON DIRECT ABOUT THIS
03:44PM	9	TEST LIST THAT WAS DATED AS OF JUNE 12, 2015.
03:44PM	10	DO YOU SEE THAT?
03:44PM	11	A. I DO.
03:44PM	12	Q. AND WAS THIS LIST REQUESTED OF THERANOS AT THE TIME THAT
03:44PM	13	THE SURVEY WAS SCHEDULED?
03:44PM	14	A. YES, IT WAS.
03:44PM	15	Q. OKAY. AND SO THIS INFORMATION WAS DISCLOSED BY THERANOS
03:44PM	16	TO THE REQUESTOR AT CMS?
03:44PM	17	A. YES.
03:44PM	18	Q. OKAY. WAS THAT MR. YAMAMOTO?
03:44PM	19	A. I DON'T KNOW IF HE OR I REQUESTED IT. I DON'T RECALL.
03:45PM	20	Q. FAIR ENOUGH.
03:45PM	21	AND THEN YOU REVIEWED SOME OF THE LISTS AND THE NUMBER OF
03:45PM	22	FDA APPROVED, CLEARED OR APPROVED TESTS AND LDT'S.
03:45PM	23	DO YOU SEE THAT?
03:45PM	24	A. I SEE THAT.
03:45PM	25	Q. OKAY. NOW, FOR SOME OF THESE TESTS, FOR EXAMPLE, ON

03:45PM	1	PAGE 1 YOU'LL LOOK AT AND YOU'LL SEE AT THE TOP 10 OR 15
03:45PM	2	ASSAYS, ALBUMIN.
03:45PM	3	DO YOU SEE THAT?
03:45PM	4	A. I DO.
03:45PM	5	Q. AND ALBUMIN IS LISTED WITH TWO METHODS, THERE'S AN FDA
03:45PM	6	CLEARED OR APPROVED AND AS WELL AS AN LDT?
03:45PM	7	A. YES.
03:45PM	8	Q. AND THERE'S NOTHING UNUSUAL ABOUT THAT, A LAB USING TWO
03:45PM	9	DIFFERENT METHODS?
03:45PM	10	A. IT'S NOT UNUSUAL FOR A LABORATORY TO USE TWO DIFFERENT
03:45PM	11	METHODS.
03:45PM	12	WE TYPICALLY DON'T SEE ONE ON AN FDA APPROVED DEVICE AND
03:45PM	13	AN LDT.
03:45PM	14	Q. OKAY. BUT THE FACT THAT A LAB USES TWO DIFFERENT METHODS
03:45PM	15	FOR THE SAME TESTS ON ITS OWN IS NOT UNUSUAL?
03:45PM	16	A. IT DEPENDS ON THE SIZE OF THE LAB AND THE TESTING THAT THE
03:46PM	17	LAB IS DOING.
03:46PM	18	Q. FAIR ENOUGH.
03:46PM	19	AND THEN YOU SEE ON THE SAME FIRST PAGE, AUTOMATED
03:46PM	20	PLATELET COUNT.
03:46PM	21	DO YOU SEE THAT?
03:46PM	22	A. YES.
03:46PM	23	Q. AND SIMILARLY, THERANOS USED BOTH AN LDT METHOD AS WELL AS
03:46PM	24	AN FDA APPROVED METHOD?
03:46PM	25	A. YES.

AND THEN YOU WERE ASKED QUESTIONS BY MR. LEACH IDENTIFYING 1 03:46PM THE NUMBER OF LDT'S ON THE PAGES AND OBVIOUSLY JUST BY LOOKING 2 03:46PM AT THE PAGES, YOU CAN SEE THE NUMBER OF LDT'S IS FAR LESS THAN 3 03:46PM 03:46PM 4 THE NUMBER OF FDA APPROVED TESTS AT THE TIME; CORRECT? ACCORDING TO THIS DOCUMENT, YES. 03:46PM OKAY. HOWEVER, SOME OF THE LDT'S -- FOR EXAMPLE, CALCIUM, 6 Ο. 03:46PM AT THE BOTTOM OF PAGE 1, CALCIUM WAS A RELATIVELY COMMONLY USED 03:46PM TEST; CORRECT? 8 03:46PM 9 IT IS. Α. 03:46PM SO THERE MIGHT BE A LOT OF CALCIUM TESTS ORDERED IN THE 10 03:46PM Q. LAB RELATIVE TO SOME OF THE OTHER TESTS IDENTIFIED IN THE LIST 03:46PM 11 12 THAT MAY BE LESS COMMONLY USED; IS THAT FAIR? 03:46PM 13 Α. YES. 03:46PM 14 OKAY. AGAIN, I WON'T BELABOR THEM ALL, BUT ON PAGE 2, FOR 03:47PM 15 EXAMPLE, CHLORIDE IS IDENTIFIED AS BEING FDA APPROVED AS WELL 03:47PM 16 AS LDT. 03:47PM 17 DO YOU SEE THAT? 03:47PM 18 03:47PM Α. YES. 03:47PM 19 Q. AND CHLORIDE IS ANOTHER RELATIVELY COMMONLY USED TEST; 20 CORRECT? 03:47PM 21 YES. NOT TYPICALLY AN LDT. 03:47PM Α. 22 BUT HERE IT WAS AN LDT? 0. 03:47PM IT WAS IDENTIFIED ON THIS LIST AS AN LDT. 23 Α. 03:47PM 24 FOR EXAMPLE, ON PAGE 3 OF THE LIST AGAIN, HEMOGLOBIN IN Q. 03:47PM 25 THE MIDDLE OF THE PAGE, BOTH LDT AND FDA APPROVED. 03:47PM

03:47PM	1	DO YOU SEE THAT?
03:47PM	2	A. YES.
03:47PM	3	Q. WHEREAS THERE WERE SOME TESTS THAT THERANOS DID NOT HAVE
03:47PM	4	LDT'S FOR. FOR EXAMPLE, HIV, ABOUT TWO-THIRDS OF THE WAY DOWN,
03:47PM	5	DO YOU SEE THOSE ARE ALL FDA APPROVED?
03:48PM	6	A. I DO.
03:48PM	7	Q. AND TOP OF PAGE 4, AGAIN, FEWER LDT'S.
03:48PM	8	BUT HDL AND LDL TESTS, THOSE ARE COMMONLY USED TESTS;
03:48PM	9	CORRECT?
03:48PM	10	A. THEY ARE COMMON TESTS, YES.
03:48PM	11	Q. OKAY. YOU CAN SET THAT ASIDE.
03:48PM	12	IF WE COULD TAKE A LOOK AT EXHIBIT 5830. YOU WERE ALSO
03:48PM	13	ASKED SOME QUESTIONS ABOUT THAT BY MR. LEACH.
03:48PM	14	5830 IS AN EMAIL FROM HEATHER KING TO MR. BALWANI BEING
03:49PM	15	ASKED A QUESTION ABOUT THE POWERPOINT PRESENTATION.
03:49PM	16	DO YOU REMEMBER BEING ASKED QUESTIONS ABOUT THAT?
03:49PM	17	A. ABOUT THE POWERPOINT? YES.
03:49PM	18	Q. AND THEN AGAIN, TURNING TO PAGE 3 OF THE EXHIBIT LOOKING
03:49PM	19	AT THE PRESENTATION, YOU WERE ASKED SOME QUESTIONS BY MR. LEACH
03:49PM	20	ABOUT THE NUMBER OF PATIENT SAMPLES PER DAY THAT WAS
03:49PM	21	REPRESENTED TO YOU AT THE OPENING OF THE SURVEY.
03:49PM	22	DO YOU REMEMBER THAT?
03:49PM	23	A. I DO.
03:49PM	24	Q. AND THE NUMBER WAS REPRESENTED ABOUT 200 SAMPLES A DAY AT
03:49PM	25	THE TIME ANYWAY.

03:49PM	1	DO YOU SEE THAT?
03:49PM	2	A. I DO.
03:49PM	3	Q. AND NOW NEXT TO THAT IS THE IT LOOKS LIKE TO BE AN
03:49PM	4	IMAGE OF THE CLINICAL LABORATORY LICENSE FOR THERANOS.
03:49PM	5	DO YOU SEE THAT?
03:49PM	6	A. I DO.
03:49PM	7	Q. AND MR. LEACH POINTED OUT THERE WERE TWO DIRECTORS
03:49PM	8	IDENTIFIED IN THE LICENSE.
03:49PM	9	DO YOU SEE THAT?
03:49PM	10	A. I DO.
03:49PM	11	Q. AND THERE WAS NOTHING WRONG WITH THAT; CORRECT?
03:49PM	12	A. THAT'S A CALIFORNIA STATE LICENSE.
03:49PM	13	A CLIA CERTIFICATE IS ONLY ALLOWED TO HAVE ONE DIRECTOR.
03:50PM	14	Q. OKAY. SO UNDER STATE LAW THEY WERE ALLOWED TO HAVE TWO,
03:50PM	15	BUT FOR PURPOSES OF THE CLIA CERTIFICATE, THERE IS ONE
03:50PM	16	LABORATORY DIRECTOR WHO IS RESPONSIBLE?
03:50PM	17	A. I CAN'T REALLY SPEAK TO THE STATE REQUIREMENTS, BUT I CAN
03:50PM	18	TELL YOU FOR CLIA THEY'RE ALLOWED TO HAVE ONE DESIGNATED
03:50PM	19	LABORATORY DIRECTOR.
03:50PM	20	Q. AND THAT PERSON IS THE ULTIMATE RESPONSIBLE PERSON AT THE
03:50PM	21	LAB; CORRECT?
03:50PM	22	A. THAT PERSON IS RESPONSIBLE FOR THE OVERALL ADMINISTRATION
03:50PM	23	AND OPERATION OF THE LABORATORY.
03:50PM	24	Q. I'M SORRY. WE'RE BOTH DRIFTING FROM OUR MICROPHONES.
03:50PM	25	I'LL TRY TO DO BETTER MYSELF. I'M SORRY.

03:50PM	1	IF WE CAN GO TO PAGE 14 OF THE DECK.
03:50PM	2	SO YOU MENTIONED INDIVIDUALS WHO WERE PRESENT ON THAT
03:51PM	3	FIRST DAY OF THE SURVEY.
03:51PM	4	DO YOU HAVE A RECOLLECTION OF THAT?
03:51PM	5	A. YES.
03:51PM	6	Q. AND I THINK YOU DESCRIBED MR. BALWANI WAS PRESENT AT THE
03:51PM	7	TIME?
03:51PM	8	A. YES.
03:51PM	9	Q. DR. DANIEL YOUNG WAS PRESENT?
03:51PM	10	A. YES.
03:51PM	11	Q. DR. SURAJ SAKSENA WAS PRESENT?
03:51PM	12	A. YES.
03:51PM	13	Q. LANGLY GEE WAS PRESENT?
03:51PM	14	A. YES.
03:51PM	15	Q. YOU DESCRIBED GURBIR SIDHU, ONE OF THE THE GENERAL
03:51PM	16	SUPERVISOR OR A TECHNICAL SUPERVISOR?
03:51PM	17	A. GURBIR SIDHU WAS THERE, YES.
03:51PM	18	Q. OKAY. AND MS. ALAMDAR, HODA ALAMDAR
03:51PM	19	A. YES.
03:51PM	20	Q WAS ALSO PRESENT?
03:51PM	21	AND AT THE TIME, YOU RECALL IT WAS REPRESENTED TO YOU,
03:51PM	22	THAT MR. SAKSENA WAS EXPECTED TO BECOME THE NEXT LAB DIRECTOR
03:51PM	23	AT THERANOS; CORRECT?
03:51PM	24	A. I DON'T RECALL THAT.
03:51PM	25	Q. YOU DON'T RECALL THAT BEING MENTIONED?

I DON'T. 1 Α. 03:51PM OKAY. BUT YOU DO RECALL ENGAGING WITH DR. SAKSENA DURING 2 Q. 03:51PM THE COURSE OF THE LABORATORY -- THE SURVEY AND THE TWO VISITS 3 03:51PM IN SEPTEMBER AND NOVEMBER OF 2015? 03:51PM 4 I DEFINITELY REMEMBER SEPTEMBER, YES. 03:51PM NOW, YOU DESCRIBED FRUSTRATION THAT YOU HAD A BIT IN THE 0. 03:52PM SURVEY, KIND OF -- I'LL SPEAK LARGELY, I GUESS, AND TRY TO GET 03:52PM IT CORRECT -- THAT YOU WERE REQUESTING DOCUMENTATION AS YOU 8 03:52PM 9 NORMALLY WOULD FOR THE SURVEY, AND THERANOS'S STAFF, 03:52PM PARTICULARLY MR. GEE, WERE NOT AS RESPONSIVE AS YOU WOULD HAVE 10 03:52PM EXPECTED? 03:52PM 11 03:52PM 12 IS THAT FAIR? 03:52PM 13 I WOULD SAY IT WAS VERY FRUSTRATING WHEN WE WOULD REOUEST 14 DOCUMENTS AND THERE WOULD BE A LONG DELAY BEFORE WE GOT THEM, 03:52PM IF WE GOT THEM AT ALL. 15 03:52PM AND MR. GEE WAS ONE OF THE LAB STAFF OR PERSONNEL WHO WERE 16 03:52PM 17 ENGAGED OR INVOLVED IN THIS, LET'S SAY NOT ALWAYS SUCCESSFUL 03:52PM 18 EFFORT, TO OBTAIN THE DOCUMENTATION THAT YOU WERE REQUESTING; 03:52PM 03:52PM 19 IS THAT RIGHT? 20 03:52PM Α. YES. 21 OKAY. BUT YOU DESCRIBED TODAY THAT MR. BALWANI WAS 03:52PM Ο. 22 TELLING HIS STAFF, TELLING THE TEAM TO GET THE DOCUMENTS THAT 03:53PM YOU WERE REQUESTING; IS THAT RIGHT? 23 03:53PM 24 YES. Α. 03:53PM 25 BECAUSE YOU DESCRIBED MR. BALWANI AS, YOU KNOW, SOMEWHAT 03:53PM Q.

03:53PM	1	BEING THE LEAD AND BEING IN CHARGE; IS THAT FAIR?
03:53PM	2	A. I WOULD SAY THAT HE APPEARED TO BE THE ONE WHO WAS IN
03:53PM	3	CHARGE, YES.
03:53PM	4	Q. OKAY. AND HE WAS TELLING HIS TEAM TO GET MS. BENNETT THE
03:53PM	5	DOCUMENTS THAT SHE'S ASKING FOR; RIGHT?
03:53PM	6	A. CORRECT.
03:53PM	7	MR. CAZARES: YOUR HONOR, THIS MIGHT BE A GOOD PLACE
03:53PM	8	BECAUSE I'LL BE SHIFTING INTO SOME PRETTY DENSE MATERIAL.
03:53PM	9	THE COURT: OKAY. WE'RE NOT GOING TO FINISH THIS
03:53PM	10	WITNESS TODAY.
03:53PM	11	DO YOU ANTICIPATE ANOTHER LENGTHY PERIOD OF TIME DO YOU
03:53PM	12	THINK?
03:53PM	13	MR. CAZARES: I EXPECT TO FINISH MS. BENNETT
03:53PM	14	TOMORROW. I CAN'T PROMISE BECAUSE I DON'T KNOW HOW LONG THE
03:53PM	15	FIRST WITNESS TOMORROW IS GOING TO GO, BUT I WILL DO EVERYTHING
03:53PM	16	I CAN.
03:53PM	17	THE COURT: NO, NO. I'M JUST MAKING AN INQUIRY.
03:53PM	18	SO, LADIES AND GENTLEMEN, LET'S TAKE OUR RECESS NOW.
03:53PM	19	I SHOULD TELL YOU, TOMORROW, AS I UNDERSTAND IT, WE'RE
03:53PM	20	GOING TO RESUME WITH MR. JHAVERI'S TESTIMONY IN THE MORNING,
03:54PM	21	AND YOU'LL SEE PLEASE RECALL THAT MR. JHAVERI'S TESTIMONY
03:54PM	22	WAS INTERRUPTED BECAUSE OF SCHEDULING, SO MS. BENNETT WILL HAVE
03:54PM	23	TO WAIT UNTIL THAT WITNESS'S TESTIMONY IS FINISHED.
03:54PM	24	AND THEN, MS. BENNETT, YOU'LL BE RECALLED TO COMPLETE YOUR
03:54PM	25	TESTIMONY. I'M SURE YOU CAN OCCUPY YOUR TIME IN THE MEANTIME.

03:54PM	1	SO LET'S TAKE OUR BREAK, LADIES AND GENTLEMEN. I'LL
03:54PM	2	REMIND YOU OF THE ADMONITION. DO NOT DO ANY INDEPENDENT
03:54PM	3	RESEARCH, DISCUSS, READ, LISTEN TO, OR IN ANY WAY LEARN
03:54PM	4	ANYTHING ABOUT THIS CASE.
03:54PM	5	9:00 O'CLOCK IS OUR ANTICIPATED START TIME TOMORROW
03:54PM	6	MORNING. I'M SURE WE'LL BE ABLE TO KEEP TO THAT.
03:54PM	7	HAVE A GOOD EVENING. WE'LL SEE YOU TOMORROW.
03:54PM	8	MS. BENNETT, YOU CAN JUST BE ON STANDBY. YOU WILL BE ON
03:54PM	9	THE STAND TOMORROW. I'M QUITE CONFIDENT OF THAT. THANK YOU.
03:55PM	10	(JURY OUT AT 3:55 P.M.)
03:55PM	11	THE COURT: THE RECORD SHOULD REFLECT THAT OUR JURY
03:55PM	12	HAS LEFT FOR THE DAY.
03:55PM	13	MS. BENNETT HAS LEFT THE COURTROOM.
03:55PM	14	ALL COUNSEL AND MR. BALWANI REMAIN.
03:55PM	15	SO JUST SCHEDULING TOMORROW? MR. BOSTIC AND
03:55PM	16	MR. COOPERSMITH?
03:55PM	17	MR. BOSTIC: YES, YOUR HONOR. THANK YOU.
03:55PM	18	I THINK IT IS A GOOD IDEA TO TOUCH BASE BRIEFLY JUST ON
03:56PM	19	SCHEDULING TOMORROW.
03:56PM	20	WE'RE BEGINNING WITH MR. JHAVERI AND THEN WE CAN CONTINUE
03:56PM	21	WITH THE CROSS-EXAMINATION OF MS. BENNETT.
03:56PM	22	AFTER THAT, THE GOVERNMENT WILL HAVE DR. SAWYER READY TO
03:56PM	23	TESTIFY, IF NECESSARY. I UNDERSTAND THAT HER DIRECT
03:56PM	24	EXAMINATION WILL BE SIGNIFICANTLY LESS THAN HALF AN HOUR,
03:56PM	25	15 MINUTES TO HALF AN HOUR.

1 03:56PM 2 03:56PM 3 03:56PM 03:56PM 4 03:56PM 5 03:56PM 6 03:56PM 7 THEM FLY OUT UNNECESSARILY. 03:56PM 8 THE COURT: SURE. 03:56PM 9 03:56PM 10 03:56PM 11 03:56PM 12 03:56PM 13 REGARD. THE COURT: SURE. WELL, LET ME SAY WE'RE --03:56PM 14 03:57PM 15 03:57PM 16 03:57PM 17 03:57PM 18 ON WHAT I'M TOLD --03:57PM 19 MR. COOPERSMITH: YES, YOUR HONOR, I THINK THAT'S 03:57PM 20 ACCURATE. 03:57PM 21 03:57PM 22 03:57PM 23 OBVIOUSLY I DON'T KNOW WHAT THE REDIRECT WOULD BE, IF ANY.

03:57PM 24

03:57PM 25

THE GOVERNMENT IS TRYING TO DECIDE WHETHER TO FLY IN AN ADDITIONAL WITNESS FOR TOMORROW. WE'RE AT THE POINT NOW IN THE TRIAL WHERE THE MAJORITY OF OUR REMAINING WITNESSES, ALMOST ALL OF THEM, ARE OUT-OF-TOWN WITNESSES. AND WE REALLY DO WANT TO MINIMIZE OCCASIONS WHERE THE JURY IS HERE AND WE DON'T HAVE A WITNESS TO PUT ON AT THE END OF THE DAY. WE'RE TRYING TO BALANCE THAT AGAINST NOT INCONVENIENCING WITNESSES AND HAVING

MR. BOSTIC: SO IT WOULD BE HELPFUL TO GET SOME GUIDANCE FROM THE COURT AND THE DEFENSE ON WHAT THE SCHEDULE TOMORROW LOOKS LIKE AND WHAT THE COURT'S PREFERENCE IS IN THAT

TOMORROW IS OUR LAST DAY FOR THE WEEK AS I RECALL.

SO I -- MY SENSE IS THAT IF WE GET THROUGH MR. JHAVERI AND MS. BENNETT, I THINK WE'LL BE FORTUNATE, TOMORROW. JUST BASED

WE CONFERRED WITH THE GOVERNMENT AND GAVE THEM THE REST FOR MR. JHAVERI WOULD BE TWO AND A HALF TO THREE HOURS, AND

AS YOU JUST HEARD MR. CAZARES, HE EXPECTS TO HAVE TO SPEND SOME TIME WITH MS. BENNETT.

03:57PM	1	SO I WOULD, FRANKLY, BE SURPRISED IF, AS THE COURT JUST
03:57PM	2	SAID, WE EVEN HAD TIME FOR ANOTHER WITNESS BEYOND THOSE TWO.
03:57PM	3	OBVIOUSLY THINGS COULD GO REALLY, YOU KNOW, SMOOTHLY AND
03:57PM	4	MAYBE THAT WOULD HAPPEN.
03:57PM	5	BUT IT SOUNDS LIKE THE GOVERNMENT HAS ONE ADDITIONAL
03:57PM	6	WITNESS AND THEY'RE, IF I'M RIGHT, IF I HEARD MR. BOSTIC RIGHT,
03:57PM	7	HIS QUESTION WAS WHETHER THEY WOULD EVEN HAVE A FOURTH WITNESS
03:58PM	8	FOR TOMORROW?
03:58PM	9	IS THAT
03:58PM	10	MR. BOSTIC: THAT'S RIGHT.
03:58PM	11	DR. SAWYER IS LOCAL, SO SHE CAN BE AVAILABLE. THE OTHER
03:58PM	12	WITNESS WE WOULD NEED TO FLY IN THIS EVENING.
03:58PM	13	THE COURT: MAY I JUST SAY AND MAKE AN OBSERVATION,
03:58PM	14	I DON'T THINK WE SHOULD FLY IN THE WITNESS THIS EVENING.
03:58PM	15	DO YOU JOIN IN THAT? DO YOU WANT TO TALK TO YOUR TEAM
03:58PM	16	ABOUT THAT?
03:58PM	17	MR. COOPERSMITH: NO. I THINK THAT SOUNDS RIGHT,
03:58PM	18	YOUR HONOR.
03:58PM	19	THE COURT: YES.
03:58PM	20	MR. COOPERSMITH: AND, LOOK, I THINK OUR GOAL, ALL
03:58PM	21	OF OUR GOALS IS TO FILL ALL OF THE TIME THAT IS AVAILABLE.
03:58PM	22	THE COURT: SURE.
03:58PM	23	MR. COOPERSMITH: BUT IF IT WERE 15 OR 20 MINUTES,
03:58PM	24	I'M NOT SURE THAT WOULD JUSTIFY FLYING THE WITNESS IN FOR THAT.
03:58PM	25	THE COURT: RIGHT. I JUST DON'T SEE THE VALUE IN

HAVING A WITNESS COME OUT, SIT ALL DAY WAITING, AND THEN 1 03:58PM 2 PERHAPS HAVE HIS OR HER TESTIMONY, HAVE TO FLY BACK TO COMPLETE 03:58PM LATER TESTIMONY. THAT'S JUST -- IF WE HAVE TO BURN 30 MINUTES, 3 03:58PM SO BE IT. THERE ARE A LOT OF THINGS THAT WE CAN TALK ABOUT IN 03:58PM 4 THAT REGARD. 03:58PM SO I WOULD -- I CAN'T DIRECT YOU WHAT TO DO WITH YOUR 03:58PM 6 03:58PM 7 CASE, BUT AS FAR AS AN ADDITIONAL WITNESS, OUT-OF-TOWN WITNESS, I DON'T THINK THAT WE'LL GET TO THEM TOMORROW. 03:59PM 8 AND IF WE RUN OUT OF TIME AND YOU DON'T FLY THIS WITNESS 03:59PM 9 03:59PM 10 IN, YOU ARE NOT GOING TO INCUR THE WRATH OF THIS COURT -- THIS 03:59PM 11 COURT DOESN'T HAVE WRATH -- BUT I'M NOT GOING TO GET UPSET WITH 03:59PM 12 YOU ABOUT ANYTHING. AND I THINK, MR. COOPERSMITH, YOU'RE NOT GOING TO ASK THAT 03:59PM 13 THE CASE BE DISMISSED BECAUSE THEY CAN'T GO FORWARD. FOR OTHER 03:59PM 14 03:59PM 15 REASONS YOU MIGHT, BUT NOT FOR THAT REASON. MR. COOPERSMITH: IF THAT'S WHAT HAPPENS TOMORROW, I 03:59PM 16 WON'T ASK FOR IT ON THAT BASIS. 03:59PM 17 03:59PM 18 THE COURT: ALL RIGHT. MR. BOSTIC: THANK YOU, YOUR HONOR. THAT'S HELPFUL. 03:59PM 19 03:59PM 20 BASED ON THE DEFENSE'S PREDICTIONS AND THE COURT'S 03:59PM 21 EXPECTATIONS, WE'LL HOLD OFF ON FLYING THAT WITNESS OUT. 03:59PM 22 THE COURT: GREAT. OKAY. ALL RIGHT. 03:59PM 23 AND THEN I THINK OUR GOAL SHOULD BE FOCUSSED, IF WE CAN, 03:59PM 24 WE CAN, BUT IF WE CAN'T, WE CAN'T, TO FINISH THE TWO WITNESSES, 03:59PM 25 THAT IS, MR. JHAVERI AND MS. BENNETT. SHE'S FROM OUT OF TOWN.

03:59PM	1	MR. BOSTIC: YES, YOUR HONOR.
03:59PM	2	THE COURT: WELL, THEY BOTH ARE, AREN'T THEY?
03:59PM	3	MR. BOSTIC: YES, YOUR HONOR.
03:59PM	4	THE COURT: IT WOULD BE NICE TO GET THEM ON PLANES
03:59PM	5	TOMORROW IF WE CAN. AND, OF COURSE, THE DEFENSE HAS TO DO WHAT
04:00PM	6	YOU HAVE TO DO.
04:00PM	7	MR. COOPERSMITH: I APPRECIATE THAT, YOUR HONOR.
04:00PM	8	OBVIOUSLY WE WILL DO THAT, BUT IF AT THE SAME TIME WE CAN
04:00PM	9	GET THE WITNESSES OUT OF HERE, THEN THAT'S ALSO FINE.
04:00PM	10	THE COURT: RIGHT.
04:00PM	11	MR. COOPERSMITH: RIGHT.
04:00PM	12	MR. BOSTIC: YOUR HONOR, JUST ONE VERY BRIEF
04:00PM	13	HOUSEKEEPING MATTER.
04:00PM	14	DURING THE DIRECT EXAM OF MR. MENDENHALL, I PUBLISHED TO
04:00PM	15	THE JURY EXHIBIT 1776. MY MISTAKE, IT TURNS OUT THAT HAD NOT
04:00PM	16	BEEN ADMITTED. IT WAS A DIFFERENT VERSION OF THE
04:00PM	17	"FORTUNE" ARTICLE FROM JUNE 2014.
04:00PM	18	THE ARTICLE HAD BEEN ADMITTED AS AN ATTACHMENT TO AN EMAIL
04:00PM	19	UNDER A DIFFERENT EXHIBIT NUMBER.
04:00PM	20	1776 IS THE SAME CONTENT, IT'S THE SAME ARTICLE, JUST
04:00PM	21	UNDER A DIFFERENT EXHIBIT NUMBER.
04:00PM	22	A COUPLE OF WAYS WE CAN HANDLE THIS. I PROPOSE THAT THE
04:00PM	23	PARTIES STIPULATE TO THE ADMISSION OF 1776, BUT I JUST WANTED
04:00PM	24	TO RAISE IT WITH THE COURT. I'LL GIVE MR. COOPERSMITH A CHANCE
04:00PM	25	TO RESPOND, OR WE CAN COME BACK AND TAKE CARE OF THAT

04:00PM	1	THE COURT: AND I JUST
04:00PM	2	MR. BOSTIC: OR TOMORROW MORNING.
04:00PM	3	THE COURT: I JUST TOLD MR. COOPERSMITH, THERE WILL
04:01PM	4	BE ANOTHER GROUNDS FOR HIM TO ASK FOR DISMISSAL AND PERHAPS
04:01PM	5	THIS IS IT.
04:01PM	6	MR. COOPERSMITH: I'M NOT SURE THAT'S GOING TO BE IT
04:01PM	7	EITHER, YOUR HONOR.
04:01PM	8	BUT I DID NOTICE THAT, AND I AM AWARE THAT THIS IS THE
04:01PM	9	ROGER PARLOFF ARTICLE IN "FORTUNE."
04:01PM	10	THE COURT: RIGHT.
04:01PM	11	MR. COOPERSMITH: IT WAS, AS MR. BOSTIC SAID, IT WAS
04:01PM	12	ADMITTED AS AN ATTACHMENT. EXHIBIT 1776 IS THE SAME ARTICLE.
04:01PM	13	WE HAD OBJECTIONS TO THE FIRST ONE. I DON'T HAVE THE
04:01PM	14	EXHIBIT NUMBER OF THE FIRST ONE HANDY. MAYBE MR. BOSTIC HAS
04:01PM	15	IT.
04:01PM	16	MR. BOSTIC: I DON'T HAVE IT HANDY.
04:01PM	17	MR. COOPERSMITH: YOU DON'T? OKAY. BUT THE FIRST
04:01PM	18	ONE THAT WAS ACTUALLY ADMITTED, THAT WAS ADMITTED OVER THE
04:01PM	19	DEFENSE OBJECTION.
04:01PM	20	SO WE HAVE THE SAME OBJECTIONS TO 1776.
04:01PM	21	THE COURT: SURE.
04:01PM	22	MR. COOPERSMITH: BUT GIVEN THE COURT'S RULING
04:01PM	23	THE COURT: PARDON ME FOR INTERRUPTING YOU.
04:01PM	24	I DON'T WANT YOU TO HAVE TO STIPULATE TO SOMETHING THAT
04:01PM	25	YOU OBJECTED TO. I'M NOT GOING TO HAVE YOU DO THAT

1 MR. COOPERSMITH: RIGHT. 04:01PM THE COURT: -- IF YOU DON'T WANT TO DO THAT OR IF 2 04:01PM IT'S AWKWARD FOR YOU TO DO THAT, AND IT MIGHT BE FOR THE RECORD 3 04:01PM 04:01PM 4 CANDIDLY, AND SO I'M NOT GOING TO ASK YOU TO DO THAT. BUT I CAN MAKE A STATEMENT TO THE JURY THAT INDICATES THAT 04:01PM THIS -- WE'LL GET THE NUMBERS, AND I CAN TELL THEM TOMORROW, 04:02PM 6 04:02PM 7 YOU KNOW, WHEN I INVITE YOU TO SUGGEST LANGUAGE, AND 1776 WAS THE SAME DOCUMENT, IT WAS ALSO ADMITTED, AND I CAN INDICATE 04:02PM 8 THAT THE DEFENSE OBJECTED IF YOU WANT ME TO, OR NOT. 04:02PM 9 04:02PM 10 MR. COOPERSMITH: THANK YOU, YOUR HONOR. 04:02PM 11 I THINK THAT IS FINE. I WOULD ASK THE COURT, IT'S NOT 04:02PM 12 NECESSARY TO TELL THE JURY "AND THE DEFENSE ALSO OBJECTS TO 1776" AS LONG AS THE COURT NOTES THAT THAT IS THE DEFENSE 04:02PM 13 OBJECTION FOR THE RECORD. 04:02PM 14 04:02PM 15 THE COURT: I SAID THAT PROPHYLACTICALLY. IF YOU WANT ME TO PUT THAT ON THE RECORD IN FRONT OF THE JURY, I WILL 04:02PM 16 04:02PM 17 DO THAT. 04:02PM 18 IF YOU DON'T, I CAN UNDERSTAND WHY YOU WOULDN'T, I WON'T. 04:02PM 19 AND YOUR OBJECTION WILL REMAIN FOR BOTH ITERATIONS OF THE 04:02PM 20 DOCUMENT. MR. COOPERSMITH: THAT SOUNDS EXACTLY RIGHT, 04:02PM 21 YOUR HONOR. THANK YOU. 04:02PM 22 04:02PM 23 THE COURT: RIGHT. 04:02PM 24 MR. BOSTIC: SO ARE WE ADMITTING 1776 BUT WITH THE 04:02PM 25 UNDERSTANDING THAT THE DEFENSE PRESERVES ITS OBJECTION, OR DO

04:03PM	1	WE PLAN TO OR WILL THE COURT INSTRUCT THE JURY THAT WHAT WAS
04:03PM	2	PUBLISHED AS 1776 WAS ADMITTED UNDER A DIFFERENT EXHIBIT
04:03PM	3	NUMBER?
04:03PM	4	EITHER IS FINE FOR THE GOVERNMENT, YOUR HONOR.
04:03PM	5	THE COURT: WELL, IT WAS ADMITTED, AND I THINK IT
04:03PM	6	SHOULD, AT THE RISK OF BEING DUPLICATIVE, IT'S ADMITTED. AND
04:03PM	7	SO I SHOULD TELL THEM THAT 1776 IS THE SAME AS WHATEVER THE
04:03PM	8	OTHER NUMBER IS. IT WAS ADMITTED IN A DIFFERENT 1994
04:03PM	9	1944, EXCUSE ME.
04:03PM	10	1944 WAS ADMITTED AS AN EMAIL. 1776 THE ARTICLE
04:03PM	11	IDENTIFIED IN 1776 WAS AN ATTACHMENT. THAT WAS
04:03PM	12	MR. BOSTIC: YES, YOUR HONOR, THE SAME ARTICLE WAS
04:03PM	13	ATTACHED TO THE EMAIL.
04:03PM	14	THE COURT: RIGHT. SO 1776 WAS ALSO ADMITTED. IT'S
04:03PM	15	THE ATTACHMENT TO 1944, LADIES AND GENTLEMEN. I JUST TELL YOU
04:03PM	16	THAT FOR YOUR INFORMATION.
04:03PM	17	MR. COOPERSMITH: AND OUR OBJECTION IS NOTED FOR
04:03PM	18	BOTH AND THAT SOUNDS JUST FINE, YOUR HONOR.
04:03PM	19	THE COURT: ALL RIGHT. I'LL DO THAT TOMORROW
04:04PM	20	MORNING.
04:04PM	21	MR. BOSTIC: THANK YOU, YOUR HONOR. I APOLOGIZE FOR
04:04PM	22	THE CONFUSION.
04:04PM	23	THE COURT: NO. I'M SORRY I LET THAT SLIP.
04:04PM	24	OKAY. RIGHT. AND THEN TOMORROW IS OUR LAST DAY FOR THE
04:04PM	25	WEEK. WE'LL SEE IF WE CAN I EXPECT IF WE'RE CLOSE TO

04:04PM	1	FINISHING, THIS JURY IS NOT GOING TO OBJECT TO US GOING OVER
04:04PM	2	4:00 O'CLOCK A LITTLE BIT TOMORROW.
04:04PM	3	MR. COOPERSMITH: OKAY, YOUR HONOR. FINE.
04:04PM	4	THE COURT: THEY SEEM TO BE ENGAGED.
04:04PM	5	THANK YOU. HAVE A GOOD EVENING.
04:04PM	6	MR. BOSTIC: THANK YOU, YOUR HONOR.
04:04PM	7	THE CLERK: COURT IS ADJOURNED.
04:04PM	8	(COURT ADJOURNED AT 4:04 P.M.)
	9	
	10	
	11	
	12	
	13	
	14	
	15	
	16	
	17	
	18	
	19	
	20	
	21	
	22	
	23	
	24	
	25	

1	
2	
3	CERTIFICATE OF REPORTERS
4	
5	
6	
7	WE, THE UNDERSIGNED OFFICIAL COURT REPORTERS OF THE
8	UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF
9	CALIFORNIA, 280 SOUTH FIRST STREET, SAN JOSE, CALIFORNIA, DO
10	HEREBY CERTIFY:
11	THAT THE FOREGOING TRANSCRIPT, CERTIFICATE INCLUSIVE, IS
12	A CORRECT TRANSCRIPT FROM THE RECORD OF PROCEEDINGS IN THE
13	ABOVE-ENTITLED MATTER.
14	Ovene Rodriguez
15	Chark woulded
16	IRENE RODRIGUEZ, CSR, CRR CERTIFICATE NUMBER 8076
17	
18	Spe-Am Shorting
19	LEE-ANNE SHORTRIDGE, CSR, CRR CERTIFICATE NUMBER 9595
20	
21	DATED: MAY 3, 2022
22	
23	
24	
25	